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2 
Abstract 
Upregulation	  of	  the	  extracellular	  signal-­‐regulated	  kinase	  (ERK)	  pathway	  has	  been	  shown	  
to	  contribute	  to	  tumour	  invasion	  and	  progression.	  Since	  the	  two	  predominant	  ERK	  
isoforms	  (ERK1	  and	  ERK2)	  are	  highly	  homologous	  and	  have	  indistinguishable	  kinase	  
activities	  in	  vitro,	  both	  enzymes	  were	  believed	  to	  be	  redundant	  and	  interchangeable.	  To	  
challenge	  this	  view,	  here	  we	  show	  that	  ERK2	  silencing	  inhibits	  invasive	  migration	  of	  
MDA-­‐MB-­‐231	  cells,	  and	  re-­‐expression	  of	  ERK2	  (but	  not	  ERK1)	  restores	  the	  normal	  invasive	  
phenotype.	  A	  detailed	  quantitative	  analysis	  of	  cell	  movement	  on	  3D	  matrices	  indicates	  
that	  ERK2	  knockdown	  impairs	  cellular	  motility	  by	  decreasing	  the	  migration	  velocity	  as	  well	  
as	  increasing	  the	  time	  that	  cells	  remain	  stationary.	  We	  used	  gene	  expression	  arrays	  to	  
identify	  rab17	  and	  liprin-­‐β2	  as	  genes	  whose	  expression	  was	  increased	  by	  knockdown	  of	  
ERK2	  and	  restored	  to	  normal	  levels	  following	  re-­‐expression	  of	  ERK2	  (but	  not	  ERK1).	  
Moreover,	  we	  established	  that	  both	  Rab17	  and	  Liprin-­‐β2	  play	  inhibitory	  roles	  in	  the	  
invasive	  behaviour	  of	  three	  independent	  cancer	  cell	  lines,	  indicating	  a	  suppressive	  role	  for	  
these	  proteins	  in	  tumour	  progression.	  Importantly,	  knockdown	  of	  either	  Rab17	  or	  
Liprin-­‐β2	  restores	  invasiveness	  of	  ERK2-­‐depleted	  cells,	  indicating	  that	  ERK2	  drives	  
invasion	  of	  MDA-­‐MB-­‐231	  cells	  by	  suppressing	  expression	  of	  these	  genes.	  
Taken	  together,	  our	  data	  provides	  evidence	  that	  true	  functional	  disparities	  between	  ERK1	  
and	  ERK2	  exist	  with	  regards	  to	  cell	  migration	  and	  identifies	  Rab17	  and	  Liprin-­‐β2	  as	  two	  
novel	  motility	  suppressors	  downstream	  of	  ERK2.	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1.1 The nature of cancer 
1.1.1 Hallmarks of malignancy 
Cancer,	  a	  disease	  with	  more	  than	  100	  distinct	  types	  and	  subtypes,	  is	  driven	  by	  randomly	  
occurring	  mutations	  and	  epigenetic	  changes	  [1].	  These	  genetic	  alterations	  produce	  
oncogenes	  with	  a	  dominant	  gain	  of	  function	  and	  ablate	  tumour	  suppressor	  genes,	  giving	  
rise	  to	  a	  recessive	  loss	  of	  function	  [2].	  Several	  lines	  of	  evidence	  have	  shown	  that	  
tumourigenesis	  is	  a	  multistep	  process	  analogous	  to	  Darwinian	  evolution	  in	  which	  normal	  
cells	  gradually	  evolve	  into	  malignant	  tumour	  cells	  through	  dynamic	  changes	  in	  the	  
genome	  [3-­‐5].	  Depending	  on	  the	  degree	  of	  aggressiveness	  tumours	  are	  divided	  into	  two	  
main	  categories.	  Those	  which	  grow	  at	  the	  site	  of	  origin	  without	  invading	  the	  surrounding	  
tissue	  are	  classed	  as	  benign	  tumours,	  whereas	  tumours	  which	  have	  infiltrated	  the	  nearby	  
tissue	  or	  spread	  to	  distant	  organs	  are	  classified	  as	  malignant.	  The	  term	  cancer	  refers	  to	  a	  
malignant	  tumour	  [6].	  	  
Histological	  analysis	  of	  cancer	  tissues	  allows	  further	  subdivision	  into	  four	  main	  classes.	  
The	  most	  common	  type,	  the	  carcinoma,	  arises	  from	  epithelial	  cells	  and	  accounts	  for	  more	  
than	  80%	  of	  cancer-­‐related	  deaths.	  Sarcomas,	  which	  derive	  from	  a	  variety	  of	  
mesenchymal	  cell	  types,	  constitute	  approximately	  1%	  of	  clinically-­‐treated	  cancers.	  The	  
third	  class	  of	  cancers	  are	  termed	  hematopoietic	  cancers,	  which	  arise	  from	  blood-­‐forming	  
and	  immune	  cells.	  Lastly,	  neuroectodermal	  tumours	  form	  the	  fourth	  class	  and	  derive	  
from	  cells	  of	  the	  central	  and	  peripheral	  nervous	  system.	  It	  is	  important	  to	  stress	  that	  
some	  types	  of	  cancers,	  such	  as	  melanoma,	  do	  not	  neatly	  fit	  into	  this	  classification	  
scheme	  [7].	  	  
Surprisingly,	  taking	  into	  account	  the	  vast	  variety	  of	  genomic	  changes	  identified	  as	  drivers	  
of	  oncogenesis,	  only	  nine	  physiological	  hallmarks	  in	  tumour	  cell	  development	  have	  thus	  
far	  been	  declared	  essential	  for	  malignant	  growth	  (Figure	  1-­‐1)	  [1,	  8].	  Firstly,	  tumour	  cells	  
must	  acquire	  to	  ability	  to	  grow	  autonomously.	  Tumour	  cells	  reduce	  their	  dependency	  on	  
extracellular	  stimuli	  either	  by	  generating	  their	  own	  growth	  signals,	  altering	  the	  
ligand-­‐dependency	  of	  the	  growth	  receptors	  or	  by	  modifying	  the	  cytoplasmic	  circuitry	  
downstream	  of	  growth	  receptors.	  Secondly,	  tumour	  cells	  must	  become	  insensitive	  to	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Figure 1-1 Nine hallmarks acquired by cancer 
Adapted from [8]. 
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anti-­‐growth	  signals,	  which	  either	  induce	  cell	  differentiation	  or	  force	  proliferating	  cells	  into	  
a	  quiescent	  G0	  state.	  Thirdly,	  tumour	  cells	  must	  find	  a	  way	  to	  evade	  programmed	  cell	  
death,	  a	  process	  termed	  apoptosis.	  Abnormal	  signalling	  caused	  by	  oncogenes	  can	  be	  
recognised	  by	  apoptotic	  sensors	  and	  trigger	  the	  onset	  of	  apoptosis,	  thereby	  providing	  a	  
means	  by	  which	  transformed	  cells	  are	  removed	  from	  the	  tissue.	  Having	  gained	  the	  ability	  
to	  grow	  and	  proliferate,	  tumour	  cells	  furthermore	  have	  to	  overcome	  the	  hurdle	  of	  a	  finite	  
cellular	  lifespan	  of	  60	  to	  70	  doublings.	  Every	  DNA	  replication	  results	  in	  a	  shortening	  of	  the	  
chromosome	  ends,	  called	  telomeres,	  due	  to	  the	  inability	  of	  the	  DNA	  polymerases	  to	  
completely	  replicate	  the	  3’	  ends	  of	  the	  chromosomes.	  In	  order	  to	  overcome	  this	  natural	  
limit	  of	  replication,	  tumour	  cells	  acquire	  the	  trait	  to	  maintain	  and	  renew	  telomeres,	  thus	  
becoming	  immortal.	  	  
The	  resulting	  uncontrolled	  proliferation,	  however,	  demands	  a	  good	  supply	  of	  oxygen	  and	  
nutrients	  by	  the	  vasculature,	  which	  is	  ensured	  when	  a	  cell	  resides	  within	  100	  µm	  of	  a	  
capillary	  blood	  vessel.	  As	  the	  tumour	  mass	  grows	  past	  a	  diameter	  of	  0.1-­‐0.2	  mm,	  tumour	  
cells	  must	  acquire	  the	  ability	  to	  induce,	  attract	  and	  sustain	  new	  blood	  vessel	  formation	  in	  
a	  process	  termed	  angiogenesis.	  	  Moreover,	  the	  increase	  in	  proliferation	  requires	  rapid	  
production	  of	  adenosine	  triphosphate	  (ATP),	  lipids,	  nucleotides	  and	  amino	  acids.	  Thus,	  a	  
metabolic	  switch	  in	  tumour	  cells	  to	  meet	  the	  growing	  demand	  for	  energy	  and	  cellular	  
building	  blocks	  has	  been	  proposed	  as	  a	  hallmark	  of	  tumour	  cells.	  	  Another	  important	  trait	  
of	  tumour	  cells	  is	  the	  ability	  to	  evade	  immunosurveillance.	  Immune	  cells	  are	  an	  important	  
player	  in	  tissue	  homeostasis	  and	  can	  eliminate	  transformed	  cells	  by	  triggering	  an	  innate	  
immune	  response.	  However,	  as	  the	  disease	  progresses	  tumour	  cell	  variants,	  which	  are	  
able	  to	  escape	  the	  immune	  attack,	  develop.	  Paradoxically,	  immune	  cells	  have	  also	  been	  
shown	  to	  promote	  tumourigenesis,	  thus,	  inflammation	  has	  emerged	  as	  a	  new	  hallmark	  of	  
cancer	  in	  the	  last	  decade.	  Immune	  cells	  contribute	  towards	  the	  development	  of	  cancer	  by	  
supplying	  tumour	  cells	  with	  growth	  signals,	  promoting	  epithelial-­‐to-­‐mesenchymal	  (EMT)	  
transition	  and	  by	  remodelling	  the	  extracellular	  matrix,	  which	  facilitates	  tumour	  cell	  
migration,	  invasion	  and	  the	  process	  of	  angiogenesis	  [9].	  Lastly,	  malignant	  tumour	  cells	  
gain	  the	  ability	  to	  invade	  and	  metastasise	  at	  distant	  sites	  in	  the	  body	  [1,	  10,	  11].	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1.1.2 Invasion-metastasis cascade 
The	  metamorphosis	  of	  a	  normal	  cell	  to	  a	  malignant	  one	  requires	  many	  phenotypic	  and	  
biochemical	  changes,	  which	  are	  acquired	  in	  a	  multi-­‐step	  process	  called	  the	  
invasion-­‐metastasis	  cascade.	  The	  development	  of	  metastases	  has	  been	  subdivided	  into	  
five	  crucial	  steps:	  primary	  invasion,	  intravasation,	  circulation,	  extravasation	  and	  
homing	  (Figure	  1-­‐2)	  [12,	  13].	  	  
In	  the	  first	  instance	  tumour	  cells	  need	  to	  detach	  from	  the	  primary	  tumour	  mass,	  which	  is	  
achieved	  through	  the	  alteration	  of	  cell	  adhesion	  molecules	  (CAMs),	  mediating	  cell-­‐cell	  
and	  cell-­‐matrix	  interactions.	  One	  of	  the	  most	  common	  changes	  in	  carcinomas	  allowing	  
detachment	  is	  the	  functional	  loss	  of	  E-­‐cadherin,	  a	  homotypic	  CAM,	  which	  is	  an	  important	  
signalling	  molecule	  for	  conveying	  anti-­‐growth	  signals	  to	  the	  intracellular	  signalling	  circuit	  
of	  β-­‐catenin	  and	  the	  Lef/Tcf	  transcription	  factor.	  E-­‐cadherin	  function	  is	  lost	  by	  several	  
mechanisms	  including	  mutational	  inactivation,	  transcriptional	  repression	  and	  proteolysis	  
of	  the	  extracellular	  domain	  [14].	  A	  loss	  in	  E-­‐cadherin	  is	  often	  accompanied	  by	  increased	  
N-­‐cadherin	  expression.	  The	  display	  of	  N-­‐cadherin	  molecules	  on	  the	  cell	  surface	  allows	  
binding	  to	  stromal	  cells	  and	  eventually	  favours	  migration	  from	  the	  epithelium	  towards	  
the	  connective	  tissue	  called	  stroma	  [15,	  16].	  Yet,	  epithelium	  and	  stroma	  are	  separated	  by	  
the	  basement	  membrane,	  a	  dense	  meshwork	  of	  glycoproteins	  and	  proteoglycans	  
consisting	  mainly	  of	  type	  IV	  collagen	  and	  laminin.	  The	  secretion	  of	  matrix-­‐degrading	  
proteases	  by	  tumour	  cells	  or	  recruited	  stromal	  cells	  disrupts	  this	  structural	  barrier	  and	  
allows	  migration	  into	  the	  adjacent	  connective	  tissue.	  Under	  normal	  circumstances,	  
protease	  activity	  is	  tightly	  regulated	  through	  both	  autoinhibition	  and	  secreted	  inhibitors.	  
However,	  in	  tumours	  the	  expression	  of	  proteases	  is	  commonly	  augmented,	  while	  
protease	  inhibitors	  are	  down-­‐regulated	  [17].	  The	  biochemical	  and	  phenotypical	  changes	  
observed	  during	  the	  invasive	  process	  additionally	  facilitate	  intrusion	  of	  tumour	  cells	  into	  
the	  lumen	  of	  lymphatic	  or	  blood	  vessels.	  During	  this	  step,	  which	  is	  termed	  intravasation,	  
tumour	  cells	  penetrate	  into	  the	  lumen	  of	  either	  lymphatic	  or	  blood	  vessels	  and	  are	  then	  
transported	  to	  distant	  tissue	  sites.	  This	  mode	  of	  travel,	  however,	  poses	  many	  risks	  for	  
tumour	  cells.	  Firstly,	  they	  have	  to	  evade	  anoikis,	  a	  special	  form	  of	  programmed	  cell	  death	  
activated	  upon	  loss	  of	  anchorage	  as	  normal	  (untransformed)	  cells	  cannot	  survive	  in	  
conditions	  when	  cell-­‐cell	  or	  cell-­‐substratum	  interactions	  are	  lost.	  Tumour	  cells	  therefore	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Figure 1-2 The invasion-metastasis cascade 
Metastasis formation is a multistep process during which tumour cells invade the surrounding, enter blood 
vessels, adhere at distant sites, where the leave the blood stream to form new secondary lesions. Figure 
adapted from [7]  
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have	  to	  gain	  the	  ability	  to	  proliferate	  and	  survive	  in	  an	  anchorage-­‐independent	  
manner	  [18].	  Secondly,	  high	  shear	  forces	  pose	  the	  risk	  of	  damaging	  the	  cells	  physically.	  As	  
a	  way	  to	  oppose	  these	  non-­‐viable	  conditions,	  tumour	  cells	  form	  so	  called	  micro-­‐emboli,	  
which	  are	  aggregations	  of	  tumour	  cells	  with	  thrombocytes	  and	  erythrocytes.	  This	  
clumping	  is	  driven	  by	  a	  protein	  called	  tissue	  factor,	  which	  is	  highly	  expressed	  in	  malignant	  
carcinomas	  cells	  [19,	  20].	  Mice	  deficient	  in	  micro-­‐emboli	  formation	  show	  an	  over	  90%	  
decrease	  in	  metastasis	  formation,	  stressing	  the	  adverse	  conditions	  tumour	  cells	  face	  
when	  in	  circulation	  [21].	  
Next,	  cancer	  cells	  need	  to	  lodge	  at	  a	  distant	  site	  before	  extravasating	  from	  the	  
vasculature.	  Specific	  cell	  surface	  receptors,	  such	  as	  integrins	  and	  the	  CXCR4-­‐receptor,	  
have	  been	  demonstrated	  to	  facilitate	  lodging	  at	  the	  endothelium	  of	  blood	  vessels	  of	  
specific	  organs	  [22,	  23].	  The	  process	  of	  extravasation	  is	  thought	  to	  occur	  in	  two	  different	  
ways.	  Tumour	  cells	  either	  start	  to	  proliferate	  in	  the	  lumen	  of	  the	  vessel,	  thereby	  
destroying	  the	  adjacent	  endothelium.	  Alternatively,	  they	  can	  penetrate	  a	  distant	  tissue	  in	  
a	  process	  similar	  to	  intravasation	  by	  invading	  the	  endothelium	  and	  	  then	  degrading	  
basement	  membrane	  with	  the	  help	  of	  proteases	  [12].	  Yet,	  in	  order	  to	  colonise	  and	  
proliferate	  successfully	  at	  ectopic	  sites,	  cancer	  cells	  need	  to	  adapt	  to	  the	  new	  
micro-­‐environment,	  where	  survival	  and	  growth	  signals	  differ	  from	  the	  original	  tumour	  
site.	  Indeed,	  homing	  represents	  the	  most	  complex	  and	  challenging	  step	  of	  the	  
invasion-­‐metastasis	  cascade.	  Thus,	  most	  cells	  that	  have	  spread	  to	  ectopic	  sites	  do	  not	  
develop	  into	  macroscopic	  lesions,	  but	  die	  rapidly	  or	  survive	  as	  dormant	  micro-­‐metastases.	  
In	  the	  early	  1990s,	  genes,	  which	  inhibit	  colonisation,	  were	  identified.	  These	  so-­‐called	  
metastasis	  suppressor	  genes	  often	  alter	  fundamental	  signalling	  pathways	  regulating	  
cellular	  growth	  and	  proliferation	  such	  as	  the	  MAPK/ERK	  (mitogen	  activated	  protein	  
kinase/extracellular	  signal-­‐regulated	  kinase)	  pathway.	  One	  example	  is	  the	  histidine	  
kinase,	  nm23-­‐Hi,	  the	  first	  metastasis	  suppressor	  gene	  to	  be	  identified.	  Nm23-­‐Hi	  
phosphorylates	  the	  kinase	  suppressor	  of	  Ras	  (KSR)	  protein	  and	  thereby	  inhibits	  
Ras-­‐mediated	  activation	  of	  ERK	  [24-­‐26].	  	  
The	  molecular	  principles	  of	  cancer	  invasion	  and	  metastasis	  are	  highly	  complex	  and	  
therefore	  remain	  a	  major	  challenge	  in	  basic	  cancer	  research.	  Moreover,	  malignant	  
tumours	  account	  for	  approximately	  90%	  of	  all	  cancer-­‐related	  deaths,	  thus	  new	  insight	  
into	  the	  invasion-­‐metastasis	  cascade	  may	  open	  up	  a	  novel	  therapeutic	  window.	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1.1.3 Modes of tumour cell migration 
Cell	  migration	  is	  an	  essential	  characteristic	  during	  embryonic	  development,	  immune	  
system	  function	  and	  tissue	  repair,	  but	  is	  also	  playing	  an	  important	  role	  in	  inflammatory	  
diseases	  and	  tumourigenesis	  [27].	  Cellular	  motility	  relies	  on	  the	  establishment	  of	  two	  
physical	  forces.	  At	  the	  cellular	  front	  protrusive	  forces	  initiated	  by	  actin	  polymerisation	  
and	  depolymerisation	  allow	  membrane	  extension,	  whereas	  at	  the	  cellular	  rear	  retraction	  
forces	  generated	  by	  myosin-­‐based	  motors	  initiate	  contraction	  [27].	  Protrusion	  and	  
retraction	  need	  to	  be	  tightly	  regulated	  in	  order	  to	  allow	  net	  translocation	  of	  the	  cellular	  
body.	  This	  is	  achieved	  through	  an	  internal	  spatial	  asymmetry	  called	  cellular	  polarisation,	  
which	  defines	  a	  cellular	  front	  and	  rear.	  Indeed,	  unpolarised	  cells,	  which	  simultaneously	  
extend	  protrusions	  in	  opposite	  directions,	  have	  been	  shown	  to	  be	  immobile	  [28].	  Thus,	  
polarisation	  is	  a	  prerequisite	  for	  all	  modes	  of	  cellular	  migration,	  and	  the	  interplay	  of	  
physical	  and	  molecular	  parameters	  of	  the	  cell	  and	  its	  surroundings	  determines	  how	  a	  cell	  
migrates	  (Figure	  1-­‐3).	  
1.1.3.1 Amoeboid migration 
Leukocytes	  [29]	  and	  hematopoietic	  stem	  cells	  [30]	  exhibit	  a	  crawling	  type	  of	  cell	  
movement,	  which	  relies	  on	  rapid	  cycles	  of	  membrane	  extensions	  and	  contractions	  and	  is	  
referred	  to	  as	  amoeboid	  migration.	  Amoeboid	  locomotion	  relies	  on	  cellular	  blebbing	  
which	  is	  driven	  by	  cortical	  actin	  fibre	  contractions.	  Contractile	  forces	  initiate	  membrane	  
blebbing	  by	  separating	  the	  plasma	  membrane	  from	  the	  cortex,	  thus	  allowing	  the	  inherent	  
hydrostatic	  potential	  to	  cause	  bleb	  formation.	  A	  concentration	  of	  blebs	  at	  the	  cellular	  
front	  creates	  a	  protrusive	  force	  necessary	  for	  cellular	  locomotion	  [31].	  One	  of	  the	  
features	  of	  amoeboid	  migration	  is	  the	  low	  and	  short-­‐lived	  binding	  force	  towards	  the	  
extracellular	  matrix	  (ECM).	  Thus,	  β1	  integrin	  mediated	  adhesions	  are	  completely	  or	  
partially	  dispensable	  during	  amoeboid	  migration	  [32,	  33].	  The	  lack	  of	  stable	  focal	  contacts	  
marks	  another	  feature	  of	  amoeboid	  migration,	  i.e.	  extraordinary	  deformability.	  Thus,	  cells	  
overcome	  matrix	  barriers	  by	  means	  of	  shape	  adaptations	  rather	  than	  ECM	  remodelling.	  
This	  shape-­‐driven	  mode	  of	  cell	  movement	  is	  controlled	  by	  the	  small	  GTPase	  RhoA	  and	  its	  
effector	  kinase	  ROCK	  (Rho-­‐associated	  coiled-­‐coil	  protein	  kinase)	  [34].	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Figure 1-3 Characteristics of different modes of migration 
A. Depiction of the well-established five-step migration cycle characteristic of mesenchymal cells. 
B. Comparison of individual migration modes, comprising amoeboid and mesenchymal migration, with 
collective cell migration in the form of cell clusters and strands. Adapted from [35] 
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Amoeboid	  tumour	  cells,	  commonly	  observed	  in	  lymphomas	  and	  small-­‐cell	  lung	  
carcinomas,	  express	  low	  levels	  of	  β1	  and	  β3	  integrins,	  which	  is	  thought	  to	  account	  for	  
their	  highly	  metastatic	  and	  motile	  behaviour	  [36,	  37].	  
1.1.3.2 Mesenchymal migration 
In	  contrast	  to	  the	  path-­‐finding	  motility	  described	  for	  amoeboid	  migration,	  mesenchymal	  
cells	  follow	  a	  path-­‐generating	  strategy	  which	  involves	  ECM	  degradation	  and	  remodelling.	  
Mesenchymal	  cells	  are	  characterised	  by	  an	  elongated,	  spindle-­‐shaped	  morphology	  which	  
is	  brought	  about	  by	  stable	  integrin-­‐mediated	  adhesions	  with	  the	  ECM	  [34].	  This	  mode	  of	  
motility	  follows	  a	  well-­‐defined	  five-­‐step	  migration	  cycle	  (Figure	  1-­‐3).	  Actin	  protrusions	  at	  
the	  cellular	  front	  lead	  to	  pseudopod	  formation,	  where	  adhesion	  molecules,	  most	  notably	  
integrin	  receptors,	  initiate	  binding	  to	  the	  matrix	  [35].	  Enrichment	  of	  integrins	  at	  the	  cell	  
front	  subsequently	  leads	  to	  formation	  of	  stable	  focal	  contacts.	  As	  different	  integrins	  bind	  
to	  different	  ECM	  substrates,	  e.g.	  α5β1	  binds	  fibronectin	  [38]	  and	  α2β1	  binds	  fibrillar	  
collagen	  [39],	  this	  mode	  of	  motility	  is	  highly	  dependent	  on	  the	  ECM	  composition.	  
Engagement	  of	  surface	  receptors	  with	  the	  matrix	  triggers	  recruitment	  of	  surface	  
proteases	  to	  focal	  contacts	  [40].	  Subsequent	  degradation	  of	  ECM	  components	  in	  the	  
proximity	  of	  the	  leading	  edge	  paves	  the	  way	  for	  the	  advancing	  cell	  body.	  In	  contrast,	  focal	  
adhesions	  at	  the	  cellular	  back	  are	  disassembled	  and	  contractile	  forces	  propel	  the	  cellular	  
body	  forward	  [35].	  Mesenchymal	  migration	  is	  dependent	  on	  the	  coordination	  of	  three	  
small	  GTPases,	  namely	  Rac,	  Cdc42	  and	  RhoA.	  At	  the	  cellular	  front	  Rac	  and	  Cdc42	  activity	  
promote	  rapid	  turnover	  of	  focal	  contacts,	  whereas	  RhoA	  activity	  at	  the	  cellular	  back	  
controls	  contractions	  forces,	  which	  propel	  the	  cell	  body	  forward	  [41,	  42].	  High	  turnover	  of	  
focal	  adhesion	  results	  in	  low	  adhesiveness	  and	  increases	  the	  migratory	  speed,	  while	  
strong	  integrin-­‐substrate	  linkages	  impair	  cell	  motility.	  Given	  that	  cells	  employing	  an	  
amoeboid	  mode	  of	  migration	  form	  very	  weak	  ECM	  interactions,	  it	  is	  not	  surprising	  that	  
they	  move	  with	  velocities	  of	  up	  to	  10-­‐30	  fold	  higher	  than	  mesenchymal	  cells	  [43].	  
1.1.3.3 Collective cell migration 
Collective	  migration,	  as	  the	  name	  suggests,	  describes	  the	  locomotion	  of	  a	  multicellular	  
contractile	  body,	  where	  cell-­‐cell	  junctions	  are	  kept	  intact.	  This	  phenomenon	  occurs	  
naturally	  during	  embryonic	  [44,	  45]	  as	  wells	  as	  mammary	  development	  [46].	  In	  tumours,	  
two	  types	  of	  collective	  migration	  have	  been	  described	  histologically,	  i.e.	  the	  invasion	  of	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sheets	  and	  strands	  of	  tumour	  cells	  which	  retain	  contact	  with	  the	  primary	  tumour,	  and	  the	  
invasion	  of	  detached	  cell	  clusters.	  Collective	  migration	  can	  only	  be	  achieved	  when	  
contractile	  forces	  are	  coordinated.	  Therefore,	  the	  contractile	  body	  is	  divided	  into	  highly	  
motile	  path-­‐generating	  cells	  at	  the	  front,	  which	  engage	  with	  the	  ECM	  and	  remodel	  it	  with	  
the	  help	  of	  proteolytic	  degradation,	  and	  cells	  in	  the	  inner	  or	  trailing	  regions	  which	  are	  
thought	  to	  be	  dragged	  along	  passively.	  One	  characteristic	  of	  collective	  migration	  is	  the	  
assembly	  of	  a	  specific	  form	  of	  cortical	  actin	  filaments	  along	  cell-­‐cell	  junctions,	  which	  allow	  
the	  concerted	  movement	  of	  the	  multicellular	  body	  [47].	  
Collective	  cell	  migration	  is	  predominantly	  found	  in	  highly	  differentiated	  tumours,	  such	  as	  
oral	  squamous-­‐cell	  carcinoma	  [48]	  and	  colon	  carcinoma	  [49],	  whereas	  single	  cell	  
migration	  is	  believed	  to	  provide	  a	  means	  for	  the	  dissemination	  of	  haematological	  
neoplasias.	  Travelling	  as	  a	  connective	  unit	  is	  thought	  to	  provide	  advantages	  during	  
tumourigenesis.	  Firstly,	  the	  large	  cell	  mass	  can	  produce	  a	  higher	  concentration	  of	  
pro-­‐migratory	  as	  well	  as	  pro-­‐survival	  signals	  than	  single	  cells,	  thereby	  increasing	  the	  
overall	  chances	  of	  survival	  and	  invasion.	  Secondly,	  inner	  cells	  of	  the	  sheet	  or	  cluster	  are	  
protected	  from	  immunosurveillance,	  irradiation	  and	  cytostatic	  drugs	  [50].	  Thirdly,	  less	  
motile	  cells,	  which	  may	  possess	  other	  advantageous	  biological	  abilities,	  can	  work	  together	  
with	  highly	  mobile	  cells	  as	  one	  functional	  unit	  [35].	  
1.1.3.4 Plasticity in tumour cell migration 
Although	  most	  cell	  types	  preferentially	  employ	  a	  particular	  type	  of	  migration,	  changes	  in	  
the	  microenvironment	  (such	  as	  fluctuations	  in	  the	  ECM	  density)	  or	  cellular	  properties	  
(such	  as	  loss-­‐of-­‐function	  mutations	  of	  adhesion	  receptors)	  can	  induce	  a	  switch	  from	  one	  
migration	  mode	  to	  another,	  rather	  than	  inhibiting	  motility	  altogether	  (Figure	  1-­‐4)	  [51].	  
The	  most	  well-­‐established	  example	  of	  tumour	  cell	  plasticity	  is	  called	  
epithelial-­‐to-­‐mesenchymal	  transition	  (EMT)	  and	  is	  marked	  by	  the	  loss	  of	  cell-­‐cell	  junctions	  
while	  adhesive	  and	  proteolytic	  capacities	  are	  retained.	  EMT	  spontaneously	  occurs	  during	  
the	  course	  of	  tumour	  progression	  and	  has	  been	  linked	  to	  an	  increased	  risk	  in	  metastatic	  
spread	  and	  poor	  prognosis	  [52-­‐54].	  In	  contrast,	  the	  process	  of	  collective-­‐to-­‐amoeboid	  
transition	  (CAT)	  is	  characterised	  by	  the	  dissemination	  of	  single	  cells	  displaying	  an	  
amoeboid	  migration	  mode,	  which	  can	  dispense	  with	  β1	  integrin-­‐mediated	  adhesion	  and	  
ECM	  proteolysis.	  In	  addition,	  factors,	  including	  weakening	  of	  cell-­‐matrix	  interactions	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observed	  in	  loose	  interstitial	  tissues,	  inhibition	  of	  ECM	  remodelling	  or	  augmentation	  of	  
RhoA/ROCK	  signalling,	  can	  trigger	  mesenchymal-­‐to-­‐amoeboid	  transition	  (MAT)	  [35,	  51].	  
Notably,	  anti-­‐invasive	  drugs,	  targeting	  one	  mode	  of	  migration	  only,	  can	  induce	  a	  switch	  in	  
motile	  behaviour	  [34].	  Therefore,	  it	  is	  believed	  that	  a	  successful	  anti-­‐invasive	  therapeutic	  
strategy	  must	  target	  multiple	  motility	  pathways.	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Figure 1-4 Plasticity of tumour cell migration 
Changes in the microenvironment can induce a switch from one migration mode to another rather than 
inhibiting cell motility. Depicted are migration transitions monitored in vivo. Adapted from [35] 
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1.2 Mammalian MAPK pathways 
1.2.1 The history of the MAPK cascade 
The	  first	  mammalian	  mitogen-­‐activated	  protein	  kinase	  (MAPK)	  was	  identified	  in	  1990	  in	  
an	  attempt	  to	  isolate	  protein	  kinases	  activated	  by	  growth	  factors.	  The	  purified	  protein	  
was	  phosphorylated	  following	  insulin	  treatment,	  44	  kDa	  in	  size	  and	  contained	  sequences	  
reminiscent	  of	  serine/threonine	  protein	  kinases.	  With	  the	  help	  of	  degenerate	  primers	  
based	  on	  these	  sequences,	  extracellular	  signal-­‐regulated	  kinase	  1	  (ERK1)	  was	  cloned	  from	  
rat	  fibroblasts	  [55].	  ERK1	  showed	  an	  over	  50%	  sequence	  identity	  to	  the	  yeast	  protein	  
kinases,	  Kss1	  and	  Fus3,	  which	  had	  previously	  been	  shown	  to	  regulate	  the	  cell	  cycle	  in	  
response	  to	  pheromones	  [56,	  57].	  Subsequent	  screening	  of	  a	  rat	  brain	  cDNA	  library	  with	  
an	  ERK1	  probe	  under	  low	  stringency	  led	  to	  the	  identification	  of	  ERK2	  and	  ERK3,	  and	  this	  
marked	  the	  birth	  of	  a	  new	  protein	  kinase	  family	  [58].	  Traditionally,	  kinase	  activities	  of	  
ERK1	  and	  -­‐2	  were	  measured	  using	  the	  two	  substrates,	  myelin	  basic	  protein	  (MBP)	  and	  
microtubule-­‐associated	  protein-­‐2	  (MAP2),	  which	  gave	  rise	  to	  the	  historic	  nomenclature	  of	  
MBP	  kinase	  and	  MAP2	  kinase.	  In	  the	  following	  years	  the	  MAP	  acronym	  was	  retained	  with	  
a	  novel	  denotation	  in	  order	  to	  acknowledge	  the	  activation	  of	  the	  kinases	  after	  mitogen	  
stimulation,	  which	  originally	  led	  to	  its	  identification	  [59].	  
MAPK	  enzymes	  are	  activated	  via	  a	  phosphorylation	  (kinase)	  cascade,	  which	  is	  
evolutionary	  conserved	  in	  plants,	  fungi	  and	  animals.	  Classically,	  the	  cascade	  is	  organised	  
into	  a	  four-­‐tier	  module	  comprising	  the	  MAP	  kinase	  kinase	  kinase	  (MAPKKK),	  MAP	  kinase	  
kinase	  (MAPKK),	  MAP	  kinase	  (MAPK)	  and	  the	  MAP	  kinase-­‐activated	  
protein	  (MAPKAP)	  [59].	  The	  sequential	  activation	  of	  kinases	  enables	  amplification	  of	  the	  
input	  signal,	  feedback	  regulation	  as	  well	  as	  the	  integration	  of	  information	  from	  other	  
signalling	  pathways.	  Thus,	  crosstalk	  of	  members	  of	  the	  MAPK	  pathway	  with	  other	  
signalling	  circuits	  enables	  fine	  tuning	  (i.e.	  enhancement,	  suppression	  and	  localisation)	  of	  
the	  transmitted	  signal.	  
1.2.2 Overview of the six distinct mammalian MAPK pathways 
In	  mammals,	  nearly	  20	  MAPK	  have	  thus	  far	  been	  identified	  (Table	  1-­‐1).	  Based	  on	  their	  
sequence	  similarity	  they	  are	  grouped	  into	  six	  distinct	  MAPK	  pathways,	  which	  regulate	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MAPK1 ERK2, p42MAPK, 
MAPK2 
85% identical to ERK1 [58] 
MAPK3 ERK1, p44MAPK First MAPK to be identified [55] 
MAPK4 ERK4, p63MAPK Cloned in 1992 by virtue of its homology to 
ERK1 
[60] 
MAPK6 ERK3, p97MAPK Suggested to have evolved recently through 
gene duplication 
[59] 
MAPK7 ERK5, BMK1 N-terminal domain exhibits a 66% sequence 
similarity to ERK1/2  
[61] 
MAPK8 JNK1, SAPKγ Ubiquitously expressed with multiple splice 
variants 
[62] 
MAPK9 JNK2, SAPKα Ubiquitously expressed with multiple splice 
variants 
[62] 
MAPK10 JNK3, SAPKβ Expression restricted to brain, heart and testis [62] 
MAPK11 p38β Phosphorylates MK2 and is sensitive to 
pyridinyl imidazole compounds 
[63] 
MAPK12 p38γ, ERK6 Selectively activated by hypoxia in a Ca2+-
dependent manner 
[64] 
MAPK13 p38δ Activated by novel PKC (nPKC) in response to 
TPA 
[65] 
MAPK14 p38α Phosphorylates MK2 and is sensitive to 
pyridinyl imidazole compounds 
[63] 
MAPK15 ERK7, ERK8 Breast cancer progression correlated with loss 






























NLK Nemo-like kinase Regulates Wnt/β-catenin signalling positively 
and negatively 
Phosphoacceptor site: TQY 
[67, 
68] 
MAK Male germ cell 
associated kinase 
Transcriptionally induced by androgen in 
prostate cancer 
Phosphoacceptor site: TDY 
[69] 
MRK MAK-related kinase 87% identical to MAK, role in heart 
development  




Activated by okadaic acid and phorbol ester, 
Phosphoacceptor site: TEY 
[71] 
KKIALRE CDKL1 Related to cdc2 kinase,  
Phosphoacceptor site: TDY 
[72] 
KKIAMRE CDKL2 Phosphorylation of TDY motif not required for 
kinase activity 
Phosphoacceptor site: TDY 
[73] 
Table 1-1 Overview of all Mammalian MAPK identified 
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diverse	  cellular	  functions	  such	  as	  embryogenesis,	  growth,	  proliferation,	  apoptosis,	  
differentiation	  and	  migration	  [59,	  62,	  63].	  Phylogenetically,	  MAPKs	  belong	  to	  the	  CMGC	  
family	  of	  protein	  kinases	  (termed	  after	  its	  members,	  i.e.	  cyclin-­‐dependent	  kinases	  (CDKs),	  
MAPKs,	  glycogen	  synthase	  kinases	  (GSKs)	  and	  CDK-­‐like	  kinases	  (CLK))	  [74].	  Members	  of	  
the	  MAPK	  branch	  are	  further	  subdivided	  into	  conventional	  and	  atypical	  kinases	  (Table	  
1-­‐2).	  Conventional	  MAPK	  include	  ERK1/2,	  ERK5,	  p38s	  and	  JNKs	  (c-­‐Jun	  N-­‐terminal	  kinases),	  
which	  contain	  a	  Thr-­‐Xaa-­‐Tyr	  motif	  in	  the	  activation	  loop	  and	  are	  activated	  by	  MEKs	  
(MAP/ERK	  kinases).	  Atypical	  kinases,	  including	  ERK3/4	  and	  ERK7/8,	  either	  contain	  a	  single	  
phosphoacceptor	  site	  in	  the	  activation	  loop	  or	  possess	  a	  novel	  activation	  mechanism	  
dispensable	  of	  MEKs	  [75].	  All	  MAPKs,	  however,	  display	  two	  common	  features.	  Firstly,	  
they	  all	  preferentially	  phosphorylate	  serine	  or	  threonine	  residues	  followed	  by	  proline	  in	  
their	  respective	  MAPKAP.	  Secondly,	  all	  MAPKs	  are	  activated	  by	  phosphorylation	  in	  the	  
absence	  of	  a	  regulatory	  subunit	  [59].	  
The	  following	  subsections	  aim	  to	  highlight	  the	  main	  features	  of	  the	  different	  MAPK	  
groups	  identified	  to	  date	  with	  the	  exception	  of	  ERK1/2,	  which	  will	  be	  covered	  in	  detail	  in	  
section	  1.3.	  	  
1.2.2.1 c-Jun N-terminal kinases (JNKs)/stress-activated protein kinases (SAPK) 
The	  first	  JNK	  family	  member	  was	  purified	  from	  rat	  livers	  after	  cycloheximide	  treatment	  in	  
1990	  [76].	  Shortly	  afterwards,	  two	  further	  JNKs	  were	  purified	  in	  GST-­‐pulldown	  assays	  
using	  c-­‐Jun	  as	  a	  bait	  [77].	  The	  JNK	  family	  of	  MAPK	  is	  encoded	  by	  three	  genes	  (jnk1,	  jnk2	  
and	  jnk3),	  which	  give	  rise	  to	  13	  splice	  variants.	  JNK1	  and	  -­‐2	  are	  ubiquitously	  expressed,	  
whereas	  JNK3’s	  expression	  is	  restricted	  to	  the	  brain,	  heart	  and	  testis.	  Notably,	  JNKs	  are	  
predominantly	  activated	  by	  stress	  signals	  such	  as	  cytokines,	  UV	  radiation,	  oxidative	  stress,	  
growth	  factor	  deprivation	  and	  DNA-­‐damaging	  agents.	  Hence,	  these	  kinases	  have	  also	  
been	  described	  as	  the	  family	  of	  stress-­‐activated	  protein	  kinases	  (SAPK)	  [59,	  78].	  MEK4	  
and	  -­‐7	  activate	  JNKs	  synergistically	  at	  the	  Thr-­‐Pro-­‐Tyr	  motif	  in	  the	  activation	  loop,	  with	  
MEK4	  preferentially	  phosphorylating	  the	  tyrosine	  residue	  and	  MEK7	  phosphorylating	  the	  
threonine	  residue.	  Following	  activation,	  JNKs	  translocate	  from	  the	  cytoplasm	  to	  the	  
nucleus,	  where	  they	  phosphorylate	  and	  regulate	  transcription	  factors	  such	  as	  c-­‐Jun,	  ATF2	  
and	  p53	  [79,	  80].	  To	  date	  very	  little	  is	  known	  about	  JNKs’	  role	  in	  regulating	  cytoplasmic	  
effectors.	  MEK4	  and	  -­‐7	  themselves	  are	  activated	  by	  numerous	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MAPKKKs,	  including	  MEKK1-­‐4,	  MLK2/3,	  YTpl-­‐2,	  DLK,	  TAO1/2,	  TAK1	  and	  ASK1/2	  (Table	  
1-­‐2)	  [62].The	  role	  of	  JNK	  kinases	  in	  tumour	  development	  is	  highly	  controversial.	  Some	  
reports	  have	  shown	  a	  pro-­‐tumourigenic	  role	  [81-­‐83],	  whereas	  others	  have	  demonstrated	  
an	  anti-­‐tumourigenic	  capacity	  for	  JNK	  signalling	  [84].	  JNK	  activity	  enhances	  tumour	  
development	  by	  decreasing	  the	  proliferation	  inhibitor	  p21CIP1,	  increasing	  signalling	  of	  the	  
growth	  promoter	  c-­‐Myc,	  and	  allowing	  the	  formation	  of	  an	  inflammatory	  environment,	  
which	  has	  recently	  been	  appreciated	  as	  a	  novel	  hallmark	  of	  cancer.	  In	  contrast,	  JNK	  
signalling	  is	  also	  required	  for	  the	  induction	  of	  apoptosis,	  which	  might	  account	  for	  its	  
putative	  tumour	  suppressive	  function	  [85].	  Thus,	  the	  usefulness	  of	  JNK	  inhibitors	  in	  
clinical	  settings	  is	  still	  in	  debate.	  
1.2.2.2 p38 kinases 
The	  family	  of	  p38	  kinases	  form	  another	  group	  of	  MAPKs	  activated	  by	  stress	  signals.	  In	  
contrast	  to	  JNK	  enzymes,	  stress	  stimuli	  not	  only	  activate	  p38s,	  but	  also	  induce	  their	  gene	  
expression.	  Four	  genes	  encode	  this	  group	  of	  enzymes	  comprising,	  i.e.	  p38α,	  p38β,	  p38γ	  
(which	  has	  also	  been	  termed	  ERK6),	  and	  p38δ.	  Only	  the	  gene	  encoding	  the	  α-­‐isoform	  
gives	  rise	  to	  four	  splice	  variants.	  p38α	  and	  –β	  are	  ubiquitously	  expressed,	  whereas	  p38γ	  
and	  –δ	  expression	  is	  tissue	  restricted	  [63].	  Notably,	  p38α	  and	  –β	  activity	  is	  inhibited	  by	  
pyridinyl	  imidazole,	  which	  originally	  led	  to	  its	  identification	  in	  1994	  [86],	  whereas	  p38γ	  
and	  –δ	  are	  insensitive	  to	  the	  drug.	  Furthermore,	  p38	  isoforms	  show	  differences	  in	  their	  
substrate	  specificity.	  Whereas	  the	  α-­‐	  and	  β-­‐isoform	  phosphorylate	  MAPKAP	  kinase-­‐2	  
(MK2),	  p38γ	  and	  –δ	  do	  not	  [63].	  p38	  enzymes	  are	  generally	  activated	  by	  MEK3	  and	  MEK6,	  
although	  MEK4	  has	  also	  been	  shown	  to	  contribute	  to	  the	  phosphorylation	  of	  the	  distinct	  
Thr-­‐Gly-­‐Tyr	  motif	  upon	  UV	  radiation	  in	  vivo	  [87].	  MEK3	  and	  -­‐6	  in	  turn	  are	  activated	  by	  
MAPKKKs	  similar	  to	  JNK	  enzymes	  such	  as	  MEKK1-­‐4,	  TAO1/2,	  TAK1	  and	  ASK1/2.	  To	  date	  
little	  is	  known	  as	  to	  how	  stress	  stimuli	  can	  produce	  a	  distinct	  p38	  or	  JNK	  signalling	  output	  
with	  overlapping	  MAPKKKs	  (Table	  1-­‐2).	  
Interestingly,	  disruption	  of	  the	  p38	  pathway	  in	  mice	  leads	  to	  increased	  tumourigenesis	  
due	  to	  defects	  in	  growth	  arrest	  [87].	  Furthermore,	  a	  decrease	  in	  p38	  activity	  has	  been	  
observed	  in	  hepatocellular	  carcinomas	  in	  comparison	  to	  the	  adjacent	  normal	  tissue	  [88].	  
Taking	  these	  finding	  together,	  p38	  signalling	  might	  have	  tumour	  suppressive	  functions	  by	  
inducing	  cell	  cycle	  arrest,	  senescence	  and	  apoptosis	  [89].	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TEY TPY TGY TEY SEG TEY 
Predicted size 
(kDa) 
41/43 46 38 98 97/63 60 
Encoding genes 2 3 4 1 2 1 









4 1 (ERK3) 
1 (ERK4) 
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2 1 (ERK3) 
1 (ERK4) 
3 
Table 1-2 Overview of the common and divergent features of the 6 distinct mammalian MAPK 
pathways 
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1.2.2.3 ERK5 
ERK5	  was	  identified	  by	  two	  independent	  research	  groups	  in	  1995	  [90,	  91]	  and	  is	  one	  of	  
the	  largest	  MAPKs	  known	  to	  date	  (98	  kDa).	  Therefore,	  it	  was	  originally	  termed	  the	  big	  
MAP	  kinase	  1	  (BMK1)	  by	  Lee	  et	  al.	  [90].	  Alternative	  splicing	  gives	  rise	  to	  4	  distinct	  
transcript	  variants	  and	  2	  isoforms.	  The	  N-­‐terminal	  half	  of	  the	  protein,	  comprising	  the	  
kinase	  domain	  with	  a	  Thr-­‐Glu-­‐Tyr	  activation	  motif,	  exhibits	  a	  66%	  sequence	  similarity	  to	  
ERK1/2	  [61].	  ERK5’s	  unique	  C-­‐terminal	  domain,	  which	  contains	  a	  bipartite	  nuclear	  
localisation	  signal	  (NLS)	  [92]	  and	  has	  transcriptional	  activation	  activity	  [93],	  sets	  this	  
enzyme	  apart	  from	  other	  MAPKs	  [94].	  In	  unstimulated	  cells,	  intramolecular	  interactions	  
between	  the	  N-­‐	  and	  C-­‐terminal	  domain	  promote	  nuclear	  export.	  It	  is	  believed	  that	  the	  
association	  between	  the	  two	  domains	  allows	  the	  formation	  of	  a	  region	  which	  itself	  might	  
constitute	  a	  nuclear	  export	  signal	  (NES),	  or	  allow	  binding	  to	  a	  cytoplasmic	  anchor	  protein.	  
Upon	  kinase	  activation	  a	  conformational	  change	  disrupts	  this	  association	  and	  promotes	  
nuclear	  localisation	  of	  ERK5	  [92],	  where	  its	  two	  functional	  domains	  allow	  either	  
phosphorylation	  of	  target	  molecules	  (N-­‐terminal	  region)	  or	  enhancement	  of	  transcription	  
activity	  (C-­‐terminal	  region)	  [93].	  Despite	  the	  similarity	  to	  ERK1/2,	  this	  enzyme	  is	  activated	  
by	  a	  unique	  MAPKK,	  namely	  MEK5,	  which	  itself	  is	  phosphorylated	  by	  MEKK2/3,	  also	  
associated	  with	  p38	  and	  JNK	  signalling	  [94].	  ERK5	  is	  activated	  in	  response	  to	  stress	  signals,	  
such	  as	  oxidative	  stress	  and	  hyperosmolarity,	  and	  to	  a	  lesser	  extent	  by	  mitogenic	  signals,	  
such	  as	  serum	  and	  nerve	  growth	  factor	  (NFG).	  Functional	  studies	  in	  cultured	  cells	  have	  
demonstrated	  a	  role	  for	  ERK5	  in	  cell	  proliferation	  [95],	  and	  migration	  [96].	  In	  vivo,	  ERK5	  
was	  shown	  to	  play	  a	  role	  in	  blood	  vessel	  and	  heart	  development	  [97]	  as	  well	  as	  neural	  
differentiation	  (Table	  1-­‐2)	  [98].	  
The	  first	  ERK5	  substrate	  identified	  was	  myocyte	  enhancer	  factor	  2C	  (MEF2C),	  which	  upon	  
phosphorylation	  enhances	  c-­‐jun	  gene	  expression	  in	  luciferase	  assays	  [99].	  Moreover,	  
ERK5	  was	  shown	  to	  phosphorylate	  known	  ERK1/2	  substrates	  such	  as	  Sap1a	  and	  c-­‐Myc	  in	  
vitro	  [100,	  101].	  However,	  to	  what	  extent	  ERK5	  signalling	  regulates	  these	  transcription	  
factors	  in	  vivo	  in	  comparison	  to	  ERK1/2	  remains	  to	  be	  determined.	  The	  understanding	  of	  
ERK5’s	  involvement	  in	  tumourigenesis	  is	  still	  in	  its	  infancy.	  Recent	  work,	  however,	  showed	  
MEK5	  overexpression	  in	  metastatic	  prostate	  cancer	  biopsies	  [102]	  and	  increased	  ERK5	  
activity	  in	  a	  panel	  of	  human	  cancer	  cell	  lines	  [103].	  This	  increased	  signalling	  is	  thought	  to	  
drive	  tumour	  cell	  proliferation,	  motility	  and	  invasion.	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1.2.2.4 ERK3/4 
ERK3	  was	  one	  of	  the	  first	  MAPKs	  to	  be	  identified	  alongside	  ERK2	  in	  an	  attempt	  to	  clone	  
ERK1-­‐related	  serine/threonine	  protein	  kinases	  [58].	  It	  is	  encoded	  by	  one	  gene	  and	  
translates	  into	  a	  97	  kDa	  protein.	  In	  1992	  a	  shorter	  isoform	  (63	  kDa),	  highly	  homologous	  to	  
ERK3,	  was	  identified	  and	  termed	  ERK4	  [60].	  Comparative	  analysis	  highlighted	  a	  similar	  
genomic	  arrangement	  of	  introns	  and	  exons	  as	  well	  as	  high	  sequence	  identity	  in	  the	  
catalytic	  domain	  [104].	  These	  observations,	  in	  conjunction	  with	  the	  lack	  of	  
ERK3/4-­‐encoding	  genes	  in	  yeast	  and	  Caenorhabditis	  elegans	  [105,	  106],	  suggest	  a	  very	  
recent	  evolutionary	  emergence	  via	  gene	  duplication.	  In	  contrast	  to	  conventional	  MAPK,	  
ERK3	  and	  -­‐4	  possess	  a	  single	  phosphoacceptor	  site	  (Ser-­‐Glu-­‐Gly).	  Moreover,	  both	  kinases	  
are	  characterised	  by	  a	  Ser-­‐Pro-­‐Arg	  motif	  in	  the	  activation	  loop,	  which	  replaces	  the	  highly	  
conserved	  Ala-­‐Pro-­‐Glu	  motif	  found	  in	  almost	  all	  protein	  kinases	  (Table	  1-­‐2)	  [61].	  Although	  
the	  glutamic	  acid	  residue	  has	  been	  linked	  to	  structural	  stabilisation	  and	  ultimately	  kinase	  
activity	  [107],	  substitution	  of	  this	  residue	  has	  also	  been	  observed	  in	  casein	  protein	  
kinases	  [108].	  Therefore,	  an	  arginine	  replacement	  is	  still	  compatible	  with	  kinase	  activity.	  
Despite	  the	  absence	  of	  a	  NLS	  ERK4	  is	  predominantly	  found	  in	  the	  nucleus	  [109].	  In	  
contrast,	  ERK3	  is	  localised	  to	  nuclear	  and	  cytoplasmic	  compartments.	  Efforts	  to	  identify	  
stimuli	  altering	  the	  subcellular	  localisation	  of	  ERK3	  have	  proven	  unsuccessful	  [110].	  
Another	  difference	  between	  ERK3	  and	  ERK4	  is	  their	  respective	  half-­‐lives,	  which	  argues	  for	  
isoform-­‐specific	  functions.	  ERK3	  is	  highly	  unstable	  with	  a	  half-­‐life	  of	  30-­‐40	  min,	  whereas	  
ERK4	  is	  very	  stable	  [75].	  ERK3/4	  kinases	  are	  activated	  by	  phorbol	  ester	  and	  serum	  
treatment,	  but	  not	  insulin	  or	  EGF	  [111].	  No	  research	  group	  has	  yet	  identified	  upstream	  
MAPKKKs	  or	  MAPKKs	  for	  ERK3	  and	  -­‐4.	  Although	  Cheng	  et	  al.	  described	  an	  ERK3	  kinase	  
capable	  of	  specifically	  phosphorylating	  ERK3,	  they	  did	  not	  identify	  the	  enzyme	  [112].	  
Moreover,	  data	  on	  ERK3/4	  substrates	  is	  limited	  and	  contradictory.	  Although	  Sauma	  et	  al.	  
have	  demonstrated	  phosphorylation	  of	  MBP	  [113],	  Cheng	  et	  al.	  did	  not	  observe	  
phosphorylation	  of	  traditional	  MAPK	  effectors	  such	  as	  MBP,	  MAP-­‐2,	  c-­‐Jun	  or	  Elk-­‐1	  in	  
vitro	  [109].	  ERK3	  expression	  is	  markedly	  increased	  during	  early	  organogenesis	  in	  
mice	  [104].	  Moreover,	  cell	  culture	  studies	  have	  shown	  stabilisation	  of	  ERK3	  upon	  cellular	  
differentiation	  [114].	  	  Thus,	  ERK3	  might	  play	  a	  role	  in	  committing	  cells	  to	  acquire	  a	  
quiescent	  differentiated	  state.	  Future	  studies,	  in	  particular	  ERK3-­‐/-­‐	  and	  ERK4-­‐/-­‐	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phenotypes,	  will	  hopefully	  shed	  more	  light	  on	  the	  biological	  functions	  and	  regulation	  of	  
this	  MAPK	  subfamily.	  	  
1.2.2.5 ERK7 
ERK7	  was	  cloned	  in	  1999	  from	  a	  neonatal	  rat	  brain	  cDNA	  library	  [115]	  and	  consists	  of	  an	  
N-­‐terminal	  kinase	  domain,	  which	  is	  45%	  identical	  to	  ERK1.	  A	  further	  C-­‐terminal	  extension,	  
unique	  to	  ERK7,	  which	  contains	  a	  putative	  NLS	  and	  two	  alleged	  SH3-­‐binding	  domains	  [75].	  
The	  ERK7	  gene	  translates	  into	  a	  60	  kDa	  protein	  and	  is	  widely	  expressed	  [116].	  Notably,	  
this	  kinase,	  although	  found	  across	  many	  species,	  is	  less	  conserved	  throughout	  evolution	  
than	  other	  MAPK	  [75].	  To	  date	  work	  on	  the	  biological	  regulation	  and	  function	  of	  this	  
MAPK	  is	  limited.	  Overexpressed	  ERK7	  is	  predominantly	  localised	  to	  the	  nucleus,	  whereas	  
the	  localisation	  of	  the	  endogenous	  protein	  is	  unknown	  [115].	  The	  enzymatic	  regulation	  of	  
this	  MAPK	  is	  unique	  in	  that	  the	  Thr-­‐Glu-­‐Tyr	  motif	  within	  the	  activation	  loop	  is	  subject	  to	  
autophosphorylation	  and	  not	  to	  be	  phosphorylated	  by	  upstream	  MAPKKs	  (Table	  1-­‐2)	  
[115].	  This	  poses	  the	  question;	  how	  can	  ERK7	  be	  regulated	  in	  vivo?	  So	  far,	  there	  is	  
evidence	  that	  ERK7	  activity	  and	  expression	  is	  regulated	  by	  protein	  turnover	  [117].	  
Although	  ERK7	  can	  phosphorylate	  classical	  MAPK	  substrates	  such	  as	  MBP	  in	  vitro,	  
physiological	  substrates	  remain	  unidentified.	  Notably,	  ERK7	  can	  phosphorylate	  MBP	  on	  
sites	  that	  are	  distinct	  from	  ERK1/2	  phosphorylation.	  Thus,	  ERK7	  exhibits	  distinct	  substrate	  
specificity	  in	  comparison	  to	  ERK1/2	  [115,	  116].	  Physiological	  functions	  of	  ERK7	  also	  
remain	  to	  be	  determined.	  So	  far,	  ERK7	  has	  been	  proposed	  to	  play	  a	  role	  in	  
proliferation	  [115],	  chloride	  transport	  [118]	  and	  nuclear	  receptor	  signalling	  [66].	  
Intriguingly,	  ERK7	  displays	  functions	  dependent	  (degradation	  of	  estrogen	  receptor	  α)	  and	  
independent	  (regulation	  of	  S-­‐phase	  entry)	  of	  its	  catalytic	  activity.	  
Interestingly,	  ERK7	  has	  also	  been	  implicated	  in	  tumourigenesis.	  A	  small	  study	  comparing	  
ERK7	  protein	  levels	  in	  normal	  and	  tumour	  tissues	  of	  the	  breast	  observed	  an	  ERK7	  loss	  in	  
the	  cancerous	  samples	  [66].	  Yet,	  future	  work	  with	  larger	  patient	  cohorts	  and	  mice	  models	  
will	  be	  necessary	  to	  further	  substantiate	  these	  observations.	  
  
Chapter 1 – Introduction  35 
1.2.3 MAPK docking sites 
MAPK	  cascades	  regulate	  a	  variety	  of	  biological	  functions,	  such	  as	  cell	  proliferation,	  
differentiation	  and	  stress	  responses.	  Moreover,	  aberrant	  MAPK	  signalling	  has	  been	  
associated	  with	  numerous	  diseases	  such	  as	  cancer	  (ERK1/2),	  rheumatoid	  arthritis	  (p38	  
kinases)	  and	  Alzheimer’s	  disease	  (JNKs)	  [119-­‐121].	  Besides	  the	  need	  for	  tight	  regulation,	  
these	  cascades	  require	  high	  efficiency	  and	  fidelity	  in	  signal	  transduction,	  which	  is	  
achieved	  through	  substrate	  binding	  motifs,	  also	  known	  as	  substrate	  docking	  sites.	  
Conventional	  MAPKs	  and	  their	  substrate	  binding	  motifs	  have	  been	  studied	  extensively	  in	  
search	  for	  putative	  drug	  inhibition	  sites.	  On	  the	  other	  hand,	  our	  understanding	  of	  atypical	  
MAPKs	  is	  still	  in	  its	  infancy	  in	  regards	  to	  regulation	  and	  biological	  functions.	  Thus,	  no	  
docking	  domains	  have	  yet	  been	  described	  for	  this	  MAPK	  subgroup.	  
1.2.3.1 Common docking site 
As	  the	  name	  suggests,	  this	  docking	  site	  mediates	  binding	  of	  numerous	  proteins,	  such	  as	  
MEKs,	  phosphatases	  and	  transcription	  factors	  [63].	  It	  was	  originally	  identified	  in	  an	  
attempt	  to	  abolish	  MEK	  binding	  to	  ERK2	  through	  mutations	  and	  termed	  the	  cytoplasmic	  
retention	  sequence	  (CRS)	  [122].	  Later,	  however,	  this	  region	  was	  shown	  to	  facilitate	  
interaction	  of	  ERK	  with	  a	  variety	  of	  proteins	  and	  therefore	  termed	  the	  common	  docking	  
(CD)	  domain	  [123].	  Moreover,	  this	  binding	  site,	  which	  is	  located	  C-­‐terminal	  to	  the	  
catalytic	  domain,	  is	  conserved	  among	  all	  conventional	  MAPKs	  (Figure	  1-­‐5)	  and	  comprises	  
negatively-­‐charged	  aspartate	  (D)	  and	  glutamate	  (E)	  residues	  [123].	  Crystal	  structures	  of	  
ERK2,	  p38α	  and	  JNK3	  have	  shown	  that	  the	  conserved	  amino	  acids	  are	  not	  only	  exposed	  
on	  the	  surface	  of	  these	  enzymes,	  but	  also	  reside	  close	  to	  one	  another,	  thus	  forming	  a	  
negatively	  charged	  interaction	  platform	  opposite	  to	  the	  catalytic	  centre	  [124-­‐126].	  
Indeed,	  this	  region	  was	  shown	  to	  bind	  to	  a	  conserved	  sequence	  of	  basic	  amino	  acids	  in	  
MAPK	  substrates,	  termed	  the	  D-­‐motif	  [123,	  127].	  Notably,	  ERK1/2	  substrates	  generally	  
possess	  two	  consecutive	  basic	  amino	  acids	  in	  their	  D-­‐motif,	  whereas	  substrates	  for	  JNK	  
and	  p38	  kinases	  display	  three	  or	  more	  consecutive	  lysines	  (L)	  and	  arginines	  (R)	  (Table	  
1-­‐3).	  Thus,	  substrate	  specificity	  might	  be	  achieved	  through	  varying	  numbers	  of	  positively	  
charged	  amino	  acids	  on	  the	  D-­‐motif	  [124,	  128].	  
 	  
Chapter 1 – Introduction  36 
MAPK substrate Proposed D-motif MAPK 
specificity 









MEK5 LKKSSAELRKIL ERK5 











CADKISRRRLQQGKITV p38, JNK 
Table 1-3 Overview of proposed D-motifs of various MAPK substrates 
The D-motif is characterised by a cluster of positively charged amino acids (coloured in grey). The number 
of consecutive arginines or lysines determines the MAPK-binding specificity.  
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Figure 1-5 MAPK docking sites 
A. Human amino acid sequences of the CD domains of various members of the MAPK family. Coloured 
characters represent negatively charged amino acids in the CD domain, which are supposed to be exposed at 
the surface and mediate substrate binding. Adapted from [124].  
B. MAPKs comprise various docking domains, which mediate substrate binding. ED and CD domains 
mediate docking of D-motifs, whereas the FXFP-docking site allows binding of DEF-motifs. 
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1.2.3.2 ERK docking site 
The	  ERK	  docking	  (ED)	  site	  is	  located	  close	  to	  the	  CD	  domain	  in	  the	  crystal	  structure	  and	  
consists	  of	  hydrophobic	  residues	  from	  helices	  αD,	  αE	  and	  a	  reverse	  turn	  of	  β7-­‐β8	  [129].	  
This	  docking	  site	  is	  significantly	  different	  in	  ERK1/2,	  p38	  kinases	  and	  JNKs	  and	  therefore	  
provides	  a	  means	  for	  substrate	  specificity	  within	  the	  MAPK	  family	  [130].	  Moreover,	  the	  
CD	  and	  ED	  domains,	  which	  are	  close	  to	  one	  another	  in	  the	  folded	  protein,	  form	  a	  docking	  
groove	  on	  the	  surface	  of	  the	  kinases	  (Figure	  1-­‐5).	  Thus,	  structural	  differences	  brought	  
about	  by	  different	  hydrophobic	  residues	  can	  confer	  substrate	  specificity	  and	  alter	  
substrate	  affinity	  [124].	  Indeed,	  exchange	  of	  only	  two	  amino	  acids	  in	  the	  ED	  domain	  of	  
p38α	  and	  ERK2	  (Glu160	  and	  Asp161	  in	  p38	  with	  Thr157	  and	  Thr158	  in	  ERK2)	  is	  enough	  to	  
alter	  substrate	  specificity	  [124].	  It	  has	  to	  be	  noted,	  however,	  that	  amino	  acids	  close	  to	  the	  
docking	  groove	  are	  likely	  to	  also	  be	  involved	  in	  docking	  interactions.	  Moreover,	  substrates	  
might	  differentially	  recognise	  the	  ED	  and	  CD	  domain,	  thus	  providing	  another	  means	  of	  
variability.	  
1.2.3.3 FXFP binding site 
In	  addition	  to	  the	  hydrophobic	  groove,	  another	  interaction	  motif	  has	  been	  described	  for	  
ERK1/2	  and	  p38α,	  which	  is	  called	  the	  FXFP	  binding	  site.	  This	  site	  was	  identified	  using	  
hydrogen	  exchange	  mass	  spectrometry,	  and	  is	  marked	  by	  a	  cluster	  of	  hydrophobic	  amino	  
acids	  distinct	  from	  the	  ED	  domain,	  which	  specifically	  interacts	  with	  a	  Phe-­‐X-­‐Phe	  (FXF)	  
motif	  [131,	  132].	  The	  FXFP	  binding	  site	  is	  situated	  close	  to	  the	  active	  centre	  and	  is	  
occluded	  in	  the	  inactive	  enzyme	  through	  intramolecular	  interactions	  (Figure	  1-­‐5).	  Many	  
ERK1/2	  substrates,	  including	  SAP-­‐1	  and	  Elk-­‐1,	  have	  been	  shown	  to	  bind	  to	  the	  FXFP	  
binding	  site	  with	  their	  corresponding	  DEF	  domain	  (docking	  site	  for	  ERK	  and	  FXFP)	  [132].	  
Notably,	  the	  hydrophobic	  residues	  important	  in	  ERK-­‐DEF	  binding	  are	  conserved	  among	  
various	  MAPK	  family	  members,	  yet	  DEF	  motif	  interactions	  have	  only	  been	  observed	  in	  
ERK1/2	  and	  p38α,	  but	  not	  p38β/γ/δ	  and	  JNK2	  [131].	  This	  suggests	  differences	  in	  the	  
tertiary	  structure	  of	  these	  kinases	  which	  lead	  to	  the	  exposure	  of	  specific	  substrate	  
recognition	  patterns.	  
1.2.3.4 Other MAPK-binding domains 
Although	  many	  MAPK	  substrates	  and	  regulators	  contain	  one	  or	  more	  MAPK	  dockings	  sites	  
described	  above,	  some	  interacting	  proteins	  lack	  these	  conserved	  domains,	  but	  still	  bind	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to	  the	  enzymes	  efficiently.	  One	  such	  MAPK	  target	  is	  the	  well-­‐known	  transcription	  factor	  
Ets-­‐1,	  which	  has	  been	  shown	  to	  bind	  to	  ERK2	  via	  a	  unique	  pointed	  domain	  [133].	  MITF	  
(microphtalmia-­‐associated	  transcription	  factor)	  also	  falls	  into	  this	  category,	  as	  its	  C-­‐
terminal	  sequence	  required	  for	  ERK2	  binding	  does	  not	  resemble	  a	  D-­‐	  or	  DEF-­‐motif	  [134].	  
1.2.3.5 Kinase inhibitor binding sites 
Due	  to	  the	  involvement	  of	  MAPKs	  in	  numerous	  diseases,	  significant	  effort	  has	  been	  made	  
by	  the	  pharmaceutical	  industry	  to	  develop	  inhibitors	  that	  block	  specific	  MAPK	  pathways.	  
This	  has	  led	  to	  the	  identification	  of	  two	  novel	  inhibitor	  binding	  sites,	  i.e.	  backside	  binding	  
pocket	  and	  the	  “DFG-­‐out”-­‐site,	  where	  inhibitor	  interactions	  do	  not	  compete	  with	  ATP	  
binding	  [135].	  The	  backside	  binding	  pocket	  is	  a	  region	  in	  the	  vicinity	  of	  the	  CD	  domain	  in	  
p38α	  and	  binds	  inhibitors	  such	  as	  PD98056	  [136].	  In	  contrast,	  the	  “DFG-­‐out”-­‐site	  is	  a	  
docking	  domain	  adjacent	  to	  the	  active	  site.	  Inhibitor	  binding	  to	  the	  conserved	  DFG	  
sequence	  induces	  a	  conformational	  change	  in	  the	  activation	  loop	  of	  the	  enzyme	  and	  
thereby	  blocks	  its	  activity	  [135,	  137].	  “DFG-­‐out”-­‐sites,	  however,	  are	  not	  unique	  for	  MAPK	  
as	  they	  have	  also	  been	  described	  for	  MEK1/2	  [138]	  and	  c-­‐Abl	  [139].	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1.3 The ERK-MAPK pathway 
The	  ERK-­‐MAPK	  pathway	  is	  one	  of	  the	  best	  studied	  mammalian	  kinase	  cascades	  and	  it	  has	  
diverse	  cellular	  and	  physiological	  functions.	  ERK1/2	  signalling	  modulates	  cellular	  
processes	  such	  as	  cell	  cycle	  progression,	  proliferation,	  differentiation,	  migration,	  
apoptosis	  and	  senescence	  [140].	  Physiologically,	  this	  pathway	  is	  involved	  in	  cardiogenesis,	  
immune	  system	  development	  and	  homeostasis,	  and	  plays	  a	  critical	  role	  in	  transducing	  
responses	  to	  many	  hormones,	  growth	  factors	  and	  insulin.	  Thus,	  aberrant	  ERK1/2	  
signalling	  has	  been	  associated	  with	  equally	  diverse	  pathologies,	  including	  cancer	  [141-­‐
143],	  diabetes	  [144],	  and	  cardiovascular	  disease	  [145].	  The	  cascade	  can	  be	  activated	  by	  a	  
variety	  of	  extracellular	  stimuli,	  such	  as	  mitogens,	  growth	  factors,	  phorbol	  esters,	  
cytokines,	  and	  insulin	  [63].	  Moreover,	  ERK	  signalling	  can	  be	  induced	  by	  means	  of	  
membrane	  depolarisation	  and	  Ca2+	  influx	  [142].	  	  
The	  ERK-­‐MAPK	  cascade	  is	  generally	  initiated	  through	  the	  activation	  of	  small	  GTPases,	  such	  
as	  Ras	  or	  Rap1,	  which	  recruit	  Raf	  kinases	  to	  the	  plasma	  membrane	  [146].	  To	  date	  three	  
Raf	  kinase	  family	  members,	  namely	  A-­‐Raf,	  B-­‐Raf	  and	  c-­‐Raf,	  have	  been	  identified.	  All	  
isoforms	  contain	  three	  conserved	  regions,	  termed	  CR1,	  CR2	  and	  CR3	  [147].	  The	  first	  two	  
conserved	  regions	  have	  been	  implicated	  in	  regulating	  the	  catalytic	  domain,	  which	  is	  
located	  in	  CR3.	  Activation	  of	  Raf	  kinases	  is	  a	  complex	  process,	  requiring	  protein-­‐protein	  
interaction,	  dimerization,	  as	  well	  as	  various	  phosphorylation	  and	  dephosphorylation	  
events	  [147,	  148].	  In	  addition,	  Raf	  kinase	  activity	  can	  exist	  in	  multiple	  graded	  states,	  
which	  are	  regulated	  by	  various	  kinases	  from	  other	  signalling	  pathways	  and	  allow	  signal	  
modulation.	  For	  example,	  c-­‐Raf	  phosphorylation	  at	  Ser338	  and	  Tyr340/341	  by	  PAK	  
(p21-­‐activated	  kinase)	  or	  Src,	  respectively,	  enhances	  the	  catalytic	  activity,	  whereas	  
phosphorylation	  of	  Ser259	  by	  AKT	  or	  PKA	  is	  inhibitory	  [149-­‐151].	  
Activated	  Rafs	  subsequently	  phosphorylate	  and	  thereby	  activate	  MEK1/2	  at	  two	  serine	  
residues	  located	  in	  the	  Ser-­‐Xaa-­‐Ala-­‐Xaa-­‐Ser/Thr	  motif	  common	  to	  all	  MAPKKs	  [152].	  
During	  this	  step	  the	  incoming	  signal	  is	  amplified,	  as	  MEKs	  are	  more	  abundant	  than	  Raf	  
kinases.	  MEK1/2	  constitute	  an	  evolutionary	  conserved	  group	  of	  dual	  specificity	  kinases,	  
which	  share	  an	  85%	  sequence	  homology.	  Structurally,	  MEK	  isoforms	  are	  composed	  of	  a	  
kinase	  domain,	  which	  is	  surrounded	  by	  an	  N-­‐terminal	  regulatory	  and	  a	  short	  C-­‐terminal	  
domain	  [138].	  The	  two	  genes	  encoding	  MEK1/2	  give	  rise	  to	  three	  isoforms,	  which	  are	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MEK1,	  its	  alternatively	  spliced	  form	  MEK1b,	  and	  MEK2	  [153].	  Although	  all	  kinases	  display	  
catalytic	  activity,	  MEK1b	  does	  not	  phosphorylate	  the	  canonical	  ERK1/2	  proteins,	  but	  
stimulates	  activation	  of	  the	  splice	  variant	  ERK1c	  [154].	  Once	  activated,	  MEK	  isoforms	  
phosphorylate	  ERK1/2	  at	  the	  conserved	  Thr-­‐Glu-­‐Tyr	  motif	  (human	  ERK1:	  aa	  202-­‐204,	  
human	  ERK2:	  aa	  185-­‐187)	  in	  a	  two-­‐collision,	  distributive	  manner	  rather	  than	  a	  
single-­‐collision,	  processive	  manner	  [155].	  This	  allows	  the	  establishment	  of	  a	  threshold,	  
where	  tyrosine-­‐phosphorylated	  ERKs	  have	  to	  accumulate	  before	  phosphorylation	  of	  the	  
threonine	  residue	  can	  occur.	  As	  singly	  phosphorylated	  ERK1/2	  show	  very	  little	  kinase	  
activity,	  this	  mode	  of	  activation	  allows	  signal	  propagation	  only	  when	  MEKs	  are	  activated	  
for	  a	  prolonged	  period.	  Upon	  stimulation,	  ERK1/2	  phosphorylate	  a	  multitude	  of	  
substrates,	  including	  transcription	  factors,	  membrane	  proteins,	  cytoskeletal	  elements,	  
phosphatases	  and	  kinases.	  So	  far	  more	  than	  160	  ERK	  substrates	  have	  been	  identified,	  yet	  
the	  number	  is	  ever-­‐growing	  [156].	  ERKs	  are	  proline-­‐directed	  kinases,	  which	  phosphorylate	  
substrates	  on	  a	  Pro-­‐Xaa-­‐Ser/Thr-­‐Pro	  consensus	  site.	  However,	  not	  all	  substrates	  contain	  
this	  perfect	  consensus	  motif,	  but	  a	  shorter	  Ser/Thr-­‐Pro	  sequence,	  which	  is	  still	  sufficient	  
to	  direct	  ERK’s	  phosphorylation	  [157].	  
1.3.1 ERK1/2 isoforms and splice variants 
The	  two	  predominant	  ERK	  isoforms,	  namely	  ERK1	  (44	  kDa)	  and	  ERK2	  (42	  kDa),	  are	  
evolutionary	  conserved	  enzymes,	  which	  show	  an	  overall	  sequence	  identity	  of	  nearly	  
85%	  [58].	  Both	  kinases	  are	  ubiquitously	  expressed,	  albeit	  their	  relative	  abundance	  may	  
vary	  across	  tissues.	  For	  example,	  ERK1	  is	  highly	  expressed	  in	  intestines	  and	  placenta,	  
whereas	  ERK2	  expression	  predominates	  in	  muscle,	  thymus	  and	  heart	  tissues	  [58].	  
Notably,	  two	  genes,	  located	  on	  chromosomes	  16	  (erk1)	  and	  22	  (erk2),	  give	  rise	  to	  the	  
canonical	  transcripts	  of	  ERK1,	  ERK2,	  and	  alternatively	  spliced	  forms	  [158,	  159].	  
To	  date,	  two	  transcript	  variants	  have	  been	  described	  for	  ERK2,	  which	  encode	  the	  same	  
protein,	  but	  differ	  in	  their	  3ˊuntranslated	  region	  (UTR).	  In	  contrast,	  alternative	  splicing	  of	  
the	  ERK1	  transcript	  results	  in	  three	  distinct	  isoforms	  (Figure	  1-­‐6	  B).	  Isoform	  1	  represents	  
the	  canonical	  ERK1	  sequence,	  which	  translates	  into	  a	  44	  kDa	  protein	  [55,	  58].	  In	  
comparison,	  isoform	  3	  lacks	  an	  in-­‐frame	  exon	  in	  the	  3ˊ	  coding	  region,	  thus	  rendering	  a	  
shorter	  transcript.	  So	  far,	  there	  is	  no	  evidence	  for	  expression	  of	  this	  variant	  at	  a	  protein	  
level,	  thus	  questioning	  its	  physiological	  function.	  On	  the	  other	  hand,	  isoform	  2	  retains	  the	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Figure 1-6 Structural differences between ERK1b and ERK1c 
A. Sequence alignment of the intron 7 of human ERK1c and rat ERK1b. Identical amino acids are marked as 
(:). Introduced gaps to maximise the alignment are indicated by a dash.  
B. Exon organisation of human ERK1, ERK1c and rat ERK1c. Adapted from [158]. 
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intron	  7,	  which,	  depending	  on	  its	  sequence,	  results	  in	  an	  ERK1	  isoform	  of	  varying	  size.	  In	  
the	  case	  of	  rodents,	  the	  78	  bp	  intron	  sequence	  is	  translated	  in	  frame	  and	  gives	  rise	  to	  a	  
46	  kDa	  protein,	  called	  ERK1b	  [159].	  In	  primates,	  however,	  the	  intron	  sequence	  (103	  bp	  
long)	  contains	  a	  premature	  stop	  codon,	  thus	  creating	  a	  shorter	  40	  kDa	  protein,	  termed	  
ERK1c	  (Figure	  1-­‐6)	  [158].	  Rodent	  ERK1b	  and	  primate	  ERK1c	  share	  many	  common	  
features	  (Table	  1-­‐4).	  Firstly,	  both	  proteins	  are	  catalytically	  active,	  as	  demonstrated	  by	  in	  
vitro	  kinase	  assays.	  Secondly,	  the	  inserted	  region	  sterically	  alters	  the	  CD-­‐docking	  site,	  
which	  leads	  to	  reduced	  interaction	  with	  D-­‐motif	  containing	  proteins,	  such	  as	  MEK1	  and	  
ELK1	  [156].	  Thus,	  unlike	  ERK1/2,	  both	  splice	  variants	  fail	  to	  bind	  to	  the	  cytoplasmic	  
retention	  signal	  in	  MEK	  and	  are	  constitutively	  localised	  to	  the	  nucleus	  [158,	  159].	  
Moreover,	  reduced	  binding	  of	  protein	  tyrosine	  phosphatases	  (PTP),	  such	  as	  PTP-­‐SL,	  
results	  in	  a	  prolonged	  activation	  of	  these	  enzymes	  [158,	  159].	  Despite	  the	  latter	  
similarities,	  ERK1b	  and	  ERK1c	  also	  possess	  distinct	  features	  (Table	  1-­‐4).	  For	  example,	  
ERK1b	  is	  activated	  by	  MEK1/2	  with	  comparable	  kinetics	  to	  those	  of	  ERK1	  and	  ERK2,	  
whereas	  ERK1c	  is	  activated	  primarily	  by	  the	  alternatively	  spliced	  isoform	  MEK1b	  [154,	  
159].	  Moreover,	  mono-­‐ubiquitination	  of	  ERK1c	  directs	  this	  enzyme	  to	  the	  Golgi	  
apparatus,	  where	  it	  induces	  Golgi	  fragmentation	  [160].	  Interestingly,	  ERK1c	  expression	  is	  
increased	  in	  tumour	  tissues,	  suggesting	  a	  putative	  role	  for	  this	  enzyme	  in	  
tumourigenesis	  [160].	  In	  contrast,	  physiological	  functions	  for	  ERK1b	  are	  still	  unknown.	  It	  is	  
assumed,	  however,	  that	  ERK1b	  is	  particularly	  important	  for	  signal	  transduction	  via	  the	  
ERK-­‐MAPK	  pathway	  in	  conditions,	  where	  the	  active	  pool	  of	  ERK1/2	  is	  limited	  [159].	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Derivation Alternative splicing leads to incorporation of intron 7 
Enzymatic activity Catalytically active 
Structure Disrupted CD domain 
Protein-protein 
interaction 
Weak interaction with MEK and phosphatases 
Subcellular 
localisation 










Predicted size 46 kDa 40 kDa  
Insert size 78 bp 103 bp with in-frame stop codon 
Activation by MEK Activated by MEK1/2 with similar kinetics to ERK1/2 
Activated by splice variant MEK1b 
Posttranslational 
modification 
• Phosphorylation of TEY motif 
• No ubiquitination 
• Phosphorylation of TEY motif 




Unknown Involved in Golgi fragmentation  
necessary during mitosis 
Table 1-4 Common and distinct features of the alternatively spliced ERK1 isoforms 
  
Chapter 1 – Introduction  45 
1.3.2 ERK signalling specificity 
One	  of	  the	  intriguing	  features	  of	  the	  ERK-­‐MAPK	  pathway	  is	  its	  ability	  to	  stimulate	  
different,	  and	  sometimes	  even	  opposing,	  cellular	  functions.	  This	  raises	  the	  question	  as	  to	  
how	  different	  input	  signals	  can	  evoke	  distinct	  functional	  outcomes.	  Several	  mechanisms,	  
determining	  signalling	  specificity,	  have	  been	  identified	  in	  recent	  years,	  including:	  
(i)	  duration	  and	  strength	  of	  signals	  [161],	  (ii)	  interaction	  with	  scaffold	  and	  adaptor	  
proteins	  [148],	  (iii)	  subcellular	  localisation	  [162,	  163],	  (iv)	  crosstalk	  and	  interplay	  between	  
the	  ERK-­‐MAPK	  pathway	  and	  other	  signalling	  cascades	  [149-­‐151,	  164],	  (v)	  isoform	  
specificity	  [59,	  154],	  and	  (vi)	  cell-­‐specific	  ERK	  substrates	  [156].	  Notably,	  these	  
mechanisms	  work	  cooperatively,	  rather	  than	  independently,	  to	  ensure	  proper	  
downstream	  signalling.	  The	  following	  subsections	  focus	  on	  how	  ERK	  activity	  is	  regulated	  
in	  a	  cellular	  context	  by	  means	  of	  protein	  phosphatases,	  scaffold	  proteins,	  subcellular	  
localisation	  and	  feedback	  loops.	  
1.3.2.1 Regulation of ERK activity through protein phosphatases 
Phosphorylation	  events	  are	  key	  regulators	  of	  the	  ERK-­‐MAPK	  pathway.	  Not	  only	  are	  all	  
members	  of	  the	  MAPK	  cascade	  activated	  by	  phosphorylation,	  the	  addition	  of	  phospho	  
groups	  to	  MEKs	  and	  Rafs	  can	  also	  inhibit	  kinase	  activity.	  Thus,	  protein	  phosphates	  can	  
impact	  both	  negatively	  and	  positively	  on	  ERK	  signalling.	  Full	  activation	  of	  ERK1/2	  requires	  
dual	  phosphorylation	  of	  the	  Thr-­‐Glu-­‐Tyr	  motif.	  Single	  phosphorylation	  of	  either	  threonine	  
or	  tyrosine	  results	  in	  a	  marginally	  active	  kinase.	  Therefore,	  ERK	  activity	  can	  be	  inhibited	  
through	  the	  removal	  of	  either	  one	  or	  two	  phospho	  groups.	  Generally,	  three	  groups	  of	  
protein	  phosphatases	  act	  on	  ERK1/2	  (Table	  1-­‐5),	  i.e.	  serine/threonine	  protein	  
phosphatases	  (Ser/Thr-­‐PPs),	  phosphotyrosine	  phosphatases	  (PTPs)	  and	  MAPK	  
phosphatases	  (MKPs).	  MAPK	  phosphatases,	  as	  the	  name	  suggests,	  constitute	  a	  unique	  
class	  of	  dual	  specificity	  phosphatases	  that	  act	  selectively	  on	  MAPKs	  and	  remove	  both	  
phospho	  groups	  simultaneously	  (Figure	  1-­‐7).	  
Despite	  its	  broad	  substrate	  specificity,	  the	  Ser/Thr	  protein	  phosphatase,	  PP2A,	  is	  an	  
important	  regulator	  of	  the	  ERK-­‐MAPK	  pathway	  [165-­‐167].	  The	  holoenzyme	  consists	  of	  
three	  subunits,	  i.e.	  a	  scaffolding	  subunit	  A,	  a	  regulatory	  subunit	  B,	  and	  a	  catalytic	  subunit	  
C.	  Different	  combinations	  of	  A,	  B	  and	  C	  give	  rise	  to	  over	  50	  PP2A	  trimers	  [168,	  169].	  B	  
subunits,	  which	  target	  PP2A	  to	  distinct	  subcellular	  localisations	  and	  are	  involved	  in	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NAME Alternative name Size (kDa) Substrate specificity Localisation 
A. Ser/Thr PP     
PP2A  37 ERK (when trimer 
with B  subunit) 
cytosolic 
B. PTP     
He-PTP  38 ERK = p38 cytosolic 
STEP  20-61 ERK cytosolic 
PTP-SL PCPTP-1 42,65 ERK = p38 cytosolic 
C. MKPs     
DUSP1* MKP-1, CL100 39 P38 = JNK > ERK nuclear 
DUSP2* PAC-1 34 ERK = p38 > JNK nuclear 
DUSP 4* MKP-2 43 ERK = p38 > JNK nuclear 
DUSP5* hVHR3 42 ERK nuclear 
DUSP6 MKP-3 43 ERK > JNK = p38 cytosolic 
DUSP7 MKP-X 40 ERK > JNK = p38 cytosolic 
DUSP8 hVH5 66 JNK = p38 > ERK nuclear and cytosolic 
DUSP9 MKP-4 42 ERK > p38 > JNK nuclear and cytosolic 
DUSP10* MKP-5 53 P38 = JNK > ERK nuclear and cytosolic 
DUSP16 MKP-7 73 JNK = p38 > ERK cytosolic 
Table 1-5 Overview of the different groups of ERK phosphatases 
Phosphatases marked with * are encoded by ERK1/2 inducible genes. 
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Figure 1-7 ERK signalling is regulated by cytoplasmic and nuclear phosphatases 
ERK activity is regulated by three groups of phosphatases, namely Ser/Thr PPs, PTPs and DUSPs, which 
possess specific subcellular localisations. DUSP6 is subject to ERK phosphorylation, which targets the 
phosphatase for proteasomal degradation. Thus, ERK can prolong its own activity by inhibiting cytoplasmic 
inactivation. On the other hand, ERK can induce its inhibition, as the expression of multiple phosphatases 
marked here with (*) is induced by ERK signalling. 
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substrate	  recognition,	  have	  been	  divided	  into	  three	  gene	  families,	  named	  B	  (or	  PR55),	  Bˊ	  
(or	  B56)	  and	  Bˊˊ	  (PR72)	  [170].	  Dephosphorylation	  of	  ERK1/2	  is	  mediated	  by	  Bˊ	  subunit	  
containing	  enzymes	  in	  a	  process	  that	  is	  not	  yet	  fully	  understood.	  Interestingly,	  ERK1/2	  
itself	  can	  modulate	  PP2A	  activity	  by	  phosphorylating	  the	  Bˊ	  subunits	  at	  a	  conserved	  serine	  
residue.	  This	  process,	  however,	  requires	  expression	  of	  the	  immediate	  early	  gene	  IEX-­‐1,	  
which	  serves	  as	  an	  adaptor	  protein	  by	  positioning	  the	  Bˊ	  subunit	  for	  ERK-­‐mediated	  
phosphorylation	  [171].	  Thus,	  IEX-­‐1	  induction	  results	  in	  enhanced	  phosphorylation	  of	  Bˊ,	  
subsequent	  inhibition	  of	  PP2A	  and	  prolonged	  ERK	  activation.	  
Phosphorylation	  represents	  a	  common	  mechanism	  for	  regulating	  phosphatase	  activity.	  
For	  example,	  interaction	  of	  the	  hematopoietic	  protein	  tyrosine	  phosphatase	  (He-­‐PTP)	  
with	  ERK1/2	  is	  inhibited	  by	  PKA-­‐mediated	  phosphorylation	  of	  the	  D-­‐motif	  [172].	  Likewise,	  
phosphorylation	  of	  the	  striatal-­‐enriched	  protein	  tyrosine	  phosphatase	  (STEP)	  prevents	  
ERK1/2	  dephosphorylation	  [173].	  Thus	  far,	  three	  PTPs	  with	  ERK1/2	  activity	  have	  been	  
identified:	  He-­‐PTP,	  which	  is	  the	  only	  PTP	  expressed	  in	  hematopoietic	  cells,	  STEP,	  which	  is	  
mainly	  expressed	  in	  the	  brain	  and	  PTP-­‐SL,	  which	  is	  expressed	  in	  lung,	  heart	  and	  
brain	  [174].	  Interestingly,	  PTPs	  and	  PP2A	  sometimes	  form	  a	  complex	  with	  dual	  specificity,	  
thus	  mimicking	  the	  activity	  of	  MKPs	  [174].	  
MKPs	  represent	  a	  well-­‐characterised	  subgroup	  of	  dual	  specificity	  phosphatases	  (DUSP),	  
which	  antagonize	  MAPK	  signalling.	  In	  general,	  MKPs	  are	  subdivided	  into	  two	  groups:	  
(i)	  MKPs,	  which	  are	  encoded	  by	  growth	  factor	  or	  stress-­‐inducible	  genes	  and	  are	  largely	  
located	  in	  the	  nucleus,	  or	  (ii)	  MKPs,	  whose	  activity	  is	  not	  regulated	  by	  gene	  transcription	  
and	  are	  primarily	  found	  in	  the	  cytoplasm	  [59].	  All	  MKPs,	  however,	  are	  composed	  of	  an	  
N-­‐terminal	  regulatory	  and	  a	  C-­‐terminal	  catalytic	  domain.	  Some	  MKPs,	  such	  as	  DUSP5	  and	  
DUSP6	  demonstrate	  an	  increased	  specificity	  towards	  ERK1/2,	  whereas	  others,	  such	  as	  
DUSP1,	  preferentially	  dephosphorylate	  p38s	  and	  JNKs	  [175].	  The	  activity	  of	  MKPs	  can	  be	  
regulated	  by	  means	  of	  protein-­‐protein	  interaction,	  phosphorylation	  and	  oxidation.	  For	  
example,	  DUSP6	  interaction	  with	  ERK1/2	  induces	  a	  conformational	  change,	  which	  results	  
in	  the	  activation	  of	  the	  phosphatase.	  However,	  DUSP6	  contains	  an	  ERK	  consensus	  site,	  
which,	  when	  phosphorylated,	  targets	  the	  enzyme	  for	  proteasomal	  degradation	  without	  
altering	  its	  catalytic	  activity	  [176].	  In	  contrast,	  phosphorylation	  of	  DUSP1	  by	  ERK1/2	  
results	  in	  the	  stabilisation	  of	  the	  phosphatase	  [177].	  Additionally,	  reactive	  oxygen	  species,	  
such	  as	  H2O2,	  oxidise	  MKPs,	  rendering	  the	  enzymes	  inactive	  [178].	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1.3.2.2 Regulation of ERK activity through upstream and downstream scaffold 
proteins 
One	  important	  determinant	  of	  ERK	  signalling	  strength	  and	  duration	  is	  the	  efficiency	  of	  its	  
activation.	  When	  all	  components	  of	  the	  cascade	  are	  brought	  into	  close	  proximity,	  optimal	  
pathway	  activation	  through	  sequential	  phosphorylation	  of	  Rafs,	  MEK1/2,	  and	  ERK1/2	  can	  
occur.	  One	  way	  of	  bringing	  these	  protein	  kinases	  into	  the	  vicinity	  of	  one	  another,	  is	  
through	  direct	  interaction	  of	  pathway	  members.	  For	  example,	  MEK1/2	  bind	  inactive	  ERK	  
constitutively	  and	  thereby	  not	  only	  serve	  as	  cytoplasmic	  anchor	  proteins,	  but	  also	  allow	  
the	  formation	  of	  a	  signalling	  module,	  which	  facilitates	  ERK	  activation	  [179].	  The	  same	  is	  
valid	  for	  RSK	  (ribosomal	  S6	  kinase)	  proteins,	  which	  bind	  inactive	  ERK	  and	  thereby	  retain	  
the	  kinase	  in	  the	  cytoplasm	  [180].	  Alternatively,	  members	  of	  the	  ERK-­‐MAPK	  pathway	  can	  
be	  organised	  into	  multi-­‐enzyme	  complexes	  through	  scaffold	  proteins.	  By	  definition,	  
scaffolds	  serve	  as	  structural	  docking	  platforms,	  which	  bind	  two	  or	  more	  members	  of	  a	  
signalling	  pathway	  and	  facilitate	  signal	  transduction.	  Besides	  this	  obvious	  function,	  
however,	  scaffold	  proteins	  also	  influence	  pathway	  signalling	  by	  targeting	  multi-­‐enzyme	  
complexes	  to	  specific	  subcellular	  localisations	  (Figure	  1-­‐8	  and	  Table	  1-­‐6).	  Moreover,	  
scaffolds	  can	  prevent	  crosstalk	  with	  other	  signalling	  pathways	  by	  masking	  interaction	  or	  
modification	  sites	  of	  its	  binding	  partners.	  Additionally,	  scaffolds	  can	  integrate	  signals	  from	  
otherwise	  discrete	  signalling	  pathways,	  as	  their	  ability	  to	  bind	  signalling	  molecules	  can	  be	  
regulated	  through	  post-­‐translational	  modifications.	  Furthermore,	  adaptor	  proteins	  can	  
link	  a	  signalling	  pathway	  to	  specific	  activating	  signals.	  Taken	  together,	  scaffolds	  can	  
provide	  signalling	  specificity	  to	  the	  multi-­‐functional	  ERK-­‐MAPK	  pathway.	  An	  overview	  of	  
the	  ERK-­‐MAPK	  scaffolds	  known	  to	  date	  will	  be	  given	  in	  the	  following	  sections.	  	  
Kinase suppressor of Ras (KSR; binds Rafs, MEK1/2, ERK1/2 and 14-3-3) 
Kinase	  suppressor	  of	  Ras	  (KSR)	  was	  originally	  identified	  as	  a	  suppressor	  of	  an	  activated	  
Ras	  phenotype	  in	  genetic	  studies	  of	  C.	  elegans	  and	  Drosophila	  [181,	  182].	  To	  date,	  two	  
KSR	  proteins	  (KSR1	  and	  KSR2)	  have	  been	  discovered	  in	  mammals,	  both	  of	  which	  contain	  
five	  conserved	  domains	  (CA1-­‐5).	  The	  presence	  of	  a	  kinase-­‐like	  domain	  and	  structural	  
similarity	  to	  c-­‐Raf	  sparked	  investigations	  into	  a	  putative	  catalytic	  activity.	  Whether	  or	  not	  
the	  kinase	  domain	  is	  functionally	  active,	  however,	  remains	  an	  open	  issue	  [148,	  183].	  KSR	  
proteins	  interact	  with	  all	  members	  of	  the	  ERK-­‐MAPK	  cascade	  [184,	  185].	  Both	  MEK	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Figure 1-8 Subcellular localisation of ERK activity through scaffold proteins 
Scaffold proteins facilitate ERK activation by assembling cascade components into functional modules. 
Moreover, scaffolds localise ERK activity at specific subcellular localisations and link the ERK activation to 
specific extracellular signals. 
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Acronym Name Size 
(kDa) 
Protein interactions Subcellular target 
KSR Kinase suppressor of Ras ~100 Raf, 14-3-3, MEK1/2, 
ERK1/2 
plasma membrane 
MP1 MEK partner 1 13.5 MEK1, ERK1 MP1/p14:  
late endosomes 
MP1/Morg-1: 
vesicular structures  
β-arrestin  ~46 c-Raf, MEK1/2, ERK1/2 early endosomes 
MEKK1 MEK kinase 1 195 c-Raf, MEK1/2, ERK1/2 cytoskeleton 
CNK Connector enhancer of KSR 61-117 Rafs plasma membrane 
Sur-8 Suppressor of Ras 8 65 K-/N-Ras, Rafs plasma membrane 
IQGAP1  190 B-Raf, MEK1/2, ERK1/2 cytoplasm 
Paxillin  68 Raf, MEK1/2, ERK1/2 focal adhesions 
PEA-15 Phosphoprotein enriched in 
astrocytes 
15 ERK1/2, RSK2 cytoplasm 
RKIP Raf kinase inhibitor protein 21 c-Raf, MEK1/2, ERK1/2  
Table 1-6 Mammalian scaffold proteins for the ERK-MAPK pathway 
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isoforms	  bind	  directly	  to	  the	  kinase-­‐like	  domain,	  CA5,	  ERK1/2	  interact	  with	  the	  DEF-­‐motif	  
found	  in	  CA4	  and	  Raf	  association,	  at	  least	  in	  Drosophila,	  is	  mediated	  via	  the	  CA1	  
domain	  [183,	  186].	  KSR	  localisation	  is	  dynamic	  and	  regulated	  by	  phosphorylation	  and	  
protein	  interactions.	  In	  quiescent	  cells,	  KSR,	  which	  is	  phosphorylated	  at	  Ser392,	  binds	  to	  
14-­‐3-­‐3	  to	  localise	  the	  signalling	  complex	  to	  the	  cytoplasm.	  Upon	  Ras	  activation,	  this	  
critical	  residue	  is	  dephosphorylated	  and	  14-­‐3-­‐3	  association	  is	  disrupted.	  Subsequently,	  
the	  KSR	  signalling	  complex	  is	  translocated	  to	  the	  plasma	  membrane	  where	  the	  kinase	  
cascade	  becomes	  activated.	  Upon	  activation,	  ERK	  is	  released	  from	  the	  KSR	  platform	  and	  
accumulates	  e.g.	  in	  the	  nucleus	  to	  regulate	  gene	  transcription.	  
MEK partner 1 (MP1; binds MEK1 and ERK1) 
MP1	  was	  identified	  in	  a	  yeast	  two-­‐hybrid	  screen	  for	  MEK1	  interacting	  partners	  in	  
1998	  [187].	  Original	  work	  demonstrated	  a	  selective	  binding	  of	  MP1	  to	  MEK1	  and	  ERK1	  
and	  suggested	  specific	  activation	  of	  ERK1	  over	  ERK2.	  Subsequent	  work,	  however,	  
challenged	  this	  by	  showing	  that	  MP1	  is	  required	  for	  activation	  of	  both	  ERK1	  and	  
ERK2	  [188].	  Thus,	  in	  contrast	  to	  the	  original	  data,	  MP1	  might	  either	  represent	  a	  docking	  
platform	  for	  MEK2	  and	  ERK2,	  or	  activate	  ERK2	  indirectly	  as	  part	  of	  the	  same	  signalling	  
complex.	  Interaction	  with	  the	  adaptor	  protein,	  p14,	  localises	  the	  MP1	  complex	  to	  late	  
endosomes,	  where	  it	  enhances	  PAK1	  phosphorylation	  and	  drives	  cellular	  spreading	  [189,	  
190].	  Interestingly,	  the	  MP1/p14	  complex	  is	  required	  for	  full	  ERK	  activation	  upon	  EGF	  
stimulation,	  whereas	  another	  MP1	  adaptor,	  namely	  Morg-­‐1	  (mitogen-­‐activated	  protein	  
kinase	  organiser	  1)	  promotes	  ERK	  signalling	  in	  response	  to	  serum,	  lysophosphatidic	  acid,	  
and	  phorbol	  ester	  [191].	  Thus,	  MP1	  links	  the	  ERK-­‐MAPK	  cascade	  to	  EGF	  signalling	  through	  
p14	  interaction	  and	  to	  G-­‐protein	  coupled	  receptor	  (GPCR)	  signalling	  through	  Morg-­‐1	  
association.	  Like	  p14,	  Morg-­‐1	  targets	  MP1	  to	  vesicular	  structures,	  the	  nature	  of	  which	  has	  
not	  been	  determined	  yet	  [191].	  
β-Arrestins (bind c-Raf, MEK1/2 and ERK1/2) 
It	  is	  well-­‐established	  that	  β-­‐arrestins	  terminate	  GPCR	  signalling	  by	  mediating	  receptor	  
internalisation	  [192].	  However,	  evidence	  is	  emerging	  that	  suggests	  an	  additional	  
scaffolding	  function	  for	  β-­‐arrestins	  [193].	  In	  mammalian	  tissues,	  two	  β-­‐arrestin	  proteins,	  
named	  β-­‐arrestin	  1	  and	  β-­‐arrestin	  2,	  are	  expressed.	  Following	  activation	  of	  GPCRs,	  
β-­‐arrestins	  translocate	  from	  the	  cytoplasm	  to	  the	  plasma	  membrane,	  which	  targets	  the	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receptors	  for	  internalisation.	  During	  subsequent	  endocytosis,	  a	  multi-­‐enzyme	  signalling	  
complex	  encompassing	  the	  internalised	  GPCR,	  β-­‐arrestin,	  c-­‐Raf,	  MEK1/2	  and	  ERK1/2	  is	  
formed	  and	  ERK	  signalling	  is	  activated	  [194,	  195].	  Interestingly,	  β-­‐arrestins	  enhance	  
cytosolic	  ERK	  activity	  and	  reduce	  transcriptional	  responses,	  thereby	  providing	  a	  counter	  
to	  KSR-­‐mediated	  ERK	  signalling	  [196].	  
MEK Kinase 1 (binds to c-Raf, MEK1/2 and ERK1/2) 
MEK	  kinase	  1	  (MEKK1)	  is	  a	  multi-­‐functional	  protein	  that	  is	  mainly	  appreciated	  as	  an	  
upstream	  MAPKKK	  for	  JNK	  and	  p38	  (Table	  1-­‐2)	  [62,	  197].	  In	  addition	  to	  its	  kinase	  activity,	  
MEKK1	  exhibits	  an	  E3	  ubiquitin	  ligase	  activity	  [198]	  and	  can	  act	  as	  a	  scaffold	  for	  members	  
of	  the	  ERK-­‐MAPK	  cascade	  due	  to	  its	  large	  non-­‐catalytic	  N-­‐terminal	  domain,	  which	  serves	  
as	  a	  docking	  platform	  [199].	  MEKK1	  binds	  c-­‐Raf,	  MEK1/2,	  ERK1/2	  constitutively	  [200]	  and	  
is	  believed	  to	  regulate	  ERK	  activation.	  This	  is	  based	  on	  its	  ability	  to	  enhance	  ERK	  signalling	  
when	  overexpressed	  [197]	  and	  because	  ERK	  activation	  is	  reduced	  in	  MEKK1-­‐deficient	  
cells	  [201].	  Intriguingly,	  MEKK1	  is	  tightly	  associated	  with	  the	  cytoskeleton,	  and	  this	  might	  
therefore	  provide	  a	  means	  of	  targeting	  ERK	  signalling	  to	  cytoskeletal	  elements.	  In	  
addition,	  MEKK1	  can	  serve	  to	  reduce	  ERK	  activity	  by	  ubiquitinating	  ERK1/2	  and	  thus	  
targeting	  it	  for	  proteasomal	  degradation	  [198].	  	  
Connector enhancer of KSR (CNK; binds c-Raf and B-Raf) 
In	  an	  attempt	  to	  identify	  functional	  binding	  partners	  of	  KSR,	  the	  connector	  enhancer	  of	  
KSR	  (CNK)	  was	  identified	  in	  Drosophila	  in	  1998.	  CNK	  is	  a	  large	  non-­‐catalytic	  adaptor	  
protein	  with	  multiple	  protein	  interaction	  domains.	  It	  contains	  a	  sterile	  α	  motif	  (SAM),	  a	  
conserved	  region	  in	  CNK	  (CRIC),	  a	  PDZ	  domain,	  Src-­‐homology-­‐3	  (SH3)-­‐binding	  sites	  and	  a	  
pleckstrin	  homology	  (PH)	  domain,	  which	  mediates	  membrane	  localisation	  [202].	  In	  
mammals,	  three	  CNK	  isoforms	  (CNK1,	  CNK2A	  and	  its	  truncated	  splice	  variant	  CNK2B)	  have	  
been	  identified	  [203,	  204],	  all	  of	  which	  associate	  with	  Raf	  but	  no	  other	  member	  of	  the	  
ERK	  cascade	  and	  enhance	  its	  activation	  via	  Src	  and	  Ras	  [205,	  206].	  So	  far,	  it	  has	  been	  
shown	  that	  CNK	  enhances	  ERK	  activation,	  but	  the	  exact	  mechanism	  through	  which	  this	  is	  
achieved	  remains	  to	  be	  elucidated.	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Suppressor of Ras 8 (Sur-8; binds Ras and c-Raf) 
The	  Suppressor	  of	  Ras	  has	  been	  isolated	  in	  C.	  elegans	  as	  an	  adaptor	  protein,	  which	  
increases	  Ras-­‐mediated	  signal	  transduction	  [207].	  Sur-­‐8	  is	  a	  conserved	  protein,	  which	  
mainly	  consists	  of	  leucine	  repeats	  and	  forms	  a	  complex	  with	  mammalian	  Ras	  and	  c-­‐Raf,	  
thus	  coupling	  Raf	  to	  the	  plasma	  membrane	  in	  the	  vicinity	  of	  its	  upstream	  regulator	  [208].	  
Interestingly,	  Sur-­‐8	  may	  provide	  signalling	  specificity	  by	  binding	  to	  N-­‐Ras	  and	  K-­‐Ras,	  but	  
not	  H-­‐Ras	  in	  vitro	  [207].	  	  
IQGAP1 (binds B-Raf, MEK1/2 and ERK1/2) 
IQGAPs	  form	  a	  conserved	  class	  of	  multidomain	  proteins,	  which	  mediate	  interactions	  with	  
a	  variety	  of	  signalling	  molecules	  and	  regulate	  multiple	  cellular	  processes,	  such	  as	  cell-­‐cell	  
adhesion,	  transcription	  and	  cytoskeletal	  remodelling.	  To	  date,	  three	  IQGAP	  isoforms	  
(IQGAP1,	  -­‐2	  and	  -­‐3)	  have	  been	  identified	  in	  humans,	  with	  IQGAP1	  being	  the	  most	  
intensively	  studied.	  IQGAP1	  has	  recently	  been	  identified	  as	  a	  novel	  MAPK	  scaffold,	  which	  
binds	  directly	  to	  B-­‐Raf,	  MEK1/2	  and	  ERK1/2	  [209-­‐211].	  This	  is	  particularly	  interesting	  as	  
oncogenic	  Ras,	  prevalent	  in	  over	  15%	  of	  all	  human	  cancers,	  primarily	  signals	  through	  
B-­‐Raf	  [212,	  213].	  Thus,	  IQGAP1’s	  function	  as	  a	  MAPK	  scaffold	  might	  be	  an	  important	  
contributor	  to	  tumourigenesis.	  Intriguingly,	  IQGAP1	  binding	  to	  B-­‐Raf	  enhances	  its	  activity	  
in	  vitro	  and	  this	  may	  provide	  a	  novel	  mechanism	  for	  pathway	  regulation.	  Although	  EGF	  
stimulation	  of	  ERK	  signalling	  requires	  IQGAP1,	  the	  exact	  mechanism	  of	  ERK	  activation	  
remains	  to	  be	  elucidated	  [210].	  
Paxillin (binds Raf, MEK1/2 and ERK1/2) 
Paxillin	  is	  a	  scaffold	  protein,	  which	  recruits	  both	  structural	  and	  signalling	  molecules	  to	  
adhesion	  sites	  and	  regulates	  cell	  migration	  and	  gene	  transcription.	  It	  is	  essential	  for	  
adhesion-­‐mediated	  activation	  of	  ERK	  [214],	  and	  several	  mechanisms	  have	  been	  proposed	  
to	  explain	  how	  this	  occurs.	  One	  mechanism	  suggests	  the	  assembly	  of	  a	  functional	  ERK	  
module	  on	  paxillin	  itself,	  which	  exhibits	  distinct	  binding	  efficiencies	  for	  all	  members	  of	  the	  
ERK	  cascade.	  It	  associates	  constitutively	  with	  MEK,	  but	  only	  interacts	  with	  activated	  Raf.	  
ERK	  association	  with	  this	  scaffold	  is	  regulated	  by	  Src.	  During	  cell	  adhesion	  Src	  
phosphorylates	  paxillin	  at	  Tyr118,	  which	  promotes	  binding	  of	  inactive	  ERK	  to	  the	  scaffold	  
and	  initiates	  ERK	  activation	  [215].	  ERK,	  in	  turn,	  phosphorylates	  paxillin,	  which	  enhances	  
the	  binding	  of	  focal	  adhesion	  kinase	  (FAK)	  to	  the	  scaffold	  and	  activates	  Rac	  signalling	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further	  downstream	  [216].	  As	  a	  result,	  FAK	  promotes	  the	  turnover	  of	  focal	  adhesions,	  
whereas	  Rac	  initiates	  lamellipodia	  formation.	  Thus,	  a	  functional	  ERK	  module	  on	  paxillin	  
gives	  rise	  to	  a	  positive	  feedback	  loop	  that	  coordinates	  cell	  motility.	  Alternatively,	  the	  
paxillin	  binding	  protein	  GIT1	  may	  provide	  a	  docking	  platform	  for	  ERK	  signalling	  molecules	  
at	  focal	  complexes	  [217].	  GIT1	  interacts	  with	  MEK	  and	  ERK1/2	  to	  induce	  ERK	  signalling	  in	  
response	  to	  EGF	  [218,	  219].	  Another	  mechanism	  for	  localising	  ERK	  at	  focal	  adhesions	  
involves	  FAK.	  Indeed,	  FAK	  can	  recruit	  MEKK1,	  which	  itself	  is	  a	  docking	  platform	  for	  the	  
ERK-­‐MAPK	  cascade	  [220].	  
Phosphoprotein enriched in astrocytes 15 (PEA-15; binds ERK1/2 and RSK2) 
The	  phosphoprotein	  PEA-­‐15	  was	  originally	  identified	  in	  astrocytes,	  where	  its	  expression	  is	  
enriched	  [221].	  It	  consists	  of	  a	  death	  effector	  domain	  (DED)	  and	  an	  unstructured	  
C-­‐terminal	  tail,	  which	  is	  involved	  in	  ERK	  binding	  [222].	  PEA-­‐15	  is	  the	  only	  downstream	  ERK	  
scaffold	  known	  to	  date	  and	  forms	  a	  complex	  with	  ERK1/2	  and	  RSK2	  (ribosomal	  S6	  
kinase)	  [223].	  Furthermore,	  PEA-­‐15	  functions	  as	  a	  cytoplasmic	  anchor	  protein,	  although	  it	  
is	  not	  completely	  understood	  how.	  The	  phosphoprotein	  contains	  a	  NES,	  which	  might	  
represent	  one	  possibility	  for	  keeping	  ERK	  signalling	  in	  the	  cytoplasm	  [224].	  Moreover,	  
PEA-­‐15	  and	  nucleoporins	  compete	  for	  the	  same	  binding	  site	  on	  ERK.	  Thus,	  PEA-­‐15	  
complex	  formations	  blocks	  nuclear	  import	  of	  ERK	  and	  might	  provide	  another	  means	  of	  
cytoplasmic	  anchoring	  [225].	  	  
Raf kinase inhibitor protein (RKIP; binds c-Raf/B-Raf, MEK1/2 and ERK1/2) 
The	  Raf	  kinase	  inhibitor	  protein	  is	  set	  apart	  from	  other	  known	  scaffolds	  in	  that	  it	  prevents	  
efficient	  ERK	  activation	  rather	  than	  facilitating	  it.	  RKIP	  contains	  overlapping	  docking	  sites	  
for	  MEK1/2	  and	  Raf.	  Thus,	  binding	  of	  these	  two	  kinases	  is	  mutually	  exclusive	  and	  RKIP	  
either	  forms	  a	  ternary	  complex	  with	  MEK	  and	  ERK,	  or	  interacts	  with	  Raf	  in	  a	  binary	  
complex.	  Competitive	  binding	  of	  MEK	  and	  Raf	  prevents	  the	  assembly	  of	  a	  functional	  ERK	  
module	  and	  thereby	  suppresses	  ERK	  activation	  [226].	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1.3.2.3 Localising ERK activity to specific subcellular compartments 
The	  localisation	  of	  ERK	  to	  specific	  subcellular	  compartments	  provides	  an	  important	  means	  
of	  controlling	  downstream	  substrates	  and	  biological	  outcomes.	  Neuronal	  differentiation	  
of	  PC12	  cells,	  for	  example,	  requires	  nuclear	  ERK	  signalling.	  Thus,	  blocking	  ERK’s	  
translocation	  to	  the	  nucleus	  through	  cytoplasmic	  anchoring	  proteins	  inhibits	  the	  
formation	  of	  neurite	  extensions	  [227].	  As	  the	  previous	  section	  (1.3.2.2)	  has	  highlighted	  
how	  docking	  platforms	  can	  act	  to	  localise	  ERK	  to	  distinct	  subcellular	  locations,	  the	  
following	  paragraphs	  aim	  to	  describe	  how	  ERK-­‐specific	  anchoring	  proteins	  other	  than	  
scaffolds	  can	  function	  to	  recruit	  ERKs	  to	  specific	  cellular	  locales.	  
The	  cellular	  distribution	  of	  ERK	  changes	  upon	  its	  activation.	  Whereas,	  in	  quiescent	  cells	  
the	  enzyme	  is	  mainly	  cytoplasmic,	  ERK	  activation	  triggers	  its	  redistribution	  to	  different	  
cellular	  loci.	  Thus,	  active	  enzyme	  then	  accumulates	  in	  the	  nucleus,	  where	  it	  drives	  or	  
inhibits	  transcriptional	  events.	  This	  dynamic	  shuttling	  of	  ERK	  is	  controlled	  by	  various	  
anchoring	  proteins,	  including	  MEK,	  which	  was	  the	  first	  cytoplasmic	  retainer	  to	  be	  
identified	  [179].	  ERK	  activation	  by	  MEK1/2	  triggers	  a	  conformational	  change,	  which	  
disrupts	  the	  interaction	  between	  the	  two	  kinases	  [130].	  Thus,	  MEK-­‐mediated	  retention	  of	  
ERK	  is	  stimulus-­‐dependent	  and	  reversible.	  In	  contrast,	  PEA-­‐15	  association	  with	  ERK	  is	  
non-­‐reversible	  and	  therefore	  independent	  of	  ERK’s	  phosphorylation	  status	  [224].	  
Although	  the	  biggest	  portion	  of	  active	  ERK	  is	  either	  localised	  in	  the	  cytoplasm	  or	  nucleus,	  
about	  10%	  of	  the	  enzyme	  translocates	  to	  the	  surface	  of	  organelles.	  Sef-­‐1	  (similar	  
expression	  to	  fgf	  1	  [228])	  is	  an	  example	  of	  an	  organelle	  recruiter,	  that	  targets	  ERK	  
specifically	  to	  membrane	  ruffles	  and	  the	  Golgi.	  Interestingly,	  Ras	  has	  also	  been	  found	  to	  
reside	  at	  the	  Golgi,	  where	  it	  is	  activated	  by	  the	  RasGRP1,	  rather	  than	  SOS.	  Thus,	  localising	  
ERK	  at	  the	  Golgi	  might	  specifically	  induce	  kinase	  activity	  through	  mechanisms	  other	  than	  
the	  canonical	  stimuli	  [229].	  Moreover,	  Sef-­‐1	  inhibits	  nuclear	  ERK	  translocation	  without	  
altering	  phosphorylation	  of	  cytoplasmic	  targets.	  It	  acts	  as	  a	  cytoplasmic	  retainer	  by	  
binding	  to	  activated	  MEK	  and	  inhibiting	  stimulus-­‐dependent	  dissociation	  of	  ERK	  from	  
MEK	  [230].	  In	  contrast,	  a	  protein	  called	  Mxi2	  has	  recently	  been	  shown	  to	  promote	  
stimulus-­‐independent	  translocation	  of	  ERK	  to	  the	  nucleus	  [231].	  Two	  features	  of	  this	  
p38α	  splice	  isoform	  [232]	  aid	  to	  accumulate	  ERK	  molecules	  in	  the	  nucleus.	  Firstly,	  Mxi2	  
binds	  directly	  to	  ERK1/2	  and	  thereby	  disrupts	  pre-­‐existing	  PEA-­‐15/ERK	  complexes	  [140].	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Secondly,	  Mxi2	  interacts	  with	  nucleoporins,	  thus	  localising	  ERK	  in	  the	  vicinity	  of	  nuclear	  
transporters	  and	  in	  doing	  so	  increasing	  its	  nuclear	  import	  [231].	  Moreover,	  Mxi2	  has	  been	  
shown	  to	  prolong	  nuclear	  ERK	  activity	  [233].	  One	  possible	  explanation	  for	  this	  observation	  
is	  that	  Mxi2	  masks	  phosphatase	  binding	  sites	  on	  ERK.	  Future	  work,	  including	  competition	  
binding	  assays	  and	  crystal	  structures	  of	  the	  Mxi2/ERK	  complex,	  will	  shed	  light	  on	  how	  
Mxi2	  extends	  nuclear	  ERK	  signalling.	  
DUSPs	  (described	  in	  1.3.2.1)	  may	  also	  serve	  as	  nuclear	  or	  cytoplasmic	  anchoring	  proteins.	  
DUSP6,	  for	  example,	  anchors	  ERK	  molecules	  in	  the	  cytoplasm	  via	  its	  NES	  [234].	  In	  
contrast,	  DUSP5	  comprises	  a	  NLS	  adjacent	  to	  its	  D-­‐motif	  and	  this	  sequesters	  ERK	  in	  the	  
nucleus	  [235].	  In	  addition,	  DUSP2	  and	  -­‐4	  have	  also	  been	  shown	  to	  retain	  ERK	  in	  the	  
nucleus	  through	  direct	  binding	  [236].	  Given	  the	  significant	  role	  of	  ERK	  signalling	  in	  
regulating	  transcriptional	  events,	  more	  nuclear	  anchoring	  proteins	  are	  expected	  to	  be	  
identified.	  
1.3.2.4 Regulating ERK activity through feedback loops 
ERK	  plays	  a	  central	  role	  in	  regulating	  many	  biological	  processes.	  Previous	  sections	  have	  
described	  how	  targeting	  ERK	  activity	  to	  subcellular	  loci	  can	  achieve	  signalling	  specificity.	  
Studies	  in	  PC12	  cells,	  however,	  provide	  evidence	  that	  signal	  duration	  can	  also	  be	  a	  
determining	  factor	  in	  biological	  outcomes;	  as	  sustained	  activation	  of	  ERK	  by	  NGF	  induces	  
differentiation	  in	  this	  cell	  system,	  whereas	  transient	  signalling	  results	  in	  
proliferation	  [237].	  Therefore,	  ERK	  substrates	  that	  either	  feedback	  to	  increase	  or	  
decrease	  signal	  duration	  are	  of	  particular	  interest	  in	  understanding	  the	  MAPK	  cascade.	  	  
Several	  points	  of	  negative	  feedback	  have	  been	  described	  for	  the	  ERK-­‐MAPK	  
pathway	  (Figure	  1-­‐9).	  Firstly,	  ERK	  regulates	  its	  own	  activation	  by	  phosphorylating	  MEK	  at	  
Thr292.	  The	  added	  phospho	  group	  prevents	  further	  enhancement	  of	  MEK	  activity	  and	  
diminishes	  ERK	  signalling	  [238].	  Another	  example	  of	  a	  negative	  feedback	  loop	  involves	  
PAK1	  phosphorylation.	  Generally,	  PAK1	  influences	  the	  ERK-­‐MAPK	  pathway	  by	  priming	  
MEK	  for	  c-­‐Raf	  activation.	  By	  phosphorylating	  Thr212,	  ERK	  inhibits	  priming	  of	  MEK	  and	  
therefore	  limits	  its	  own	  signalling	  [239,	  240].	  Additionally,	  multiple	  ERK	  phosphorylation	  
sites	  on	  Raf	  have	  been	  described.	  Hyperphosphorylation	  of	  these	  residues	  inhibits	  
membrane	  recruitment	  of	  Raf	  and	  promotes	  its	  inactivation	  by	  PP2A	  [241].	  Intriguingly,	  a	  
positive	  feedback	  loop	  to	  Raf	  has	  also	  been	  reported.	  Thus,	  Raf	  phosphorylation	  by	  ERK	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Figure 1-9 ERK pathway regulation by feedback loops 
Canonical activation of the ERK-MAPK pathway is depicted in its simplest form. EGF molecules bind to 
EGFR receptors and initiate receptor dimerisation followed by transphosphorylation. Next, Grb-2 binds to 
phosphotyrosine residues in the cytoplasmic receptor tail and recruits the guanine nucleotide exchange factor 
SOS. Subsequent activation of Ras leads to the recruitment of Raf to the plasma membrane, where the kinase 
is activated and sequential phosphorylation of MEK and ERK finalise the activation of the pathway. Active 
ERK can increase its activity through positive feedback loops (depicted in green) or diminish its signalling 
capacity through negative feedback loops (depicted in red). Negative feedback loops display a mechanisms 
by which ERK signalling can be shut down to basal levels following pathway activation. Adapted from 
[140]. 
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can	  either	  increase	  or	  reduce	  its	  activity	  [242].	  Phosphoacceptor	  sites	  identified	  to	  
increase	  Raf	  signalling	  are	  also	  involved	  in	  inhibiting	  the	  kinase,	  and	  it	  is	  unclear	  what	  
determines	  a	  positive	  or	  negative	  feedback	  loop	  to	  Raf.	  	  
The	  guanine	  nucleotide	  exchange	  factor	  SOS	  (son	  of	  sevenless)	  is	  subject	  to	  ERK	  
phosphorylation.	  SOS	  activates	  Ras	  by	  promoting	  a	  GTP-­‐bound	  state	  and	  is	  usually	  
localised	  in	  the	  cytoplasm.	  Upon	  activation	  of	  transmembrane	  receptor	  tyrosine	  
kinases	  (RTK),	  SOS	  is	  recruited	  to	  the	  plasma	  membrane	  to	  activate	  Ras.	  Phosphorylation	  
by	  ERK	  prevents	  this	  recruitment	  and	  blocks	  pathway	  activation	  [243].	  Furthermore,	  
sustained	  ERK	  activation	  induces	  the	  transcription	  of	  MKPs,	  such	  as	  DUSP2	  and	  -­‐5,	  which	  
turn	  off	  ERK	  signalling	  by	  dephosphorylating	  the	  enzyme	  [244].	  In	  addition,	  DUSPs	  may	  
also	  be	  subject	  to	  ERK	  phosphorylation,	  although	  this	  can	  initiate	  a	  positive	  or	  negative	  
feedback	  loop	  depending	  on	  the	  phosphatase.	  Phosphorylation	  of	  DUSP1	  stabilises	  the	  
phosphatase	  and	  ultimately	  decreases	  ERK	  activity	  in	  the	  nucleus	  [177].	  On	  the	  other	  
hand,	  DUSP6	  phosphorylation	  marks	  the	  phosphatase	  for	  proteasomal	  degradation	  
without	  altering	  its	  activity	  [176].	  Moreover,	  direct	  interaction	  of	  ERK	  and	  DUSPs	  (e.g.	  
DUSP5)	  may	  stabilise	  the	  phosphatases	  and	  reinforce	  their	  enzymatic	  activity	  [245].	  Taken	  
together,	  feedback	  loops	  play	  an	  important	  role	  in	  regulating	  ERK	  activity.	  They	  enable	  
fine-­‐tuning	  signalling	  strength	  and	  duration,	  which	  ultimately	  governs	  biological	  
processes.	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1.4 The ERK-MAPK pathway in cancer 
It	  has	  long	  been	  appreciated	  that	  the	  ERK-­‐MAPK	  pathway	  has	  a	  key	  role	  in	  regulating	  
fundamental	  cellular	  processes	  such	  as	  proliferation,	  differentiation	  and	  cell	  motility.	  
Cellular	  homeostasis,	  therefore,	  requires	  tight	  regulation	  of	  the	  cascade	  and	  aberrant	  ERK	  
signalling	  contributes	  to	  multiple	  diseases,	  including	  cancer.	  Indeed,	  hyperactivation	  of	  
the	  ERK-­‐MAPK	  pathway	  is	  prevalent	  in	  one	  third	  of	  all	  human	  tumours	  and	  is	  implicated	  
in	  many	  hallmarks	  of	  cancer	  [246].	  Subsequent	  sections	  will	  describe	  how	  ERK	  signalling	  
promotes	  tumourigenesis	  and	  discuss	  therapeutic	  strategies	  targeting	  the	  pathway.	  
1.4.1 Activating mutations of the ERK-MAPK pathway 
Aberrant	  ERK	  signalling	  is	  triggered	  by	  activating	  mutations	  and/or	  overexpression	  of	  
upstream	  components	  of	  the	  cascade.	  Canonically,	  ERK	  is	  stimulated	  by	  growth	  factors,	  
which	  bind	  to	  transmembrane	  receptor	  tyrosine	  kinases	  (RTK),	  such	  as	  PDGFR,	  EGFR,	  
ErbB2	  and	  c-­‐Met.	  Ligand	  binding	  activates	  the	  receptor	  by	  initiating	  receptor	  dimerisation	  
(or	  in	  some	  cases	  oligomerisation)	  and	  subsequent	  transphosphorylation.	  In	  cancer,	  
several	  mechanisms	  can	  stimulate	  inappropriate	  receptor	  activation.	  Firstly,	  tumour	  cells	  
often	  synthesize	  their	  own	  growth	  factors,	  which	  trigger	  constitutive	  receptor	  activation	  
in	  an	  autocrine	  manner.	  Clinical	  examples	  include	  PDGF	  and	  TGFα	  (a	  ligand	  for	  EGFR)	  
secretion	  in	  glioblastomas	  and	  sarcomas,	  respectively	  [1].	  Moreover,	  cell	  surface	  
receptors	  themselves	  can	  be	  subject	  to	  deregulation.	  In	  many	  tumours	  genes,	  encoding	  
RTKs,	  are	  amplified	  and	  lead	  to	  receptor	  overexpression.	  Examples	  include	  egfr	  
amplification	  in	  brain	  and	  breast	  tumours	  [247,	  248]	  or	  Her2	  overexpression	  in	  mammary	  
and	  ovarian	  carcinomas	  [249,	  250].	  Increasing	  the	  concentration	  of	  one	  particular	  
receptor	  changes	  the	  overall	  composition	  of	  surface	  receptors	  in	  the	  plasma	  membrane	  
and	  switches	  growth	  factor	  responsiveness	  of	  the	  tumour	  cell	  to	  previously	  
non-­‐stimulating	  ligands.	  Intriguingly,	  gross	  overexpression	  of	  surface	  receptors	  can	  trigger	  
receptor	  dimerization	  and	  subsequent	  activation	  in	  the	  absence	  of	  extracellular	  
ligands	  [251].	  Moreover,	  activating	  truncations	  and	  mutations	  of	  RTKs	  have	  been	  
observed	  in	  human	  tumours	  [252].	  
Further	  downstream,	  Ras	  proteins,	  of	  which	  there	  are	  four	  isoforms	  (N-­‐Ras,	  H-­‐Ras,	  K-­‐Ras	  
a	  and	  b),	  may	  be	  subject	  to	  deregulation.	  Indeed,	  Ras	  mutations	  occur	  very	  frequently	  in	  
human	  tumours	  and	  are	  found	  in	  90%	  of	  pancreatic	  lesions,	  50%	  of	  colon	  carcinomas	  and	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40%	  of	  lung	  carcinomas	  [213].	  Ras	  proteins	  belong	  to	  the	  protein	  family	  of	  small	  GTPases,	  
which	  have	  been	  characterised	  as	  molecular	  switches,	  because	  they	  cycle	  between	  an	  
inactive	  GDP-­‐bound	  and	  an	  active	  GTP-­‐bound	  state.	  GTP	  exchange	  factors	  (GEFs)	  can	  turn	  
these	  molecular	  switches	  on	  by	  promoting	  GDP	  dissociation	  and	  subsequent	  GTP	  binding.	  
In	  contrast,	  GTPase	  activating	  proteins	  (GAPs)	  act	  to	  accelerate	  GTP	  hydrolysis,	  thus	  
turning	  Ras	  signalling	  off.	  In	  human	  cancers,	  single	  amino	  acid	  substitutions	  impair	  the	  
intrinsic	  hydrolase	  activity,	  thus	  rendering	  Ras	  constitutively	  GTP-­‐bound	  and	  activated.	  
Single	  point	  mutations	  have	  been	  identified	  for	  codon	  12,	  61	  and	  less	  frequently	  13	  [253,	  
254].	  
Raf	  oncogenes	  comprise	  another	  group	  of	  deregulated	  signalling	  molecules	  in	  human	  
cancers.	  Among	  the	  three	  Raf	  kinases,	  B-­‐Raf	  is	  frequently	  mutated	  in	  many	  cancer	  
subtypes,	  such	  as	  melanomas	  (70%),	  thyroid	  cancer	  (53%),	  colorectal	  cancer	  (22%)	  and	  
ovarian	  carcinoma	  (30%)	  [255,	  256].	  Interestingly,	  c-­‐Raf	  mutations	  are	  rare	  and	  very	  little	  
evidence	  exists	  for	  A-­‐Raf	  mutations.	  A	  screen	  of	  colorectal	  adenocarcinomas	  identified	  
one	  silent	  exogenic	  mutation	  in	  the	  A-­‐raf	  gene	  and	  no	  exogenic	  mutation	  for	  c-­‐Raf	  [257].	  
In	  contrast,	  over	  30	  mutations	  have	  been	  detected	  for	  the	  B-­‐raf	  gene,	  with	  the	  V600E	  
mutation	  being	  the	  most	  frequent	  one	  (>90%).	  It	  is	  not	  entirely	  clear,	  why	  A-­‐Raf	  and	  c-­‐Raf	  
mutations	  are	  underpresented	  in	  human	  tumours.	  One	  possible	  explanation	  is	  based	  on	  
the	  activation	  mechanism	  of	  the	  three	  kinases,	  which	  requires	  a	  negative	  charge	  in	  the	  
N-­‐region.	  In	  A-­‐Raf	  and	  c-­‐Raf,	  this	  is	  achieved	  through	  activating	  phosphorylation	  of	  two	  
residues.	  In	  B-­‐Raf	  however,	  the	  N-­‐region	  is	  constitutively	  phosphorylated	  and	  thereby	  
primed	  for	  activation.	  Consequently,	  activation	  of	  B-­‐Raf	  can	  be	  accomplished	  in	  a	  single	  
mutation	  event,	  whereas	  constitutive	  activation	  of	  either	  A-­‐Raf	  or	  C-­‐Raf	  requires	  at	  least	  
two	  genetic	  alterations	  [258].	  In	  general,	  B-­‐Raf	  mutations	  are	  subdivided	  into	  two	  groups:	  
(i)	  those	  which	  give	  rise	  to	  a	  constitutively	  active	  kinases	  and	  (ii)	  mutations,	  which	  entail	  
an	  impaired	  or	  unaltered	  kinase	  activity	  [259].	  The	  V600E	  mutation	  constitutively	  
activates	  B-­‐Raf	  and	  triggers	  continuous	  phosphorylation	  of	  MEK	  in	  the	  absence	  of	  
extracellular	  stimuli	  and	  active	  Ras.	  In	  contrast,	  some	  B-­‐Raf	  mutations	  are	  compromised	  
in	  their	  ability	  to	  activate	  MEK,	  but	  rather	  elevate	  ERK	  signalling	  indirectly	  by	  activating	  
wildtype	  c-­‐Raf	  in	  an	  uncontrolled	  manner	  [259].	  
Notably,	  no	  activating	  MEK	  or	  ERK	  mutations	  have	  been	  identified	  in	  human	  cancers.	  This	  
is	  no	  surprise,	  as	  both	  kinases	  require	  dual	  phosphorylation	  for	  full	  enzymatic	  activity.	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Thus,	  two	  genetic	  alterations	  would	  be	  required	  for	  constitutive	  activation	  of	  these	  
enzymes.	  
1.4.2 The role of ERK in growth and proliferation 
Enhanced	  biosynthesis	  of	  macromolecules,	  membranes	  and	  organelles,	  increases	  the	  
cellular	  volume	  and	  represents	  a	  prerequisite	  for	  cell	  division.	  Thus,	  it	  is	  no	  surprise	  that	  
cell	  growth	  and	  cell	  cycle	  entry	  are	  tightly	  coordinated	  to	  maintain	  a	  constant	  cell	  size.	  
ERK	  signalling	  stimulates	  protein	  synthesis	  through	  various	  mechanisms	  (see	  Table	  1-­‐7).	  
Firstly,	  ERK1/2	  phosphorylate	  and	  thereby	  activate	  MAPKAPKs,	  MNK1	  and	  MNK2,	  which	  
subsequently	  phosphorylate	  the	  translation	  initiation	  factor	  eIF4E	  at	  Ser209	  [260,	  261].	  
Although	  eIF4E	  is	  a	  general	  translation	  initiation	  factor,	  the	  phosphorylated	  protein	  
preferentially	  augments	  translation	  of	  mRNAs	  with	  extensive	  5ˊUTRs,	  including	  ribosomal,	  
growth-­‐related	  and	  anti-­‐apoptotic	  mRNAs	  [262].	  Moreover,	  the	  ERK-­‐MAPK	  cascade	  
impinges	  on	  the	  mTOR	  (mammalian	  target	  of	  rapamycin)	  pathway,	  which	  is	  regarded	  as	  
the	  master	  regulator	  of	  growth,	  because	  it	  modulates	  ribosome	  biogenesis	  and	  
translation	  initiation.	  The	  mTOR	  kinase	  is	  sterically	  activated	  by	  a	  small	  GTPase	  called	  
Rheb	  [263].	  The	  heterodimer	  of	  the	  tuberous	  sclerosis	  complex	  1	  and	  2	  (TSC1/TSC2)	  acts	  
as	  a	  GAP	  for	  Rheb	  and	  thus	  antagonises	  mTOR	  stimulation.	  Direct	  phosphorylation	  of	  
TSC2	  by	  ERK1/2	  disrupts	  heterodimer	  formation	  and	  consequently	  enhances	  mTOR	  
signalling	  [264].	  Moreover,	  RSK1,	  a	  downstream	  ERK	  substrate,	  has	  also	  been	  shown	  to	  
inactivate	  the	  TSC1/TSC2	  complex	  through	  phosphorylation	  of	  Ser1798	  [265].	  
Additionally,	  RNA	  polymerase	  I	  (Pol	  I)-­‐mediated	  transcription	  of	  ribosomal	  genes	  is	  
subject	  to	  ERK	  regulation.	  Initiation	  of	  Pol	  I	  transcription	  requires	  the	  sequential	  binding	  
of	  two	  transcription	  factors,	  i.e.	  UBF	  and	  SL1,	  at	  the	  transcription	  initiation	  site.	  First,	  the	  
upstream	  binding	  factor	  (UBF)	  binds	  to	  the	  promoter	  element	  and	  the	  upstream	  control	  
element,	  thus	  bringing	  them	  together	  and	  creating	  a	  platform	  for	  SL1	  (selectivity	  factor	  1)	  
binding.	  Subsequently,	  Pol	  I	  is	  recruited	  to	  the	  promoter	  site	  and	  an	  initiation	  complex	  is	  
formed.	  Interestingly,	  UBF	  is	  subject	  to	  direct	  phosphorylation	  by	  ERK1/2	  and	  only	  
modified	  UBF	  can	  recognise	  rRNA	  promoter	  sites.	  Thus,	  the	  initiation	  of	  Pol	  I	  transcription	  
directly	  depends	  on	  ERK1/2	  signalling	  [266].	  In	  addition,	  ERK1/2	  phosphorylate	  the	  
transcription	  initiation	  factor-­‐1A	  (TIF1A)	  at	  Ser633	  to	  promote	  RNA	  Pol	  I	  
transcription	  [267].	  Interestingly,	  transcriptional	  events	  of	  Pol	  II	  and	  III	  are	  also	  modulated	  
through	  ERK-­‐mediated	  phosphorylation	  events.	  Thus,	  TFII-­‐I	  promotes	  transcriptional	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Cellular function Protein Name Phosphorylation site(s) Ref 
Cellular growth TSC2 tuberous sclerosis complex 2 Ser664 [264] 
TFII-I transcription factor II-I Ser627, Ser633 [268] 
Brf1 subunit of transcription factor 
III B 
unknown [269] 
TIF1A transcription factor 1A Ser633 [267] 
UBF upstream binding factor Thr117 [266] 
RNA Pol II RNA polymerase II multiple sites [270] 
Proliferation Tob1 transducer of Erbb2 Ser152, Ser154, Ser164 [271] 
c-Myc myelocytomatosis oncogene Ser62 [272] 
Survival FOXO3A forkhead box O3 Ser294, Ser344, Ser425 [273] 
BimEL Bcl-2 like 11 Ser109, Thr110 [274] 
Caspase 9  Thr125 [275] 
Cell migration FAK focal adhesion kinase Ser910 [276] 
MLCK myosin light chain kinase Ser13 [277] 
Cortactin  Ser405, Ser418 [278] 
Paxillin  unknown, Ser83 (mouse) [216] 
Stathmin  Ser16, Ser25, Ser38 [279] 
Vinexinβ  Ser189 [280] 
Calpain  Ser50 [281] 
Table 1-7 Bona fide ERK substrates grouped according to their biological functions 
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activity	  on	  the	  c-­‐Fos	  promoter	  as	  a	  result	  of	  direct	  phosphorylation	  by	  ERK	  [268].	  
Moreover,	  the	  transcriptional	  activity	  of	  RNA	  Pol	  II	  is	  induced	  through	  direct	  
phosphorylation	  of	  ERK	  at	  multiple	  sites	  [270].	  Likewise,	  RNA	  Pol	  III	  transcription	  is	  
induced	  as	  a	  result	  of	  direct	  phosphorylation	  of	  the	  TFIIIB	  subunit,	  Brf1	  [269].	  
In	  addition	  to	  an	  increased	  demand	  for	  proteins,	  growing	  cells	  require	  de	  novo	  synthesis	  
of	  RNA,	  DNA,	  lipids	  and	  glycogen.	  Pyrimidine	  nucleotides	  are	  precursors	  for	  the	  
production	  of	  all	  these	  molecules	  and	  its	  biosynthesis	  is	  carried	  out	  by	  a	  multi-­‐enzyme	  
complex	  called	  CAD.	  ERK1/2	  phosphorylates	  CAD	  on	  Thr456	  and	  thereby	  promotes	  
pyrimidine	  synthesis	  [282].	  
The	  process	  of	  cell	  division	  is	  governed	  by	  three	  regulatory	  molecules,	  namely	  cyclins,	  
cyclin-­‐dependent	  kinases	  (CDKs)	  and	  cyclin-­‐dependent	  kinase	  inhibitors	  (CDKI).	  During	  the	  
first	  step	  of	  the	  cell	  cycle,	  which	  marks	  the	  progression	  from	  G0/G1	  to	  S	  phase,	  cyclin	  D	  
expression	  is	  initiated	  and	  accumulates	  in	  the	  nucleus.	  The	  regulatory	  subunit	  interacts	  
with	  CDK4	  and	  CDK6,	  to	  form	  a	  catalytic	  complex,	  which	  phosphorylates	  the	  
retinoblastoma	  (Rb)	  protein.	  In	  quiescent	  cells,	  Rb	  inhibits	  members	  of	  the	  E2F	  family	  of	  
transcription	  factors	  through	  direct	  interaction.	  Phosphorylation	  of	  Rb,	  however,	  disrupts	  
the	  association	  with	  E2F	  and	  promotes	  expression	  of	  E2F	  target	  genes,	  such	  as	  cyclin	  E.	  
Subsequent	  accumulation	  of	  cyclin	  E	  induces	  an	  active	  E/CDK2	  complex,	  which	  
phosphorylates	  Rb	  further	  and	  stimulates	  S	  phase	  entry	  [283].	  Interestingly,	  cyclin	  D	  
expression	  is	  under	  the	  control	  of	  sustained	  ERK	  activation.	  Thus,	  active	  ERK	  induces	  
transcription	  of	  the	  immediate	  early	  genes	  (including	  fos,	  jun	  and	  egr)	  first,	  then	  stabilises	  
the	  resulting	  AP1	  transcription	  factors	  through	  direct	  phosphorylation,	  which	  then	  
promotes	  transcription	  of	  the	  delayed	  early	  genes,	  one	  of	  which	  is	  cyclin	  D	  [284].	  
Moreover,	  ERK1/2	  decreases	  expression	  of	  anti-­‐proliferative	  genes,	  such	  as	  tob1.	  Tob1	  is	  
a	  transcriptional	  co-­‐repressor,	  which	  inhibits	  cyclin	  D	  expression	  by	  recruiting	  histone	  
deacetylases	  to	  the	  cyclin	  D	  promoter	  [285].	  Moreover,	  existing	  Tob1	  proteins	  are	  
inhibited	  by	  ERK1/2-­‐dependent	  phosphorylation,	  although	  it	  is	  unclear	  how	  the	  phospho	  
transfer	  renders	  the	  TF	  inactive	  [271].	  In	  addition,	  Rb/E2F	  association	  can	  be	  disrupted	  by	  
direct	  phosphorylation	  of	  Rb	  by	  ERK1/2,	  thus	  relieving	  the	  inhibitory	  function	  of	  Rb	  [286].	  
The	  transcription	  factor	  c-­‐Myc	  is	  another	  critical	  regulator	  of	  the	  cell	  cycle.	  Its	  expression	  
is	  induced	  upon	  mitogen	  stimulation	  as	  part	  of	  the	  immediate	  early	  genes	  [287].	  c-­‐Myc	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heterodimerises	  with	  other	  members	  of	  the	  Myc	  family	  of	  transcription	  factors,	  including	  
Max	  and	  Miz-­‐1.	  The	  Myc/Max	  transcription	  factor	  complex	  induces	  cyclin	  D2	  and	  CDK4	  
expression	  [288,	  289],	  while	  the	  Myc/Miz-­‐1	  complex	  represses	  the	  expression	  of	  the	  CDK	  
inhibitors	  p15INK4	  and	  p21Cip1	  [290-­‐292].	  Additionally,	  c-­‐Myc	  impacts	  profoundly	  on	  
cellular	  growth	  by	  activating	  gene	  transcription	  of	  ribosomal	  proteins	  and	  translation	  
factors	  [293].	  However,	  c-­‐Myc	  has	  an	  extremely	  short	  half-­‐life	  (less	  than	  30	  minutes	  in	  
growing	  cells)	  [294].	  Thus,	  in	  order	  to	  induce	  cell	  cycle	  progression,	  the	  protein	  must	  be	  
stabilised.	  Active	  ERK1/2	  markedly	  enhance	  c-­‐Myc	  stability	  as	  a	  result	  of	  direct	  
phosphorylation	  of	  Ser62	  [287,	  295].	  Thus,	  ERK	  signalling	  promotes	  both	  the	  expression	  
of	  c-­‐Myc	  and	  subsequently	  increases	  the	  protein’s	  half-­‐life.	  
Moreover,	  stimulation	  of	  the	  ERK-­‐MAPK	  pathway	  induces	  the	  transcription	  of	  the	  CDK	  
inhibitors,	  p21Cip1,	  which	  paradoxically	  promotes	  cell	  cycle	  progression.	  The	  inhibitor	  has	  
conflicting	  functions:	  While	  it	  inhibits	  the	  activity	  of	  cyclin	  E/CDK2	  and	  cyclin	  A/CDK2,	  
p21Cip1	  stimulates	  cyclin	  D/CDK4/6	  complexes	  upon	  binding.	  Thus,	  an	  ERK-­‐dependent	  
expression	  of	  the	  protein	  promotes	  G1	  progression	  to	  S	  phase	  [296].	  
It	  has	  to	  be	  noted	  that	  signal	  duration	  as	  well	  as	  signal	  strength	  of	  the	  ERK-­‐MAPK	  cascade	  
are	  key	  in	  determining	  whether	  or	  not	  a	  cell	  commits	  to	  mitosis,	  as	  strong	  activation	  of	  
ERK	  cause	  cell	  cycle	  arrest	  [297].	  Mutational	  activation	  of	  other	  signalling	  molecules,	  e.g.	  
Rb,	  however,	  can	  override	  this	  halt	  and	  drive	  proliferation	  despite	  strong	  ERK	  signalling.	  	  
1.4.3 The role of ERK in cell survival 
A	  dual	  signal	  model,	  proposed	  by	  Harrington	  et	  al.,	  suggests	  a	  direct	  link	  between	  cell	  
proliferation	  and	  cell	  death.	  It	  argues	  that	  proliferative	  signals	  prime	  the	  cell	  death	  
machinery,	  which,	  unless	  overruled	  by	  survival	  signals,	  will	  promote	  apoptosis	  [298].	  
Consequently,	  proliferative	  autonomy	  conveyed	  by	  oncogenes	  can	  trigger	  apoptosis	  
unless	  cell	  survival	  signals	  countermand	  the	  death	  programme	  [299].	  It	  is	  therefore	  not	  
surprising	  that	  the	  ERK	  pathway	  cooperatively	  enhances	  cellular	  growth,	  proliferation	  and	  
survival	  (see	  Table	  1-­‐7).	  
The	  mitochondrial	  (or	  intrinsic)	  apoptotic	  pathway	  is	  regulated	  by	  the	  Bcl-­‐2	  family	  of	  
proteins,	  which	  are	  generally	  subdivided	  into	  pro-­‐apoptotic	  factors	  (e.g.	  Bax	  and	  Bak),	  
pro-­‐survival	  factors	  (e.g.	  Bcl-­‐2,	  Bcl-­‐xL	  and	  Mcl-­‐1)	  and	  apoptotic	  sensors	  (e.g.	  Bid,	  Bim	  and	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Puma).	  All	  Bcl-­‐2	  proteins	  comprise	  multiple	  Bcl-­‐homology	  (BH)	  domains	  (BH1-­‐4)	  with	  the	  
exception	  of	  the	  apoptotic	  sensors,	  which	  only	  contain	  the	  BH3	  domain.	  Therefore,	  they	  
are	  termed	  BH3-­‐only	  proteins	  (BOPs).	  In	  general,	  cell	  death	  is	  inhibited	  when	  the	  
pro-­‐apoptotic	  proteins	  like	  Bax	  and	  Bak	  are	  kept	  in	  a	  complex	  with	  pro-­‐survival	  Bcl-­‐2	  
proteins.	  Cellular	  stress	  stimulates	  the	  expression	  or	  activation	  of	  BOPs,	  which	  
subsequently	  form	  a	  complex	  with	  pro-­‐survival	  proteins	  to	  release	  Bax	  and	  Bak	  at	  the	  
mitochondria	  and	  induce	  cytochrome	  C	  release	  [300,	  301].	  
ERK1/2	  stimulates	  cell	  survival	  by	  modulating	  multiple	  components	  of	  the	  apoptotic	  
programme.	  Firstly,	  it	  represses	  Bim	  expression	  by	  phosphorylating	  the	  regulatory	  
transcription	  factor	  FOXO3A	  and	  targeting	  it	  for	  proteasomal	  degradation	  [273].	  
Moreover,	  the	  most	  abundant	  splice	  isoform	  of	  Bim,	  BimEL,	  is	  subject	  to	  ERK	  
phosphorylation,	  which	  promotes	  dissociation	  from	  pro-­‐survival	  factors	  [302]	  and	  
subsequent	  degradation	  [303,	  304].	  The	  apoptotic	  sensor	  Bad	  contains	  three	  inhibitory	  
phosphorylation	  sites.	  Ser112	  is	  phosphorylated	  by	  the	  ERK	  substrate	  RSK	  [305],	  Ser136	  
phosphorylation	  is	  catalysed	  by	  AKT	  [306]	  and	  Ser155	  is	  phosphorylated	  by	  PKA	  [307].	  
ERK-­‐dependent	  phosphorylation	  of	  Ser112	  might	  facilitate	  phospho	  transfer	  onto	  Ser155	  
by	  PKA,	  which	  ultimately	  blocks	  association	  with	  pro-­‐survival	  proteins	  [308].	  Moreover,	  
phosphorylation	  at	  Ser112	  targets	  Bad	  for	  ubiquitination	  followed	  by	  proteasomal	  
degradation	  [309].	  ERK,	  furthermore,	  mediates	  the	  phosphorylation	  of	  caspase	  9	  and	  
inhibits	  subsequent	  caspase	  3	  cleavage,	  thus	  preventing	  the	  onset	  of	  the	  caspase	  
cascade	  [275].	  
There	  is	  evidence	  that	  signalling	  of	  the	  ERK-­‐MAPK	  pathway	  stimulates	  the	  transcription	  of	  
pro-­‐survival	  factors,	  Bcl-­‐2,	  Bcl-­‐xL	  and	  Mcl-­‐1	  [310].	  Notably,	  the	  5ˊ	  regulatory	  elements	  of	  
all	  three	  genes	  contain	  a	  CREB-­‐binding	  site	  and	  the	  transcription	  factor	  CREB	  (cAMP	  
responsive	  element	  binding	  protein)	  is	  activated	  as	  a	  result	  of	  RSK	  or	  MSK	  (mitogen-­‐	  and	  
stress-­‐activated	  protein	  kinase)	  phosphorylation	  at	  Ser133	  [311,	  312].	  Additionally,	  direct	  
phosphorylation	  of	  Mcl-­‐1	  at	  Thr163	  by	  ERK1/2	  stabilises	  this	  pro-­‐survival	  factor	  which	  
otherwise	  has	  a	  very	  short	  half-­‐life	  [313].	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1.4.4 The role of ERK in cell migration 
Over	  the	  past	  decade,	  more	  and	  more	  evidence	  supporting	  a	  critical	  role	  for	  the	  
ERK-­‐MAPK	  pathway	  in	  the	  acquisition	  of	  an	  invasive	  phenotype	  has	  been	  revealed.	  Most	  
importantly,	  an	  invasive	  response	  requires	  ERK	  activity	  in	  the	  nucleus	  as	  well	  as	  in	  the	  
cytoplasm	  [314].	  However,	  the	  underlying	  mechanisms	  by	  which	  ERK	  signalling	  is	  
connected	  to	  migratory	  processes	  are	  still	  being	  unravelled.	  Thus,	  the	  following	  
paragraphs	  will	  try	  to	  give	  an	  overview	  of	  ERK-­‐mediated	  responses	  linked	  to	  cell	  
migration	  and	  invasion	  and	  discuss	  how	  bona	  fide	  targets	  of	  the	  kinases	  may	  be	  linked	  to	  
these	  processes	  (see	  Table	  1-­‐7	  also).	  
Cell	  migration	  is	  a	  complex	  and	  highly	  regulated	  process,	  which	  requires	  the	  continuous	  
assembly	  and	  disassembly	  of	  adhesion	  complexes.	  There	  is	  evidence	  that	  ERK	  regulates	  
both	  of	  these	  processes	  by	  modulating	  the	  signalling	  of	  the	  RHO	  family	  of	  small	  GTPases,	  
including	  Rho,	  Rac	  and	  Cdc42,	  although	  the	  precise	  mechanism	  by	  which	  it	  does	  so	  is	  still	  
unknown.	  Together,	  these	  three	  GTPases	  are	  central	  regulators	  of	  cell	  motility	  and	  
require	  tight	  spatial	  and	  temporal	  regulation.	  At	  the	  leading	  edge	  Rac	  and	  Cdc42	  promote	  
actin	  polymerisation	  and	  branching	  through	  WAVE	  and	  WASP,	  respectively.	  In	  contrast,	  
RhoA	  activity	  can	  oppose	  Rac	  and	  Cdc42	  function	  by	  promoting	  stress	  fibre	  formation	  and	  
initiating	  cellular	  contraction	  [315].	  	  
At	  the	  cell	  front	  ERK	  signalling	  has	  been	  shown	  to	  drive	  lamellipodium	  and	  pseudopod	  
formation	  by	  enhancing	  actin	  protrusions.	  One	  important	  player	  in	  this	  process	  is	  
cortactin,	  a	  cytoskeletal	  scaffold	  protein	  that	  can	  be	  directly	  phosphorylated	  by	  ERK	  at	  
Ser405	  and	  Ser418.	  This	  post-­‐translational	  modification	  enhances	  cortactin-­‐mediated	  
N-­‐WASP	  activation	  and	  promotes	  actin	  polymerisation	  at	  the	  leading	  edge	  [278].	  
Interestingly,	  ERK	  signalling	  is	  proposed	  to	  spatially	  restrict	  Rac,	  Cdc42	  and	  RhoA	  
activation	  by	  regulating	  GEF	  localisation	  and	  this	  may	  be	  achieved	  by	  controlling	  
microtubule	  dynamics.	  ERK	  has	  been	  shown	  to	  phosphorylate	  stathmin,	  also	  known	  as	  
oncoprotein	  18	  at	  Ser25	  which	  inhibits	  sequestration	  of	  tubulin	  and	  frees	  the	  molecular	  
building	  block	  for	  microtubule	  assembly	  at	  the	  cellular	  front	  [279,	  316].	  Moreover,	  kinesin	  
motors	  are	  implicated	  in	  transporting	  GEFs	  along	  polarised	  microtubules	  [315].	  Given	  that	  
small	  GTPases	  of	  the	  Rab	  family,	  which	  interact	  with	  motor	  proteins,	  were	  shown	  to	  be	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subject	  to	  ERK	  phosphorylation	  [315,	  317],	  it	  is	  conceivable	  that	  ERK	  might	  also	  regulate	  
microtubule-­‐directed	  transport	  of	  GEFs	  to	  the	  cell	  front.	  
Stress	  fibres	  are	  important	  to	  the	  contractility	  of	  migrating	  cells,	  and	  it	  is	  known	  that	  they	  
contribute	  to	  the	  retraction	  of	  the	  cell	  rear	  to	  enable	  effective	  forward	  movement.	  Stress	  
fibres	  are	  composed	  of	  actin	  filaments	  associated	  with	  myosin	  filaments.	  In	  non-­‐muscle	  
cells	  myosin	  activity	  is	  known	  to	  be	  controlled	  by	  phosphorylation	  and	  the	  interplay	  of	  
three	  regulatory	  proteins;	  namely	  the	  myosin	  kinases	  ROCK	  (Rho	  kinase)	  and	  MLCK	  
(myosin	  light	  chain	  kinase),	  and	  the	  myosin	  light	  chain	  phosphatase,	  which	  dictate	  the	  
phosphorylation	  state	  of	  myosin	  and	  thus	  control	  cellular	  contractility.	  Intriguingly,	  ERK	  
can	  enhance	  MLCK	  activity	  by	  phosphorylating	  the	  myosin	  kinase	  at	  Ser13	  and	  possibly	  
Ser19	  [156,	  277,	  314].	  Moreover,	  ERK	  indirectly	  controls	  ROCK	  signalling	  by	  altering	  the	  
activity	  of	  RhoA	  as	  mentioned	  above	  [315].	  	  
There	  are	  several	  lines	  of	  evidence	  that	  suggest	  an	  important	  role	  for	  the	  ERK-­‐MAPK	  
pathway	  in	  driving	  focal	  adhesion	  disassembly	  (Figure	  1-­‐10).	  Firstly,	  the	  scaffolding	  
protein	  paxillin	  has	  been	  identified	  as	  a	  bona	  fide	  ERK	  target,	  which	  regulates	  integrin	  
signalling	  at	  focal	  complexes.	  Phosphorylation	  of	  paxillin	  by	  ERK	  promotes	  the	  
recruitment	  and	  activation	  of	  FAK,	  which	  ultimately	  induces	  adhesion	  disassembly	  [156].	  
Paradoxically,	  FAK	  itself	  is	  subject	  to	  ERK	  phosphorylation,	  which	  renders	  the	  kinase	  
inactive,	  thereby	  impairing	  focal	  adhesion	  turnover	  [276].	  Thus,	  ERK	  localisation	  with	  
respect	  to	  paxillin	  and	  FAK	  can	  be	  a	  determining	  factor	  in	  the	  stability	  of	  focal	  adhesions.	  
Vinexin-­‐β	  poses	  another	  interesting	  ERK	  substrate,	  which	  is	  enriched	  at	  the	  leading	  edge	  
of	  migrating	  cells.	  Indeed,	  phosphorylation	  of	  vinexin-­‐β	  at	  Ser189	  is	  implicated	  in	  
promoting	  adhesion	  turnover	  and	  thus	  inhibiting	  cellular	  spreading	  [280,	  318].	  Lastly,	  the	  
protease	  calpain	  2	  is	  subject	  to	  ERK	  phosphorylation	  at	  Ser50	  which	  increases	  its	  
proteolytic	  activity	  and	  promotes	  its	  association	  with	  FAK	  at	  focal	  complexes,	  where	  
calpain	  cleaves	  cytoskeletal	  proteins	  [281,	  319].	  Depending	  on	  the	  downstream	  effector,	  
calpain-­‐induced	  cleavage	  can	  have	  opposing	  effects	  on	  adhesion	  stability.	  For	  example,	  
paxillin	  cleavage	  stabilises	  focal	  adhesions	  [320],	  whereas	  severing	  of	  talin	  was	  shown	  to	  
promote	  adhesion	  turnover	  [321].	  Moreover,	  proteolysis	  of	  the	  protein	  tyrosine	  
phosphatase	  PTP1B	  enhances	  Src	  activity,	  which	  in	  turn	  promotes	  adhesion	  
disassembly	  [322].	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Figure 1-10 Role of ERK in cell contractility and focal adhesion disassembly 
Multiple ERK substrates are involved in focal adhesion turnover. Firstly, myosin light chain kinase (MLCK) 
regulates cell contractility which promotes forward migration and is activated by phosphorylation. Secondly, 
ERK-mediated phosphorylation of calpain enhances its proteolytic activity and subsequent cleavage of talin 
and protein tyrosine phosphatase (PTP1B) stimulate focal adhesion turnover. Moreover, phosphorylation of 
the adaptor protein paxillin promotes the recruitment of focal adhesion kinase (FAK), a central regulator of 
adhesion disassembly.  
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Besides	  many	  cytoplasmic	  effectors,	  nuclear	  ERK	  targets	  also	  play	  a	  pivotal	  role	  in	  
stimulating	  cell	  migration.	  One	  of	  the	  best-­‐studied	  nuclear	  targets	  is	  Elk-­‐1	  [323,	  324].	  
Phosphorylation	  enhances	  DNA-­‐binding	  and	  increases	  the	  transcriptional	  activity	  of	  Elk-­‐1,	  
which	  drives	  the	  transcription	  of	  c-­‐fos	  [156,	  325].	  c-­‐Fos	  is	  a	  basic	  leucine	  zipper	  
transcription	  factor	  that,	  together	  with	  Jun	  or	  ATF	  proteins,	  forms	  the	  AP-­‐1	  transcription	  
factor.	  Sustained	  nuclear	  ERK	  signalling	  provokes	  phosphorylation	  of	  the	  newly	  
synthesised	  c-­‐Fos	  protein	  by	  ERK,	  which	  stabilises	  the	  transcription	  factor	  and	  allows	  the	  
formation	  of	  a	  functional	  AP-­‐1	  complex	  [326].	  Subsequently,	  AP-­‐1	  drives	  the	  transcription	  
of	  many	  proteolytic	  enzymes	  such	  as	  matrix	  metalloproteinase-­‐1	  (MMP-­‐1),	  MMP-­‐3,	  
MMP-­‐7,	  MMP-­‐9,	  urokinase-­‐type	  plasminogen	  activator	  (uPA)	  [314].	  These	  proteases	  in	  
turn	  regulate	  matrix	  degradation	  –	  an	  important	  parameter	  of	  tumour	  invasion	  and	  
metastasis	  [1,	  327].	  
1.4.5 The role of ERK in angiogenesis 
Highly	  proliferating	  tumour	  cells	  display	  an	  increased	  demand	  for	  oxygen	  and	  nutrients.	  
Yet,	  when	  tumour	  islets	  grow	  past	  a	  diameter	  of	  0.2	  mm,	  this	  demand	  cannot	  be	  met	  and	  
tumour	  cells	  become	  hypoxic.	  This,	  in	  turn,	  triggers	  the	  onset	  of	  apoptosis	  and	  provides	  a	  
natural	  constraint	  to	  grow	  past	  a	  critical	  volume.	  However,	  tumour	  cells	  eventually	  
overcome	  this	  limitation	  by	  activating	  angiogenesis.	  In	  normal	  tissues	  vascular	  sprouting	  
is	  suppressed	  by	  angiogenic	  inhibitors,	  such	  as	  thrombospondin,	  endostatin	  and	  
angiostatin.	  During	  tumourigenesis,	  however,	  an	  enhanced	  expression	  of	  pro-­‐angiogenic	  
factors,	  such	  as	  VEGF	  (vascular	  endothelial	  growth	  factor),	  PDGF	  and	  TGF-­‐β,	  with	  a	  
concomitant	  decrease	  of	  angiogenic	  inhibitors	  and	  stromal	  remodelling,	  triggers	  the	  
onset	  of	  vascular	  sprouting	  [328].	  
Oncogenic	  Ras	  signalling	  increases	  angiogenesis	  in	  a	  process,	  which	  mainly	  relies	  on	  AKT	  
activation	  [329].	  However,	  inhibition	  of	  MEK1/2	  markedly	  reduces	  the	  expression	  of	  VEGF	  
in	  response	  to	  hypoxia	  and	  suggests	  at	  least	  some	  role	  for	  the	  ERK-­‐MAPK	  pathway	  in	  
regulating	  vascular	  sprouting	  [330].	  Although	  it	  is	  still	  unclear	  how	  ERK	  signalling	  
contributes	  to	  VEGF	  expression,	  all	  evidence	  points	  towards	  AP-­‐1	  (activating	  protein-­‐1).	  
VEGF	  expression	  is	  dependent	  on	  AP-­‐1	  activity	  and	  the	  vegf	  promoter	  contains	  an	  AP-­‐1	  
consensus	  site	  [331].	  ERK’s	  role	  in	  regulating	  AP-­‐1	  is	  well-­‐established	  and	  thus	  ERK	  may	  
induce	  transcription	  of	  vegf	  by	  activating	  AP-­‐1.	  Moreover,	  ERK	  signalling	  has	  recently	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been	  shown	  to	  mediate	  the	  downregulation	  of	  thrombospondin-­‐1	  [332].	  The	  underlying	  
mechanism,	  however,	  remains	  to	  be	  elucidated.	  	  
The	  extracellular	  matrix	  (ECM)	  functions	  as	  a	  natural	  barrier	  during	  the	  process	  of	  
angiogenesis,	  because	  it	  efficiently	  sequesters	  angiogenic	  factors	  and	  physically	  obstructs	  
infiltration	  of	  newly	  forming	  vessels.	  With	  the	  help	  of	  proteolytic	  enzymes,	  which	  liberate	  
angiogenic	  factors	  and	  create	  space	  for	  newly	  forming	  vessels,	  this	  barrier	  can	  be	  
overcome	  [333,	  334].	  Interestingly,	  the	  promoters	  of	  many	  proteinases	  contain	  an	  AP-­‐1	  
consensus	  site,	  thus	  linking	  ERK	  signalling	  to	  the	  proteolytic	  induction	  of	  angiogenesis.	  
Moreover,	  the	  ERK-­‐MAPK	  pathway	  stimulates	  the	  expression	  of	  tissue	  factor,	  an	  
important	  regulator	  of	  angiogenesis,	  which	  triggers	  stromal	  remodelling	  and	  promotes	  
VEGF	  expression	  [335,	  336].	  
1.4.6 ERK-MAPK pathway and multi-drug resistance 
Tumour	  cells	  are	  marked	  by	  highly	  instable	  genomes	  which	  give	  rise	  to	  continuous	  
generation	  of	  novel	  genetic	  configurations.	  Thus,	  a	  cancer	  cell	  has	  scope	  to	  adapt	  to	  
changes	  in	  the	  microenvironment	  and	  modify	  signalling	  circuits	  to	  promote	  survival	  and	  
proliferation.	  This	  hallmark,	  however,	  complicates	  therapeutic	  intervention	  and	  
ultimately	  decreases	  clinical	  success	  rates,	  when	  tumour	  cells	  acquire	  the	  ability	  to	  
withstand	  cytotoxic	  drugs	  or	  become	  resistance	  in	  response	  to	  ionisation.	  The	  ERK-­‐MAPK	  
pathway	  has	  been	  linked	  to	  acquired	  resistance	  during	  e.g.	  radiation	  therapy	  [337]	  or	  
doxorubicin	  treatment	  [338].	  As	  described	  in	  section	  1.4.3,	  ERK	  signalling	  promotes	  cell	  
survival	  by	  stimulating	  the	  expression	  pro-­‐survival	  factors	  and	  inhibiting	  BH3-­‐only	  
proteins	  (BOPs).	  This	  mechanism	  may	  also	  provide	  a	  means	  by	  which	  cancer	  cells	  can	  be	  
protected	  from	  drug-­‐induced	  apoptosis.	  Moreover,	  increased	  ERK	  signalling	  has	  been	  
shown	  to	  either	  stimulate	  or	  enhance	  the	  expression	  of	  multi-­‐drug	  resistance	  (MDR)	  
genes,	  which	  encode	  transmembrane	  drug	  efflux	  pumps	  [339,	  340].	  The	  MDR	  transporter	  
belongs	  to	  the	  superfamily	  of	  ATP-­‐binding	  cassette	  (ABC)	  transporters	  which	  enable	  
cancer	  cells	  to	  actively	  expel	  various	  chemical	  compounds	  from	  the	  cytoplasm,	  thereby	  
decreasing	  the	  intracellular	  concentration	  of	  the	  drugs	  to	  sub-­‐toxic	  levels.	  Drug	  resistance	  
represents	  a	  general	  challenge	  in	  cancer	  treatment	  and	  has	  led	  to	  the	  introduction	  of	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combination	  therapies,	  which	  are	  thought	  to	  minimise	  tumour	  cell	  adaptions	  and	  provide	  
a	  promising	  strategy	  to	  curing	  cancer.	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1.4.7 Inhibiting ERK signalling as a therapeutic strategy 
Owing	  to	  the	  fact	  that	  the	  ERK-­‐MAPK	  pathway	  is	  commonly	  deregulated	  in	  cancer	  and	  
plays	  an	  important	  role	  in	  the	  acquisition	  of	  a	  malignant	  phenotype,	  the	  cascade	  and	  its	  
upstream	  activators	  are	  attractive	  targets	  for	  the	  development	  of	  anticancer	  drugs.	  
Overexpression	  of	  EGFR	  is	  commonly	  observed	  in	  cancer	  [341]	  and	  this	  triggers	  activation	  
of	  the	  ERK	  cascade.	  Two	  strategies	  have	  been	  employed	  to	  inhibit	  EGFR	  signalling,	  and	  
they	  include	  the	  development	  of	  monoclonal	  antibodies	  (mAbs)	  directed	  against	  the	  
extracellular	  domain	  of	  EGFR,	  and	  small-­‐molecule	  tyrosine	  kinase	  inhibitors	  which	  block	  
the	  intracellular	  kinase	  domain.	  Cetuximab	  was	  the	  first	  FDA-­‐approved	  chimeric	  antibody	  
directed	  against	  EGFR	  [342].	  Although	  the	  drug	  has	  proven	  successful	  in	  the	  clinic,	  the	  
patient	  response	  did	  not	  correlate	  with	  the	  degree	  of	  EGFR	  overexpression.	  Moreover,	  
the	  risk	  for	  anaphylactic	  reactions	  led	  to	  the	  development	  of	  humanised	  (e.g.	  
matuzumab)	  and	  fully	  human	  (e.g.	  panitumumab)	  mAbs	  [343,	  344].	  Panitumumab	  has	  
shown	  a	  significant	  improvement	  on	  progression-­‐free	  survival	  and	  demonstrated	  no	  
antibody-­‐dependent	  cell-­‐mediated	  cytotoxicity,	  thus	  proving	  promising	  candidate	  for	  
future	  therapies	  [345].	  
Ras	  is	  mutationally	  activated	  in	  approximately	  one	  third	  of	  all	  human	  cancers	  [213]	  and	  
therefore	  huge	  efforts	  have	  been	  made	  to	  target	  the	  small	  GTPase	  in	  therapeutic	  
strategies.	  As	  mutational	  activation	  of	  the	  Ras	  molecules	  inhibits	  GTP	  hydrolysis,	  original	  
work	  attempted	  to	  reactivate	  the	  intrinsic	  GTPase	  or	  antagonise	  GTP	  binding	  to	  Ras	  
molecules.	  However,	  these	  efforts	  were	  not	  successful.	  As	  Ras	  requires	  correct	  subcellular	  
localisation	  for	  downstream	  signalling,	  researchers	  then	  attempted	  to	  block	  membrane	  
localisation	  of	  Ras	  by	  inhibiting	  farnesylation	  of	  its	  C-­‐terminus	  [346].	  Farnesyltransferase	  
inhibitors,	  however,	  did	  not	  prove	  very	  effective	  in	  blocking	  membrane	  targeting,	  as	  
N-­‐	  and	  K-­‐Ras	  can	  undergo	  alternative	  prenylation	  in	  the	  absence	  of	  farnesyltransferase.	  
Current	  work	  focuses	  on	  the	  development	  of	  inhibitors	  against	  Rce1	  (Ras	  converting	  
enzyme	  1)	  and	  ICMT	  (isoprenylcysteine-­‐O-­‐carboxyl	  methyltransferase),	  which	  prime	  the	  
C-­‐terminus	  of	  Ras	  for	  farnesylation	  or	  prenylation	  [341].	  	  
Considerable	  efforts	  have	  also	  been	  made	  to	  develop	  chemical	  inhibitors	  targeting	  Raf	  
kinases.	  One	  of	  the	  most	  successful	  Raf	  inhibitors	  is	  sorafenib,	  which	  binds	  to	  the	  
ATP-­‐binding	  pocket	  and	  prevents	  kinase	  activation	  [259].	  Although	  phase	  III	  clinical	  trials	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showed	  improved	  survival,	  it	  is	  difficult	  to	  determine	  whether	  sorafenib’s	  success	  can	  be	  
attributed	  to	  Raf	  inhibition,	  as	  it	  also	  potently	  inhibits	  VEGFR,	  PDGRR,	  FGFR	  and	  c-­‐Kit	  
signalling	  [347].	  Other	  inhibitors,	  which	  selectively	  target	  mutant	  B-­‐Raf	  have	  been	  
developed.	  One	  such	  example	  is	  PLX4032	  also	  known	  as	  verumafenib,	  which	  proved	  very	  
successful	  in	  phase	  III	  clinical	  trials	  and	  is	  currently	  awaiting	  FDA-­‐approval	  [348].	  Yet,	  
sorafenib’s	  success	  has	  sparked	  the	  debate	  on	  whether	  multi-­‐kinase	  inhibitors	  due	  to	  
their	  resemblance	  to	  combination	  therapy	  are	  more	  potent	  in	  cancer	  therapy.	  
In	  contrast	  to	  sorafenib,	  MEK	  inhibitors,	  which	  prevent	  MEK	  activation	  in	  a	  non-­‐ATP	  
competitive	  manner,	  are	  highly	  specific.	  The	  first	  two	  inhibitors	  developed	  against	  MEK	  
were	  PD98059	  and	  U0126	  and	  proved	  not	  suitable	  as	  clinical	  candidates	  [349].	  However,	  
due	  to	  their	  potent	  inhibition,	  they	  have	  been	  invaluable	  tools	  in	  academic	  research.	  The	  
first	  MEK	  inhibitor	  to	  enter	  clinical	  trials	  was	  PD184352.	  Despite	  the	  fact	  that	  poor	  
pharmacokinetic	  properties	  rendered	  the	  compound	  unsuitable	  in	  phase	  II	  clinical	  
trials	  [350],	  derivatives	  of	  PD184352	  with	  better	  pharmacokinetic	  features	  have	  been	  
developed	  and	  are	  currently	  undergoing	  clinical	  trials	  in	  phase	  I.	  
So	  far,	  no	  ERK	  inhibitors	  have	  entered	  clinical	  trials	  although,	  in	  principle,	  ERK	  represents	  
a	  putative	  drug	  target	  in	  cancer	  therapy.	  Potential	  inhibitors	  can	  be	  designed	  to	  block	  ERK	  
activity	  by	  competing	  with	  ATP	  binding	  or	  inhibiting	  specific	  substrate	  binding.	  As	  the	  two	  
primary	  docking	  domains	  on	  ERK	  are	  sterically	  separated,	  small	  molecular	  weight	  
compounds	  could	  be	  designed	  to	  interfere	  with	  the	  interactions	  of	  DEF-­‐motif	  or	  D-­‐motif	  
containing	  substrates.	  In	  this	  way,	  a	  subset	  of	  ERK	  targets	  may	  specifically	  be	  inhibited	  
while	  other	  ERK	  functions	  are	  unaltered.	  Future	  studies	  expanding	  our	  knowledge	  on	  how	  
ERK	  substrates	  are	  involved	  in	  acquiring	  malignant	  phenotypes	  and	  a	  better	  
understanding	  of	  ERK	  docking	  platforms,	  will	  facilitate	  the	  design	  of	  such	  ERK-­‐specific	  
inhibitors.	  
 	  
Chapter 1 – Introduction  75 
1.5 Project Aims 
Upregulation	  of	  the	  ERK/MAPK	  pathway	  occurs	  in	  approximately	  one	  third	  of	  all	  human	  
cancers	  and	  was	  shown	  to	  promote	  tumour	  cell	  invasion	  and	  progression	  [314].	  To	  date,	  
however,	  it	  is	  unclear	  whether	  or	  not	  the	  two	  predominant	  ERK	  isoforms	  have	  distinct	  
functions	  in	  these	  processes.	  Therefore,	  this	  project	  set	  out	  to	  address	  the	  question	  in	  
dispute	  by	  studying	  the	  role	  of	  ERK1	  and	  ERK2	  in	  tumour	  cell	  migration	  in	  2D	  and	  3D	  
microenvironments.	  Moreover,	  we	  aimed	  to	  investigate	  whether	  true	  isoform-­‐specific	  
functions	  with	  regard	  to	  cell	  migration	  do	  exist	  or	  whether	  gene	  dosage	  effects	  are	  
accountable.	  	  	  
Although	  some	  cytoplasmic	  and	  nuclear	  ERK	  targets	  involved	  in	  migratory	  processes	  have	  
recently	  been	  identified,	  the	  underlying	  mechanisms	  by	  which	  invasive	  cell	  migration	  is	  
linked	  to	  ERK	  signalling	  are	  at	  present	  poorly	  understood.	  To	  shine	  light	  on	  this	  
understudied	  area,	  we	  set	  out	  to	  identify	  novel	  ERK	  effectors	  by	  carrying	  out	  a	  
comparative	  gene	  expression	  analysis	  in	  a	  3D-­‐like	  microenvironment.	  Putative	  ERK	  
mediators	  were	  subsequently	  studied	  in	  cell	  migration	  assays.	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2 Materials and methods 
2.1 Materials 
2.1.1 Reagents 
Reagent	   Details	   Supplier	  
2%	  gelatine	   diluted	  in	  PBS	   Sigma	  
2-­‐Propanol	   	   Merck	  
Agarose	  (High	  Gel	  Strength)	   	   Melford	  
Laboratories	  Ltd	  
Ascorbic	  acid	   	   Sigma	  
Blue/Orange	  Loading	  Dye	   	  6X	   Fermentas	  
Calcein-­‐AM	   	   Invitrogen	  
Calf	  intestine	  alkaline	  
phosphatase	  
	   New	  England	  
Biolabs	  
Cryo-­‐SFM	   	   PromoCell	  
DB3.1	  Competent	  Cells	   	   Invitrogen	  
DNase1	   	   Roche	  
dNTP	   100	  mM	   Invitrogen	  
Dulbecco's	  Modified	  Eagle	  
Medium	  (DMEM)	  
	   Gibco	  
ECL	  Western	  blotting	  
substrate	  
	   Pierce	  
EGF	   	   Peprotech	  
Ethidium	  bromide	   10	  mg/ml	   Sigma	  
Foetal	  Calf	  Serum	   	   Autogen	  
Bioclear	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Reagent	   Details	   Supplier	  
Fungizone	   250	  µg	  of	  amphotericin	  B	  and	  205	  µg	  of	  
sodium	  deoxycholate	  per	  ml	  of	  distilled	  
water	  
Invitrogen	  
Gateway®	  BP	  CLONASETM	  II	  
Enzyme	  Mix	  
	   Invitrogen	  
Gateway®	  LR	  CLONASETM	  II	  
Enzyme	  Mix	  
	   Invitrogen	  
GeneRuler™	   1kb	  DNA	  Ladder	   Fermentas	  
Glutaraldehyde	   25%	   Sigma	  
HiPerFect	   	   Qiagen	  
Hybond-­‐P	  PVDF	  membrane	   	   GE	  Healthcare	  
Illumina	  HumanHT-­‐12	  v4	  
Expression	  BeadChips	  
	   Illumina	  
ImProm-­‐IITM	  Reverse	  
Transcription	  System	  
	   Promega	  
L-­‐glutamine	   200	  mM	   Invitrogen	  
MatrigelTM	  Basement	  
Membrane	  Matrix	  
	   Becton	  
Dickinson	  
NuPAGE	  MOPS	  SDS	  Running	  
Buffer	  
20x	   Invitrogen	  
NuPAGE	  pre-­‐cast	  gels	   	   Invitrogen	  
NuPAGE	  Sample	  Buffer	   4x	   Invitrogen	  
NuPAGE	  Transfer	  Buffer	   20x	   Invitrogen	  
Orange	  G	   	   Sigma	  
Parafilm	  Wrap	   	   Fisher	  
PBS	  containing	  Calcium	  and	  
Magnesium	  
	   Sigma	  
PCRX	  Enhancer	  Solution	   10X	   Invitrogen	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Reagent	   Details	   Supplier	  
pDONRTM	  201	   	   Invitrogen	  
Penicillin/Streptomycin	   5,000	  units	  of	  penicillin	  (base)	  and	  5,000	  
µg	  of	  streptomycin	  (base)/ml	  
Invitrogen	  
PLATINUM®	  Taq	  DNA	  
Polymerase	  High	  Fidelity	  
	   Invitrogen	  
Precision	  Plus	  Protein	  All	  
Blue	  standard	  
	   Biorad	  
Rapid	  Ligation	  Buffer	   	  2X	   Promega	  
RMPI-­‐1640	  medium	   	   Gibco	  
SOC	  media	   	   Invitrogen	  
soluble	  fibronectin	   1	  mg/ml	   Sigma	  
Super	  RX	  Blue	  medical	  X-­‐ray	  
film	  
	   Fuji	  
SURE2	  Super	  Competent	  
Cells	  
	   Stratagene	  
T4	  DNA	  Ligase	   	   Promega	  
TOP10	  OneShot	  Cells	   	   Invitrogen	  
Transwell	  Permeable	  
Support	  
pore	  size	  of	  8	  µm	  diameter	   Fisher	  
Trypsin	   	   Invitrogen	  
U0126	  MEK	  inhibitor	   used	  at	  10	  µM	   Sigma	  
Vectashield	  mounting	  
medium	  with	  DAPI	  
	   Vector	  
laboratories	  
Table 2-1 List of all reagents 
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2.1.2 Solutions 
Solution	   Recipe	  
DNA	  loading	  dye	   30%	  (w/v)	  sucrose,	  0.35%	  Orange	  G	  
HEPES	  lysis	  buffer	   20	  mM	  HEPES	  pH	  7.5,	  150	  mM	  NaCl,	  2	  mM	  EDTA	  
pH	  7.4,	  1	  %	  NP-­‐40	  (v/v),	  1	  mM	  Na3VO4,	  10	  mM	  NaF,	  
1	  mM	  PMSF,	  5	  µg/ml	  leupeptin	  
LB-­‐agar:	   85	  mM	  NaCl,	  1%	  (w/v)	  bacto-­‐trypton,	  0.5%	  (w/v)	  
yeast	  extract,	  1.5%	  (w/v)	  agarose	  
addition	  of	  either:	  
100	  µg/ml	  Ampicillin,	  50	  µg/ml	  Kanamycin,	  or	  
30	  µg/ml	  Chloramphenicol	  
LB-­‐broth	   85	  mM	  NaCl,	  1%	  (w/v)	  bacto-­‐trypton,	  0.5%	  (w/v)	  
yeast	  extract	  
addition	  of	  either:	  
100	  µg/ml	  Ampicillin,	  50	  µg/ml	  Kanamycin,	  or	  30	  
µg/ml	  Chloramphenicol	  
Lysis	  buffer:	   20	  mM	  HEPES	  pH	  7.5,	  150	  mM	  NaCl,	  2	  mM	  EDTA	  pH	  
7.4,	  1	  %NP-­‐40,	  1	  mM	  Na3VO4,	  2	  mM	  NaF,	  1	  mM	  
PMSF,	  5	  µg/m	  l	  mM	  leupeptin	  
NDLB	  lysis	  buffer	   50	  mM	  Tris	  HCl	  (pH	  7.0),	  150	  mM	  NaCl,	  10	  mM	  NaF,	  
1	  mM	  Na3VO3,	  5	  mM	  EDTA,	  5	  mM	  EGTA,	  1%	  Triton	  X	  
100	  (v/v),	  0.5%	  NP	  40	  (v/v),	  5	  µg/ml	  leupeptin,	  
1	  mM	  PMSF	  
PBS	  (phosphate	  buffered	  saline)	   170	  mM	  NaCl,	  3.3	  mM	  KCl,	  1.8	  mM	  Na2HPO4,	  
10.6	  mM	  H2PO4	  
PBST	   PBS,	  0.1%	  Triton	  X-­‐100	  
PE	   PBS,	  1	  mM	  EDTA	  
Penicillin/Streptomycin	   5,000	  units	  of	  penicillin	  (base)	  and	  5,000	  µg	  of	  
streptomycin	  (base)/ml	  
RIPA	  lysis	  buffer	   50	  mM	  Tris	  HCl	  (pH	  7.0),	  150	  mM	  NaCl,	  0.5%	  sodium	  
deoxycholate,	  1%	  NP	  40	  (v/v),	  1	  mM	  PMSF,	  1	  mM	  
Na3VO4,	  10	  mM	  NaF,	  5	  µg/ml	  leupeptin	  
TBE	  10x:	   890	  mM	  Tris-­‐base,	  890	  mM	  boric	  acid,	  25	  mM	  EDTA,	  
pH	  =	  8.3	  
TBS	  (Tris-­‐buffered	  saline)	   10	  mM	  Tris-­‐HCl	  (pH	  7.4),	  150	  mM	  NaCl	  
TE	   10.0	  mM	  Tris.HCl,	  1.0	  mM	  EDTA,	  pH	  8.0	  
Table 2-2 List of all solutions 
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2.1.3 Antibodies and dyes 
Antigen	   Species	   Dilutions	   WB	  Incubation	   Supplier	  
Total	  ERK1/2	   Rabbit	   WB:	  1/5K,	  5%	  BSA	  (w/v)	   1	  hour	  at	  RT	   Sigma	  
pERK1/2	   Mouse	   WB:	  1/5K,	  5%	  BSA	  (w/v)	   1	  hour	  at	  RT	   Sigma	  
β-­‐tubulin	   Mouse	   WB:	  1/5K,	  5%	  BSA	  (w/v)	   1	  hour	  at	  RT	   Insight	  
Fra-­‐1	   Rabbit	   WB:	  1/1K,	  5%	  BSA	  (w/v)	   o/n	  at	  4˚C	   Abcam	  
PARP	   mouse	   WB:	  1/1K,	  5%	  BSA	  (w/v)	   o/n	  at	  4˚C	   BD	  
EEA-­‐1	   Mouse	   IF:	  1/100	   	   Transduction	  
Labs	  
β1	  integrin	   Mouse	   WB:	  1/2K,	  5%	  BSA	  (w/v)	  
IF:	  1/200	  
o/n	  at	  4˚C	   Chemicon	  
EGFR	   Mouse	   WB:	  1/2K,	  5%	  BSA	  (w/v)	   o/n	  at	  4˚C	   BD	  
GFP	   Mouse	   IP:	  1.5	  µl	  per	  10	  cm	  dish	   	   Abcam	  
GFP	   Rabbit	   WB:	  1/10K,	  5%	  milk	  in	  
TBST(w/v)	  
1	  hour	  at	  RT	   Abcam	  
FITC	   Mouse	   IF:	  1/200	   	   Southern	  
Biotech	  
Alexa	  488	   Rabbit	   IF:	  1/200	   	   Invitrogen	  
Table 2-3 Antibodies and dyes 
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2.1.4 Enzymes and kits 
Kit	   Supplier	  
QIAquick®	  Gel	  Extraction	  Kit	   Qiagen	  
Cell	  Line	  Nucleofactor®	  Kit	  T	   Amaxa	  
Cell	  Line	  Nucleofactor®	  Kit	  V	   Amaxa	  
F-­‐410	  DyNAmoTM	  SYBR®	  Green	  qPCR	  kit	   Thermo	  Scientific	  
Illumina®	  TotalPrepTM	  RNA	  Labelling	  Kit	  	   Ambion	  
Nuclear	  Extract	  Kit	   Active	  Motif	  
Pierce®	  BCA	  Protein	  Assay	  Kit	   Thermo	  Scientific	  
QIAGEN	  Plasmid	  Maxi	  Kit	   QIAGEN	  
QIAprep®	  Spin	  Miniprep	  Kit	   Qiagen	  
QIAquick®	  PCR	  Purification	  Kit	  	   Qiagen	  
Quick	  Change®	  Site-­‐Directed	  Mutagenesis	  Kit	   Stratagene	  
Table 2-4 List of kits 
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2.1.5 Primers for qPCR 
Gene	  name	   Assay	  name	   Catalogue	  Number	  
ERK1	   Hs_MAPK3_1S_SG	   QT00000532	  
ERK2	   Hs_MAPK1_1_SG	   QT00065933	  
Rab17	   Hs_RAB17_1_SG	   QT00009590	  
Liprin-­‐β2	   Hs_PPFIBP2_1_SG	   QT00005012	  
Liprin-­‐β1	   Hs_PPFIBP1_2_SG	   QT01666378	  
Liprin-­‐α2	   Hs_PPFIA2_1_SG	   QT00072296	  
Liprin-­‐α4	   Hs_PPFIA4_1_SG	   QT00027251	  
Rab20	   Hs_RAB20_1_SG	   QT00229495	  
GAPDH	   Hs_GAPDH_2_SG	   QT01192646	  
CSF2	   Hs_CSF2_1_SG	   QT00000896	  
Table 2-5 List of Qiagen Quantitect primers 
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2.1.6 Tissue culture plastic ware 
Plastic	  ware	   Supplier	  
Falcon	  tissue	  culture	  dishes	  (6	  cm,	  10	  cm,	  15	  cm)	   BD	  Biosciences	  
Falcon	  multi-­‐well	  plates	   BD	  Biosciences	  
IWAKI-­‐3cm	  glass	  bottom	  dishes	   Appleton	  Woods	  
Nunc	  tissue	  culture	  flasks	  and	  dishes	   TCS	  Biologicals	  
Nunc	  cryotubes	   TCS	  Biologicals	  
Table 2-6 List of plastic ware and supplier 
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2.2 Methods 
2.2.1 Molecular biology 
2.2.1.1 Polymerase chain reaction (PCR) 
PCR	  was	  performed	  using	  the	  following	  set-­‐up:	  
Reagent	   Sample	  (µl)	  
10x	  High	  Fidelity	  PCR	  Buffer	   2	  
10x	  PCRX	  Enhancer	  Solution	   2	  
50	  mM	  MgSO4	  (0-­‐4	  mM)	   0-­‐1.6	  
Template	  (10	  ng/µl):	   1	  
Primer	  fwd:	  (5	  µM)	   1	  
Primer	  rev:	  	  (5	  µM)	   1	  
2.5	  mM	  dNTPs	  	   2	  
autoclaved	  ddH2O	   9.2-­‐10.8	  
Platinum®	  High-­‐Fidelity	  Polymerase	   0.2	  
total	  volume	   20	  
Temperature	  cycling	  was	  performed	  in	  a	  DNA	  Engine	  Thermal	  Cycler	  (Biorad)	  using	  the	  
following	  conditions:	  
Initial	  denaturation	   95˚C	   2	  min	  










Final	  extension	   72˚C	   7	  min	  
Final	  hold	   4˚C	   ∞	  













The	  integrity	  of	  generated	  DNA	  fragments	  was	  tested	  by	  agarose	  gel	  electrophoresis.	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2.2.1.2 Agarose gel electrophoresis 
Depending	  on	  the	  expected	  length	  of	  the	  DNA	  fragment,	  gels	  containing	  between	  0.8%	  to	  
2%	  agarose	  were	  prepared.	  For	  this,	  the	  agarose	  was	  suspended	  in	  1x	  TBE	  and	  boiled	  in	  
the	  microwave	  oven	  until	  the	  agarose	  was	  completely	  dissolved.	  After	  the	  solution	  had	  
cooled	  down	  to	  approximately	  55°C,	  ethidium	  bromide	  from	  the	  stock	  solution	  
(0.2	  mg/ml)	  was	  added	  at	  a	  dilution	  of	  1:1000.	  As	  soon	  as	  the	  gel	  completely	  solidified,	  it	  
was	  put	  into	  a	  gel	  chamber	  containing	  1x	  TBE	  as	  running	  buffer.	  DNA	  loading	  buffer	  was	  
added	  to	  the	  respective	  nucleic	  acid	  samples	  and	  the	  gel	  was	  loaded.	  Gels	  were	  run	  at	  
75	  V	  for	  approximately	  one	  hour.	  DNA	  was	  visualised	  using	  UV	  transillumination.	  If	  DNA	  
fragments	  were	  required	  in	  subsequent	  cloning	  steps,	  gel	  slices	  containing	  the	  DNA	  were	  
excised	  from	  the	  gel	  and	  purified	  using	  the	  QIAquick	  Gel	  Extraction	  Kit	  according	  to	  the	  
manufacturer’s	  protocol.	  
2.2.1.3 Restriction digestion 
Digestion	  of	  DNA	  with	  restriction	  endonucleases	  was	  performed	  for	  2	  hours	  (plasmid	  
DNA,	  DNA	  fragments)	  with	  a	  two-­‐fold	  excess	  (2	  U/µg	  DNA)	  of	  restriction	  enzyme.	  
Temperature	  and	  buffer	  for	  the	  respective	  digestion	  were	  used	  according	  to	  the	  
manufacturer’s	  protocol.	  In	  order	  to	  separate	  digested	  DNA	  fragments	  and	  confirm	  the	  
enzymatic	  reaction,	  the	  digested	  DNA	  was	  subjected	  to	  agarose	  gel	  electrophoresis.	  DNA	  
of	  interest	  was	  then	  purified	  from	  the	  gel	  slice	  using	  the	  QIAquick	  Gel	  extraction	  Kit	  
according	  to	  the	  manufacturer’s	  protocol.	  	  
2.2.1.4 Ligation of DNA 
To	  inhibit	  self-­‐ligation,	  the	  digested	  vector	  was	  dephosphorylated	  before	  ligation.	  To	  do	  
this,	  the	  DNA	  was	  diluted	  in	  NEBuffer	  3	  to	  a	  final	  a	  concentration	  of	  0.05	  µg/µl	  and	  1	  unit	  
of	  CIP	  was	  added	  to	  the	  solution.	  After	  15	  minutes	  at	  37°C	  an	  additional	  unit	  of	  CIP	  was	  
added	  and	  incubation	  continued	  for	  another	  15	  minutes.	  Afterwards	  the	  DNA	  was	  
purified	  with	  the	  QIAquick	  PCR	  purification	  kit	  according	  to	  the	  manufacturer’s	  
instruction.	  For	  the	  actual	  ligation	  process,	  50	  ng	  of	  dephosphorylated	  vector	  and	  150	  ng	  
of	  DNA	  insert	  were	  added	  to	  5	  µl	  of	  2x	  Rapid	  ligation	  buffer	  and	  1	  µl	  ligase	  (4	  U/µl)	  to	  give	  
a	  total	  volume	  of	  10	  µl.	  Ligation	  was	  performed	  for	  2	  hours	  at	  room	  temperature.	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2.2.1.5 Recombination 
For	  the	  BP	  clonase	  reaction	  TE	  buffer	  (pH	  8.0),	  attB-­‐PCR	  product	  (15-­‐150ng)	  and	  Donor	  
vector	  (150ng/µl)	  were	  mixed	  together	  at	  room	  temperature	  in	  a	  microcentrifuge	  tube	  
(Figure	  2-­‐1	  A).	  For	  the	  LR	  clonase	  reaction	  TE	  buffer,	  entry	  vector	  and	  destination	  vector	  
were	  mixed	  together	  in	  a	  microcentrifuge	  tube	  (Figure	  2-­‐1	  B).	  The	  respective	  ClonaseTM	  II	  
enzyme	  mix	  (stored	  at	  -­‐80°C)	  was	  briefly	  thawed	  on	  ice,	  vortexed	  twice	  for	  2	  sec	  and	  spun	  
down,	  before	  it	  was	  added	  to	  the	  reaction	  mix,	  which	  was	  set	  up	  as	  follows:	  
BP	  clonase	  reaction	   Sample	  (µl)	  
attB-­‐PCR	  product	   150	  ng	  
Donor	  vector	  (pDONRTM	  201)	   150	  ng	  
TE	  Buffer	   To	  8	  
BP	  Clonase	  Enzyme	  Mix	   2	  
total	  volume	   10	  
	  
LR	  clonase	  reaction	   Sample	  (µl)	  
attB-­‐PCR	  product	   150	  ng	  
Donor	  vector	  (pDONRTM	  201)	   150	  ng	  
TE	  Buffer	   To	  8	  
LR	  Clonase	  Enzyme	  Mix	   2	  
total	  volume	   10	  
	  
The	  reaction	  was	  incubated	  at	  25°C	  for	  1	  hour.	  Then,	  1	  µl	  Proteinase	  K	  solution	  was	  added	  
and	  the	  solution	  briefly	  vortexed.	  A	  10	  minute	  incubation	  at	  37°C	  stopped	  the	  reaction.	  
1.5	  µl	  of	  this	  solution	  was	  subsequently	  used	  for	  bacterial	  transformation.	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Figure 2-1 Schematic outline of the Gateway®-system 
A. Preparation of the Entry clone containing the gene of interest. B. Construction of an expression vector via 
recombination of any destination vector with any entry vector. Images adapted from 
http://www.invitrogen.com/etc/medialib/en/filelibrary/html.Par.74823.File.tmp/gateway-entry-options-seminar.html. 
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2.2.1.6 Site-directed mutagenesis 
Site-­‐directed	  mutagenesis	  was	  performed	  using	  the	  following	  set-­‐up:	  
Reagent	   Sample	  (µl)	  
10x	  Reaction	  Buffer	   5	  
dsDNA	  template	   0.5-­‐1	  µg	  
Primer	  fwd:	  (5	  µM)	   125	  ng-­‐0.5	  µg	  
Primer	  rev:	  	  (5	  µM)	   125	  ng-­‐0.5	  µg	  
dNTPs	  (30	  µM)	   1	  
autoclaved	  ddH2O	   up	  to	  50	  
Pfu	  turbo	  DNA	  polymerase	   1	  
total	  volume	   50	  
Temperature	  cycling	  was	  performed	  in	  a	  DNA	  Engine	  Thermal	  Cycler	  (Biorad)	  using	  the	  
following	  conditions:	  
Initial	  denaturation	   95˚C	   2	  min	  










Final	  extension	   72˚C	   7	  min	  
Final	  hold	   4˚C	   ∞	  
Primers	  used	  during	  this	  project	  were	  synthesised	  by	  Invitrogen	  and	  are	  listed	  below:	  
ERK2	  forward	   5ˊ-­‐GCCTACGGCATGGTGTGTAGTGCTTATGATAATGTCAACAAAGTTCG-­‐3ˊ	  
ERK2	  reverse	   5ˊ-­‐CGAACTTTGTTGACATTATCATAAGCACTACACACCATGCCGTAGGC-­‐3ˊ	  
2.2.1.7 Bacterial strains 
E.	  coli	  DH5α	  or	  TOP10	  OneShot	  cells	  were	  utilised	  for	  most	  cloning	  procedures.	  Where	  
plasmids	  contained	  the	  ccdB	  gene,	  DB3.1	  cells	  were	  used	  instead.	  
2.2.1.8 Heat-shock transformation of competent bacteria 
A	  vial	  of	  frozen	  competent	  bacteria	  was	  thawed	  on	  ice.	  Subsequently	  1.5	  µl	  of	  the	  
respective	  ligation	  reaction	  mix	  was	  added	  to	  50	  µl	  of	  competent	  cells	  and	  incubated	  on	  
ice	  for	  30	  minutes.	  The	  bacteria	  were	  then	  heat-­‐shocked	  for	  45	  seconds	  in	  a	  water	  bath	  at	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42°C	  and	  put	  on	  ice	  for	  2	  minutes.	  After	  adding	  250	  µl	  of	  SOC	  medium	  (at	  room	  
temperature),	  the	  vials	  were	  shaken	  horizontally	  at	  37°C	  for	  1	  hour	  at	  225	  rpm	  in	  a	  rotary-­‐
shaking	  incubator.	  150	  µl	  of	  each	  transformation	  was	  then	  spread	  on	  LB	  agar	  plates	  
containing	  the	  antibiotic	  of	  choice	  (100	  µg/ml	  Ampicillin	  /	  50	  µg/ml	  Kanamycin	  /	  30	  µg/ml	  
Chloramphenicol).	  In	  the	  case	  of	  a	  retransformation	  5	  ng	  of	  vector	  DNA	  were	  used	  and	  
only	  50	  µl	  were	  plated.	  After	  the	  liquid	  was	  totally	  absorbed,	  the	  plates	  were	  inverted	  and	  
placed	  in	  a	  37°C	  incubator	  for	  at	  least	  18	  hours.	  Later	  they	  were	  wrapped	  in	  parafilm	  and	  
stored	  at	  4°C.	  
2.2.1.9 Plasmid preparation (Miniprep) 
4	  ml	  of	  LB	  media	  containing	  the	  appropriate	  antibiotic	  were	  inoculated	  with	  individual	  
colonies	  and	  incubated	  at	  37°C	  overnight.	  The	  following	  morning,	  glycerol	  stocks	  were	  
prepared	  for	  long	  term	  storage	  by	  mixing	  500	  µl	  of	  bacterial	  culture	  with	  equal	  volumes	  
of	  glycerol	  and	  stored	  at	  -­‐80°C.	  The	  remainder	  of	  the	  overnight	  bacterial	  culture	  was	  
pelleted	  by	  centrifugation	  at	  3,000	  rpm	  for	  10	  minutes	  in	  a	  Beckham	  Coulter	  centrifuge.	  
DNA	  was	  isolated	  from	  the	  pellets	  using	  the	  QIAprep®	  Spin	  Miniprep	  Kit	  according	  to	  the	  
manufacturer’s	  instructions.	  Next,	  the	  DNA	  was	  sequenced	  by	  the	  Beatson	  Molecular	  
Technology	  Services	  on	  an	  Applied	  Biosystems	  3130xl	  sequencer.	  The	  resulting	  data	  was	  
analysed	  using	  VectorNTI	  (Invitrogen).	  
2.2.1.10 Plasmid preparation (Maxiprep) 
Large	  scale	  (200-­‐500	  ml)	  overnight	  bacterial	  cultures	  were	  set	  up	  in	  LB	  media	  containing	  
the	  appropriate	  antibiotic	  and	  20	  µl	  of	  a	  starting	  culture	  were	  used	  for	  inoculation.	  The	  
following	  morning	  cultures	  were	  pelleted	  at	  3,000	  rpm	  for	  30	  minutes.	  The	  DNA	  was	  then	  
isolated	  using	  the	  QIAprep®	  Spin	  Maxiprep	  Kit	  according	  to	  the	  manufacturer’s	  protocol.	  
The	  DNA	  concentration	  of	  the	  resulting	  plasmid	  solution	  was	  measured	  using	  an	  
Eppendorf	  Biophotometer	  with	  an	  absorbance	  of	  260	  nm.	  
2.2.2 Tissue Culture 
2.2.2.1 Cell origin 
Stable	  clones	  of	  A2780-­‐DNA3	  and	  A2780-­‐Rab25	  were	  generated	  as	  previously	  described	  
by	  Cheng	  et	  al.	  [351]	  and	  generously	  provided	  by	  Gordon	  Mills.	  MDA-­‐MB-­‐231	  cells	  were	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purchased	  from	  the	  American	  Type	  Culture	  Collection	  cell	  bank.	  Various	  other	  cell	  lines	  
used	  in	  this	  project	  were	  obtained	  from	  research	  groups	  within	  the	  Beatson	  Institute	  for	  
Cancer	  Research,	  including	  Telomerase-­‐immortalised	  human	  fibroblasts	  (TIFs)	  and	  colon	  
carcinoma	  BE	  cells.	  
2.2.2.2 Cultivation of cells 
A2780	  cells	  were	  cultured	  in	  RPMI-­‐1640	  medium	  supplemented	  with	  10%	  (v/v)	  foetal	  calf	  
serum	  and	  2	  mM	  L-­‐glutamine	  at	  37°C	  in	  a	  humidified	  atmosphere	  containing	  5%	  CO2.	  All	  
other	  cell	  lines	  were	  cultured	  in	  DMEM	  containing	  10%	  (v/v)	  foetal	  calf	  serum	  and	  
2	  mM	  L-­‐glutamine	  under	  the	  same	  conditions	  as	  described	  above.	  When	  cells	  reached	  
80%	  confluence,	  they	  were	  sub-­‐cultured.	  To	  do	  this,	  the	  culture	  medium	  was	  removed,	  
the	  cellular	  monolayer	  then	  rinsed	  with	  PBS	  and	  a	  10%	  Trypsin/PE	  solution	  was	  added.	  
After	  a	  brief	  incubation,	  the	  detached	  cells	  were	  re-­‐suspended	  in	  the	  appropriate	  cell	  
culture	  medium	  and	  centrifuged	  for	  2	  minute	  at	  900	  rpm.	  Next,	  the	  cell	  pellet	  was	  
resuspended	  in	  fresh	  medium	  and	  an	  aliquot	  was	  seeded	  into	  an	  appropriate	  tissue	  
culture	  dish	  or	  flask.	  
2.2.2.3 Freezing and thawing of cells 
At	  least	  1x106	  cells	  in	  excellent	  condition	  were	  trypsinised	  and	  centrifuged	  for	  2	  minutes	  
at	  900	  rpm.	  Once	  the	  supernatant	  was	  completely	  removed,	  the	  cell	  pellet	  was	  
resuspended	  in	  1	  ml	  Cryo-­‐SFM	  medium	  and	  transferred	  into	  a	  labelled	  cryo	  vial	  and	  
placed	  in	  a	  freezing	  container	  (NALGENE™	  1°C	  Cryo	  Freezing	  Container)	  at	  -­‐80°C.	  When	  
cells	  were	  to	  be	  stored	  longer	  than	  6	  months	  they	  were	  transferred	  into	  liquid	  nitrogen	  
the	  following	  day.	  
According	  to	  the	  rule	  of	  “freeze	  slowly,	  thaw	  fast”,	  frozen	  cells	  were	  put	  immediately	  into	  
a	  37°C	  water	  bath.	  When	  only	  a	  small	  lump	  of	  ice	  was	  left,	  the	  vial	  was	  opened	  and	  the	  
cells	  were	  immediately	  transferred	  into	  5	  ml	  of	  pre-­‐warmed	  medium.	  After	  centrifugation	  
for	  2	  minutes	  at	  900	  rpm,	  the	  supernatant	  was	  removed	  and	  cells	  were	  resuspended	  in	  
their	  specified	  growth	  medium	  and	  plated	  onto	  a	  cell	  culture	  dish.	  The	  following	  morning,	  
the	  medium	  was	  replaced.	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2.2.2.4 Transfection using the Amaxa™ Nucleofector™ 
Amaxa	  nucleofection	  provides	  an	  efficient	  way	  to	  introduce	  DNA	  plasmids	  or	  siRNA	  
oligos.	  Hence,	  this	  method	  was	  used	  for	  A2780-­‐Rab25	  and	  MDA-­‐MB-­‐231	  cells,	  which	  
were	  grown	  to	  70-­‐85%	  confluency,	  trypsinised	  and	  resuspended	  in	  growth	  medium.	  
Depending	  on	  the	  cell	  line	  between	  1-­‐5x106	  cells	  were	  used	  for	  one	  transfection	  reaction.	  
The	  appropriate	  number	  of	  cells	  were	  centrifuged	  at	  900	  rpm	  for	  2	  min.	  The	  supernatant	  
was	  aspirated	  off	  and	  100-­‐200	  pmol	  of	  siRNA	  or	  appropriate	  amounts	  of	  DNA	  were	  added	  
on	  top	  of	  the	  cell	  pellet.	  Afterwards,	  100	  µl	  of	  solution	  T	  (A2780-­‐Rab25)	  or	  
V	  (MDA-­‐MB-­‐231)	  were	  added	  and	  mixed	  thoroughly	  by	  pipetting	  up	  and	  down.	  The	  
mixture	  was	  then	  transferred	  into	  a	  Nucleofector	  cuvette	  and	  inserted	  into	  the	  AmaxaTM	  
NucleofectorTM.	  Transfections	  were	  carried	  out	  using	  the	  appropriate	  programme	  (see	  
table	  below).	  Subsequently,	  transfected	  cells	  were	  taken	  up	  in	  500	  µl	  pre-­‐warmed	  growth	  
medium	  and	  seeded	  onto	  tissue	  culture	  dishes.	  Transfected	  cells	  were	  allowed	  to	  recover	  
and	  settle	  for	  at	  least	  12	  hours	  prior	  to	  any	  experiments.	  
Cell	  line	   Nucleofection	  programme	  
A2780	   A-­‐023	  
MDA-­‐MB-­‐231	   X-­‐013	  
Typically,	  3	  µg	  of	  DNA	  plasmid	  were	  transfected	  unless	  otherwise	  stated	  in	  the	  table	  
below:	  
Plasmid	   Transfected	  amount	  (µg)	  
GFP	   1	  
Destination	  vector	   1	  
SF-­‐ERK1	   0.4	  
SF-­‐ERK2	   1.5	  
2.2.2.5 Transfection using HiPerFect 
For	  RNA	  interference	  experiments,	  MDA-­‐MB-­‐231	  and	  BE	  cells	  were	  transfected	  using	  
HiPerFect,	  because	  this	  increased	  cellular	  viability.	  When	  cells	  reached	  80%	  confluence,	  a	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solution	  of	  500	  µl	  of	  DMEM	  supplemented	  with	  L-­‐glutamine	  only,	  7.5	  µl	  HiPerFect	  and	  
1.5	  µl	  siRNA	  (from	  20	  µM	  stock)	  was	  prepared	  and	  left	  at	  room	  temperature	  for	  10	  
minutes	  to	  allow	  transfection	  complex	  formation.	  Next,	  the	  mixture	  was	  added	  onto	  the	  
cells	  and	  the	  plates	  were	  gently	  swirled	  to	  ensure	  a	  uniform	  distribution.	  Transfected	  cells	  
were	  then	  incubated	  under	  normal	  growth	  conditions.	  Two	  days	  later,	  the	  cells	  were	  
passaged	  at	  a	  ratio	  of	  one	  in	  three	  and	  transfected	  immediately	  after	  sub-­‐culturing	  
following	  the	  above	  protocol.	  After	  the	  second	  round	  of	  transfection	  gene	  silencing	  was	  
monitored	  by	  Western	  blotting	  or	  qRT-­‐PCR.	  	  
2.2.2.6 Cell proliferation assays 
10.000	  cells	  were	  seeded	  per	  6-­‐well	  dish	  and	  left	  to	  settle	  overnight.	  The	  following	  
morning	  cells	  were	  counted	  for	  the	  first	  time.	  For	  each	  measurement,	  cells	  were	  
thoroughly	  trypsinised	  in	  200	  µl	  of	  Trypsin/PE	  solution.	  Next,	  the	  trypsin	  was	  inactivated	  
with	  200	  µl	  of	  medium.	  The	  cell	  number	  was	  determined	  by	  adding	  20	  ml	  of	  PBS	  to	  the	  
0.4	  ml	  of	  cell	  suspension	  and	  measuring	  the	  cell	  number	  with	  a	  Casy®	  1	  cell	  counter.	  Cell	  
proliferation	  was	  assayed	  over	  the	  course	  of	  5-­‐6	  days.	  Relative	  cell	  numbers	  were	  
determined	  by	  using	  day	  one	  as	  a	  reference	  point.	  Every	  condition	  was	  set	  up	  in	  triplicate	  
and	  the	  experiments	  were	  repeated	  twice.	  Moreover,	  Casy®	  1	  cell	  counter	  measurements	  
were	  checked	  manually	  using	  a	  haemocytometer.	  
2.2.2.7 Inverted invasion assay 
Inverted	  invasion	  assays,	  previously	  described	  by	  Hennigan	  et	  al.	  were	  modified	  as	  
follows	  [352].	  An	  aliquot	  of	  Matrigel	  was	  slowly	  thawed	  on	  ice	  and	  then	  diluted	  1:1	  in	  
ice-­‐cold	  PBS	  supplemented	  with	  25	  µg/ml	  fibronectin.	  Subsequently,	  100	  µl	  of	  this	  
solution	  was	  carefully	  pipetted	  into	  a	  Transwell	  (pore	  size	  of	  8	  µm),	  which	  had	  been	  
inserted	  into	  a	  well	  of	  a	  24-­‐well	  tissue	  culture	  plate.	  In	  order	  for	  the	  Matrigel	  to	  
polymerize,	  the	  plate	  was	  incubated	  for	  at	  least	  30	  minutes	  at	  37˚C.	  Meanwhile,	  cell	  
suspensions	  between	  1x105	  and	  4x105	  cells	  per	  ml	  were	  prepared	  in	  the	  appropriate	  
growth	  medium.	  After	  the	  Matrigel	  set,	  the	  Transwells	  were	  inverted	  and	  100	  µl	  of	  the	  
cell	  suspension	  were	  pipetted	  onto	  the	  underside	  of	  the	  filter.	  The	  Transwells	  were	  then	  
carefully	  covered	  with	  the	  base	  of	  the	  24-­‐well	  tissue	  culture	  plate	  so	  that	  it	  contacted	  the	  
droplet	  of	  cell	  suspension.	  Next,	  the	  inverted	  plate	  was	  incubated	  at	  37˚C,	  5%	  CO2	  for	  4	  
hours	  to	  allow	  cells	  to	  attach	  to	  the	  filter.	  Afterwards,	  the	  Transwells	  were	  turned	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right-­‐side-­‐up,	  washed	  by	  sequential	  dipping	  in	  1	  ml	  of	  the	  appropriate	  serum-­‐free	  growth	  
medium	  twice	  and	  finally	  placed	  into	  1	  ml	  of	  the	  serum-­‐free	  medium.	  Then,	  100	  µl	  of	  
growth	  medium	  containing	  10%	  serum	  and	  the	  chemoattractant	  EGF	  (25ng/ml)	  was	  
gently	  pipetted	  on	  top	  of	  the	  Matrigel.	  Cells	  were	  allowed	  to	  invade	  into	  the	  Matrigel	  
over	  a	  course	  of	  2-­‐3	  days	  at	  37˚C	  and	  5%	  CO2.	  
In	  order	  to	  visualize	  the	  migrated	  cells,	  the	  Transwells	  were	  transferred	  into	  a	  new	  
24-­‐well	  tissue	  plate	  and	  covered	  drop-­‐wise	  with	  1	  ml	  of	  calcein	  acetomethyl	  ester	  diluted	  
to	  4	  µM	  in	  serum	  free	  medium.	  After	  one	  hour	  at	  37˚C	  samples	  were	  assayed	  using	  a	  
LEICA	  SP2	  confocal	  microscope	  with	  a	  20x	  objective.	  The	  fluorescent	  dye	  was	  excited	  with	  
a	  wavelength	  of	  488	  nm	  and	  emitted	  at	  515	  nm.	  Optical	  sections	  were	  captured	  at	  15	  µm	  
intervals	  starting	  from	  the	  underside	  of	  the	  Transwell	  filter	  and	  moving	  upwards	  in	  the	  
direction	  of	  cell	  invasion.	  The	  resulting	  images	  were	  quantified	  using	  the	  area	  calculator	  
tool	  from	  the	  ImageJ	  software.	  The	  threshold	  fluorescence	  intensity	  was	  set	  so	  that	  
background	  intensities	  were	  erased	  and	  only	  cells	  within	  the	  optical	  slice	  were	  visualised.	  
The	  sum	  of	  fluorescence	  of	  the	  sections	  from	  45	  µm	  and	  above	  was	  divided	  by	  the	  total	  
fluorescence	  of	  all	  the	  optical	  sections,	  thus	  giving	  an	  invasion	  index	  of	  ≥45	  µm.	  Mean	  
values	  were	  generated	  from	  three	  individual	  experiments.	  Within	  one	  experiment	  each	  
condition	  was	  set	  up	  in	  duplicate	  and	  optical	  sections	  for	  three	  areas	  were	  taken	  for	  each	  
Transwell.	  	  
2.2.2.8 Generation of cell-derived matrix 
Cell-­‐derived	  matrix	  was	  generated	  as	  previously	  described	  [38,	  353].	  Briefly,	  tissue	  culture	  
plates	  were	  coated	  with	  0.2%	  sterile	  gelatine	  for	  one	  hour	  at	  37˚C.	  Next,	  the	  gelatine	  
solution	  was	  aspirated	  off	  and	  plates	  were	  washed	  twice	  with	  PBS.	  In	  order	  to	  crosslink	  
the	  layer	  of	  gelatine,	  1%	  sterile	  glutaraldehyde	  was	  added	  for	  30	  minutes	  at	  room	  
temperature.	  Following	  two	  washes	  with	  PBS,	  the	  crosslinking	  reaction	  was	  quenched	  
with	  1	  M	  sterile	  glycine	  in	  PBS	  (pH	  ~7)	  for	  20	  minutes	  at	  room	  temperature.	  After	  another	  
2	  washes,	  the	  tissue	  culture	  dishes	  were	  equilibrated	  with	  DMEM	  containing	  10%	  foetal	  
calf	  serum	  and	  2	  mM	  L-­‐glutamine.	  Then,	  human	  telomerase-­‐immortalised	  fibroblasts	  
were	  plated	  at	  near	  confluence	  (~2x104/cm2).	  The	  following	  day,	  collagen	  production	  was	  
stimulated	  through	  supplementation	  of	  the	  medium	  with	  50	  µg/ml	  ascorbic	  acid.	  
Fibroblasts	  were	  cultured	  for	  10-­‐14	  days	  and	  the	  medium	  (supplemented	  with	  ascorbic	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acid)	  was	  exchanged	  every	  other	  day.	  Matrices	  were	  then	  denuded	  of	  living	  fibroblasts	  by	  
incubating	  the	  dishes	  with	  PBS	  containing	  20	  mM	  NH4OH	  and	  0.5%	  Triton	  X-­‐100	  for	  2	  
minutes,	  after	  which	  cell	  lysis	  was	  examined	  using	  a	  phase	  light	  microscope.	  Next,	  the	  
extraction	  buffer	  was	  aspirated	  off	  and	  matrices	  were	  washed	  twice	  in	  PHS	  containing	  
calcium	  and	  magnesium.	  Residual	  DNA	  was	  digested	  with	  PBS	  containing	  calcium,	  
magnesium	  and	  10	  µg/ml	  DNase1	  at	  37˚C	  for	  30	  minutes.	  Following	  another	  two	  washes	  
with	  PBS	  containing	  magnesium	  and	  calcium,	  matrices	  were	  stored	  at	  4˚C	  in	  the	  same	  
solution	  supplemented	  with	  pen/strep	  and	  fungizone.	  Before	  use,	  the	  matrix	  condition	  
was	  examined	  by	  phase	  light	  microscopy.	  Prior	  to	  seeding	  the	  cell	  line	  of	  interest,	  
matrices	  were	  washed	  twice	  with	  PBS	  and	  equilibrated	  with	  complete	  medium	  for	  20	  
minutes	  at	  37˚C.	  
2.2.2.9 Migration on cell-derived matrix 
Respective	  cells	  (50,000	  cells	  for	  A2780-­‐Rab25	  cells,	  100,000	  cells	  in	  the	  case	  of	  
MDA-­‐MB-­‐231	  cells)	  were	  seeded	  into	  a	  well	  of	  a	  6-­‐well	  dish	  coated	  with	  cell-­‐derived	  
matrix	  and	  allowed	  to	  adhere	  for	  4	  hours	  prior	  to	  imaging.	  Migration	  was	  monitored	  using	  
a	  Nikon	  time-­‐lapse	  microscope	  and	  migration	  characteristics	  were	  analysed	  using	  the	  
Manual	  Tracking	  and	  Chemotaxis	  tool	  of	  ImageJ	  and	  a	  customised	  MATLAB	  script	  written	  
by	  Dr.	  Marc	  Birtwistle.	  
2.2.2.10 Scratch wound assays 
Cells	  were	  seeded	  into	  a	  6-­‐well	  dish,	  so	  that	  they	  reached	  confluence	  48	  hours	  post	  
transfection.	  Next,	  a	  wound	  was	  introduced	  by	  scratching	  the	  plastic	  dish	  with	  a	  200	  µl	  
pipette	  tip.	  Following	  three	  washes	  in	  fully-­‐supplemented	  medium	  wound	  closure	  was	  
monitored	  at	  10	  minute	  intervals	  using	  a	  time-­‐lapse	  microscope.	  Images	  for	  each	  
condition	  were	  taken	  from	  five	  distinct	  fields	  along	  the	  wound	  and	  a	  minimum	  of	  five	  
cells	  were	  tracked	  for	  each	  field.	  Migration	  characteristics	  from	  three	  independent	  
experiments	  were	  analysed	  using	  the	  ImageJ	  cell	  tracking	  software.	  
2.2.2.11 Immunofluorescence 
Cells	  were	  cultured	  on	  sterile	  coverslips	  placed	  in	  a	  6-­‐well	  tissue	  culture	  dish.	  Where	  
indicated,	  coverslips	  were	  coated	  with	  fibronectin	  (20	  µg/ml	  in	  PBS)	  for	  20	  minutes	  at	  
37˚C.	  Medium	  was	  removed	  and	  the	  cells	  were	  washed	  twice	  with	  PBS	  and	  fixed	  in	  a	  4%	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paraformaldehyde	  solution.	  After	  15	  minutes,	  the	  crosslinking	  reaction	  was	  quenched	  by	  
adding	  an	  equal	  volume	  of	  a	  2M	  glycine	  solution.	  Next,	  the	  coverslips	  were	  washed	  twice	  
with	  PBS,	  after	  which	  cells	  were	  permeabilised	  with	  0.05%	  Triton	  X-­‐100	  in	  PBS	  for	  
2	  minutes,	  which	  was	  followed	  by	  3	  washes	  in	  PBS.	  In	  order	  to	  block	  non-­‐specific	  antibody	  
binding,	  cells	  were	  incubated	  in	  PBS	  containing	  1%	  BSA	  for	  one	  hour.	  Then,	  primary	  
antibodies	  diluted	  in	  blocking	  solution	  were	  applied	  for	  one	  hour.	  Following	  another	  
three	  washes,	  secondary	  antibodies	  in	  blocking	  solution	  were	  applied	  for	  45	  minutes.	  
Coverslips	  were	  washed	  another	  two	  times	  with	  PBS	  before	  being	  mounted	  onto	  glass	  
slides	  using	  Vectashield	  containing	  DAPI.	  Slides	  were	  dried	  overnight	  at	  4˚C.	  Colocalisation	  
studies	  were	  performed	  on	  a	  Zeiss	  710	  upright	  confocal	  microscope	  with	  a	  64x	  objective.	  
Different	  fluorescent	  channels	  were	  recorded	  sequentially	  to	  prevent	  bleed-­‐through.	  
2.2.3 Protein biology 
2.2.3.1 Cell lysis 
After	  cells	  were	  grown	  to	  80%	  confluence,	  the	  cell	  culture	  dishes	  were	  placed	  on	  ice,	  the	  
medium	  was	  aspirated	  off	  and	  the	  cells	  were	  washed	  twice	  with	  ice-­‐cold	  PBS.	  Depending	  
on	  the	  experiment	  different	  lysis	  buffers	  were	  used	  (Table	  2-­‐7).	  Subsequently,	  protein	  
extracts	  were	  generated	  by	  adding	  lysis	  buffer	  to	  the	  dishes	  (0.4	  ml	  per	  10	  cm	  dish,	  1	  ml	  
per	  15	  cm	  dish)	  and	  scrapping	  the	  cells	  off	  the	  plate.	  The	  lysates	  were	  then	  transferred	  
into	  1.5	  ml	  microcentrifuge	  tubes	  and	  incubated	  on	  ice	  for	  10	  minutes	  with	  occasional	  
vortexing.	  Afterwards,	  lysates	  were	  cleared	  by	  centrifugation	  at	  14,000	  rpm	  in	  a	  
pre-­‐cooled	  benchtop	  centrifuge	  for	  10	  minutes.	  Cleared	  lysates	  were	  collected	  in	  new	  
tubes	  and	  either	  processed	  further	  or	  stored	  at	  -­‐20˚C.	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Lysis	  buffer	   Composition	   Application	  
HEPES	  lysis	  buffer	   20	  mM	  HEPES	  pH	  7.5	  
150	  mM	  NaCl	  
2	  mM	  EDTA	  pH	  7.4	  
1	  %	  NP-­‐40	  (v/v)	  
1	  mM	  Na3VO4	  
10	  mM	  NaF	  
1	  mM	  PMSF	  
5	  µg/ml	  leupeptin	  
Western	  blot	  
NDLB	  lysis	  buffer	   50	  mM	  Tris-­‐HCl	  (pH	  7.0)	  
150	  mM	  NaCl	  
10	  mM	  NaF	  
1	  mM	  Na3VO3	  
5	  mM	  EDTA	  
5	  mM	  EGTA	  
1%	  Triton	  X-­‐100	  (v/v)	  
0.5%	  NP-­‐40	  (v/v)	  
5	  µg/ml	  leupeptin	  
1	  mM	  PMSF	  
Immunoprecipitation	  
RIPA	  lysis	  buffer	   50	  mM	  Tris-­‐HCl	  (pH	  7.0)	  
150	  mM	  NaCl	  
0.5%	  sodium	  deoxycholate	  
1%	  NP-­‐40	  (v/v)	  
1	  mM	  PMSF	  
1	  mM	  Na3VO4	  
10	  mM	  NaF	  
5	  µg/ml	  leupeptin	  
Western	  blot,	  when	  
interested	  in	  membrane	  
proteins	  
Table 2-7 Comparison of different lysis buffers: Composition and Application 
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2.2.3.2 Protein quantification 
Protein	  concentrations	  were	  measured	  using	  the	  Pierce®	  BCA	  Protein	  Assay	  Kit	  according	  
to	  the	  manufacturer’s	  instructions.	  In	  brief,	  diluted	  albumin	  standards	  were	  prepared	  
(0.08,	  0.1,	  0.2,	  0.4,	  1,	  2	  mg/ml)	  and	  the	  appropriate	  lysis	  buffer	  was	  used	  as	  a	  blank.	  A	  
standard	  curve	  was	  determined	  by	  adding	  20	  µl	  of	  blank	  and	  standards	  to	  the	  bottom	  of	  a	  
96-­‐well	  plate.	  Protein	  lysates	  were	  also	  added	  in	  duplicate.	  200	  µl	  of	  the	  constituted	  
protein	  assay	  reagent	  (50:1,	  reagent	  A:B)	  were	  added	  to	  all	  wells	  and	  incubated	  at	  37˚C	  
for	  15	  minutes.	  Next,	  absorbance	  values	  were	  measured	  using	  a	  Dynatech	  MR7000	  plate	  
reader	  at	  595	  nm	  and	  plotted	  to	  generate	  a	  standard	  curve.	  Lastly,	  protein	  concentrations	  
were	  determined	  from	  the	  curve	  and	  lysates	  diluted	  if	  necessary.	  
2.2.3.3 Co-immunoprecipitation 
Prior	  to	  co-­‐immunoprecipitation	  experiments,	  the	  GFP	  antibody	  was	  coupled	  to	  beads.	  To	  
do	  this,	  1.5	  µl	  of	  antibody	  per	  lysate	  were	  incubated	  with	  25	  µl	  of	  magnetic	  beads	  in	  
100	  µl	  of	  PBS	  containing	  0.1%	  BSA	  for	  1	  hour	  at	  4˚C.	  After	  2	  washes	  with	  PBS	  containing	  
0.1%	  BSA,	  the	  lysate	  was	  applied	  (containing	  approximately	  400	  µg	  of	  protein)	  and	  
incubated	  at	  4˚C	  for	  2	  hours.	  Then,	  beads	  were	  washed	  3	  times	  with	  lysis	  buffer	  and	  
boiled	  in	  lysis	  buffer	  supplemented	  with	  reducing	  sample	  buffer	  at	  95˚C	  for	  5	  minutes.	  
Protein	  interactions	  were	  examined	  by	  Western	  blot.	  	  
2.2.3.4 SDS-PAGE and Coomassie staining 
SDS-­‐polyacrylamide	  gels	  were	  used	  to	  resolve	  protein	  samples	  according	  to	  their	  
molecular	  weight.	  Firstly,	  the	  protein	  lysate	  was	  mixed	  with	  4x	  reducing	  sample	  buffer	  
and	  heated	  to	  95˚C	  for	  5	  minutes	  on	  a	  thermomixer	  to	  denature	  the	  proteins.	  After	  a	  
brief	  centrifugation,	  5	  µg	  of	  protein	  were	  resolved	  on	  a	  denaturing,	  pre-­‐cast	  NuPAGE	  
polyacrylamide	  gel	  (4-­‐12%	  gradient	  or	  10%).	  Molecular	  weight	  markers	  were	  loaded	  onto	  
the	  gel	  next	  to	  lysate	  samples.	  In	  general,	  gels	  were	  run	  in	  tanks	  containing	  1x	  MOPS	  
running	  buffer	  at	  150	  V	  for	  approximately	  1.5	  hours.	  Afterwards,	  the	  gel	  was	  either	  
stained	  with	  Coomassie	  reagent	  to	  visualize	  the	  resolved	  proteins	  in	  the	  gel	  or	  transferred	  
onto	  a	  PVDF	  membrane	  by	  Western	  blotting.	  	  
For	  Coomassie	  staining,	  the	  gel	  was	  transferred	  into	  a	  clean	  bacterial	  cell	  culture	  dish	  and	  
washed	  3	  times	  for	  5	  minutes	  with	  distilled	  water.	  Afterwards,	  the	  gel	  was	  incubated	  with	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SimplyBlue	  SafesStain®	  Coomassie	  reagent	  for	  45	  minutes.	  Next,	  background	  staining	  was	  
removed	  by	  several	  washes	  with	  water	  over	  the	  course	  of	  3	  hours.	  All	  washing	  and	  
staining	  steps	  were	  carried	  out	  under	  gentle	  agitation.	  
2.2.3.5 Western Blotting 
Proteins	  previously	  separated	  by	  SDS-­‐PAGE	  were	  transferred	  onto	  a	  PVDF	  membrane	  in	  
1x	  NuPAGE	  Blotting	  buffer	  for	  one	  hour	  at	  30	  V.	  The	  membrane	  was	  then	  blocked	  for	  30	  
minutes	  with	  5%	  (w/v)	  milk	  powder	  in	  TBST.	  After	  thorough	  washing	  with	  TBST,	  the	  
primary	  antibody	  of	  choice	  was	  added	  at	  a	  suitable	  dilution	  in	  5%	  (w/v)	  BSA	  containing	  
0.02%	  (w/v)	  of	  sodium	  azide.	  Incubation	  times	  varied	  depending	  on	  the	  primary	  antibody	  
employed	  (Table	  2-­‐3).	  Membranes	  were	  then	  washed	  3	  times	  in	  TBST	  for	  5	  minutes	  each.	  
The	  blots	  were	  then	  incubated	  with	  the	  appropriate	  secondary	  antibody	  conjugated	  to	  
horseradish	  peroxidase	  for	  one	  hour	  at	  room	  temperature.	  Proteins	  were	  visualised	  by	  
chemiluminescence	  using	  the	  Pierce	  ECL	  Western	  Blotting	  Substrate	  and	  subsequent	  
autoradiography	  with	  Fuji	  Super	  RX	  medical	  X-­‐ray	  films	  using	  a	  Kodak	  X-­‐Omat	  480	  RA	  
X-­‐Ray	  processor.	  
2.2.4 Microarray screen and validation 
2.2.4.1 RNA extraction and quality control 
Total	  cellular	  RNA	  was	  extracted	  from	  respective	  cells	  grown	  on	  cell-­‐derived	  matrix	  (see	  
2.2.2.8)	  or	  plastic	  surfaces	  for	  16	  hours	  following	  transfection.	  RNA	  isolation	  was	  carried	  
out	  using	  the	  RNeasy	  kit	  according	  to	  the	  manufacturer’s	  protocol.	  Briefly,	  cells	  were	  
washed	  twice	  with	  ice-­‐cold	  PBS	  (pH	  7.4),	  and	  lysed	  in	  RLT	  buffer	  supplemented	  with	  
β-­‐mercaptoethanol.	  Next,	  cell	  lysates	  were	  homogenised	  using	  QIAshredder	  columns	  and	  
RNA	  was	  extracted	  and	  purified.	  Residual	  genomic	  DNA	  was	  removed	  through	  an	  
on-­‐column	  DNase1	  digest.	  Following	  elution	  of	  the	  purified	  RNA,	  samples	  were	  
snap-­‐frozen	  on	  dry	  ice	  and	  stored	  at	  -­‐80˚C	  until	  further	  use.	  
2.2.4.2 RNA labelling for the microarray screen 
Isolated	  RNA	  was	  labelled	  using	  the	  Illumina®	  TotalPrepTM	  RNA	  Labelling	  Kit	  according	  to	  
the	  manufacturer’s	  instructions.	  In	  brief,	  0.5	  µg	  of	  isolated	  RNA	  were	  placed	  into	  a	  PCR	  
plate	  for	  first	  strand	  cDNA	  synthesis	  and	  brought	  up	  to	  a	  volume	  of	  11	  µl	  before	  9	  µl	  of	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the	  reverse	  transcription	  master	  mix	  were	  added.	  After	  mixing	  the	  solution	  was	  incubated	  
at	  42˚C	  for	  2	  hours	  using	  a	  thermal	  cycler.	  For	  second	  strand	  cDNA	  synthesis,	  80	  µl	  of	  
master	  mix	  were	  added	  to	  each	  sample	  and	  incubated	  at	  16˚C	  for	  two	  hours.	  The	  
synthesised	  cDNA	  was	  purified	  and	  labelled	  cRNA	  was	  transcribed	  in	  vitro	  over	  14	  hours	  
at	  37˚C.	  The	  resulting	  cRNA	  was	  purified	  and	  the	  yield	  evaluated	  by	  measuring	  the	  
absorbance	  at	  260	  nm	  on	  a	  NanoVue	  spectrophotometer.	  The	  RNA	  integrity	  was	  
examined	  on	  a	  bioanalyser	  prior	  to	  comparative	  whole-­‐genome	  expression	  profiling,	  
which	  was	  performed	  using	  two	  Illumina	  HumanHT-­‐12	  v4	  Expression	  BeadChips.	  
2.2.4.3 Microarray data analysis 
Gene	  signal	  profiles	  of	  24	  samples	  were	  normalised	  and	  analysed	  in	  Partek®	  Genomics	  
Suite	  Software	  (version	  6.5).	  Quantile	  normalisation	  and	  log2	  transformation	  of	  the	  data	  
was	  followed	  by	  removal	  of	  batch	  effects	  between	  three	  groups	  of	  replicates.	  Outliers	  
were	  removed	  and	  remaining	  19	  samples	  re-­‐normalised.	  Differentiated	  genes	  were	  
identified	  by	  ANOVA	  and	  post-­‐hoc	  linear	  contrasts	  performed	  between	  all	  pairs	  of	  
experimental	  conditions.	  Multiple	  test	  corrections	  were	  performed	  for	  all	  calculated	  
p-­‐values.	  Genes,	  which	  showed	  significant	  changes	  in	  expression	  level	  when	  comparing	  
ERK2	  knockdown	  versus	  control	  (step-­‐up	  p-­‐value	  <0.05)	  and	  inverse	  changes	  when	  
comparing	  ERK2	  knockdown	  versus	  re-­‐expression	  of	  ERK2	  (step-­‐up	  p-­‐value	  <0.05,	  fold	  
change	  >±1.3)	  were	  identified.	  ERK2-­‐specific	  genes	  also	  had	  to	  meet	  the	  criteria	  of	  a	  step-­‐
up	  p-­‐values	  greater	  than	  0.5	  when	  comparing	  ERK2	  knockdown	  cells	  to	  ERK1	  
re-­‐expression.	  	  
2.2.4.4 First strand cDNA synthesis 
The	  following	  components	  were	  added	  to	  a	  nuclease-­‐free	  microcentrifuge	  tube:	  
Reagent	   Sample	  (µl)	  
oligo	  (dT)15	   1	  
purified	  RNA	   1	  µg	  
RNase/DNase-­‐free	  ddH2O	   	   up	  to	  10	  
total	  volume	   10	  
The	  mixture	  was	  heated	  to	  70˚C	  for	  10	  minutes	  and	  incubated	  on	  ice	  for	  at	  least	  1	  minute.	  
Afterwards,	  10	  µl	  of	  a	  master	  mix,	  prepared	  as	  follows,	  was	  added:	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Reagent	   Sample	  (µl)	  
ImProm-­‐IITM	  5X	  Reaction	  Buffer	   4	  
MgCl2	   3	  
dNTPs	   Mix	   1	  
RNasin	   0.5	  
IMProm-­‐IITM	  Reverse	  Transcriptase	   	   1	  
total	  volume	   10	  
The	  solution	  was	  gently	  mixed	  by	  pipetting	  up	  and	  down.	  The	  sample	  was	  then	  incubated	  
at	  25˚C	  for	  5	  minutes	  to	  allow	  initial	  annealing	  of	  the	  oligos.	  Following	  the	  annealing,	  the	  
sample	  was	  incubated	  at	  42˚C	  for	  1	  hour	  for	  cDNA	  extension.	  Afterwards,	  the	  reaction	  
was	  heat-­‐inactivated	  at	  70˚C	  for	  10	  minutes	  and	  cooled	  to	  4˚C	  before	  sample	  was	  frozen	  
at	  -­‐20˚C	  until	  further	  use.	  
2.2.4.5 qPCR 
The	  DyNAmoTM	  SYBR®	  Green	  qPCR	  kit	  was	  used	  to	  perform	  quantitative	  PCR	  on	  a	  
BioRAD	  DNA	  Engine	  thermal	  cycler	  fitted	  with	  a	  Chromo4	  Engine	  and	  coupled	  to	  Opticon	  
Monitor3	  software.	  The	  following	  reagents	  were	  pipetted	  together:	  
Reagent	   Sample	  (µl)	  
2x	  MasterMix	   10	  
Quantitect	  primer	   2	  
cDNA	  template	   1	  
RNase/DNase-­‐free	  H2O	   7	  
total	  volume	   20	  
PCR	  reactions	  were	  performed	  according	  to	  the	  following	  protocol:	  
Initial	  denaturation	   95˚C	   10	  min	  










Plate	  read	   	   	  
Final	  extension	   72˚C	   5	  min	  
Dissociation	  curve	   70˚C-­‐90˚C	  in	  0.3˚C	  increments	  
Final	  hold	   4˚C	   ∞	  
Chapter 2 – Materials and methods  101 
Extracted	  data	  was	  used	  to	  determine	  changes	  in	  gene	  expression	  according	  to	  the	  ΔΔCt	  
method	  previously	  described	  [354].	  GAPDH	  was	  used	  as	  a	  reference.	  Control	  transfected	  
transcript	  levels	  were	  assigned	  the	  arbitrary	  value	  of	  1.	  Each	  experiment	  was	  performed	  
in	  triplicate	  and	  replicas	  incorporated	  three	  technical	  repeats.	  
2.2.4.6 Statistical analysis 
All	  experiments	  were	  done	  in	  triplicates.	  Statistical	  significance	  of	  differences	  was	  
determined	  by	  nonparametric	  Mann-­‐Whitney	  U	  tests	  using	  GraphPad	  Prism	  5.	  P	  values	  of	  
less	  than	  0.05	  were	  considered	  significant.	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3 ERK2 but not ERK1 contributes to invasive cell 
migration 
3.1 Introduction 
3.1.1 Common features of ERK1 and ERK2 
The	  two	  major	  ERK	  isoforms,	  ERK1	  and	  ERK2,	  demonstrate	  an	  overall	  sequence	  identity	  of	  
nearly	  85%	  and	  are	  encoded	  by	  separate	  genes	  located	  on	  chromosome	  16	  and	  22,	  
respectively	  (Figure	  3-­‐1).	  In	  humans,	  both	  isoforms	  are	  ubiquitously	  expressed,	  albeit	  
their	  relative	  abundance	  varies	  [58].	  With	  the	  exception	  of	  a	  few	  studies	  demonstrating	  a	  
preferential	  activation	  of	  a	  single	  ERK	  isoform	  [355,	  356],	  most	  reports	  have	  
demonstrated	  that	  ERK1	  and	  -­‐2	  are	  co-­‐activated	  in	  response	  to	  extracellular	  stimuli.	  
Moreover,	  both	  enzymes	  rely	  on	  the	  same	  upstream	  kinase	  module,	  which	  does	  not	  
discriminate	  between	  them.	  Additionally,	  ERK1	  and	  ERK2	  display	  indistinguishable	  kinase	  
activities	  in	  vitro	  [357]	  and	  phosphorylate	  common	  substrates	  such	  as	  MBP	  kinase	  and	  
MAP2	  kinase	  at	  the	  same	  phosphoacceptor	  sites	  [55,	  58].	  
Owing	  to	  the	  fact	  that	  ERK1	  and	  -­‐2	  are	  highly	  homologous,	  both	  proteins	  share	  common	  
features	  in	  their	  tertiary	  structure	  and	  are	  composed	  of	  two	  domains	  (N-­‐terminal	  and	  
C-­‐terminal),	  which	  are	  connected	  by	  a	  flexible	  linker.	  The	  N-­‐terminal	  domain	  
predominantly	  consists	  of	  ß-­‐sheets,	  whereas	  the	  C-­‐terminal	  domain	  mainly	  comprises	  
α-­‐helices	  [358].	  Most	  substrates	  bind	  to	  ERK	  via	  two	  docking	  sites,	  the	  hydrophobic	  
groove	  formed	  by	  the	  CD	  and	  ED	  domain,	  or	  the	  FXFP-­‐motif	  [123,	  129,	  131-­‐133].	  
Co-­‐crystallisation	  studies	  of	  ERK	  with	  a	  D-­‐motif	  peptide	  elucidated	  which	  ERK	  amino	  acids	  
are	  involved	  in	  substrate	  binding.	  Out	  of	  the	  11	  residues	  determined,	  ERK1	  and	  ERK2	  only	  
differ	  in	  one	  amino	  acid,	  with	  ERK1	  displaying	  an	  isoleucine	  instead	  of	  a	  leucine	  [130].	  
Moreover,	  DEF-­‐motif	  interacting	  residues	  are	  fully	  conserved	  between	  ERK1	  and	  
ERK2	  [131].	  Taken	  together,	  the	  structural	  data	  points	  towards	  similar	  substrate	  
specificities	  for	  the	  two	  kinases	  and	  argues	  for	  functional	  redundancy.	  
ERK1	  and	  ERK2	  emerged	  early	  during	  vertebrate	  evolution	  with	  fish	  expressing	  both	  
isoforms	  [357].	  Moreover,	  both	  enzymes	  are	  evolutionary	  conserved,	  although	  it	  has	  to	  
be	  noted	  that	  Xenopus	  laevis	  only	  expresses	  ERK2	  and	  has	  lost	  the	  erk1	  orthologue	  [359].	  
Thus,	  the	  question	  arises	  whether	  or	  not	  both	  enzymes	  are	  functionally	  redundant	  and	  	  
Chapter 3 – ERK2 but not ERK1 contributes to invasive cell migration 103 
 
Figure 3-1 Sequence comparison of human ERK1 and ERK2  
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interchangeable	  and	  if	  so,	  why	  both	  proteins	  have	  been	  conserved	  evolutionarily.	  Lefloch	  
et	  al.	  proposed	  that	  the	  expression	  of	  two	  isoforms	  with	  functional	  redundancy	  allows	  the	  
fine-­‐tuning	  of	  ERK	  protein	  levels	  depending	  on	  the	  cellular	  needs	  and	  thereby	  represents	  
an	  evolutionary	  advantage	  to	  higher	  organisms	  [359].	  
3.1.2 ERK isoforms in whole animal studies 
In	  recent	  years,	  however,	  more	  and	  more	  evidence,	  suggesting	  non-­‐redundant	  functions	  
for	  the	  two	  ERK	  kinases,	  has	  been	  reported.	  In	  particular,	  the	  marked	  discrepancy	  
between	  the	  phenotypes	  of	  ERK1-­‐/-­‐	  and	  ERK2-­‐/-­‐	  mice	  indicates	  clear	  functional	  differences	  
in	  vivo.	  ERK1-­‐/-­‐	  mice	  are	  viable,	  fertile	  and	  of	  normal	  size	  [360],	  whereas	  ERK2-­‐/-­‐	  mice	  die	  
early	  in	  embryonic	  development	  [361-­‐363].	  Moreover,	  ERK1-­‐/-­‐	  mice	  display	  enhanced	  
behavioural	  responses	  in	  avoidance	  tasks	  and	  are	  hypersensitive	  to	  drug	  abuse	  [364].	  In	  
contrast,	  ERK2+/-­‐	  mice,	  which	  display	  a	  40%	  reduction	  in	  ERK2	  protein	  levels,	  show	  a	  
deficit	  in	  long-­‐term	  memory	  [365].	  Likewise,	  humans	  with	  only	  one	  ERK2	  allele	  show	  
learning	  disabilities	  and	  developmental	  delays,	  thus	  arguing	  for	  ERK-­‐specific	  function	  in	  
cognition	  and	  memory	  [366].	  In	  addition,	  ERK1-­‐deficient	  mice	  are	  impaired	  in	  thymocyte	  
maturation	  and	  adipogenesis	  [360,	  367].	  Interestingly,	  adipocyte	  differentiation	  in	  
isolated	  ERK1-­‐/-­‐	  pre-­‐adipocytes	  was	  not	  reduced	  further,	  when	  ERK2	  activation	  was	  
inhibited	  chemically,	  thus	  arguing	  for	  an	  isoform-­‐specific	  role	  of	  ERK1	  in	  this	  process.	  This	  
view	  is	  furthermore	  supported	  by	  the	  fact	  that,	  in	  contrast	  to	  most	  tissues,	  ERK1	  and	  
ERK2	  are	  expressed	  and	  activated	  to	  similar	  levels	  in	  adipocytes.	  Thus,	  equal	  expression	  
levels	  may	  indicate	  an	  important	  role	  for	  ERK1	  in	  fat	  tissue.	  Furthermore,	  ERK1-­‐deficient	  
mice	  exhibit	  an	  increased	  metabolic	  rate,	  and	  are	  protected	  from	  insulin	  resistance	  and	  
obesity	  [367].	  	  
Studies	  in	  zebrafish	  provide	  further	  evidence	  of	  ERK	  isoform-­‐specific	  functions.	  First,	  ERK1	  
and	  -­‐2	  display	  differential	  spatio-­‐temporal	  expression	  patterns	  during	  zebrafish	  
development.	  Second,	  ERK1	  and	  -­‐2	  morphants	  show	  distinct	  phenotypes	  during	  
embryogenesis	  [368].	  In	  agreement	  with	  mice	  studies,	  ERK2	  morphants	  are	  70%	  lethal	  
and	  portray	  severe	  developmental	  defects.	  On	  the	  contrary,	  ERK1	  ablation	  during	  
zebrafish	  development	  also	  gives	  rise	  to	  a	  distinct	  phenotype	  with	  10%	  lethality.	  
Remarkably,	  erk2	  mRNA	  is	  able	  to	  cross-­‐rescue	  the	  ERK1	  morphant	  phenotype,	  whereas	  
erk1	  mRNA	  fails	  to	  cross-­‐rescue	  developmental	  defects	  brought	  about	  by	  ERK2	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knockdown.	  Thus,	  in	  zebrafish	  ERK2	  can	  compensate	  for	  ERK1,	  while	  exhibiting	  
isoform-­‐specific	  functions	  that	  are	  distinct	  from	  ERK1	  [369].	  
3.1.3 ERK isoforms in cell culture studies 
In	  vitro	  studies	  employing	  RNA	  interference	  (RNAi)	  have	  also	  suggested	  distinct	  biological	  
functions	  for	  ERK1	  and	  ERK2.	  For	  example,	  silencing	  ERK2	  in	  C2C12	  myoblasts	  inhibits	  
myogenin	  expression	  and	  blocks	  myoblast	  fusion,	  while	  ERK1	  ablation	  has	  no	  effect	  [370].	  
Owing	  to	  the	  fact	  that	  ERK	  signalling	  plays	  a	  critical	  role	  in	  proliferation,	  multiple	  studies	  
investigated	  whether	  ERK1	  and	  ERK2	  have	  distinct	  functions	  in	  this	  cellular	  process.	  
Intriguingly,	  Vantaggiato	  et	  al.	  observed	  enhanced	  cell	  proliferation	  in	  mouse	  fibroblasts	  
upon	  ablation	  of	  ERK1	  by	  either	  gene	  targeting	  or	  RNA	  interference	  (RNAi),	  while	  
silencing	  of	  ERK2	  reduced	  the	  proliferative	  response	  to	  mitogenic	  stimuli	  [371].	  The	  
authors,	  therefore,	  suggested	  an	  antagonistic	  role	  for	  ERK1	  and	  ERK2	  in	  proliferation.	  
However,	  this	  observation	  was	  challenged	  by	  multiple	  studies	  showing	  no	  changes	  [357,	  
372]	  or	  a	  reduced	  proliferative	  response	  upon	  ERK1	  ablation	  [373-­‐375].	  In	  an	  attempt	  to	  
resolve	  these	  discrepant	  observations,	  Lefloch	  et	  al.	  turned	  their	  attention	  towards	  the	  
expression	  ratio	  of	  ERK1	  and	  ERK2	  and	  proposed	  a	  threshold-­‐dependency	  for	  ERK	  
signalling,	  i.e.	  a	  requirement	  for	  a	  certain	  pool	  of	  active	  ERK	  for	  the	  execution	  of	  
physiological	  functions	  [357].	  Thus,	  as	  ERK1	  and	  ERK2	  are	  mostly	  expressed	  at	  different	  
levels,	  with	  ERK2	  being	  the	  predominant	  kinase,	  silencing	  ERK2	  may	  decrease	  total	  ERK	  
levels	  below	  a	  threshold	  and	  result	  in	  functional	  defects,	  whereas	  ERK1	  knockdown	  may	  
not	  markedly	  decrease	  the	  pool	  of	  active	  ERK,	  therefore	  resulting	  in	  no	  or	  mild	  
phenotypic	  changes.	  Thus,	  apparent	  biological	  differences	  may	  be	  attributed	  to	  
differences	  in	  the	  expression	  levels	  rather	  than	  distinct	  biological	  features.	  Indeed,	  
redundant	  functions	  of	  ERK1	  and	  -­‐2	  in	  proliferation	  were	  subsequently	  confirmed	  in	  
experiments,	  where	  conditional	  invalidation	  of	  ERK2	  in	  the	  developing	  cortex	  of	  mice	  
significantly	  reduced	  cell	  proliferation,	  but	  could	  be	  rescued	  when	  ERK1	  was	  
overactivated	  [366].	  Moreover,	  Voisin	  et	  al.	  demonstrated	  that	  loss	  of	  either	  ERK1	  or	  
ERK2	  reduced	  proliferation	  in	  fibroblasts,	  which	  reflected	  their	  expression	  level	  [376].	  
Taken	  together,	  the	  data	  shows	  that	  both	  ERKs	  are	  positive	  regulators	  of	  proliferation	  and	  
differences	  in	  their	  expression	  levels	  may	  give	  the	  impression	  of	  distinct	  biological	  
functions.	  Thus,	  studies	  investigating	  isoform-­‐specific	  features	  have	  to	  address	  this	  issue	  
in	  order	  to	  draw	  meaningful	  conclusions	  from	  the	  data.	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3.1.4 ERK isoforms and tumourigenesis 
ERK’s	  role	  in	  tumourigenesis	  is	  well-­‐established	  with	  the	  kinases	  impinging	  on	  many	  
hallmarks	  of	  cancer.	  In	  2002,	  Adeyinka	  et	  al.	  demonstrated	  a	  direct	  correlation	  between	  
pERK1/2	  levels	  and	  tumour	  progression	  in	  breast	  cancer.	  Thus,	  a	  role	  for	  active	  ERK	  in	  the	  
metastatic	  process	  was	  proposed	  [377].	  Moreover,	  high	  levels	  of	  active	  ERK	  are	  
associated	  with	  enhanced	  cell	  motility	  [378].	  
In	  experiments	  examining	  the	  role	  of	  ERK1	  in	  skin	  homeostasis	  and	  tumourigenesis,	  
ERK1-­‐deficient	  mice	  developed	  fewer	  papillomas	  than	  wild	  type	  mice	  after	  tumour	  
induction	  with	  DMBA	  and	  promotion	  with	  TPA.	  Additionally,	  tumour	  onset	  was	  delayed	  
and	  the	  burden	  decreased.	  Moreover,	  studies	  of	  isolated	  ERK1-­‐/-­‐	  keratinocytes	  showed	  an	  
impairment	  of	  cellular	  growth,	  a	  resistance	  to	  apoptotic	  signals	  as	  well	  as	  a	  diminished	  
expression	  of	  fra1	  [373].	  Thus,	  Bourcier	  et	  al.	  concluded	  an	  important	  role	  of	  ERK1	  in	  skin	  
tumour	  development	  by	  contributing	  to	  cellular	  growth	  and	  proliferation	  and	  postulated	  
a	  role	  of	  this	  isoform	  in	  tumour	  cell	  invasion.	  
In	  2007,	  Bessard	  et	  al.	  investigated	  the	  role	  of	  ERK	  signalling	  in	  cell	  motility	  in	  human	  
hepatocarcinoma	  cells.	  The	  authors	  observed	  a	  reduction	  in	  cell	  motility	  in	  wound	  healing	  
assays	  after	  treatment	  with	  the	  MEK	  inhibitor,	  U0126.	  Moreover,	  silencing	  of	  ERK2	  but	  
not	  ERK1	  with	  short	  hairpin	  duplexes	  impaired	  wound	  closure,	  reduced	  uPAR	  expression	  
and	  S6K	  phosphorylation	  at	  Thr389	  [379].	  Although	  the	  data	  strongly	  suggest	  a	  role	  for	  
ERK	  signalling	  in	  cell	  migration,	  the	  study	  did	  not	  address	  whether	  or	  not	  the	  observations	  
can	  truly	  be	  attributed	  to	  an	  ERK2-­‐specific	  function	  or	  differences	  in	  the	  expression	  levels	  
of	  the	  two	  kinases	  [379].	  Thus,	  whether	  or	  not	  the	  major	  ERK	  isoforms	  have	  distinct	  
functions	  in	  cell	  migration	  remains	  an	  open	  issue.	  
This	  present	  study	  set	  out	  to	  address	  the	  question	  in	  dispute	  by	  studying	  the	  role	  of	  ERK1	  
and	  ERK2	  in	  tumour	  cell	  motility	  in	  2D	  and	  3D	  microenvironments	  and	  investigating	  
whether	  isoform-­‐specific	  differences	  observed	  in	  cell	  migration	  experiments	  are	  true	  
functional	  disparities	  or	  the	  result	  of	  different	  expression	  levels.	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3.2 Results 
3.2.1 The invasive phenotype of A2780-Rab25 cells is dependent on ERK 
signalling 
To	  study	  the	  contribution	  made	  by	  ERK1	  and	  ERK2	  to	  invasive	  tumour	  cell	  migration,	  we	  
required	  a	  suitable	  cancer	  cell	  line	  with	  an	  ERK-­‐dependent	  invasive	  phenotype.	  To	  this	  
end,	  we	  chose	  the	  well-­‐characterised	  invasive	  ovarian	  carcinoma	  cell	  line	  A2780-­‐Rab25	  
which,	  through	  stable	  overexpression	  of	  ectopic	  HA-­‐Rab25,	  show	  enhanced	  invasiveness	  
into	  bona	  fide	  3D	  matrices	  such	  as	  collagen	  or	  Matrigel	  [380]	  and	  increased	  
aggressiveness	  in	  xenograft	  studies	  of	  ovarian	  and	  breast	  tumours	  in	  nude	  mice	  [351].	  We	  
postulated	  that	  the	  invasive	  phenotype	  of	  A2780-­‐Rab25	  cells	  requires	  ERK	  signalling	  and	  
performed	  inverted	  invasion	  assays	  (previously	  described	  by	  Hennigan	  et	  al.	  [352]	  and	  
adapted	  by	  Caswell	  et	  al.	  [380]),	  where	  tumour	  cells	  were	  plated	  onto	  the	  underside	  of	  a	  
Matrigel	  plug	  supplemented	  with	  25	  µg/ml	  fibronectin.	  (N.B.	  The	  addition	  of	  fibronectin	  
was	  shown	  to	  be	  necessary	  for	  Rab25-­‐driven	  invasion	  [380]).	  A2780-­‐Rab25	  cells	  were	  
allowed	  to	  migrate	  through	  the	  porous	  membrane	  of	  the	  Transwell	  insert	  into	  the	  
Matrigel.	  Subsequently,	  a	  chemotactic	  gradient	  was	  established	  by	  adding	  full	  medium	  
containing	  25	  ng/ml	  EGF	  into	  the	  upper	  chamber	  and	  serum-­‐free	  medium	  into	  the	  lower	  
chamber	  (see	  Figure	  3-­‐2	  A	  for	  experimental	  set-­‐up).	  After	  36	  hours,	  living	  cells	  were	  
stained	  using	  Calcein-­‐AM	  and	  imaged	  on	  a	  confocal	  microscope.	  Optical	  sections	  were	  
gathered	  every	  15	  µm,	  starting	  at	  the	  bottom	  of	  the	  Matrigel	  plug	  and	  moving	  upwards	  in	  
the	  direction	  of	  cell	  invasion.	  To	  test	  whether	  ERK	  signalling	  was	  required	  for	  the	  invasion	  
of	  A2780-­‐Rab25	  cells,	  the	  MEK	  inhibitor,	  U0126	  was	  added	  to	  the	  lower	  and	  upper	  
chamber	  at	  a	  concentration	  of	  10	  µM.	  Figure	  3-­‐2	  B	  shows	  representative	  strips,	  which	  
were	  assembled	  from	  individual	  images	  obtained	  during	  optical	  sectioning	  of	  the	  Matrigel	  
plug.	  Cells	  are	  stained	  green	  and	  their	  migration	  from	  left	  to	  right	  indicated	  by	  the	  arrow,	  
corresponds	  to	  their	  upward	  migration.	  Quantification	  of	  three	  independent	  experiments,	  
within	  which	  each	  experimental	  condition	  was	  represented	  by	  two	  Matrigel	  plugs	  and	  
three	  regions	  (corresponding	  to	  x,y	  positions)	  of	  each	  plug,	  was	  performed	  using	  the	  
ImageJ.	  Invasive	  migration	  was	  expressed	  as	  a	  percentage	  of	  cells	  that	  migrated	  beyond	  
45	  µm	  relative	  to	  the	  control	  condition.	  When	  ERK	  activation	  was	  inhibited	  by	  U0126	  
treatment,	  we	  observed	  a	  significant	  decrease	  in	  invasion	  by	  approximately	  50%	  
(p<0.0001)	  (Figure	  3-­‐2	  C).	  Furthermore,	  ERK	  inhibition	  was	  validated	  by	  Western	  blotting	  
to	  be	  completely	  abolished	  24	  hours,	  and	  marginally	  recovered	  48	  hours	  after	  U0126	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Figure 3-2 The invasive phenotype of A2780-Rab27 cells is dependent on ERK signalling 
A. Schematic diagram on how inverse invasion assays are set up and quantified. 
B. Matrigel plugs were enriched with 25 µg/ml fibronectin and 4x104 A2780-Rab25 cells were plated onto 
the underside of each Transwell. The MEK inhibitor, U0126 (10µM), or DMSO was added to the media. 
After 36 hrs invading cells were visualized by Calcein-AM staining. Serial optical sections were captured 
every 15 µm and are presented as a sequence in which the depth increases from left to right. 
C. Invasive migration was quantified by measuring the fluorescence intensity of cells penetrating the 
Matrigel plug to depths of ≥ 45 µm and expressed relative to cells treated with DMSO. Values are means ± 
standard error of the mean (SEM) of 18 replicates from three independent experiments. Statistical 
significance of difference was determined by Mann-Whitney U test analysis. 
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treatment	  (Figure	  3-­‐2	  D).	  Taken	  together	  the	  data	  indicates	  that	  invasion	  of	  A2780-­‐Rab25	  
cells	  is	  dependent	  on	  ERK	  signalling,	  thus	  proving	  as	  a	  suitable	  cell	  line	  to	  study	  the	  
isoform-­‐specific	  contributions	  towards	  invasive	  tumour	  cell	  migration.	  
3.2.2 Silencing of ERK2 impairs invasion into Matrigel 
Next,	  we	  wanted	  to	  investigate	  the	  respective	  roles	  of	  ERK1	  and	  ERK2	  in	  invasive	  
migration.	  Therefore,	  A2780-­‐Rab25	  cells	  were	  transfected	  with	  non-­‐targeting	  (NT)	  siRNA	  
oligos	  or	  SMARTpools	  targeting	  either	  ERK1	  or	  ERK2.	  Knockdown	  of	  ERK	  was	  validated	  by	  
Western	  blotting	  48	  and	  72	  hours	  post	  transfection	  (Figure	  3-­‐3	  A).	  Surprisingly,	  silencing	  
of	  ERK1	  resulted	  in	  enhanced	  invasion	  (p<0.05),	  whereas	  knockdown	  of	  ERK2	  significantly	  
decreased	  migration	  into	  the	  Matrigel	  plug	  by	  approximately	  40%	  (p<0.0001).	  When	  both	  
ERK	  isoforms	  were	  knocked	  down	  simultaneously,	  a	  30%	  decrease	  in	  invasion	  was	  
observed	  (p<0.01)	  (Figure	  3-­‐3).	  	  
RNA	  interference	  is	  a	  commonly	  used	  method	  to	  study	  gene	  function	  in	  biological	  
processes,	  such	  as	  apoptosis,	  differentiation	  and	  cell	  migration.	  However,	  
short-­‐interfering	  RNAs	  (siRNAs)	  have	  been	  reported	  to	  silence	  unintended	  transcripts,	  
which	  are	  only	  partially	  complementary	  in	  sequence	  [465].	  Moreover,	  siRNAs	  can	  affect	  
mRNA	  translation	  [466]	  and	  induce	  an	  unspecific	  interferon	  response	  [467].	  Therefore,	  
caution	  is	  warranted	  when	  interpreting	  functional	  and	  phenotypical	  changes	  following	  
RNAi.	  The	  validity	  of	  biological	  changes	  observed	  following	  siRNA	  of	  a	  given	  target	  gene	  is	  
generally	  assessed	  by	  using	  multiple	  independent	  siRNA	  duplexes.	  Thus,	  while	  all	  
duplexes	  employed	  display	  the	  same	  on-­‐target	  activity,	  their	  non-­‐specific	  effects	  will	  
differ	  and	  functional	  changes	  observed	  with	  at	  least	  two	  siRNA	  duplexes	  are	  likely	  to	  be	  
attributed	  to	  silencing	  of	  the	  target	  gene	  rather	  than	  overlapping	  off-­‐target	  effects.	  
In	  order	  to	  control	  for	  any	  off-­‐target	  effects	  caused	  by	  the	  siRNA	  oligos	  of	  the	  
SMARTpool,	  invasion	  assays	  were	  repeated	  with	  two	  independent	  oligos	  targeting	  either	  
ERK1	  or	  ERK2.	  Silencing	  of	  the	  respective	  isoform	  was	  confirmed	  72	  and	  96	  hours	  post	  
transfection	  by	  Western	  blotting	  (Figure	  3-­‐4	  A).	  Knockdown	  of	  ERK1	  with	  oligo	  #1	  or	  #2	  
showed	  no	  significant	  effect	  on	  invasion	  when	  compared	  to	  NT	  controls.	  In	  contrast,	  
silencing	  of	  ERK2	  with	  oligos	  #1	  or	  #2	  significantly	  reduced	  invasion	  into	  Matrigel	  by	  
approximately	  50%	  (p<0.0001)	  (Figure	  3-­‐4	  B/C).	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Figure 3-3 Suppression of ERK2 levels reduces invasiveness of A2780-Rab25 cells 
A. A2780-Rab25 cells were transfected with non-targeting siRNAs (NT), or SMARTpools targeting ERK1 
or ERK2. The effectiveness of the ERK knockdown was assessed by Western blot 48 hrs and 72 hrs after 
transfection. (S) and (L) refer to a short and long exposure times, respectively. 
B. Matrigel plugs were enriched with 25 µg/ml fibronectin and 4x104 cells were plated onto the underside of 
each Transwell 24 hrs post transfection. 36 hrs following this, invading cells were visualized by Calcein-AM 
staining. Serial optical sections were captured every 15 µm and are presented as a sequence in which the 
depth increases from left to right. 
C. Invasive migration was quantified by measuring the fluorescence intensity of cells penetrating the 
Matrigel plug to depths of ≥ 45 µm and expressed relative to cells transfected with non-targeting (NT) 
siRNA. Values are means ± standard error of the mean (SEM) of 18 replicates from three independent 
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Figure 3-4 siRNA of ERK2 opposes invasion into Matrigel 
A. A2780-Rab25 cells were transfected with non-targeting siRNAs (NT), or single oligos targeting ERK1 or 
ERK2. The effectiveness of the ERK knockdown was assessed by Western blot 72 hrs and 96 hrs after 
transfection. (S) and (L) refer to a short and long exposure times, respectively. 
B. Matrigel plugs were enriched with 25 µg/ml fibronectin and 4x104 cells were plated onto the underside of 
each Transwell 24 hrs post transfection. 36 hrs following this, invading cells were visualized by Calcein-AM 
staining. Serial optical sections were captured every 15 µm and are presented as a sequence in which the 
depth increases from left to right. 
C. Invasive migration was quantified by measuring the fluorescence intensity of cells penetrating the 
Matrigel plug to depths of ≥ 45 µm and expressed relative to cells transfected with non-targeting (NT) 
siRNA. Values are means ± standard error of the mean (SEM) of 18 replicates from three independent 
experiments. Statistical significance of differences was determined by Mann-Whitney U test analysis. 
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3.2.3 Transient knockdown of ERK does not induce apoptosis or alter 
proliferation in A2780-Rab25 cells 
ERK	  signalling	  cooperatively	  enhances	  cellular	  growth,	  proliferation	  and	  cell	  survival.	  
Thus,	  diminishing	  ERK	  signalling	  through	  transient	  knockdown	  may	  affect	  cell	  viability	  and	  
thereby	  alter	  the	  invasive	  phenotype	  of	  A2780-­‐Rab25	  cells.	  Given	  that	  ERK2	  is	  the	  
predominant	  kinase	  in	  these	  cells	  (Figure	  3-­‐2	  D),	  silencing	  ERK2	  may	  greatly	  reduce	  the	  
amount	  of	  active	  ERK,	  whereas	  knockdown	  of	  ERK1	  might	  result	  in	  a	  marginal	  reduction	  
of	  pERK	  levels.	  Our	  data,	  however,	  demonstrates	  a	  compensatory	  increase	  in	  pERK1	  levels	  
upon	  ERK2	  knockdown	  and	  vice	  versa.	  Thus,	  transient	  knockdown	  of	  either	  ERK1	  or	  ERK2	  
does	  not	  alter	  the	  pool	  of	  active	  ERK	  dramatically.	  
In	  order	  to	  test,	  whether	  knockdown	  of	  either	  ERK	  isoform	  induces	  apoptosis,	  
A2780-­‐Rab25	  cells	  were	  transfected	  with	  NT	  siRNA	  and	  oligos	  targeting	  ERK1	  and	  ERK2.	  
As	  a	  positive	  control	  the	  extrinsic	  apoptotic	  pathway	  was	  induced	  in	  non-­‐transfected	  cells	  
by	  treatment	  with	  Fas-­‐ligand	  (50	  nM)	  and	  5	  µg/ml	  cycloheximide	  for	  24	  hours.	  Fas-­‐ligand	  
binding	  to	  the	  death	  receptor,	  FasR,	  activates	  the	  caspase	  cascade,	  while	  cycloheximide	  
inhibits	  protein	  synthesis	  by	  blocking	  the	  translational	  elongation	  step	  [381].	  Caspase	  
activation	  will	  ultimately	  promotes	  the	  cleavage	  of	  poly	  ADP	  ribose	  polymerase	  (PARP),	  
which	  is	  involved	  in	  DNA	  repair	  of	  single-­‐stranded	  nicks	  [382].	  PARP	  cleavage	  gives	  rise	  to	  
two	  fragments	  of	  24	  kDa	  and	  89	  kDa,	  which	  can	  be	  visualised	  by	  Western	  blotting.	  When	  
examining	  cells	  treated	  with	  Fas-­‐ligand	  and	  cycloheximide	  using	  a	  phase-­‐contrast	  light	  
microscope,	  A2780-­‐Rab25	  cells	  were	  round,	  largely	  unattached	  and	  fragmented.	  In	  order	  
to	  harvest	  any	  apoptotic	  cells,	  we	  collected	  the	  media	  of	  each	  experimental	  condition	  and	  
centrifuged	  at	  10,000	  rpm	  for	  five	  minutes	  at	  4˚C.	  The	  supernatant	  was	  discarded	  and	  the	  
pellet	  kept	  on	  ice.	  PBS	  from	  subsequent	  wash	  steps	  and	  the	  trypsinised	  cell	  suspension	  
were	  also	  spun	  down	  in	  the	  same	  tube.	  The	  final	  pellet,	  containing	  both	  apoptotic	  and	  
non-­‐apoptotic	  cells,	  was	  lysed	  in	  HEPES	  lysis	  buffer	  and	  PARP-­‐1	  cleavage	  was	  determined	  
by	  Western	  blotting.	  Interestingly,	  the	  89	  kDa	  PARP-­‐1	  fragment	  was	  clearly	  visible	  in	  
apoptosis-­‐induced	  A2780-­‐Rab25	  cells,	  whereas	  control-­‐transfected	  and	  ERK	  knockdown	  
cells	  showed	  no	  PARP-­‐1	  cleavage	  (Figure	  3-­‐5	  A).	  We,	  therefore,	  concluded	  that	  apoptosis	  
was	  not	  triggered	  as	  a	  result	  of	  transient	  ERK	  knockdown.	  
With	  the	  exception	  of	  Vantaggiato	  et	  al.	  [371],	  multiple	  reports	  studying	  the	  role	  of	  ERK1	  
and	  ERK2	  in	  proliferation	  have	  demonstrated	  that	  both	  isoforms	  positively	  contribute	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Figure 3-5 siRNA of ERK1 or ERK2 does not induce apoptosis or inhibit proliferation 
A2780-Rab25 cells were transfected with non-targeting siRNAs (NT), or those targeting ERK1 or ERK2.  
A. Apoptosis was induced in control transfected cells by Fas-ligand (50nM) and cycloheximide (5µg/ml) 
treatment. PARP-cleavage was determined 24 hours after induction. 
B. The proliferation assay was set up 24 hrs after transfection by seeding 20,000 cells into a 6-well dish. The 
following 4 days, cells were counted using a Casy counter. Relative cell number was plotted against time. 
Values are means ± standard error of the mean (SEM) of 9 replicates from three independent experiments. 
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towards	  cellular	  growth	  [357,	  359,	  366,	  376]	  and	  therefore	  reducing	  the	  pool	  of	  active	  
ERK	  by	  silencing	  either	  isoform	  may	  result	  in	  proliferative	  changes.	  To	  test	  this,	  we	  
transfected	  A2780-­‐Rab25	  cells	  with	  NT	  siRNA,	  or	  those	  targeting	  ERK1,	  or	  ERK2	  and	  
seeded	  40,000	  cells	  into	  a	  6-­‐well	  dish	  one	  day	  after	  transfection.	  As	  a	  negative	  control,	  
one	  set	  of	  control-­‐transfected	  cells	  were	  treated	  with	  the	  MEK	  inhibitor,	  U0126,	  which	  
has	  previously	  been	  shown	  to	  inhibit	  proliferation	  in	  vitro	  and	  in	  vivo	  [383-­‐385].	  Cellular	  
growth	  was	  monitored	  by	  cell	  counting	  using	  a	  Casy	  cell	  counter	  and	  a	  haemocytometer.	  
The	  cell	  number	  of	  each	  experimental	  condition	  was	  measured	  over	  the	  course	  of	  four	  
days	  and	  is	  represented	  as	  a	  relative	  cell	  number	  in	  Figure	  3-­‐5	  B.	  Three	  independent	  
experiments	  were	  performed,	  in	  which	  each	  experimental	  condition	  was	  set	  up	  in	  
triplicate.	  As	  expected,	  we	  observed	  a	  proliferative	  inhibition	  two	  days	  after	  U0126	  
treatment.	  In	  contrast,	  transient	  knockdown	  of	  either	  ERK1	  or	  ERK2	  did	  not	  affect	  cellular	  
growth,	  although	  an	  efficient	  knockdown	  was	  achieved	  during	  the	  course	  of	  the	  
experiment	  (Figure	  3-­‐5	  C).	  	  
In	  summary,	  we	  found	  that	  knocking	  down	  either	  ERK	  isoform	  had	  no	  effect	  on	  
proliferation	  or	  apoptosis	  indicating	  that	  effects	  of	  ERK	  signalling	  on	  cell	  viability	  did	  not	  
influence	  our	  invasion	  and	  motility	  results.	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3.2.4 Both ERK isoforms contribute to migration on plastic surfaces 
Rab25,	  which	  was	  shown	  to	  be	  a	  component	  of	  an	  invasive	  gene	  signature	  in	  breast	  
cancer	  cells	  [386],	  alters	  the	  way	  in	  which	  A2780	  cells	  migrate	  on	  extracellular	  matrices,	  
but	  not	  on	  2D	  plastic	  surfaces	  [380].	  Given	  that	  changes	  in	  invasiveness	  do	  not	  necessarily	  
reflect	  on	  plastic,	  we	  set	  out	  to	  investigate	  whether	  ERK2	  altered	  cell	  migration	  in	  2D.	  
Thus,	  we	  transiently	  transfected	  A2780-­‐Rab25	  cells	  with	  non-­‐targeting	  siRNAs	  (NT),	  or	  
single	  oligos	  targeting	  ERK1	  or	  ERK2.	  Subsequently,	  cells	  were	  seeded	  into	  a	  6-­‐well	  dish,	  
so	  that	  they	  were	  confluent	  48	  hours	  post	  transfection.	  After	  introducing	  a	  wound	  by	  
scratching	  the	  plastic	  dish	  with	  a	  200	  µl	  pipette	  tip,	  wound	  closure	  was	  monitored	  at	  10	  
minute	  intervals	  using	  a	  time-­‐lapse	  microscope.	  The	  movement	  of	  individual	  cells	  was	  
followed	  using	  the	  ImageJ	  cell	  tracking	  software.	  Images	  were	  taken	  from	  five	  distinct	  
fields	  along	  the	  wound	  in	  every	  well	  and	  a	  minimum	  of	  five	  cells	  were	  tracked	  in	  each	  
field.	  The	  migratory	  speed,	  persistence	  and	  FMI	  were	  extracted	  from	  the	  trackplots	  from	  
three	  independent	  experiments	  and	  are	  represented	  in	  Figure	  3-­‐6.	  Persistence	  is	  a	  
measurement	  on	  how	  direct	  a	  cell	  moves	  from	  A	  to	  B	  and	  is	  calculated	  by	  dividing	  the	  
vectorial	  cell	  path	  by	  the	  accumulated	  distance.	  The	  forward	  migration	  index	  (FMI)	  is	  
commonly	  extracted	  from	  wound	  healing	  assays,	  as	  it	  is	  a	  measurement	  of	  wound	  
sensing.	  The	  FMI	  represents	  the	  ratio	  of	  the	  perpendicular	  distance	  and	  the	  accumulated	  
path	  (Figure	  3-­‐6	  B).	  The	  migration	  speed	  of	  ERK1	  or	  ERK2	  knockdown	  cells	  was	  expressed	  
relative	  to	  the	  migration	  velocity	  of	  cells	  transfected	  with	  NT	  siRNA	  to	  account	  for	  
differences	  in	  the	  absolute	  migration	  speed	  between	  different	  experiments.	  
Treatment	  of	  A2780-­‐Rab25	  cells	  with	  the	  MEK	  inhibitor,	  U0126,	  significantly	  impaired	  
wound	  closure	  and	  severely	  reduced	  the	  migratory	  speed	  to	  approximately	  50%	  of	  
NT-­‐transfected	  cells.	  Interestingly,	  silencing	  of	  ERK1	  or	  ERK2	  with	  two	  independent	  oligos	  
significantly	  delayed	  wound	  closure	  and	  resulted	  in	  a	  25%	  decrease	  in	  migratory	  speed	  
(p<0.0001)	  (Figure	  3-­‐6	  A/C).	  In	  contrast,	  persistence	  and	  FMI	  did	  not	  change	  upon	  
inhibition	  of	  ERK	  signalling	  with	  U0126	  or	  knockdown	  of	  either	  ERK	  isoform	  (Figure	  
3-­‐6	  D/E).	  Thus,	  whereas	  invasion	  into	  Matrigel	  is	  specifically	  regulated	  by	  ERK2	  in	  
A2780-­‐Rab25	  cells,	  migration	  on	  2D	  plastic	  surfaces	  appears	  to	  be	  regulated	  by	  both	  ERK	  
isoforms	  and	  may	  depend	  on	  the	  total	  ERK	  activity	  present	  in	  the	  cell.	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Figure 3-6 Both ERK isoforms contribute towards migration on plastic in A2780-Rab25 cells 
A. A2780-Rab25 cells were transfected with non-targeting siRNAs (NT), or single oligos targeting ERK1 or 
ERK2. Subsequently, cells were seeded into a 6-well dish, so that they were confluent 48 hrs post 
transfection. After scratching wound closure was monitored and representative time frames are shown. Scale 
bar, 100 µm.  
B. Schematic outline of the cell tracking analysis. The overall migration velocity is defined as the ratio of 
accumulated path length and time. Persistence is defined as the ratio of the vectorial distance a cell travelled 
and the accumulated path length. The forward migration index (FMI) is a measure for wound sensing and is 
determined by dividing the distance travelled into the wound by the accumulated path length. The 
momentary velocity represents a frame-to-frame migration speed. 
(see next page also) 
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C-E. The movement of individual cells into the wound was followed using ImageJ cell tracking software. 
The overall migration velocity (C), persistence (D) and forward migration index (FMI) (E) were extracted 
from the trackplots. Values are means ± SEM of >75 trackplots from three independent experiments. 
Statistical significance of differences was determined by Mann-Whitney U test analysis. 
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3.2.5 Knockdown of ERK2 impairs migration on cell-derived matrices 
To	  get	  a	  better	  understanding	  of	  how	  ERK2	  silencing	  controls	  invasive	  cell	  migration,	  we	  
decided	  to	  use	  cell-­‐derived	  matrix	  (CDM),	  which	  was	  previously	  described	  by	  Cukierman	  
et	  al.,	  and	  which	  represents	  a	  good	  physiological	  model	  of	  the	  ECM	  [38].	  CDMs	  are	  
generated	  by	  human	  telomerase-­‐immortalised	  fibroblasts,	  which	  naturally	  produce	  
extracellular	  matrix-­‐like	  fibres	  around	  themselves	  and	  thereby	  create	  a	  relatively	  thick	  
(10	  µm),	  pliable	  matrix	  composed	  mainly	  of	  fibrillar	  collagen	  and	  fibronectin,	  which	  
recapitulates	  key	  aspects	  of	  the	  type	  of	  matrix	  found	  in	  connective	  tissues	  [38,	  353].	  After	  
growing	  these	  fibroblasts	  as	  a	  confluent	  monolayer	  for	  10-­‐14	  days,	  during	  which	  ECM	  
fibers	  are	  synthesized,	  the	  cells	  were	  removed	  from	  the	  surrounding	  ECM	  by	  treatment	  
with	  a	  non-­‐ionic	  detergent.	  Cancer	  cells	  may	  then	  be	  plated	  onto	  the	  remaining	  fibrillar	  
CDM	  to	  study	  their	  migratory	  and	  morphological	  characteristics	  in	  this	  quasi-­‐3D	  
environment.	  As	  expected,	  there	  is	  a	  striking	  difference	  in	  morphology	  and	  mode	  of	  
migration	  of	  A2780-­‐Rab25	  between	  plastic	  surfaces	  and	  CDM	  (Figure	  3-­‐7).	  During	  
migration	  on	  plastic	  and	  other	  rigid	  substrates	  many	  cell	  types	  migrate	  by	  forming	  
lamellipodia	  and	  stress	  fibers	  [387,	  388].	  Moreover,	  adhesion	  structures	  on	  2D	  surfaces,	  
which	  are	  divided	  into	  focal	  and	  fibrillar	  adhesions,	  are	  rich	  in	  αvβ3	  integrin,	  paxillin,	  
vinculin	  and	  FAK,	  or	  α5β1	  integrin	  and	  tensin,	  respectively	  [389].	  In	  3D,	  however,	  cells	  
either	  acquire	  an	  elongated,	  mesenchymal-­‐like	  morphology,	  which	  is	  marked	  by	  
pseudopod	  formation	  at	  the	  cellular	  front	  and	  requires	  matrix	  remodeling,	  or	  an	  
amoeboid,	  rounded	  shape,	  which	  is	  characterized	  by	  high	  Rho/ROCK	  activity	  and	  the	  
formation	  of	  bleb-­‐like	  protrusions	  [34].	  In	  addition,	  cells,	  cultured	  in	  3D,	  lose	  the	  
dorsal-­‐ventral	  asymmetry	  and	  form	  3D	  matrix	  adhesions,	  which	  are	  composed	  mainly	  of	  
paxillin	  and	  α5β1	  integrin	  [38].	  
We	  transfected	  cells	  with	  either	  NT	  siRNA,	  or	  single	  oligos	  targeting	  ERK1	  or	  ERK2.	  50,000	  
cells	  were	  seeded	  onto	  a	  6-­‐well	  cell	  culture	  dish	  coated	  with	  CDM	  48	  hours	  post	  
transfection	  and	  allowed	  to	  adhere	  to	  the	  3D	  substratum	  for	  approximately	  four	  hours.	  
Cell	  migration	  was	  monitored	  on	  a	  time-­‐lapse	  microscope	  over	  the	  course	  of	  16	  hours	  and	  
images	  were	  acquired	  every	  10	  minutes.	  Stills	  of	  representative	  movies	  are	  shown	  in	  
Figure	  3-­‐8	  A.	  Notably,	  no	  morphological	  differences	  between	  NT	  siRNA-­‐transfected,	  
U0126-­‐treated	  and	  ERK	  knockdown	  cells	  were	  observed.	  However,	  when	  cell	  movement	  
was	  analysed	  using	  the	  ImageJ	  cell	  tracking	  software,	  we	  detected	  a	  significant	  decrease	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Figure 3-7 Cell-derived matrices (CDM) represent a 3D-like environment 
A. Schematic diagram illustrating the protocol for generating CDM. 
B. Confocal sections of CDM displaying either parallel (left) or intersecting (right) fibronectin fibres. 
Fibronectin was visualised by indirect immunofluorescence using a Cy2-conjugated secondary antibody 
(green). Scale bar, 10 µm 
C. A2780-Rab25 cells were seeded onto plastic and CDM-coated dishes. After 16 hours cells were visualised 
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Figure 3-8 siRNA of ERK2 reduces migration of A2780-Rab25 cells on CDM 
A.A2780-Rab25 cells were transfected with non-targeting siRNAs (NT), or those targeting ERK1 or ERK2 
and plated onto cell-derived matrix. Images were captured every 10 minutes over a 16 hrs period using a 
Nikon time-lapse microscope. Still images from a representative movie are displayed. Scale bar, 100 µm. 
B-C. The movement of individual cells was followed using the ImageJ cell tracking software. The overall 
migration velocity (B) and persistence (C) were extracted from the trackplots. Values are means ± SEM of 
>75 trackplots from three independent experiments. Statistical significance of differences was determined by 
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in	  the	  migration	  velocity	  on	  CDM,	  when	  cells	  were	  treated	  with	  the	  U0126	  inhibitor	  or	  
ERK2	  was	  silenced	  with	  two	  independent	  oligos	  (p<0.0001).	  In	  contrast,	  knockdown	  of	  
ERK1	  did	  not	  alter	  the	  migration	  speed	  when	  compared	  to	  control	  (Figure	  3-­‐8	  B).	  
Moreover,	  we	  determined	  the	  persistence	  of	  cell	  migration	  and	  found	  no	  significant	  
difference	  between	  NT	  siRNA,	  U0126	  treatment	  and	  ERK	  knockdown	  cells	  (Figure	  3-­‐8	  C).	  
During	  our	  cell	  tracking	  analysis,	  we	  noticed	  that	  ERK2	  knockdown	  cells	  had	  a	  tendency	  to	  
remain	  stationary	  for	  extended	  periods	  of	  time.	  Thus,	  the	  previously	  observed	  difference	  
in	  the	  relative	  migration	  speed	  may	  be	  attributed	  to	  the	  stationary	  phases,	  which	  we	  
term	  ‘cellular	  resting’	  (Figure	  3-­‐9	  B).	  To	  quantify	  this	  we	  defined	  a	  cell	  that	  moved	  less	  
than	  2	  µm	  within	  90	  minutes	  as	  one	  that	  was	  engaged	  in	  ‘cellular	  resting’.	  ERK2	  
knockdown	  or	  addition	  of	  U0126	  markedly	  increased	  the	  proportion	  of	  cells	  that	  were	  
resting,	  whereas	  siRNA	  of	  ERK1	  was	  ineffective	  in	  this	  regard	  (Figure	  3-­‐9	  C).	  Moreover,	  we	  
compared	  the	  average	  duration	  of	  each	  rest	  (resting	  time)	  and	  found	  no	  significant	  
difference	  among	  our	  various	  experimental	  conditions	  (Figure	  3-­‐9	  C).	  Next,	  we	  
determined	  whether	  silencing	  of	  ERK2	  influenced	  cell	  movement	  during	  the	  period	  in	  
which	  cells	  were	  not	  resting.	  To	  do	  this,	  we	  calculated	  frame-­‐to-­‐frame	  displacement	  of	  
cells	  whilst	  they	  were	  not	  resting	  and	  termed	  the	  ‘momentary	  velocity’.	  We	  found	  the	  
momentary	  velocity	  to	  be	  significantly	  reduced	  following	  ERK2	  knockdown	  or	  addition	  of	  
U0126,	  but	  it	  was	  unaffected	  by	  siRNA	  of	  ERK1	  (Figure	  3-­‐9	  B).	  To	  represent	  this	  pictorially,	  
we	  generated	  trackplots	  of	  cells	  in	  which	  the	  migration	  speed	  is	  denoted	  by	  a	  colour	  
code,	  the	  scale	  of	  which	  is	  indicated	  on	  the	  left	  side	  of	  the	  panels,	  and	  the	  points	  at	  which	  
cells	  moved	  less	  than	  2μm	  in	  90	  min	  (cellular	  resting)	  are	  indicated	  by	  white	  dots.	  These	  
trackplots	  indicate	  that	  knockdown	  of	  ERK2	  increases	  cellular	  resting	  and	  decreases	  
momentary	  velocity	  whilst	  siRNA	  of	  ERK1	  is	  ineffective	  in	  both	  these	  regards	  (Figure	  
3-­‐9	  D)	  
Taken	  together	  these	  data	  indicate	  that	  knockdown	  of	  ERK2	  decreases	  cell	  invasiveness,	  
and	  that	  this	  corresponds	  to	  a	  combination	  of	  reduced	  momentary	  velocity	  and	  an	  
increased	  tendency	  of	  ERK2	  knockdown	  cells	  to	  remain	  immobile	  or	  rest	  for	  extended	  
periods	  on	  CDM.	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Figure 3-9	  Knockdown of ERK2 decreases the momentary velocity and increases cellular resting	  
A2780-Rab25 cells were transfected with non-targeting siRNAs (NT), or those targeting ERK1 or ERK2 and 
plated onto cell-derived matrix. Images were captured every 10 min over a 16 hrs period. Cell movement was 
followed using cell-tracking software.  
A. Schematic illustration on how the overall migration velocity can be affected by cellular resting and 
momentary velocity. 
B. Momentary migration velocities were calculated for each timeframe of the time-lapse experiment giving 
rise to over 7,000 values for each condition. Values are represented as box and whisker plots (whiskers: 
10-90 percentile) and represent three independent experiments. Statistical significance of differences was 
determined by Mann-Whitney U test analysis. 
C. Percentage of resting cells is displayed with absolute numbers for each condition above the column. The 
resting time was extracted from the trackplots and represents means ± SEM of thee independent experiments. 
D. Representative migration trackplots are displayed. The migration speed is denoted by a colour code, the 
scale of which is indicated on the left side of the panels. The points at which cells moved less than 2 μm in 
90 min (cellular resting) are indicated by white dots. Scale bar 100 μm. 
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3.2.6 ERK2 promotes invasion in the breast cancer cell line MDA-MB-231 
To	  assess	  whether	  the	  results	  obtained	  with	  A2780-­‐Rab25	  cells	  were	  more	  generally	  
applicable,	  we	  decided	  to	  repeat	  the	  invasion	  and	  migration	  assays	  in	  a	  second	  cell	  line	  
and	  chose	  the	  well-­‐characterised	  mammary	  adenocarcinoma	  cells,	  MDA-­‐MB-­‐231,	  which	  
were	  derived	  from	  a	  pleural	  effusion.	  
Having	  confirmed	  an	  efficient	  and	  prolonged	  knockdown	  of	  either	  ERK1	  or	  ERK2	  with	  two	  
independent	  oligos	  in	  MDA-­‐MB-­‐231	  cells	  (Figure	  3-­‐10	  A),	  we	  then	  performed	  inverted	  
invasion	  assays	  to	  test	  the	  role	  of	  these	  homologous	  kinases	  in	  invasive	  cell	  migration.	  As	  
a	  negative	  control,	  we	  inhibited	  ERK	  activation	  by	  treating	  NT	  siRNA-­‐transfected	  cells	  with	  
U0126.	  This	  drug	  prevents	  MEK	  activation	  and	  blocks	  ERK	  signalling	  within	  30	  minutes	  of	  
application.	  Indeed,	  the	  Western	  blot	  in	  Figure	  3-­‐10	  B	  shows	  a	  strong	  inhibition	  of	  ERK	  
signalling	  even	  after	  48	  hours	  of	  U0126	  treatment	  and	  therefore	  suggests	  an	  efficient	  
impediment	  in	  ERK	  activation	  during	  the	  assay.	  We	  analysed	  the	  relative	  contribution	  of	  
ERK1	  and	  ERK2	  during	  invasive	  cell	  migration	  using	  inverted	  invasion	  assays.	  ERK1	  
knockdown	  with	  either	  oligo	  had	  no	  significant	  effect	  on	  invasive	  migration	  into	  
fibronectin-­‐containing	  Matrigel,	  whereas	  invasion	  was	  clearly	  reduced	  by	  approximately	  
50%	  when	  ERK2	  was	  silenced	  (Figure	  3-­‐10	  C/D).	  Moreover,	  in	  the	  presence	  of	  U0126	  
invasive	  migration	  into	  the	  Matrigel	  plug	  was	  significantly	  impaired	  (p<0.0001)	  when	  
compared	  to	  control.	  Thus,	  like	  A2780-­‐Rab25,	  the	  invasive	  phenotype	  of	  MDA-­‐MB-­‐231	  
cells	  requires	  active	  ERK2,	  but	  not	  ERK1,	  signalling.	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Figure 3-10 ERK2 opposes invasion in MDA-MB-231 cells 
A. MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or those targeting ERK1 or ERK2. 
The effectiveness of the ERK knockdown was assessed by Western blot 48 hrs after transfection.  
B. ERK inhibition by U0126 (10 µM) was assessed by Western blotting 48 hrs after treatment. 
C. MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or those targeting ERK1 or ERK2 
and plated onto plugs of Matrigel supplemented with fibronectin. The MEK inhibitor, U0126 (10µM) was 
included as indicated. 36 hrs following this, invading cells were visualized by Calcein-AM staining. Serial 
optical sections were captured every 15 µm and are presented as a sequence in which the depth increases 
from left to right.  
D. Invasive migration was quantified by measuring the fluorescence intensity of cells penetrating the 
Matrigel plug to depths of ≥ 45 µm and expressed relative to cells transfected with non-targeting (NT) 
siRNA. Values are means ± standard error of the mean (SEM) of 18 replicates from three independent 
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3.2.7 Transient ERK silencing in MDA-MB-231 cells has no effect on 
apoptosis or proliferation 
As	  impaired	  cell	  viability	  may	  adversely	  affect	  cellular	  invasion	  and	  migration,	  we	  
investigated,	  whether	  ERK	  knockdown	  influenced	  apoptosis	  and	  cellular	  growth	  in	  
MDA-­‐MB-­‐231	  cells.	  To	  this	  end	  we	  transiently	  transfected	  MDA-­‐MB-­‐231	  cells	  with	  NT	  
siRNA	  or	  oligos	  targeting	  ERK1	  and	  ERK2.	  As	  a	  positive	  control,	  we	  induced	  the	  extrinsic	  
apoptotic	  pathway	  through	  treatment	  with	  the	  Fas-­‐ligand	  (50	  	  nM)	  and	  5	  µg/ml	  
cycloheximide	  for	  24	  hours.	  Similar	  to	  A2780-­‐Rab25	  cells,	  induction	  of	  the	  cell	  death	  
pathway	  induced	  cell	  rounding,	  detachment	  and	  fragmentation,	  which	  was	  visible	  with	  
the	  help	  of	  a	  phase-­‐contrast	  light	  microscope.	  When	  we	  assessed	  PARP-­‐1	  cleavage	  by	  
Western	  blotting,	  we	  detected	  an	  intense	  band	  of	  the	  89	  kDa	  fragment	  in	  Fas-­‐induced	  
cells,	  whereas	  full-­‐length	  PARP-­‐1	  was	  hardly	  visible.	  In	  contrast,	  MDA-­‐MB-­‐231	  cells	  
transfected	  with	  NT	  siRNA	  or	  oligos	  targeting	  ERK1	  and	  ERK2,	  predominantly	  exhibit	  the	  
uncleaved	  PARP-­‐1	  protein	  with	  a	  very	  faint	  band	  for	  the	  89	  kDa	  fragment	  (Figure	  3-­‐11	  A).	  
Although	  the	  89	  kDa	  fragment	  band	  is	  more	  intense	  in	  ERK2	  knockdown	  cells	  when	  
compared	  to	  the	  NT	  siRNA	  control,	  we	  conclude	  that	  cell	  viability	  is	  largely	  unaffected	  and	  
therefore	  does	  not	  account	  for	  the	  differences	  seen	  in	  the	  inverted	  invasion	  assays.	  	  
Next,	  we	  examined	  how	  ERK	  knockdown	  affected	  cellular	  growth	  in	  MDA-­‐MB-­‐231	  cells.	  
To	  this	  end,	  we	  transfected	  cells	  with	  NT	  siRNA,	  or	  those	  targeting	  ERK1,	  or	  ERK2	  and	  
seeded	  40,000	  cells	  into	  a	  6-­‐well	  dish	  one	  day	  after	  transfection.	  As	  a	  negative	  control,	  NT	  
siRNA-­‐transfected	  cells	  were	  treated	  with	  U0126.	  As	  expected,	  we	  observed	  a	  
proliferative	  inhibition	  two	  days	  after	  U0126	  treatment	  (Figure	  3-­‐11	  B).	  In	  contrast,	  
transient	  knockdown	  of	  either	  ERK1	  or	  ERK2	  did	  not	  affect	  cellular	  growth	  (Figure	  3-­‐11	  B),	  
even	  though	  an	  efficient	  knockdown	  was	  achieved	  during	  the	  course	  of	  the	  experiment	  as	  
was	  determined	  by	  Western	  blotting	  (Figure	  3-­‐11	  C).	  It	  is	  worth	  pointing	  out,	  that	  ERK1	  
activation	  increased	  in	  the	  absence	  of	  ERK2	  and	  resulted	  in	  a	  compensatory	  up-­‐regulation	  
of	  pERK1.	  Thus,	  the	  total	  amount	  of	  active	  ERK	  hardly	  changes,	  when	  the	  predominant	  
kinase	  ERK2	  is	  silenced.	  
To	  conclude,	  our	  3D	  migration	  experiments	  are	  not	  impaired	  due	  to	  changes	  in	  cellular	  
viability,	  indicating	  that	  true	  migratory	  defects	  exist	  when	  ERK2	  is	  silenced.	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Figure 3-11	  siRNA of ERK1 or ERK2 does not induce apoptosis or inhibit proliferation	  
MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or those targeting ERK1 or ERK2.  
A. Apoptosis was induced in control transfected cells by Fas-ligand (50nM) and cycloheximide (5µg/ml) 
treatment. PARP-cleavage was determined 24 hours after induction by Western blot. 
B. The proliferation assay was set up 24 hrs after transfection by seeding 40,000 cells into a 6-well dish. The 
following 4 days, cells were counted using a Casy counter. Relative cell number was plotted against time. 
Values are means ± standard error of the mean (SEM) of 9 replicates from three independent experiments. 
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3.2.8 Migration of MDA-MB-231 cells on plastic surfaces is impaired 
following knockdown of ERK2  
In	  A2780-­‐Rab25	  cells	  we	  demonstrated	  that	  silencing	  of	  ERK2	  impairs	  invasion	  into	  
Matrigel	  plugs	  and	  migration	  on	  cell-­‐derived	  matrix.	  This	  phenomenon,	  however,	  was	  not	  
mirrored	  in	  2D	  wound	  healing	  assays,	  where	  both	  ERK	  isoforms	  contributed	  to	  wound	  
closure.	  Having	  observed	  this	  discrepancy	  between	  2D	  and	  3D	  migration	  in	  A2780-­‐Rab25	  
cells,	  we	  set	  out	  to	  investigate,	  how	  knockdown	  of	  ERK1	  and	  ERK2	  affects	  migration	  on	  2D	  
surfaces	  in	  MDA-­‐MB-­‐231	  cells.	  To	  test	  this,	  we	  transiently	  knocked	  down	  either	  ERK1	  or	  
ERK2	  with	  two	  independent	  siRNA	  oligos	  for	  each	  isoform	  and	  plated	  cells,	  so	  that	  they	  
were	  confluent	  48	  hours	  post	  transfection.	  As	  a	  negative	  control,	  we	  opposed	  ERK	  
signalling	  by	  blocking	  MEK	  activation	  with	  U0126	  (10	  µM).	  After	  introducing	  a	  wound	  by	  
scratching	  the	  plastic	  dish	  with	  a	  200	  µl	  pipette	  tip,	  wound	  closure	  was	  monitored	  at	  10	  
minute	  intervals	  using	  a	  time-­‐lapse	  microscope.	  We	  found	  that	  U0126	  treatment	  and	  
knockdown	  of	  ERK2	  delayed	  wound	  closure.	  Using	  the	  manual	  tracking	  plugin	  in	  ImageJ,	  
we	  followed	  individual	  cells	  and	  extracted	  the	  migration	  velocity,	  persistence	  and	  forward	  
migration	  index	  (FMI)	  from	  the	  trackplots.	  Analysis	  of	  U0126-­‐treated	  cells	  showed	  a	  
significant	  decrease	  in	  the	  migration	  speed	  when	  compared	  to	  NT	  siRNA-­‐transfected	  cells	  
(p<0.0001)	  (Figure	  3-­‐12	  B),	  while	  persistence	  and	  the	  FMI	  were	  unaffected	  (Figure	  
3-­‐12	  C/D).	  Likewise,	  knockdown	  of	  ERK2	  with	  two	  independent	  oligos	  significantly	  
diminished	  the	  migration	  velocity	  (p<0.0001),	  while	  persistence	  and	  FMI	  were	  not	  
altered.	  In	  contrast,	  all	  of	  these	  indices	  of	  cell	  migration	  were	  unaffected,	  when	  ERK1	  was	  
silenced.	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Figure 3-12 ERK2 silencing inhibits migration of MDA-MB-231 cells on plastic 
A. MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or single oligos targeting ERK1 or 
ERK2. Subsequently, cells were seeded into a 6-well dish, so that they were confluent 48 hrs post 
transfection. After scratching, wound closure was monitored and representative time frames are shown. Scale 
bar, 100 µm.  
B-D. The movement of individual cells was followed using ImageJ cell tracking software. The overall 
migration velocity (C), persistence (D) and forward migration index (FMI) (E) were extracted from the 
trackplots. Values are means ± SEM of >75 trackplots from three independent experiments. Statistical 
significance of differences was determined by Mann-Whitney U test analysis. 
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3.2.9 Silencing of ERK2 impairs migration on CDM in MDA-MB-231 cells 
We	  set	  out	  to	  investigate	  the	  respective	  roles	  of	  ERK1	  and	  ERK2	  in	  MDA-­‐MB-­‐231	  cell	  
migration,	  when	  plated	  onto	  CDM.	  To	  do	  this,	  we	  transiently	  knocked	  down	  either	  ERK1	  
or	  ERK2	  with	  two	  independent	  oligos	  for	  each	  isoform	  and	  seeded	  100,000	  cells	  onto	  
CDM-­‐coated	  6-­‐well	  dishes,	  where	  cell	  motility	  was	  monitored	  in	  five-­‐minute	  intervals	  
using	  a	  time-­‐lapse	  microscope.	  In	  general,	  it	  is	  worth	  mentioning	  that	  MDA-­‐MB-­‐231	  cells	  
are	  smaller	  than	  A2780-­‐Rab25	  cells	  and	  adopt	  a	  spindle-­‐like	  shape	  with	  small	  
pseudopods,	  while	  migrating	  on	  CDM.	  	  
When	  ERK	  signalling	  was	  impaired	  by	  means	  of	  U0126	  treatment	  or	  knockdown	  of	  ERK,	  
we	  observed	  no	  morphological	  changes	  when	  compared	  to	  control-­‐transfected	  cells	  
(Figure	  3-­‐13	  A).	  However,	  the	  overall	  migration	  velocity	  was	  significantly	  decreased,	  when	  
MEK	  activation	  was	  inhibited	  or	  ERK2	  was	  silenced	  with	  either	  oligo	  #1	  or	  #2	  (p<0.0001).	  
On	  the	  other	  hand,	  silencing	  of	  ERK1	  had	  no	  effect	  on	  the	  overall	  migratory	  speed	  (Figure	  
3-­‐13	  B).	  Moreover,	  the	  persistence	  of	  migration	  was	  not	  significantly	  affected	  by	  
knockdown	  of	  either	  ERK	  or	  by	  addition	  of	  U0126	  (Figure	  3-­‐13	  C).	  	  
During	  our	  cell	  tracking	  analysis,	  it	  was	  apparent	  that	  MDA-­‐MB-­‐231	  cells	  silenced	  for	  
ERK2,	  like	  A2780-­‐Rab25,	  had	  a	  tendency	  to	  remain	  stationary	  for	  extended	  periods	  of	  
time.	  Thus,	  we	  quantified	  the	  momentary	  velocity	  and	  cellular	  resting,	  as	  defined	  for	  
A2780-­‐Rab25	  cells,	  and	  found	  a	  reduced	  momentary	  velocity	  and	  increased	  cellular	  
resting	  when	  cells	  were	  treated	  with	  U0126	  or	  silenced	  for	  ERK2.	  In	  contrast,	  ERK1	  
knockdown	  cells	  exhibited	  similar	  momentary	  velocities	  and	  resting	  incidences	  when	  
compared	  to	  control	  (Figure	  3-­‐14	  A-­‐C).	  Because	  only	  three	  resting	  incidences	  occurred	  in	  
control-­‐transfected	  cells,	  we	  were	  unable	  to	  carry	  out	  a	  meaningful	  statistical	  comparison	  
of	  resting	  times	  between	  our	  experimental	  conditions.	  Thus,	  the	  right	  panel	  of	  Figure	  
3-­‐14	  B	  may	  only	  be	  interpreted	  as	  a	  range	  of	  resting	  times,	  from	  which	  no	  conclusions	  
about	  differences	  in	  the	  stationary	  periods	  can	  be	  deduced.	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Figure 3-13 siRNA of ERK2 reduces migration of MDA-MB-231 cells on CDM	  
A.MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or those targeting ERK1 or ERK2 
and plated onto cell-derived matrix. Images were captured every 5 minutes over a 16 hrs period using a 
Nikon time-lapse microscope. Still images from a representative movie are displayed. Scale bar, 100 µm. 
B-C. The movement of individual cells was followed using the ImageJ cell tracking software. The overall 
migration velocity (B) and persistence (C) were extracted from the trackplots. Values are means ± SEM of 
>75 trackplots from three independent experiments. Statistical significance of differences was determined by 
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Figure 3-14	  Knockdown of ERK2 decreases the momentary velocity and increases cellular resting	  
MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or those targeting ERK1 or ERK2 
and plated onto cell-derived matrix. Images were captured every 10 min over a 16 hrs period. Cell movement 
was followed using cell-tracking software.  
A. Momentary migration velocities were calculated for each timeframe of the time-lapse experiment giving 
rise to over 7,000 values for each condition. Values are represented as box and whisker plots (whiskers: 
10-90 percentile) and represent three independent experiments. Statistical significance of differences was 
determined by Mann-Whitney U test analysis. 
B. Percentage of resting cells is displayed with absolute numbers for each condition above the column. The 
resting time was extracted from the trackplots and represents means ± SEM of thee independent experiments. 
C. Representative migration trackplots are displayed. The migration speed is denoted by a colour code, the 
scale of which is indicated on the left side of the panels. The points at which cells moved less than 2 μm in 
90 min (cellular resting) are indicated by white dots. Scale bar 100 μm. 
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3.2.10 Expression of recombinant ERK2 (but not ERK1) restores the 
migratory characteristics of MDA-MB-231 cells after ERK2 
knockdown 
Although	  our	  data	  obtained	  in	  A2780-­‐Rab25	  and	  MDA-­‐MB-­‐231	  cells	  strongly	  suggests	  an	  
ERK2-­‐specific	  function	  in	  invasive	  cell	  migration,	  our	  experimental	  design	  does	  not	  
consider	  the	  fact	  that	  ERK2	  is	  much	  more	  abundant	  than	  ERK1	  in	  these	  cells.	  Therefore,	  
observations	  that	  knockdown	  of	  ERK2	  affects	  invasion	  (whereas	  siRNA	  of	  ERK1	  does	  not)	  
do	  not	  necessarily	  reflect	  functional	  differences	  between	  the	  two	  kinases,	  but	  may	  be	  
attributable	  to	  differences	  in	  their	  expression	  level	  as	  demonstrated	  by	  Lefloch	  and	  
colleagues	  [357].	  To	  address	  this,	  we	  cloned	  expression	  plasmids	  of	  both	  ERK1	  and	  ERK2	  
and	  tagged	  the	  kinases	  N-­‐terminally	  with	  a	  Streptavidin-­‐Flag	  (SF)	  tag	  (Figure	  3-­‐15)	  [390].	  
Using	  these	  constructs,	  we	  were	  able	  to	  express	  recombinant	  ERK1	  or	  siRNA-­‐resistant	  
ERK2	  to	  equal	  levels	  after	  knocking	  down	  ERK2	  with	  oligo	  #2.	  The	  ectopically-­‐expressed	  
ERK1	  and	  ERK2	  isoforms	  were	  phosphorylated	  at	  the	  Thr-­‐Glu-­‐Tyr	  motif	  to	  the	  same	  extent	  
as	  one	  another,	  indicating	  that	  both	  of	  these	  recombinant	  ERKs	  were	  equally	  activated	  by	  
MEK	  in	  MDA-­‐MB-­‐231	  cells	  (Figure	  3-­‐16	  A).	  Moreover,	  the	  pool	  of	  activated	  ERK	  was	  
comparable	  between	  all	  conditions	  despite	  opposite	  ratios	  of	  activated	  ERK1	  and	  ERK2,	  
thus	  allowing	  us	  to	  test	  whether	  there	  is	  a	  true	  functional	  difference	  between	  the	  two	  
isoforms	  in	  cell	  migration.	  
Next,	  we	  monitored	  invasive	  cell	  migration	  by	  means	  of	  inverted	  invasion	  assays	  and	  
studied	  cell	  movement	  on	  CDM	  using	  the	  siRNA-­‐rescue	  paradigm.	  We	  found	  that	  ectopic	  
expression	  of	  ERK1	  did	  not	  reverse	  the	  inhibitory	  effect	  of	  ERK2	  knockdown	  on	  invasion,	  
whereas	  siRNA-­‐resistant	  ERK2	  expression	  completely	  rescued	  the	  invasive	  phenotype	  of	  
MDA-­‐MB-­‐231	  cells	  (Figure	  3-­‐16	  B/C).	  Moreover,	  when	  cell	  migration	  on	  CDM	  was	  
analysed,	  re-­‐expression	  of	  siRNA-­‐resistant	  ERK2	  increased	  the	  momentary	  velocity	  and	  
reduced	  the	  tendency	  of	  cells	  to	  pause	  (cellular	  resting)	  relative	  to	  that	  of	  control	  cells,	  
whereas	  re-­‐expression	  of	  ERK1	  did	  not	  rescue	  the	  migratory	  defects	  of	  ERK2	  knockdown	  
cells	  (Figure	  3-­‐17).	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Figure 3-15 ERK expression vectors	  
ERK1 (NM_002746) and ERK2 (NM_002745) genes were amplified from a cDNA library using primers 
with an attB1 and attB2 site and cloned into the N-terminal SF-TAP destination vector [390] via homologous 
recombination, giving rise to N-terminal SF-ERK1 (A) and N-terminal SF-ERK2 
C. Amino acid sequence of the SF-TAP tag is displayed. Residues marking the streptavidin (S) tag are 
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Figure 3-16 Ectopic expression of ERK2 but not ERK1 restores invasion of ERK2 knockdown cells  
A. MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNA targeting ERK2 in 
combination with expression plasmids for SF-ERK1, SF-ERK2 or an empty vector control (EV). Cells were 
harvested two days after transfection and ERK expression levels were determined by western blotting.  
B. MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNA targeting ERK2 in 
combination with expression plasmids for SF-ERK1, SF-ERK2 or an empty vector control (EV). Cells were 
plated onto plugs of fibronectin-supplemented Matrigel. 36 hrs following this, invading cells were visualized 
by Calcein-AM staining. Serial optical sections were captured every 15 µm and are presented as a sequence 
in which the depth increases from left to right.  
C. Invasive migration was quantified by measuring the fluorescence intensity of cells penetrating the 
Matrigel plug to depths of ≥ 45 µm and expressed relative to cells transfected with non-targeting (NT) 
siRNA. Values are means ± standard error of the mean (SEM) of 18 replicates from three independent 
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Figure 3-17 Ectopic expression of ERK2 but not ERK1 restores invasion of ERK2 knockdown cells  
MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNA targeting ERK2 in 
combination with expression plasmids for SF-ERK1, SF-ERK2 or an empty vector control (EV). Cells were 
plated onto cell-derived matrix. Images were captured every 10 min over a 16 hrs period. Cell movement was 
followed using cell-tracking software.  
A. Momentary migration velocities were calculated for each timeframe of the time-lapse experiment giving 
rise to over 7,000 values for each condition. Values are represented as box and whisker plots (whiskers: 
10-90 percentile) and represent three independent experiments. Statistical significance of differences was 
determined by Mann-Whitney U test analysis. 
B. Percentage of resting cells is displayed with absolute numbers for each condition above the column. The 
resting time was extracted from the trackplots and represents means ± SEM of thee independent experiments. 
C. Representative migration trackplots are displayed. The migration speed is denoted by a colour code, the 
scale of which is indicated on the left side of the panels. The points at which cells moved less than 2 μm in 
90 min (cellular resting) are indicated by white dots. Scale bar 100 μm. 
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3.3 Discussion 
3.3.1 Summary 
Although	  some	  research	  scientists	  believe	  that	  ERK1	  and	  ERK2	  are	  functionally	  redundant	  
and	  interchangeable,	  our	  data	  supports	  the	  view	  that	  these	  two	  kinases	  have	  different	  
roles	  in	  cell	  migration.	  Indeed,	  ERK2	  but	  not	  ERK1	  knockdown	  significantly	  inhibits	  
invasive	  cell	  migration	  of	  two	  independent	  cancer	  cell	  lines.	  Moreover,	  a	  detailed	  
quantitative	  analysis	  of	  cell	  movement	  on	  3D	  matrices	  indicates	  that	  ERK2	  (but	  not	  ERK1)	  
knockdown	  impairs	  cellular	  motility	  by	  decreasing	  the	  migration	  velocity	  as	  well	  as	  
increasing	  the	  time	  that	  cells	  remain	  stationary.	  Furthermore,	  we	  show	  that	  all	  these	  
migratory	  defects	  can	  be	  rescued	  by	  re-­‐expression	  of	  ERK2	  but	  not	  ERK1.	  Taken	  together,	  
our	  data	  provides	  evidence	  that	  ERK2	  is	  particularly	  important	  in	  the	  invasiveness	  of	  
cancer	  cells	  and	  that	  true	  functional	  disparities	  between	  ERK1	  and	  ERK2	  exist	  with	  regard	  
to	  cell	  migration.	  
3.3.2 Discrepancy between migration in 2D and 3D in A2780-Rab25 cells 
In	  2001,	  it	  was	  shown	  that	  inhibition	  of	  ERK	  signalling	  with	  U0126	  clearly	  compromised	  
cell	  motility	  of	  A375	  melanoma	  cells	  in	  invasion	  assays	  [391].	  Moreover,	  Bessard	  and	  
colleagues	  have	  carried	  out	  wound	  healing	  assays	  with	  hepatocarcinoma	  cells	  and	  
showed	  that	  knockdown	  of	  ERK2	  (but	  not	  ERK1)	  compromised	  motility	  in	  2D	  [379].	  In	  our	  
studies,	  we	  have	  shown	  that	  A2780-­‐Rab25	  cells	  rely	  on	  both	  ERK1	  and	  ERK2	  signalling	  
during	  scratch	  wound	  assays,	  while	  in	  MDA-­‐MB-­‐231	  cells	  silencing	  of	  ERK2	  but	  not	  ERK1	  
decreased	  wound	  closure.	  In	  3D	  experiments,	  however,	  ERK2	  was	  the	  main	  driver	  of	  cell	  
migration	  in	  both	  cell	  lines.	  What	  may	  account	  for	  the	  differences	  in	  2D	  and	  3D	  
migration?	  Firstly,	  wound	  scratch	  assays	  examine	  the	  ability	  of	  a	  cell	  culture	  to	  recolonize	  
the	  wound,	  which	  is	  dependent	  on	  both	  migration	  and	  cellular	  growth.	  Although	  this	  
method	  is	  well	  adapted	  for	  studying	  tissue	  injury,	  it	  has	  limitations	  when	  assessing	  
tumour	  cell	  motility.	  Firstly,	  tumour	  cells	  are	  asked	  to	  migrate	  across	  a	  rigid	  and	  planar	  
substrate,	  which	  hardly	  resembles	  an	  in	  vivo	  situation,	  where	  cancer	  cells	  migrate	  into	  the	  
extracellular	  matrix	  [387].	  Secondly,	  scratching	  the	  cell	  monolayer	  induces	  morphological	  
changes	  and	  physically	  stresses	  the	  cells	  at	  the	  edge	  of	  the	  wound,	  which	  changes	  
intracellular	  signalling	  events	  [392,	  393].	  Thirdly,	  cells	  cultured	  in	  2D	  exhibit	  completely	  
different	  gene	  expression	  signatures,	  portray	  differences	  in	  proliferation,	  morphology,	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and	  migration,	  when	  compared	  to	  3D	  [38,	  394,	  395].	  Moreover,	  cell	  movement	  in	  2D	  is	  
characterized	  by	  stress	  fibre	  formation	  and	  membrane	  ruffling	  at	  the	  cell	  front,	  which	  
have	  been	  linked	  to	  p38,	  JNK	  as	  well	  as	  ERK	  signalling	  [315,	  396,	  397].	  In	  3D,	  cells	  migrate	  
by	  extending	  a	  pseudopod	  at	  the	  cellular	  front,	  which	  attaches	  to	  the	  extracellular	  matrix	  
while	  the	  cell’s	  rear	  detaches	  and	  retracts.	  We	  believe	  that	  signalling	  differences	  are	  the	  
cause	  of	  these	  distinct	  modes	  of	  motility	  and	  therefore	  believe	  that	  it	  is	  plausible	  that	  
ERK’s	  role	  in	  2D	  migration	  might	  be	  different	  from	  3D	  and	  that	  these	  differences	  might	  be	  
cell-­‐type	  specific.	  
3.3.3 Roles of ERK in tumour cell migration 
Our	  data	  clearly	  shows	  that	  ERK2	  signalling	  orchestrates	  the	  cell	  migration	  machinery	  as	  
the	  momentary	  velocity	  of	  migrating	  cells	  was	  compromised	  in	  ERK2	  knockdown	  cells.	  
Moreover,	  we	  observed	  an	  increase	  in	  cellular	  resting,	  where	  A2780-­‐Rab25	  cells,	  in	  
particular,	  developed	  two	  opposing	  pseudopods	  and	  struggled	  to	  form	  a	  single	  dominant	  
pseudopod	  required	  for	  migration.	  Persistent	  cellular	  movement	  during	  chemotactic	  
experiments,	  such	  as	  inverted	  invasion	  assays,	  requires	  the	  establishment	  of	  a	  front	  to	  tail	  
polarity	  towards	  the	  chemotactic	  gradient,	  which	  is	  achieved	  by	  the	  interplay	  of	  three	  
central	  signalling	  events.	  Firstly,	  developing	  pseudopods	  display	  high	  Cdc42	  and	  Rac1	  
activity,	  which	  are	  linked	  to	  cellular	  polarisation	  and	  F-­‐actin	  formation	  respectively.	  
Moreover,	  increased	  phosphoinositide	  3-­‐kinase	  (PI3K)	  activity	  at	  the	  cellular	  front	  
elevates	  phosphatidylinositol-­‐3,4,5-­‐phosphate	  (PIP3)	  levels,	  which	  allows	  the	  recruitment	  
of	  PH-­‐domain	  containing	  signalling	  proteins	  and	  ensures	  further	  pseudopod	  extension.	  In	  
order	  to	  allow	  forward	  migration	  the	  formation	  of	  lateral	  or	  opposing	  pseudopods	  at	  the	  
cellular	  rear	  must	  be	  suppressed	  [398].	  This	  is	  achieved	  through	  the	  establishment	  of	  a	  
contractile	  myosin	  cortex,	  where	  active	  RhoA	  binds	  to	  its	  downstream	  effector	  protein,	  
Rho-­‐associated	  kinase	  (ROCK),	  which	  generates	  a	  contractile	  force	  by	  phosphorylating	  
and	  inactivating	  the	  myosin	  binding	  subunit	  of	  myosin	  phosphate	  (MYPT1),	  and	  
phosphorylating	  myosin	  light	  chain	  (MLC)	  directly	  [399].	  As	  our	  data	  clearly	  demonstrates	  
a	  migratory	  defect	  in	  ERK2	  knockdown	  cells,	  we	  believe	  that	  ERK2	  may	  partly	  regulate	  
some	  of	  the	  aforementioned	  signalling	  events.	  Indeed,	  a	  link	  between	  ERK	  signalling	  and	  
the	  small	  GTPases	  central	  to	  cell	  migration	  has	  been	  well-­‐established,	  albeit	  the	  exact	  
mechanism	  of	  regulation	  is	  still	  unknown.	  It	  is	  thought	  that	  ERK	  signalling	  may	  control	  
Rac1	  and	  Cdc42	  activity	  by	  regulating	  GEF	  localisation	  and/or	  activity.	  Thus,	  chemotactic	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extracellular	  stimuli	  may	  activate	  ERK	  signalling,	  which	  in	  turn	  induce	  Rac1	  and	  Cdc42	  
activation	  and	  thereby	  promote	  pseudopod	  formation	  towards	  the	  chemotactic	  
gradient	  [190,	  398].	  However,	  Rac1	  and	  Cdc42	  have	  also	  been	  shown	  to	  induce	  ERK	  
activation	  via	  PAK	  [400-­‐402].	  Thus,	  rather	  than	  ERK	  activating	  Rac1	  and	  Cdc42	  at	  the	  
leading	  edge,	  these	  small	  GTPases	  might	  be	  responsible	  for	  activating	  ERK	  signalling	  in	  the	  
forming	  pseudopod,	  where	  the	  kinase	  regulates	  extracellular	  matrix	  (ECM)	  
adhesions	  [216,	  276,	  403],	  which	  are	  crucial	  in	  stabilising	  the	  developing	  pseudopod.	  
Moreover,	  ERK	  activity	  induces	  myosin	  light	  chain	  phosphorylation	  by	  activating	  MLCK	  
(myosin	  light	  chain	  kinase)	  [277]	  and	  thereby	  controls	  the	  generation	  of	  a	  contractile	  
force	  required	  to	  translocate	  the	  cell	  body	  following	  pseudopodial	  extension	  [404].	  When	  
comparing	  the	  pseudopod	  length	  of	  ERK2	  knockdown	  cells	  with	  control,	  however,	  we	  do	  
not	  observe	  significant	  changes	  (data	  not	  shown),	  which	  argues	  that	  inhibition	  of	  ERK2	  
does	  not	  influence	  pseudopod	  extension	  or	  retraction	  at	  the	  leading	  edge.	  Our	  data	  
rather	  suggests	  a	  defect	  in	  the	  suppression	  of	  lateral	  or	  opposing	  pseudopods	  at	  the	  
cellular	  back,	  when	  ERK2	  is	  silenced.	  Thus,	  ERK2	  might	  be	  important	  in	  regulating	  RhoA	  
signalling	  at	  the	  cellular	  rear.	  Indeed,	  ERK	  was	  shown	  activate	  GEF-­‐H1,	  a	  RhoA	  GEF,	  
through	  direct	  phosphorylation	  [405]	  and	  might	  thus	  provide	  a	  means	  by	  which	  ERK	  
promotes	  cellular	  retraction.	  Moreover,	  ERK	  is	  involved	  in	  focal	  adhesion	  
disassembly	  [276],	  which	  is	  required	  for	  effective	  forward	  migration.	  Defects	  in	  adhesion	  
turnover	  or	  RhoA	  activation	  brought	  about	  by	  ERK2	  silencing	  may	  allow	  lateral	  
pseudopod	  formation,	  prevent	  the	  acquisition	  of	  a	  dominant	  pseudopod	  and	  may	  
ultimately	  decrease	  cellular	  motility.	  Moreover,	  failure	  or	  delay	  in	  Golgi	  and	  centrosome	  
orientation	  may	  slow	  down	  cell	  migration	  or	  induce	  cellular	  resting	  as	  seen	  in	  our	  
experiments.	  Notably,	  ERK	  has	  been	  shown	  to	  regulate	  Golgi	  and	  centrosome	  orientation	  
towards	  the	  leading	  edge	  of	  migrating	  cells	  [406].	  Thus,	  an	  ERK2-­‐specific	  function	  in	  this	  
process	  is	  also	  possible.	  
3.3.4 Isoform-specific functions for ERK1 and ERK2 
In	  recent	  years,	  much	  evidence	  supporting	  ERK	  isoform-­‐specific	  functions	  has	  
accumulated	  (see	  3.1.2	  and	  3.1.3).	  First	  and	  foremost,	  striking	  discrepancies	  between	  the	  
ERK1-­‐/-­‐	  and	  ERK2-­‐/-­‐	  phenotypes	  in	  mice	  argue	  for	  distinct	  roles	  for	  these	  kinases	  in	  
embryogenesis	  [360-­‐364,	  367].	  Moreover,	  ERK2	  may	  play	  specific	  roles	  in	  learning	  and	  
memory	  as	  well	  as	  differentiation	  [365,	  370].	  However,	  this	  data	  was	  challenged	  by	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Lefloch	  et	  al.	  in	  2008,	  who	  proposed	  erk	  gene	  dosage	  as	  the	  reason	  for	  the	  differences	  in	  
the	  ERK-­‐/-­‐	  phenotypes	  [357].	  They	  showed	  that	  ERK1	  and	  ERK2	  kinase	  activities	  were	  
indistinguishable	  in	  vitro	  and	  suggested	  that	  both	  isoforms	  contribute	  towards	  signalling	  
outcomes	  according	  to	  their	  expression	  ratio	  [357].	  However,	  experimental	  limitations	  
did	  not	  allow	  Lefloch	  and	  colleagues	  to	  show	  that	  an	  increase	  in	  ERK1	  expression	  in	  the	  
absence	  of	  ERK2	  could	  indeed	  rescue	  the	  proliferation	  defects	  observed	  [357].	  However,	  
subsequent	  work	  by	  Samuels	  and	  colleagues	  showed	  that	  proliferative	  defects	  in	  the	  
developing	  cortex	  of	  mice	  with	  conditional	  ERK2	  knockout	  could	  be	  rescued	  by	  ERK1	  
overactivation,	  thus	  showing	  that	  ERK’s	  role	  in	  regulating	  proliferation	  is	  indeed	  
dependent	  on	  erk	  gene	  dosage	  [366].	  Here,	  we	  show	  that	  ERK2	  is	  crucial	  for	  invasive	  
migration,	  as	  knockdown	  of	  ERK2	  severely	  compromised	  invasion	  into	  Matrigel	  plugs	  and	  
migration	  on	  CDM.	  The	  fact	  that	  we	  observed	  a	  compensatory	  increase	  in	  pERK1	  upon	  
ERK2	  knockdown	  and	  vice	  versa	  in	  either	  A2780-­‐Rab25	  or	  MDA-­‐MB-­‐231	  cells	  contradict	  
assumptions	  that	  total	  ERK	  signalling,	  regardless	  of	  the	  isoform,	  regulates	  cell	  invasion.	  
Moreover,	  by	  developing	  a	  system,	  in	  which	  we	  can	  knockdown	  ERK2	  and	  then	  
ectopically	  express	  either	  ERK1	  or	  ERK2	  to	  similar	  levels,	  we	  have	  shown	  that	  ERK2	  is	  the	  
main	  driver	  of	  cell	  migration	  and	  invasion	  in	  3D	  microenvironments	  in	  a	  way	  that	  is	  not	  
influenced	  by	  gene	  dosage.	  
The	  role	  of	  the	  ERKs	  in	  cell	  migration	  has	  been	  studied	  extensively	  and	  it	  is	  established	  
that	  these	  kinases	  play	  a	  key	  role	  in	  tumour	  progression	  by	  regulating	  cell	  invasiveness	  
[277,	  314,	  407-­‐409].	  However	  little	  is	  known	  about	  the	  respective	  contributions	  of	  ERK1	  
and	  ERK2	  to	  cell	  migration.	  Our	  finding	  that	  it	  is	  ERK2,	  and	  not	  ERK1,	  that	  contributes	  to	  
cell	  migration	  in	  3D	  microenvironments	  is	  certainly	  in	  agreement	  with	  observations	  in	  
vivo,	  where	  ERK2+/-­‐	  mice	  show	  a	  delay	  in	  wound	  healing	  after	  partial-­‐thickness	  burn	  in	  
comparison	  to	  ERK2+/+	  mice	  [410].	  Satoh	  and	  colleagues	  hypothesized	  that	  differences	  
observed	  in	  wound	  healing	  were	  due	  to	  defects	  in	  proliferation	  as	  well	  as	  migration.	  
Studies	  in	  Zebrafish	  further	  support	  this	  view	  as	  ERK2	  but	  not	  ERK1	  morphants	  showed	  
defects	  in	  cytoskeletal	  reorganisation	  processes,	  which	  led	  to	  anterior-­‐to-­‐posterior	  
migration	  retardations	  [411].	  More	  recently,	  by	  using	  a	  retroviral	  system	  to	  express	  ERK	  1	  
and	  -­‐2	  to	  similar	  levels,	  a	  study	  has	  demonstrated	  a	  specific	  role	  for	  ERK2	  in	  cell	  migration	  
in	  MCF-­‐10A	  cells,	  which	  was	  due	  to	  the	  participation	  of	  this	  ERK	  isoform	  in	  Ras-­‐induced	  
epithelial-­‐to-­‐mesenchymal	  transformation	  (EMT)	  [412].	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The	  ERK	  pathway	  has	  been	  a	  favourable	  target	  in	  anti-­‐cancer	  drug	  development	  since	  a	  
study	  of	  breast	  cancer	  carcinomas	  in	  2001	  showed	  a	  correlation	  between	  high	  pERK	  levels	  
and	  low	  survival	  from	  the	  initiation	  of	  therapy	  [413].	  Our	  data	  suggests	  that	  specific	  
targeting	  of	  ERK2	  rather	  than	  blocking	  both	  ERKs	  might	  prove	  to	  be	  a	  more	  selective	  
anti-­‐invasive	  strategy.	  This	  hypothesis	  is	  strongly	  supported	  by	  data	  from	  Milde-­‐Langosch	  
and	  colleagues	  who	  showed	  that	  high	  pERK1	  expression	  in	  tumours	  correlated	  with	  low	  
frequencies	  of	  relapses	  and	  higher	  survival.	  Moreover,	  patients	  with	  weak	  pERK1	  levels	  
showed	  an	  increased	  number	  of	  recurrences	  and	  deaths	  of	  disease.	  The	  same	  trend	  was	  
seen	  when	  high	  levels	  of	  pERK2	  were	  detected	  in	  the	  patients’	  tumours	  [414].	  Consistent	  
with	  this,	  ERK1	  has	  been	  hypothesized	  as	  a	  negative	  modulator	  of	  ERK	  signalling	  in	  recent	  
years,	  as	  ectopic	  expression	  of	  this	  kinase	  attenuates	  colony	  formation	  of	  
Ras-­‐transformed	  cells	  as	  well	  as	  Ras-­‐dependent	  tumour	  growth	  in	  nude	  mice	  [371].	  
Hence,	  the	  data	  suggest	  that	  a	  therapy	  aiming	  at	  decreasing	  pERK2	  and	  increasing	  pERK1	  
levels	  might	  be	  most	  beneficial.	  Our	  work	  with	  the	  MDA-­‐MB-­‐231	  and	  A2780-­‐Rab25	  cells	  
showed	  a	  clear	  compensatory	  increase	  of	  pERK1	  levels	  after	  ERK2	  knockdown.	  The	  
compensatory	  increase	  in	  pERK1	  levels	  after	  ERK2	  silencing	  has	  been	  observed	  in	  other	  
cell	  lines,	  such	  as	  NIH	  3T3	  [371]	  as	  well	  as	  rat	  and	  mouse	  hepatocytes	  [372].	  Furthermore,	  
a	  compensation	  in	  pERK	  has	  also	  been	  observed	  in	  ERK2+/-­‐	  mice	  compared	  to	  ERK2+/+	  
[415].	  As	  MEK1	  and	  -­‐2	  do	  not	  discriminate	  between	  the	  ERKs,	  we	  speculate	  that	  silencing	  
of	  ERK2	  might	  not	  only	  compromise	  invasive	  migration,	  but	  also	  result	  in	  a	  beneficial	  
increase	  in	  pERK1	  levels.	  Thus,	  changing	  the	  ratio	  of	  ERK1	  and	  ERK2	  should	  result	  in	  
enhanced	  activation	  of	  the	  remaining	  kinase.	  
Our	  findings	  have	  shown	  a	  clear	  ERK2-­‐dependent	  role	  in	  3D	  migration.	  How	  can	  this	  
isoform-­‐specificity	  be	  achieved	  on	  a	  cellular	  level,	  if	  both	  kinases	  show	  indistinguishable	  
kinase	  activities	  in	  vitro?	  Marchi	  et	  al.	  have	  shown	  isoform-­‐specific	  nuclear	  shuttling	  rates	  
caused	  by	  differences	  in	  the	  N-­‐terminal	  amino	  acid	  sequence,	  suggesting	  that	  ERK1	  and	  
ERK2	  may	  perform	  different	  roles	  within	  the	  nucleus	  [416].	  As	  ERK	  isoforms	  are	  
dephosphorylated	  and	  therefore	  inactivated	  in	  the	  nucleus	  [175],	  high	  shuttling	  rates	  are	  
required	  to	  maintain	  an	  active	  pool	  of	  ERK.	  Therefore,	  lower	  ERK1	  shuttling	  rates	  make	  
ERK2	  a	  better	  candidate	  for	  the	  activation	  of	  nuclear	  targets	  [416].	  ERK1/2	  have	  been	  
shown	  to	  drive	  transcription	  of	  numerous	  proteins	  involved	  in	  migration,	  such	  as	  MMP-­‐9,	  
MMP-­‐1	  and	  uPA	  [391,	  417,	  418].	  It	  is,	  therefore,	  possible,	  that	  ERK2	  is	  the	  main	  driver	  of	  
transcription	  of	  these	  pro-­‐invasive	  proteins.	  However,	  it	  is	  unlikely	  that	  ERK2’s	  role	  in	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invasive	  tumour	  cell	  migration	  can	  solely	  be	  triggered	  by	  higher	  nuclear	  activity,	  as	  ERK	  
signalling	  has	  also	  been	  linked	  cytosolic	  effectors	  involved	  in	  migration,	  such	  as	  vinexin-­‐β,	  
stathmin	  and	  myosin	  light	  chain	  kinase	  (MLCK)	  [316,	  403,	  419].	  	  
Isoform	  specificity	  within	  the	  cytoplasm	  may	  be	  achieved	  via	  distinct	  subcellular	  
localisation	  of	  the	  two	  enzymes.	  However,	  there	  are	  currently	  no	  ERK	  isoform-­‐specific	  
antibodies,	  which	  allow	  this	  hypothesis	  to	  be	  tested	  using	  immunofluorescence	  
microscopy.	  Moreover,	  isoform-­‐specific	  scaffolds,	  as	  well	  as	  uncharacterized	  
isoform-­‐specific	  substrate	  binding	  domains,	  may	  exist.	  Indeed,	  Shin	  et	  al.	  demonstrated	  
an	  ERK2	  specificity	  in	  Fra1	  phosphorylation,	  which	  was	  dependent	  on	  ERK2’s	  FXFP	  motif	  
[412].	  Intriguingly,	  previous	  work	  by	  Lee	  and	  colleagues	  showed	  that	  the	  residues	  
constituting	  the	  FXFP-­‐motif	  are	  fully	  conserved	  between	  ERK1	  and	  ERK2	  [131].	  To	  explain	  
this	  discrepancy,	  we	  speculate	  that	  the	  Tyr261Ala	  mutation	  in	  the	  FXFP-­‐motif	  may	  
sterically	  distort	  an	  unknown	  isoform-­‐specific	  substrate	  binding	  domain	  in	  ERK2	  and	  
therefore	  abrogate	  Fra1	  stabilisation.	  	  
To	  conclude,	  this	  study	  is	  the	  first	  to	  show	  a	  pivotal	  role	  of	  ERK2	  in	  invasive	  tumour	  cell	  
migration	  and	  suggests	  that	  ERK1	  and	  -­‐2	  do	  have	  distinct	  functions.	  Our	  data	  challenges	  
the	  belief	  that	  both	  ERK	  isoforms	  are	  interchangeable	  and	  redundant,	  and	  propose	  a	  new	  
level	  of	  complexity	  of	  the	  Raf-­‐MEK-­‐ERK	  pathway.	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4 ERK2 regulates expression of CSF2, Rab17 and 
Liprin-β2 in 3D microenvironments 
4.1 Introduction 
4.1.1 Regulation of gene expression through ERK1/2 
Growth	  factors	  and	  mitogens	  induce	  synthesis	  of	  new	  proteins	  required	  for	  cellular	  
responses.	  Changes	  in	  protein	  expression	  can	  be	  detected	  within	  minutes	  following	  
growth	  factor	  addition,	  and	  genes	  encoding	  these	  proteins	  are	  known	  as	  immediate	  early	  
genes	  (IEGs).	  This	  rapid	  burst	  in	  mRNA	  synthesis	  requires	  a	  switch-­‐like	  activation	  of	  
transcription	  factors	  in	  the	  nucleus,	  which	  can	  be	  achieved	  through	  post-­‐translational	  
modifications.	  Indeed,	  activation	  of	  the	  ERK-­‐MAPK	  pathway	  promotes	  translocation	  of	  
ERK1/2	  to	  the	  nucleus,	  where	  the	  kinases	  phosphorylate	  transcription	  factors	  such	  as	  Elk1	  
and	  c-­‐Fos	  to	  drive	  expression	  of	  IEGs	  [420].	  Phosphorylation	  can	  affect	  transcription	  
factor	  function	  in	  various	  ways.	  Whereas	  phosphorylation	  of	  Elk1	  enhances	  DNA	  binding	  
and	  may	  induce	  the	  recruitment	  of	  transcriptional	  co-­‐activators,	  such	  as	  p300	  or	  
CREB-­‐binding	  protein	  (CBP)	  [323],	  phosphorylation	  of	  c-­‐Fos	  by	  ERK	  itself	  or	  its	  
downstream	  target,	  RSK,	  prevents	  proteasomal	  degradation	  and	  thus	  stabilises	  the	  
transcription	  factor	  [326].	  In	  contrast,	  nuclear	  ERK	  may	  also	  inhibit	  transcriptional	  events	  
through	  direct	  or	  indirect	  phosphorylation.	  For	  example,	  phosphorylation	  of	  Ser307	  of	  
heat	  shock	  factor-­‐1	  (HSF1)	  by	  ERK1/2	  represses	  its	  transcriptional	  activity	  during	  growth	  
and	  development	  [421].	  Furthermore,	  ERK-­‐mediated	  phosphorylation	  of	  inducible	  cAMP	  
early	  repressor	  (ICER)	  targets	  the	  transcription	  factor	  for	  ubiquitin-­‐mediated	  
degradation	  [422].	  
In	  addition	  to	  direct	  or	  indirect	  phosphorylation	  of	  transcription	  factors,	  the	  ERK-­‐MAPK	  
pathway	  has	  been	  implicated	  in	  altering	  the	  chromatin	  structure	  of	  actively	  transcribed	  
genes	  [423-­‐425].	  Nucleosomal	  proteins,	  such	  as	  histone	  H3	  and	  high	  mobility	  group	  
protein	  (HMG)-­‐14,	  are	  phosphorylated	  by	  ERK	  effectors	  (i.e.	  MSK1,	  MSK2,	  and	  RSK2)	  on	  
Ser10	  and	  Ser6,	  respectively	  [426-­‐428].	  Phosphorylated	  histone	  H3	  and	  HMG-­‐14	  are	  
primarily	  found	  at	  actively	  transcribed	  genes,	  e.g.	  IEGs,	  and	  are	  thought	  to	  provide	  a	  
docking	  domain	  for	  the	  recruitment	  of	  histone	  acetyltransferases,	  such	  as	  p300	  and	  
CBP	  [427].	  Indeed,	  phosphorylation	  and	  acetylation	  can	  coexist	  on	  the	  same	  histone	  H3	  
tail,	  as	  was	  recently	  shown	  for	  the	  c-­‐fos	  gene	  [429].	  Thus,	  a	  function	  of	  histone	  H3	  and	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HMG-­‐14	  phosphorylation	  may	  be	  to	  prime	  the	  histone	  tail	  for	  acetylation.	  However,	  the	  
precise	  role	  of	  this	  ERK-­‐mediated	  modification	  in	  regulating	  gene	  transcription	  remains	  to	  
be	  elucidated.	  
The	  ERK-­‐MAPK	  pathway	  has	  been	  shown	  to	  regulate	  pre-­‐mRNA	  processing	  and	  
alternative	  splicing	  [430,	  431].	  The	  heterogeneous	  nuclear	  ribonucleoprotein	  (hnRNP)-­‐K	  is	  
a	  bona-­‐fide	  ERK	  target	  protein	  and	  phosphorylation	  at	  Ser284	  and	  Ser353	  stimulates	  its	  
nuclear	  export	  [431].	  In	  the	  cytoplasm	  hnRNP-­‐K’s	  function	  are	  diverse.	  It	  can	  inhibit	  
mRNA	  translation	  by	  binding	  to	  the	  differentiation-­‐control	  element	  in	  the	  3ˊ	  untranslated	  
region	  (UTR)	  of	  target	  mRNAs	  [431],	  stabilise	  mRNA	  transcripts	  and	  thereby	  increase	  the	  
expression	  of	  certain	  proteins,	  such	  as	  thymidine	  phosphorylase	  [432],	  or	  promote	  
splicing	  of	  mRNA	  precursors,	  such	  as	  EGR1	  [433].	  Thus,	  ERK	  signalling	  indirectly	  impinges	  
on	  pre-­‐mRNA	  processing	  by	  regulating	  hnRNP-­‐K	  localisation	  and	  thus	  affects	  gene	  
expression	  both	  transcriptionally	  and	  post-­‐transcriptionally.	  
Additionally,	  ERK	  signalling	  has	  recently	  been	  shown	  to	  regulate	  gene	  expression	  by	  
altering	  microRNA	  (miRNA)	  biogenesis	  [434].	  MicroRNAs	  are	  small	  ribonucleic	  acid	  
molecules	  with	  an	  average	  length	  of	  21	  nucleotides.	  They	  bind	  to	  specific	  sequences	  of	  
their	  target	  mRNAs	  and	  inhibit	  gene	  expression	  by	  promoting	  mRNA	  degradation,	  
sequestration,	  or	  translational	  suppression	  [435].	  In	  mammals,	  miRNA	  biogenesis	  follows	  
a	  well-­‐defined	  maturation	  process.	  Firstly,	  the	  transcribed	  precursor	  molecules	  called	  
pri-­‐miRNAs	  fold	  into	  a	  double	  stranded	  hairpin-­‐like	  structure,	  which	  is	  processed	  into	  
mature	  miRNA	  molecules	  in	  two	  consecutive	  cleavage	  processes	  involving	  RNase	  III	  type	  
endonucleases.	  In	  the	  nucleus	  the	  pri-­‐miRNA	  is	  converted	  into	  a	  70	  nucleotides	  long	  
pre-­‐miRNA	  by	  a	  complex	  containing	  Drosha	  and	  DGCR8	  (DiGeorge	  syndrome	  critical	  
region	  gene	  8).	  Following	  export	  from	  the	  nucleus,	  a	  further	  maturation	  process	  driven	  by	  
the	  miRNA-­‐generating	  complex,	  consisting	  of	  DICER	  and	  phospho-­‐TRBP	  (TAR	  RNA-­‐binding	  
protein),	  yields	  a	  mature	  miRNA,	  which	  is	  subsequently	  assembled	  into	  functionally	  active	  
ribonucleoprotein	  complexes	  [435].	  ERK1/2	  have	  been	  shown	  to	  interact	  with	  TRBP	  in	  
vivo	  and	  phosphorylate	  this	  component	  of	  the	  miRNA-­‐generating	  complex	  in	  vitro.	  
Moreover,	  phosphorylation	  of	  TRBP	  enhances	  the	  stability	  of	  the	  miRNA-­‐generating	  
complex,	  resulting	  in	  an	  increase	  in	  miRNA	  biogenesis	  and	  miRNA-­‐mediated	  gene	  
silencing	  [434].	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4.1.2 Nuclear translocation of ERK1/2 
The	  nuclear	  envelope	  separates	  the	  nucleus	  from	  the	  cytoplasm	  and	  ensures	  selective	  
transport	  between	  the	  two	  cellular	  compartments.	  Although	  small	  molecules	  can	  
passively	  enter	  and	  exit	  the	  nucleus,	  transport	  of	  larger	  entities,	  such	  as	  proteins	  or	  RNAs,	  
is	  tightly	  controlled	  by	  transport	  channels	  called	  nuclear	  pore	  complexes	  (NPCs).	  A	  family	  
of	  proteins	  called	  nucleoporins	  (NUPs)	  assemble	  to	  form	  these	  channels,	  which	  are	  also	  
known	  as	  nuclear	  pores	  [436].	  In	  general,	  proteins,	  which	  are	  designated	  for	  nuclear	  
transport,	  carry	  a	  nuclear	  localisation	  signal	  (NLS),	  which	  is	  recognised	  and	  bound	  by	  
importins.	  Once	  importins	  are	  loaded	  with	  cargo	  proteins,	  they	  interact	  with	  the	  NPC	  and	  
travel	  through	  the	  transport	  channels.	  In	  the	  nucleus,	  the	  small	  GTPase	  RAN	  binds	  to	  the	  
importin-­‐cargo	  complex	  and	  induces	  a	  conformational	  change,	  which	  promotes	  
dissociation	  of	  the	  cargo	  from	  importins	  and	  renders	  RAN	  inactive.	  Subsequently,	  
RAN-­‐GDP	  and	  importin	  are	  exported	  to	  the	  cytoplasm,	  where	  RAN	  can	  be	  activated	  by	  
GTP	  loading	  and	  importins	  can	  bind	  new	  cargo	  proteins	  [437].	  
Neither	  ERK1/2	  nor	  MEK1/2	  contain	  conventional	  [438]	  or	  non-­‐conventional	  [439]	  NLSs,	  
which	  suggests	  that	  the	  kinases	  must	  depend	  on	  alternative	  mechanisms	  driving	  their	  
nuclear	  import.	  It	  is	  possible	  that	  ERK1/2	  interact	  with	  proteins	  containing	  NLS,	  and	  thus,	  
hitch	  a	  ride	  into	  the	  nucleus.	  However,	  no	  direct	  interaction	  partner	  comprising	  a	  NLS	  has	  
so	  far	  been	  identified,	  suggesting	  that	  other	  mechanisms	  drive	  ERK	  translocation	  into	  the	  
nucleus.	  In	  1999,	  ERK1/2	  were	  shown	  to	  penetrate	  the	  NPC	  by	  means	  of	  passive	  diffusion	  
as	  a	  monomer	  or	  active	  transport	  as	  a	  dimer	  [440].	  Whether	  active	  import	  really	  involves	  
ERK	  dimerization,	  however,	  is	  controversial,	  as	  mutants	  impaired	  in	  dimerization	  were	  
still	  translocated	  using	  an	  energy-­‐dependent	  mechanism	  [441].	  Moreover,	  Casar	  et	  al.	  
demonstrated	  that	  ERKs	  accumulate	  in	  the	  nucleus	  as	  monomers,	  and	  that	  
phosphorylation	  of	  transcription	  factors	  by	  ERK1/2	  does	  not	  require	  protein	  
dimerization	  [442].	  Yet,	  Lidke	  et	  al.	  showed	  that	  inhibition	  of	  ERK	  dimerization	  resulted	  in	  
delayed	  nuclear	  ERK	  accumulation,	  suggesting	  that	  ERK	  dimers	  and	  monomers	  are	  
transported	  across	  nuclear	  pores	  with	  different	  kinetics	  [443].	  Intriguingly,	  Marchi	  et	  al.	  
demonstrated	  clear	  differences	  in	  the	  nuclear	  shuttling	  frequencies	  between	  ERK1	  and	  
ERK2,	  with	  ERK1	  being	  imported	  and	  exported	  at	  a	  much	  slower	  rate	  than	  ERK2	  [416].	  
Moreover,	  domain	  swapping	  inverted	  the	  shuttling	  frequencies	  of	  ERK1	  and	  ERK2	  and	  
attributed	  the	  discrepancy	  in	  nuclear	  trafficking	  to	  differences	  in	  the	  N-­‐terminal	  amino	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acid	  sequence.	  Owing	  to	  the	  fact	  that	  ERKs	  are	  predominantly	  inactivated	  in	  the	  nucleus,	  
continuous	  cytoplasmic-­‐nuclear	  shuttling	  ensures	  a	  constant	  level	  of	  active	  ERK.	  Thus,	  
lower	  shuttling	  rates	  for	  ERK1	  may	  make	  the	  kinase	  more	  susceptible	  for	  nuclear	  
inactivation	  and	  ERK2	  the	  predominant	  kinase	  driving	  gene	  expression	  [416].	  
Yet,	  how	  are	  ERK	  proteins	  targeted	  for	  nuclear	  translocation?	  Three	  residues	  on	  ERK,	  i.e.	  
Ser246-­‐Pro247-­‐Ser248	  (for	  ERK2),	  have	  been	  shown	  to	  be	  important	  in	  regulating	  nuclear	  
translocation.	  This	  motif	  resides	  in	  the	  kinase	  insert	  domain	  (KID)	  of	  ERK	  and	  both	  serine	  
residues	  undergo	  phosphorylation	  following	  TEY	  motif	  activation	  by	  MEK1/2	  [444].	  
Synergistic	  phosphorylation	  of	  the	  Ser-­‐Pro-­‐Ser	  motif	  induces	  binding	  to	  importin7,	  which	  
is	  believed	  to	  escort	  ERK1/2	  through	  nuclear	  pores.	  Moreover,	  ERK1/2	  may	  promote	  
nuclear	  entry	  through	  energy-­‐independent	  and	  energy-­‐dependent	  mechanisms	  by	  
phosphorylating	  NUPs	  (NUP50,	  NUP153	  and	  NUP214)	  directly	  [445,	  446].	  	  
Another	  important	  regulator	  of	  nuclear	  ERK	  shuttling	  is	  Mxi2,	  which	  promotes	  
translocation	  of	  ERK1/2	  in	  a	  stimulus-­‐independent	  manner	  by	  acting	  as	  an	  adapter	  
molecule.	  Mxi2	  interacts	  with	  both	  ERKs	  and	  NUPs	  directly,	  and	  thereby	  promotes	  
nuclear	  import	  [231].	  More	  work	  is	  required	  to	  deduce	  how	  ERK1/2	  are	  shuttled	  into	  the	  
nucleus	  and	  whether	  ERK-­‐mediated	  phosphorylation	  of	  NUPs	  promotes	  nuclear	  entry.	  
Moreover,	  future	  research	  will	  have	  to	  address	  the	  isoform-­‐specific	  shuttling	  frequencies	  
of	  ERK1	  and	  ERK2	  questioning	  how	  these	  are	  provoked	  mechanistically.	  
4.1.3 The role of extracellular matrix adhesions on nuclear ERK signalling 
The	  ERK-­‐MAPK	  pathway	  serves	  to	  convert	  extracellular	  stimuli	  into	  physiological	  
responses	  by	  transducing	  input	  signals	  to	  subcellular	  compartments	  and	  thereby	  
regulating	  fundamental	  cellular	  processes,	  such	  as	  proliferation,	  differentiation	  and	  cell	  
migration.	  This	  role	  in	  signal	  transduction,	  however,	  demands	  a	  link	  between	  pathway	  
activation	  and	  the	  extracellular	  environment	  to	  ensure	  adequate	  signalling	  responses.	  
Interestingly,	  a	  body	  of	  work	  has	  shown	  that	  cell	  adhesion	  via	  integrin	  engagement	  is	  
frequently	  required	  for	  efficient	  ERK	  activation,	  as	  growth	  factors	  fail	  to	  induce	  ERK	  
signalling,	  when	  cells	  were	  kept	  in	  suspension	  [447-­‐450].	  Moreover,	  anchorage	  
dependency	  has	  also	  been	  demonstrated	  for	  ERK’s	  role	  in	  regulating	  gene	  expression,	  as	  
phosphorylation	  of	  the	  transcription	  factor	  ELK	  at	  Ser385	  is	  reduced	  in	  the	  absence	  of	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integrin-­‐mediated	  adhesions	  [451].	  This	  suggests	  that	  extracellular	  matrix	  adhesions	  play	  
an	  important	  role	  in	  activating	  the	  ERK-­‐MAPK	  cascade	  as	  well	  as	  localising	  ERK1/2	  to	  
subcellular	  localisations.	  Integrins	  are	  cell	  surface	  receptors,	  which	  contribute	  to	  the	  
tethering	  of	  the	  actin	  cytoskeleton	  to	  the	  membrane	  at	  adhesion	  sites,	  and	  can	  also	  
recruit	  a	  variety	  of	  structural	  and	  signalling	  molecules.	  It	  is	  well-­‐established	  that	  ERK	  
signalling	  is	  enhanced	  at	  focal	  adhesions	  sites	  [214],	  but	  it	  has	  yet	  to	  be	  determined	  how	  
integrin	  engagement	  controls	  ERK	  trafficking.	  It	  is	  possible,	  however,	  that	  
integrin-­‐mediated	  organisation	  of	  the	  cytoskeleton	  facilitates	  transport	  and/or	  nuclear	  
entry	  of	  activated	  ERK	  molecules.	  
4.1.4 Experimental paradigm 
In	  the	  previous	  chapter	  we	  showed	  that	  ERK2	  but	  not	  ERK1	  drives	  tumour	  cell	  invasion	  
and	  migration	  on	  3D	  matrices	  by	  increasing	  the	  momentary	  migration	  velocity	  and	  
decreasing	  cellular	  resting.	  Although	  we	  were	  able	  to	  demonstrate	  clear	  functional	  
disparities	  between	  the	  two	  kinases	  with	  regards	  to	  cell	  motility,	  the	  underlying	  
mechanism	  remained	  unresolved.	  Given	  that	  Marchi	  et	  al.	  demonstrated	  differential	  
nuclear	  shuttling	  frequencies	  for	  ERK1	  and	  ERK2,	  and	  proposed	  ERK2	  to	  be	  the	  
predominant	  kinase	  driving	  gene	  expression	  [416],	  we	  decided	  to	  perform	  a	  mRNA	  
microarray	  screen	  to	  search	  for	  genes	  that	  are	  expressed	  in	  an	  ERK2-­‐specific	  manner.	  As	  
cells	  cultured	  in	  3D	  exhibit	  completely	  different	  gene	  expression	  signatures	  when	  
compared	  to	  2D	  [395]	  and	  nuclear	  translocation	  of	  ERK	  is	  altered	  by	  matrix	  
adhesions	  [451],	  we	  chose	  to	  perform	  our	  comparative	  gene	  expression	  analysis	  in	  a	  3D	  
microenvironment.	  A	  diagram	  illustrating	  the	  experimental	  set-­‐up	  and	  our	  data	  filtering	  
strategy	  is	  presented	  in	  Figure	  4-­‐1.	  ERK2-­‐regulated	  genes	  are	  expected	  to	  show	  an	  
increase	  (or	  decrease)	  in	  mRNA	  levels	  upon	  ERK2	  silencing.	  Re-­‐expression	  of	  ectopic	  ERK2	  
(but	  not	  ERK1)	  should	  be	  able	  to	  revert	  the	  induction	  (or	  inhibition)	  of	  mRNA	  levels	  to	  
control.	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Figure 4-1 Experimental paradigm 
Diagram illustrating the experimental approach for the identification of an ERK2-dependent gene expression 
signature in a 3D microenvironment. In brief, MDA-MB-231 cells are transfected with NT siRNA, single 
oligos targeting ERK1 or ERK2 in combination with expression plasmids for SF-ERK1, siRNA-resistant 
SF-ERK2 or an empty vector control (EV) and plated onto cell-derived matrix. Bar graphs show possible 
mRNA expression levels for genes, which are induced or suppressed in an ERK2-dependent manner.  
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4.2 Results 
4.2.1 Microarray analysis identified an ERK2-specific gene expression 
signature 
4.2.1.1 Quality control of microarray samples 
To	  determine	  whether	  isoform-­‐specific	  regulation	  of	  gene	  expression	  was	  responsible	  for	  
ERK2’s	  influence	  over	  cell	  migration	  and	  invasion,	  MDA-­‐MB-­‐231	  cells	  were	  transfected	  
with	  non-­‐targeting	  siRNAs	  (NT),	  or	  single	  oligos	  targeting	  ERK1	  or	  ERK2	  in	  combination	  
with	  expression	  plasmids	  for	  SF-­‐ERK1,	  siRNA-­‐resistant	  SF-­‐ERK2	  or	  an	  empty	  vector	  control	  
(EV)	  and	  plated	  onto	  cell-­‐derived	  matrix.	  16	  hours	  following	  plating,	  the	  cells	  were	  lysed.	  
The	  efficacy	  of	  ERK	  knockdown	  and	  expression	  of	  SF-­‐ERKs	  were	  determined	  by	  Western	  
blotting	  (Figure	  4-­‐2	  A),	  and	  this	  showed	  that	  both	  ERK	  isoforms	  were	  efficiently	  silenced	  
by	  their	  respective	  siRNAs.	  Furthermore,	  SF-­‐ERK1	  and	  siRNA-­‐resistant	  SF-­‐ERK2	  were	  
expressed	  to	  equal	  levels	  after	  knocking	  down	  ERK2,	  thus	  ensuring	  that	  disparities	  in	  the	  
expression	  levels	  of	  these	  kinases	  were	  not	  responsible	  for	  any	  results	  obtained	  from	  the	  
microarray.	  
Total	  RNA	  was	  harvested	  from	  MDA-­‐MB-­‐231	  cells	  using	  the	  RNeasy	  Kit	  (Qiagen)	  and	  
traces	  of	  genomic	  DNA	  were	  removed	  by	  mechanical	  shear	  and	  DNase1.	  The	  
concentration	  and	  purity	  of	  the	  isolated	  RNA	  were	  determined	  by	  measuring	  the	  
absorbance	  at	  260	  nm	  and	  280	  nm	  using	  a	  NanoVue	  spectrophotometer.	  All	  samples	  
exhibited	  A260nm/A280nm	  absorbance	  ratios	  greater	  than	  1.8,	  indicating	  that	  contamination	  
with	  protein	  was	  negligible.	  We	  then	  labelled	  the	  isolated	  RNA	  using	  the	  Illumina®	  
TotalPrepTM	  RNA	  labelling	  Kit	  (Ambion).	  In	  brief,	  the	  mRNA	  of	  each	  sample	  was	  converted	  
into	  cDNA,	  which	  was	  then	  used	  as	  a	  template	  for	  in	  vitro	  transcription	  with	  
biotin-­‐16-­‐UTP	  to	  produce	  labelled	  cRNA	  molecules.	  The	  yield	  of	  the	  cRNA	  amplification	  
step	  was	  assessed	  by	  measuring	  the	  absorbance	  at	  260	  nm.	  After	  adjusting	  the	  cRNA	  
concentrations	  to	  0.2	  µg/µl,	  the	  samples	  were	  sent	  to	  the	  Wellcome	  Trust	  Clinical	  
Research	  Facility	  in	  Edinburgh,	  where	  the	  integrity	  of	  the	  biotinylated	  cRNA	  was	  assessed	  
using	  an	  Agilent	  Bioanalyser.	  The	  electropherograms	  for	  each	  sample	  displayed	  a	  
distribution	  of	  RNA	  molecules	  of	  varying	  sizes	  ranging	  from	  250	  to	  5500	  nucleotides	  with	  
most	  of	  the	  cRNAs	  at	  1000	  to	  1500	  nucleotides.	  This	  suggests	  that	  no	  mRNA	  or	  cRNA	  
degradation	  occurred	  during	  sample	  preparation	  (Figure	  4-­‐2	  B).	  Subsequently,	  the	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Figure 4-2 Quality control of the microarray samples 
MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or single oligos targeting ERK1 or 
ERK2 in combination with expression plasmids for SF-ERK1, siRNA-resistant SF-ERK2 or an empty vector 
control (EV) and plated onto cell-derived matrix.  
A. The efficacy of RNAi and ectopic ERK expression was assessed by Western blot 16 hours post 
nucleofection for all three microarray samples. 
B. Total RNA was isolated using the RNeasy kit (Qiagen) and subsequently converted into labelled cRNA 
using the TotalPrep RNA Labeling Kit (Ambion). The integrity and concentration of the cRNA samples were 
assessed with the help of an Agilent Bioanalyser. Representative electropherogram scans for all conditions of 
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Genetic	  Core	  Facility	  performed	  whole	  genome	  expression	  analysis	  on	  
HumanHT-­‐12	  v4	  Expression	  BeadChips,	  which	  allows	  comparative	  expression	  analysis	  of	  
over	  47,000	  transcripts.	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4.2.1.2 Normalisation of microarray data yields good clustering of experimental 
replicas 
As	  non-­‐biological	  variations	  between	  bead	  chips	  (such	  as	  technical	  variations	  during	  bead	  
chip	  generation,	  sample	  labelling	  and	  hybridisation)	  may	  obscure	  changes	  in	  gene	  
alterations,	  it	  is	  imperative	  to	  normalise	  raw	  data	  obtained	  from	  the	  BeadArray	  
Reader	  [452].	  We	  acquired	  24	  gene	  signal	  profiles	  after	  direct	  hybridisation	  of	  the	  
HumanHT-­‐12	  v4	  Expression	  BeadChips,	  which	  were	  normalised	  and	  analysed	  with	  the	  
help	  of	  the	  Partek®	  Genomics	  Suite	  Software,	  version	  6.5	  by	  Dr.	  Gabriela	  Kalna.	  All	  values	  
were	  adjusted	  by	  quantile	  normalisation	  and	  log2	  transformation,	  which	  was	  previously	  
shown	  to	  give	  the	  best	  results	  for	  Illumina	  gene	  expression	  data	  [453].	  Subsequent	  
principle	  component	  analysis	  gave	  rise	  to	  scatter	  plots,	  which	  showed	  a	  good	  overlap	  of	  
sample	  replicates	  from	  two	  chips	  (Figure	  4-­‐3	  A)	  but	  also	  an	  undesirable	  experimental	  
replica	  clustering	  (Figure	  4-­‐3	  B).	  To	  remove	  this	  batch-­‐dependent	  effect	  a	  mixed	  model	  
ANOVA	  (analysis	  of	  variances)	  was	  performed,	  which	  adjusts	  the	  data	  in	  such	  a	  way	  that	  
batches	  are	  comparable	  to	  one	  another	  (Figure	  4-­‐3	  C)	  [454].	  Finally,	  outliers	  of	  samples	  
were	  removed	  according	  to	  standard	  protocol	  and	  the	  remaining	  19	  samples	  
renormalized	  as	  described	  above,	  which	  resulted	  in	  good	  clustering	  of	  the	  experimental	  
microarray	  replicas	  (Figure	  4-­‐3	  D).	  Differentially	  expressed	  genes	  were	  identified	  by	  
ANOVA	  (analysis	  of	  variances)	  and	  post-­‐hoc	  linear	  contrasts	  performed	  between	  all	  pairs	  
of	  experimental	  conditions.	  Multiple	  test	  corrections	  (Bonferroni	  and	  step	  up	  Benjamini-­‐
Hochberg)	  were	  performed	  for	  all	  calculated	  p-­‐values.	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Figure 4-3 Normalisation results in good clustering of experimental replicas 
Microarray raw data was normalised and analysed in PARTEK ® Genomics Suite Software. Demonstrated 
are: 
A. Clustering patterns of all 24 samples after normalisation and Log2 transformation. 
B. Scatter plots of batch effects from different biological replicas. 
C. Clustering patterns after batch effect removal through mixed model ANOVA. 
D. Data clustering after the removal of outliers, renormalisation and Log2 transformation. 
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4.2.1.3 Microarray analysis identifies genes whose expression is down-regulated 
following ERK2 knockdown 
Following	  normalisation,	  batch	  effect	  removal	  and	  log	  transformation,	  Multiway	  ANOVA	  
(analysis	  of	  variances)	  was	  used	  to	  identify	  genes	  whose	  expression	  was	  down-­‐regulated	  
following	  ERK2	  silencing.	  Multiple	  filtering	  steps	  were	  performed	  to	  generate	  a	  list	  of	  
ERK2-­‐regulated	  genes.	  Thus,	  genes	  had	  to	  show	  (i)	  a	  significant	  decrease	  in	  expression	  
when	  ERK2	  depleted	  cells	  were	  compared	  to	  NT	  siRNA	  (step-­‐up	  p-­‐value	  ≤	  0.05)	  and	  
(ii)	  inverse	  changes	  with	  respect	  to	  fold	  changes	  and	  p-­‐value	  when	  siRNA-­‐resistant	  
SF-­‐ERK2	  was	  re-­‐expressed	  (step-­‐up	  p-­‐value	  ≤	  0.05,	  fold	  change	  ≥	  1.3).	  After	  applying	  these	  
filtering	  criteria,	  we	  obtained	  a	  set	  of	  47	  genes,	  whose	  expression	  was	  decreased	  
following	  ERK2	  depletion	  (Figure	  4-­‐4).	  These	  genes	  were	  then	  ranked	  according	  to	  fold	  
changes	  obtained	  when	  ERK2	  knockdown	  was	  compared	  to	  ERK2	  re-­‐expression.	  	  
To	  further	  refine	  the	  list	  of	  genes	  whose	  expression	  was	  regulated	  in	  an	  ERK2-­‐dependent	  
manner,	  we	  introduced	  two	  additional	  filter	  criteria.	  Thus,	  when	  comparing	  
overexpression	  of	  SF-­‐ERK1	  versus	  ERK2	  depletion,	  no	  significant	  changes	  in	  gene	  
expression	  were	  expected	  with	  respect	  to	  fold	  changes	  and	  p-­‐value	  (fold	  changes	  of	  ≤	  1.1,	  
step-­‐up	  p-­‐values	  of	  ≥	  0.35).	  Indeed,	  these	  criteria	  allowed	  the	  identification	  of	  13	  genes,	  
whose	  expression	  was	  regulated	  in	  an	  isoform-­‐specific	  manner	  (Figure	  4-­‐4).	  ERK2	  itself	  
fell	  into	  this	  group	  of	  genes,	  validating	  our	  experimental	  set-­‐up	  and	  filtering	  strategy.	  
Moreover,	  our	  data	  suggest	  that	  the	  egr1	  gene	  is	  regulated	  by	  both	  ERK	  isoforms,	  as	  
ectopic	  expression	  of	  either	  ERK1	  or	  ERK2	  restored	  gene	  expression	  to	  control	  levels.	  This	  
observation	  is	  in	  agreement	  with	  data	  published	  by	  Lefloch	  et	  al.,	  who	  demonstrated	  that	  
re-­‐expression	  of	  either	  ERK	  isoform	  in	  ERK2	  depleted	  cells	  is	  sufficient	  to	  restore	  egr1	  
mRNA	  levels	  [357].	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Figure 4-4 List of genes down-regulated upon ERK2 silencing 
MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNAs targeting ERK1 or ERK2 
in combination with expression plasmids for SF-ERK1, SF-ERK2 or empty vector control (EV) and plated 
onto CDM. Total RNA was extracted, labelled, and comparative whole-genome expression profiling was 
performed using Illumina HT-12 v4 expression chips.  
(see next page also) 
 	  
A Genes downregulated by ERK2 siRNA
B
C
 ERK1 siRNA vs. NT siRNA ERK2 siRNA vs. NT siRNA SF-ERK1 vs. ERK2 siRNA SF-ERK2 vs. ERK2 siRNA 
Gene Symbol stepup p-value Fold-Change stepup p-value Fold-Change stepup p-value Fold-Change stepup p-value Fold-Change 
CSF2 0.28708 -1.20 0.01091 -1.53 0.91193 1.033 0.00467 1.90 
ERK2 0.98365 1.00 1.99E-06 -2.62 0.96436 1.01 0.00532 1.59 
SRGN 0.26015 1.09 0.03350 -1.17 0.60708 -1.06 0.00020 1.54 
SRXN1 0.070469 -1.21 0.00792 -1.36 0.84486 -1.04 0.01776 1.43 
ASAM 0.26712 1.09 0.03500 -1.17 0.35304 1.09 0.00106 1.42 
MT1G 0.80039 -1.04 0.02803 -1.27 0.58442 1.09 0.02702 1.38 
AKR1C3 0.24908 1.07 0.02509 -1.14 0.94541 -1.01 0.00030 1.38 
FAM107B 0.05318 -1.24 0.00064 -1.57 0.64543 1.08 0.04006 1.38 
CD83 0.75155 -1.03 0.00042 -1.30 0.45285 1.07 0.00131 1.34 
DNER 0.09728 -1.17 0.00200 -1.39 0.80219 -1.04 0.03532 1.32 
EREG 0.48842 1.07 0.03306 -1.20 0.45378 1.09 0.01646 1.32 
IL24 0.45073 -1.08 1.61E-05 -1.82 0.54048 1.09 0.03798 1.31 
ARL14 0.11769 -1.16 0.00057 -1.48 0.71827 1.06 0.04763 1.30 
 
Genes downregulated by ERK2 siRNA
Gene Symbol Gene Name 
CSF2 Granulocyte-macrophage colony stimulating factor 2 
MAPK1 Extracellular signal- regulated kinase 2 
SRGN Serglycin 
SRXN1 Sulfiredoxin 
ASAM Adipocyte adhesion molecule 
MT1G Metallothionein-1G 
AKR1C3 Aldo-keto reductase family 1 member C3 
FAM107B Protein FAM107B 
CD83 CD83 antigen 
DNER Delta and Notch- like epidermal growth factor-related receptor 
EREG Epiregulin 
IL24 Interleukin-24 
ARL14 ADP-ribosylation factor- like protein 14 
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A. The heat map displays genes, which are down-regulated in an ERK2-dependent manner. Genes, which 
showed significant changes in expression level when comparing ERK2 knockdown versus NT siRNA 
(step-up p-value < 0.05) and inverse changes when comparing ERK2 knockdown versus re-expression of 
siRNA resistant SF-ERK2 (step-up p-value < 0.05, fold change ≥ 1.3) were identified and ranked according  
to fold changes. The expression of the first 13 genes is regulated in an ERK2-dependent manner (step-up 
 p-values > 0.35, fold change ≤ 1.1 when comparing ERK2 knockdown cells to SF-ERK1 overexpression). 
The colour and intensity of the boxes allocated to each data point represent fold changes in expression level: 
low expression (green), high expression (red). 
B. Table of genes, whose expression is down-regulated in an ERK2-dependent manner. Listed are: gene 
symbols, step-up p-values (significant p-values are in red), and fold changes for experimental comparisons. A 
significant decrease in fold change following ERK2 knockdown is marked by a green background colour, 
while inverse changes upon re-expression of ERK2 are marked by a red background colour. 
C. List of gene names for ERK2-regulated genes from (B).  
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4.2.1.4 Microarray analysis identifies genes whose expression is up-regulated 
following ERK2 knockdown 
Having	  identified	  genes,	  whose	  expression	  is	  induced	  by	  ERK2,	  we	  asked	  whether	  this	  
kinase	  may	  also	  act	  to	  suppress	  gene	  expression.	  Thus,	  we	  set	  out	  to	  identify	  a	  set	  of	  
genes,	  whose	  expression	  is	  up-­‐regulated	  in	  cells	  lacking	  ERK2.	  We	  normalised	  and	  
processed	  the	  data	  as	  for	  Figure	  4-­‐1.	  Subsequent	  filtering	  steps	  generated	  a	  list	  of	  
ERK2-­‐regulated	  genes,	  which	  met	  the	  following	  criteria:	  genes	  showed	  (i)	  a	  significant	  
increase	  in	  gene	  expression	  when	  ERK2	  knockdown	  was	  compared	  to	  NT	  siRNA	  (step-­‐up	  
p-­‐value	  ≤	  0.05)	  and	  (ii)	  inverse	  changes	  with	  respect	  to	  fold	  changes	  and	  p-­‐value,	  when	  
siRNA	  resistant	  SF-­‐ERK2	  was	  re-­‐expressed	  (step-­‐up	  p-­‐value	  ≤	  0.05,	  fold	  change	  ≥	  1.3).	  This	  
produced	  a	  set	  of	  36	  genes,	  whose	  expression	  was	  decreased	  following	  ERK2	  
depletion	  (Figure	  4-­‐5)	  which	  were	  then	  ranked	  according	  to	  fold	  changes	  as	  before.	  	  
To	  further	  refine	  this	  list	  we	  introduced	  an	  additional	  filter	  criterion	  by	  predefining	  that	  
genes	  had	  to	  exhibit	  no	  significant	  changes	  in	  gene	  expression	  when	  ERK1	  was	  
overexpressed	  (fold	  changes	  of	  ≥	  -­‐1.1,	  step-­‐up	  p-­‐values	  of	  ≥	  0.4).	  This	  allowed	  the	  
identification	  of	  14	  genes	  whose	  expression	  was	  suppressed	  in	  an	  ERK2-­‐specific	  
fashion	  (Figure	  4-­‐5).	  Interestingly,	  ERK1	  depletion	  significantly	  induced	  gene	  expression	  of	  
C10ORF10	  (fold	  change=1.40,	  step-­‐up	  p-­‐value=0.0061),	  SELENBP1	  (fold	  change=1.36,	  
step-­‐up	  p-­‐value=0.0047),	  and	  GPR64	  (fold	  change=1.44,	  step-­‐up	  p-­‐value=0.0002),	  
suggesting	  that	  both	  ERK	  isoforms	  suppress	  their	  expression	  (Figure	  4-­‐5).	  Yet,	  
overexpression	  of	  ERK1	  in	  cells	  depleted	  for	  ERK2	  was	  not	  sufficient	  to	  restore	  mRNA	  
levels	  to	  control,	  which	  indicates	  that	  these	  mRNA	  transcripts	  are	  regulated	  
post-­‐transcriptionally	  in	  an	  ERK2-­‐dependent	  manner.	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Figure 4-5 List of genes up-regulated upon ERK2 silencing 
MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNAs targeting ERK1 or ERK2 
in combination with expression plasmids for SF-ERK1, SF-ERK2 or an empty vector control (EV) and 
plated onto CDM. Total RNA was extracted, labelled, and comparative whole-genome expression profiling 
was performed using Illumina HT-12 v4 expression chips. 
(see next page also) 
 	  
β
Genes upregulated by ERK2 siRNAA
B
C Gene Symbol Gene Name 
TXNIP Thioredoxin-interacting protein 
RAB17 Ras-related protein 17 
PPFIBP2 Liprin-β2 
DRD1IP Neuron-specific vesicular protein calcyon 
FLVCR2 Calcium-chelate transporter 
UCP2 Mitochondrial uncoupling protein 2 
C10ORF10 Protein DEPP 
SLC12A9 Solute carrier family 12 member 9 
GOLM1 Golgi membrane protein 1 
SELENBP1 Selenium-binding protein 1 
GPR64 G-protein coupled receptor 64 
SLC44A2 Choline transporter-like protein 2 
PALM Paralemmin 
MLXIPL Class D basic helix-loop-helix protein 14 
 
 ERK1 siRNA vs. NT siRNA ERK2 siRNA vs. NT siRNA SF-ERK1 vs. ERK2 siRNA SF-ERK2 vs. ERK2 siRNA 
Gene Symbol stepup p-value Fold-Change stepup p-value Fold-Change stepup p-value Fold-Change stepup p-value Fold-Change 
TXNIP 0.27141 1.23 0.01506 1.55 0.89481 1.05 0.00399 -2.04 
RAB17 0.70367 1.05 0.00042 1.52 0.06569 1.25 0.00045 -1.71 
PPFIBP2 0.67640 -1.04 0.00030 1.38 0.40412 -1.09 0.00019 -1.56 
DRD1IP 0.90481 1.02 0.00000 2.09 0.88305 -1.02 0.00010 -1.55 
FLVCR2 0.53329 1.06 0.00017 1.47 0.78177 -1.04 0.00377 -1.40 
UCP2 0.93571 1.02 0.02342 1.30 0.87347 -1.04 0.04242 -1.38 
C10ORF10 0.00609 1.40 0.02280 1.31 0.90116 1.03 0.04975 -1.37 
SLC12A9 0.54041 1.06 0.00032 1.39 0.61508 1.06 0.00399 -1.36 
GOLM1 0.06422 1.21 0.03084 1.25 0.71478 -1.06 0.04763 -1.32 
SELENBP1 0.00467 1.36 0.00155 1.43 0.68077 -1.07 0.04763 -1.32 
GPR64 0.00024 1.44 0.02226 1.29 0.49142 -1.08 0.00704 -1.32 
SLC44A2 0.02955 1.17 0.00006 1.46 0.99673 -1.00 0.00533 -1.32 
PALM 0.04248 1.15 0.00004 1.51 0.96763 -1.01 0.00646 -1.31 
MLXIPL 0.70000 -1.04 0.0122159 1.20 0.56620 -1.06 0.00698 -1.31 
 
Genes upregulated by ERK2 siRNA
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A. The heat map displays genes, which are up-regulated in an ERK2-dependent manner. Genes, which 
showed significant changes in expression level when comparing ERK2 knockdown versus NT siRNA 
(step-up p-value < 0.05) and inverse changes when comparing ERK2 knockdown versus re-expression of 
siRNA resistant SF-ERK2 (step-up p-value < 0.05, fold change ≥ -1.3) were identified and ranked according 
to fold changes. The expression of the first 14 genes is regulated in an ERK2-dependent manner (step-up 
p-values > 0.4, fold change ≥ -1.1 when comparing ERK2 knockdown cells to SF-ERK1 overexpression). 
The colour and intensity of the boxes allocated to each data point represent fold changes in expression level: 
low expression (green), high expression (red). 
B. Table of genes, whose expression is up-regulated in an ERK2-dependent manner. Listed are: gene 
symbols, step-up p-values (significant p-values are in red), and fold changes for experimental comparisons. A 
significant increase in fold change following ERK1 or ERK2 knockdown is marked by a green background 
colour, while inverse changes upon re-expression of ERK2 are marked by a red background colour. 
C. List of gene names for ERK2-regulated genes from (B).  
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4.2.2 Validation of ERK2-dependent gene expression using qRT-PCR 
4.2.2.1 qRT-PCR primer pairs amplify a single product in a linear manner over a 
range of cDNA concentrations 
Quantitative	  real-­‐time	  polymerase	  chain	  reaction	  (qRT-­‐PCR)	  is	  methodically	  based	  on	  the	  
polymerase	  chain	  reaction,	  but	  allows	  simultaneous	  quantification	  of	  the	  amplified	  
template.	  Moreover,	  when	  qRT-­‐PCR	  is	  combined	  with	  reverse	  transcription,	  mRNA	  levels	  
of	  different	  tissues	  or	  experimental	  conditions	  can	  be	  compared.	  To	  this	  end	  the	  quantity	  
of	  mRNA	  for	  an	  experimental	  condition	  is	  typically	  expressed	  relative	  to	  its	  control	  
sample.	  This,	  however,	  requires	  equal	  mRNA	  loading	  for	  both	  samples,	  which	  is	  ensured	  
by	  adjusting	  the	  concentration	  of	  RNA	  input	  for	  each	  reverse	  transcription	  and	  
normalising	  obtained	  values	  for	  genes	  of	  interest	  against	  a	  housekeeping	  gene,	  such	  as	  
glyceraldehyde	  3-­‐phosphate	  dehydrogenase	  (GAPDH).	  Amplicon	  accumulation	  during	  
qRT-­‐PCR	  is	  monitored	  with	  the	  help	  of	  a	  fluorescent	  dye	  (such	  as	  SYBR	  Green),	  which	  
intercalates	  with	  dsDNA	  product.	  	  
The	  qRT-­‐PCR	  consists	  of	  four	  stages,	  which	  are	  characterised	  by	  different	  reaction	  
kinetics.	  Initially,	  product	  amplification	  does	  not	  yield	  a	  measurable	  read-­‐out,	  because	  the	  
generated	  fluorescence	  is	  below	  the	  detection	  threshold.	  This	  stage	  is	  called	  the	  lag	  phase	  
and	  is	  followed	  by	  the	  exponential	  phase,	  in	  which	  the	  copy	  number	  of	  the	  template	  
doubles	  with	  each	  amplification	  cycle	  and	  the	  fluorescent	  signal	  increases	  linearly.	  This	  
stage	  allows	  the	  determination	  of	  the	  threshold	  cycle	  (Ct),	  which	  marks	  the	  cycle	  in	  which	  
the	  fluorescent	  signal	  crosses	  the	  threshold.	  The	  Ct	  value	  is	  inversely	  proportional	  to	  the	  
log	  of	  the	  initial	  template,	  which	  means	  that	  more	  initial	  mRNA	  transcripts	  give	  rise	  to	  
lower	  Ct	  values.	  The	  exponential	  phase	  is	  followed	  by	  a	  retardation	  phase,	  where	  reaction	  
components	  become	  limiting	  and	  thus,	  the	  reaction	  rate	  decreases.	  Finally,	  amplification	  
reaches	  a	  plateau,	  when	  all	  reaction	  constituents	  are	  used	  up	  and	  if	  left	  long	  enough,	  the	  
PCR	  products	  will	  begin	  to	  degrade	  [455].	  
It	  is	  important	  to	  stress	  that	  SYBR	  Green	  will	  intercalate	  with	  any	  dsDNA	  molecules	  
present	  in	  the	  reaction	  mixture.	  Therefore,	  primer	  dimers	  as	  well	  as	  non-­‐specific	  PCR	  
products	  will	  alter	  your	  overall	  fluorescent	  signal	  and	  ultimately	  your	  quantitation	  results.	  
In	  order	  to	  ensure	  an	  accurate	  amplicon	  measurement,	  the	  choice	  of	  suitable	  primers	  is	  a	  
crucial	  step	  in	  setting	  up	  a	  successful	  qRT-­‐PCR.	  Thus,	  prior	  to	  any	  comparative	  qRT-­‐PCR	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analysis,	  the	  suitability	  for	  every	  primer	  used	  must	  be	  determined.	  To	  assess	  whether	  the	  
primer	  pairs	  amplify	  a	  single	  product,	  qRT-­‐PCR	  reaction	  mixes	  were	  resolved	  on	  agarose	  
gels	  and	  visualised	  with	  ethidium	  bromide	  (data	  not	  shown).	  Moreover,	  dissociation	  
(melting)	  curves	  for	  each	  amplification	  product	  were	  generated	  by	  the	  Opticon	  Monitor	  
Software.	  The	  melting	  curve	  analysis	  of	  each	  amplicon	  of	  interest	  confirmed	  the	  presence	  
of	  a	  single	  spike,	  indicative	  of	  a	  single	  amplification	  product	  (see	  following	  sections	  for	  
some	  representative	  images).	  
Having	  ensured	  that	  the	  primer	  pairs	  give	  rise	  to	  a	  single	  amplicon	  during	  PCR,	  we	  next	  
assessed	  whether	  primer	  pairs	  were	  amplifying	  in	  a	  linear	  manner	  over	  a	  range	  of	  
different	  input	  concentrations.	  We,	  therefore,	  performed	  qRT-­‐PCR	  on	  serial	  dilutions	  of	  
cDNA	  templates	  and	  plotted	  Ct	  values	  against	  the	  logarithmic	  values	  of	  standard	  cDNA	  
amounts,	  which	  were	  expressed	  as	  dilution	  factors	  (i.e.	  1.75x,	  1.5x,	  1.25x,	  1x,	  0.75x,	  0.5x).	  
The	  correlation	  coefficient	  (R2)	  values	  were	  greater	  than	  0.98	  for	  all	  primers	  tested,	  
suggesting	  a	  near	  perfect	  linear	  relationship	  between	  Ct	  value	  and	  cDNA	  
concentration	  (Figure	  4-­‐6).	  Moreover,	  these	  results	  indicate	  that	  the	  fluorescence	  
measured	  during	  our	  qRT-­‐PCR	  was	  proportional	  to	  the	  template	  input.	  Next,	  we	  assessed	  
the	  amplification	  efficiencies	  for	  each	  amplicon	  using	  this	  formula  𝐸 = 10!!! − 1,	  where	  
‘a’	  represents	  the	  gradient	  of	  linear	  fit	  as	  defined	  by	  Arezi	  et	  al.	  [456].	  We	  obtained	  
amplification	  efficiencies	  of	  0.78,	  0.83,	  0.73,	  0.8,	  0.75	  and	  0.73	  for	  GAPDH,	  CSF2,	  Rab17,	  
Liprin-­‐β2,	  ERK1	  and	  ERK2,	  respectively.	  
Changes	  in	  mRNA	  levels	  between	  two	  experimental	  conditions	  can	  be	  expressed	  as	  
absolute	  or	  relative	  values.	  Absolute	  quantification	  of	  input	  concentrations	  requires	  the	  
generation	  of	  standard	  curves	  from	  known	  concentrations	  of	  mRNA	  species	  and	  is	  
commonly	  used	  when	  amplification	  efficiencies	  for	  target	  and	  reference	  gene	  differ	  
greatly.	  Relative	  quantification	  can	  be	  obtained	  by	  expressing	  target	  gene	  expression	  of	  
one	  sample	  relative	  to	  another.	  One	  commonly	  used	  method	  for	  relative	  quantification	  is	  
the	  ΔΔCt	  method	  [354],	  which	  takes	  loading	  variations	  into	  account	  by	  normalising	  target	  
gene	  expression	  to	  a	  reference	  gene.	  However,	  this	  quantification	  method	  assumes	  near	  
equal	  amplification	  efficiencies	  for	  target	  and	  reference	  gene.	  As	  we	  obtained	  similar	  
amplification	  efficiencies	  for	  our	  genes	  of	  interest,	  we	  were	  confident	  in	  using	  the	  ΔΔCt	  
method	  to	  compare	  expression	  levels	  for	  CSF2,	  Rab17	  and	  Liprin-­‐β2	  in	  different	  
experimental	  conditions.	  Yet,	  we	  also	  calculated	  relative	  expression	  ratios	  for	  each	  of	  the	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Figure 4-6 qRT-PCR primer pairs amplify in a linear manner over a range of cDNA concentrations 
cDNA was synthesised from RNA isolated from MDA-MB-231 cells grown on plastic. Serial dilutions of 
cDNA were used in a qRT-PCR reaction to test the efficiency of amplification of the respective primer sets. 
Standard curves representing a plot of C(t) against the initial log2 quantity of the template and corresponding 
R2 values are shown for GAPDH (A), CSF2 (B), Rab17 (C), Liprin-β2 (D), ERK1 (E), ERK2 (F). 
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latter	  genes	  using	  a	  method	  which	  does	  not	  assume	  equal	  amplification	  efficiencies	  using	  
the	  following	  formula:	  𝑟𝑎𝑡𝑖𝑜 = !∆!"!"#$%!(!"#$%"&!!"#$!")!∆!"!"#"!"$%"(!"#$%"&!!"#$%&)	  ,	  where	  ‘E’	  represents	  the	  
efficiency	  and	  ‘ΔCP’	  the	  absolute	  deviation	  [457].	  Both	  quantification	  methods	  yielded	  
near	  identical	  expression	  ratios	  (data	  not	  shown),	  thus	  verifying	  the	  suitability	  of	  the	  ΔΔCt	  
method	  for	  relative	  quantification.	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4.2.2.2 ERK2 (but not ERK1) regulates the expression of CSF2, Rab17 and 
Liprin-β2 in cells attached to CDM 
Our	  Illumina	  gene	  expression	  array	  allowed	  the	  identification	  of	  27	  genes,	  whose	  
expression	  was	  either	  increased	  or	  decreased	  in	  an	  ERK2-­‐dependent	  manner.	  Prominent	  
amongst	  these	  were	  colony-­‐stimulating	  factor	  2	  (CSF2),	  Ras-­‐related	  protein	  17	  (Rab17)	  
and	  Liprin-­‐β2,	  whose	  mRNA	  levels	  were	  strongly	  altered	  by	  knockdown	  of	  ERK2,	  and	  
normalised	  by	  re-­‐expression	  of	  siRNA-­‐resistant	  ERK2	  (but	  not	  ERK1).	  CSF2	  is	  known	  to	  
regulate	  haematopoiesis,	  but	  recent	  evidence	  suggests	  a	  role	  for	  this	  cytokine	  in	  tumour	  
cell	  invasion	  and	  disease	  progression	  [458-­‐461].	  Rab17	  is	  a	  small	  GTPase,	  which	  has	  been	  
shown	  to	  regulate	  intracellular	  transport	  of	  proteins	  and	  lipids	  [462].	  Moreover,	  there	  are	  
indications	  that	  this	  GTPase	  is	  involved	  in	  the	  maintenance	  of	  epithelial	  polarity	  [463].	  
Liprin-­‐β2	  belongs	  to	  the	  family	  of	  LAR-­‐interacting	  proteins	  (Liprins)	  and	  has	  been	  shown	  
predominantly	  to	  localise	  to	  membrane	  structures	  [464].	  To	  verify	  these	  ERK2-­‐dependent	  
gene	  expression	  signatures	  we	  transfected	  MDA-­‐MB-­‐231	  cells	  with	  non-­‐targeting	  siRNAs	  
(NT),	  or	  siRNAs	  targeting	  ERK1	  or	  ERK2	  in	  combination	  with	  expression	  plasmids	  for	  
SF-­‐ERK1,	  SF-­‐ERK2	  or	  empty	  vector	  control	  (EV)	  and	  plated	  cells	  onto	  CDM	  for	  16	  hours.	  
After	  harvesting	  the	  total	  RNA	  for	  each	  experimental	  condition,	  we	  performed	  qRT-­‐PCR	  
combined	  with	  reverse	  transcription	  and	  normalised	  our	  data	  to	  the	  housekeeping	  gene,	  
GAPDH.	  
Firstly,	  we	  assessed	  the	  expression	  of	  CSF2	  in	  our	  different	  experimental	  settings.	  It	  is	  
important	  to	  stress	  that	  melting	  curve	  analysis	  gave	  rise	  to	  a	  single	  peak,	  which	  is	  
indicative	  of	  a	  single	  amplification	  product	  for	  CSF2	  (Figure	  4-­‐7	  A).	  Moreover,	  when	  the	  
input	  cDNA	  was	  replaced	  by	  RNase/DNase-­‐free	  water,	  no	  fluorescent	  signal	  was	  detected	  
during	  qRT-­‐PCR	  within	  40	  reaction	  cycles	  (Figure	  4-­‐7	  B).	  This	  suggests	  that	  qRT-­‐PCR	  
components	  were	  not	  contaminated	  with	  DNA	  or	  RNA,	  which	  might	  obscure	  our	  data	  
analysis.	  Interestingly,	  qRT-­‐PCR	  of	  six	  independent	  experiments	  demonstrated	  that	  
silencing	  of	  either	  ERK1	  or	  ERK2	  significantly	  decreased	  CSF2	  mRNA	  levels	  (Figure	  4-­‐7	  C).	  
This	  is	  in	  direct	  contrast	  to	  the	  numerical	  values	  obtained	  from	  the	  HumanHT-­‐12	  
Expression	  BeadChip	  scanning	  and	  suggests	  that	  both	  ERK1	  and	  ERK2	  drive	  CSF2	  
expression.	  Moreover,	  consistent	  with	  the	  microarray	  data	  the	  reduction	  in	  CSF2	  
transcript	  levels	  observed	  upon	  ERK2	  depletion	  could	  only	  be	  restored	  to	  control	  levels,	  
when	  siRNA-­‐resistant	  ERK2	  (but	  not	  ERK1)	  was	  re-­‐expressed	  (Figure	  4-­‐7	  C).	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Figure 4-7 CSF2 expression is reduced upon ERK2 silencing 
A. Primer pairs targeting CSF2 amplify a single product as shown by representative melting curves, which 
were generated using Opticon Monitor software. 
B. qRT-PCR reactions run with the omission of cDNA yield no amplicon as shown on the plot derived from 
Opticon Monitor software. 
C. MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNAs targeting ERK2 in 
combination with expression plasmids for SF-ERK1, SF-ERK2 or an empty vector control (EV) and plated 
onto CDM. RNA was extracted, converted into cDNA and qRT-PCR was performed to validate the 
differential regulation of CSF2. Data was normalised to GAPDH and values relative to the control 
transfected are expressed as means ± standard error of the mean (SEM) of 18 replicates from 6 independent 
experiments. Statistical significance of differences was determined by Mann-Whitney U test analysis. 
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Next,	  we	  used	  qRT-­‐PCR	  to	  confirm	  that	  ERK2	  was	  able	  to	  suppress	  Rab17	  and Liprin-­‐β2	  
expression	  in	  MDA-­‐MB-­‐231	  cells.	  qRT-­‐PCR	  of	  either	  Rab17	  or	  Liprin-­‐β2	  gave	  rise	  to	  
melting	  curves	  with	  one	  distinct	  peak	  (Figure	  4-­‐8	  and	  Figure	  4-­‐9	  A),	  indicating	  that	  the	  
primer	  pairs	  were	  specific.	  Moreover,	  when	  reactions	  were	  set	  up	  without	  cDNA	  as	  a	  
template,	  no	  amplicon	  was	  detected	  by	  the	  Opticon	  Monitor	  Software	  within	  40	  reaction	  
cycles,	  suggesting	  that	  reaction	  components	  were	  not	  contaminated	  with	  DNA	  or	  RNA	  
molecules,	  which	  would	  obscure	  our	  results	  (Figure	  4-­‐8	  and	  Figure	  4-­‐9	  B).	  Importantly,	  
qRT-­‐PCR	  of	  six	  independent	  experiments	  showed	  that	  transcript	  levels	  of	  either	  Rab17	  or	  
Liprin-­‐β2	  were	  significantly	  increased	  following	  knockdown	  of	  ERK2,	  while	  ERK1	  depletion	  
did	  not	  elevate	  mRNA	  levels.	  Furthermore,	  re-­‐expression	  of	  siRNA-­‐resistant	  ERK2	  but	  not	  
ERK1	  restored	  expression	  of	  Rab17	  and	  Liprin-­‐β2	  to	  levels	  displayed	  by	  control	  
cells	  (Figure	  4-­‐8	  and	  Figure	  4-­‐9	  C).	  	  
Next,	  we	  determined	  whether	  mRNA	  levels	  of	  related	  members	  of	  the	  Rab	  or	  Liprin	  
family	  were	  regulated	  by	  ERK2.	  Expression	  of	  Rab20,	  a	  Rab	  GTPase	  that	  exhibits	  close	  
homology	  to	  Rab17,	  was	  minimally,	  but	  significantly,	  affected	  by	  manipulation	  of	  ERK2	  
expression	  (Figure	  4-­‐8	  D).	  In	  contrast,	  transcript	  levels	  of	  other	  Liprin	  family	  members	  
expressed	  in	  MDA-­‐MB-­‐231	  cells	  (i.e.	  Liprin-­‐β1,	  -­‐α2,	  and	  -­‐α4)	  were	  not	  affected	  in	  the	  
same	  manner	  as	  Liprin-­‐β2	  when	  ERK2	  levels	  were	  manipulated	  (Figure	  4-­‐9	  D).	  Expression	  
of	  Liprin-­‐α2	  and	  -­‐α4	  was	  decreased	  only	  when	  siRNA-­‐resistant	  ERK2	  was	  re-­‐expressed	  
following	  ERK2	  depletion,	  whereas	  Liprin-­‐β1	  expression	  was	  reduced	  when	  ERK2	  levels	  
were	  manipulated	  by	  means	  of	  gene	  silencing	  or	  ectopic	  expression.	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Figure 4-8 Rab17 expression is induced upon ERK2 silencing 
A. Primer pairs targeting Rab17 amplify a single product as shown by representative melting curves, which 
were generated using Opticon Monitor software. 
B. qRT-PCR reactions run with the omission of cDNA yield no amplicon as shown on the plot derived from 
the Opticon Monitor software. 
C-D. MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNAs targeting ERK2 in 
combination with expression plasmids for SF-ERK1, SF-ERK2 or an empty vector control (EV) and plated 
onto CDM. RNA was extracted, converted into cDNA and qRT-PCR was performed to validate the 
differential regulation of Rab17 (C) and Rab20 (D). Data was normalised to GAPDH and values relative to 
the control transfected are expressed as means ± standard error of the mean (SEM) of 18 replicates from 6 
independent experiments. Statistical significance of differences was determined by Mann-Whitney U test 
analysis.  
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Figure 4-9 Liprin-β2 expression is induced upon ERK2 silencing 
A. Primer pairs targeting Liprin-β2 amplify a single product as shown by representative melting curves, 
which were generated using Opticon Monitor software. 
B. qRT-PCR reactions run with the omission of cDNA yield no amplicon as shown on the plot derived from 
Opticon Monitor software. 
C-D. MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNAs targeting ERK2 in 
combination with expression plasmids for SF-ERK1, SF-ERK2 or an empty vector control (EV) and plated 
onto CDM. RNA was extracted, converted into cDNA and qRT-PCR was performed to validate the 
differential regulation of Liprin-β2 (C) and Liprin-β1/α2/α4 (D). Data was normalised to GAPDH and values 
relative to the control transfected are expressed as means ± standard error of the mean (SEM) of 18 replicates 
from 6 independent experiments. Statistical significance of differences was determined by Mann-Whitney U 
test analysis. 
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4.2.2.3 Single siRNA oligos confirm an induction of Rab17 and Liprin-β2 expression 
following ERK2 depletion 
To	  determine	  whether	  altered	  expression	  of	  CSF2,	  Rab17	  and/or	  Liprin-­‐β2	  were	  the	  result	  
of	  off-­‐target	  siRNA	  effects,	  we	  silenced	  ERK1	  and	  ERK2	  with	  two	  independent	  siRNA	  
duplexes,	  plated	  the	  cells	  on	  CDM	  and	  assessed	  respective	  transcript	  levels	  by	  RT-­‐PCR.	  
This	  indicated	  that	  knockdown	  of	  either	  ERK1	  or	  ERK2	  with	  two	  independent	  oligos	  
diminished	  CSF2	  transcript	  levels	  (Figure	  4-­‐10	  A).	  Furthermore,	  levels	  of	  Rab17	  and	  
Liprin-­‐β2	  mRNA	  were	  significantly	  increased	  following	  knockdown	  of	  ERK2,	  whereas	  ERK1	  
silencing	  was	  ineffective	  in	  this	  regard	  (Figure	  4-­‐10	  B/C).	  We	  also	  confirmed	  the	  
knockdown	  of	  ERK1	  and	  ERK2	  by	  means	  of	  qRT-­‐PCR	  (Figure	  4-­‐10	  D	  and	  E).	  Taken	  together	  
these	  data	  indicate	  that	  ERK2	  (but	  not	  ERK1)	  suppresses	  expression	  of	  Rab17	  and	  
Liprin-­‐β2,	  while	  both	  ERK	  isoforms	  are	  involved	  in	  maintaining	  the	  levels	  of	  CSF2	  mRNA.	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Figure 4-10 Validation of ERK2-dependent gene expression using single siRNA oligos for ERK1 and 
ERK2 
MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or single siRNA oligos targeting 
ERK1 or ERK2 and plated onto CDM. Total RNA was isolated and converted into cDNA.  
A-C. qRT-PCR was performed to assess mRNA expression levels after ERK1 or ERK2 knockdown. Data 
was normalised to GAPDH and values relative to the control transfected are expressed as means ± standard 
error of the mean (SEM) of 9 replicates from 3 independent experiments. Statistical significance of 
differences was determined by Mann-Whitney U test analysis. 
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4.2.2.4 ERK2 also acts to suppress Rab17 and Liprin-β2 when cells are grown on 
plastic 
Given	  that	  cells	  cultured	  in	  3D	  exhibit	  completely	  different	  gene	  expression	  signatures	  
when	  compared	  to	  2D	  [395],	  and	  that	  activation	  as	  well	  as	  localisation	  of	  ERK1/2	  are	  
altered	  depending	  on	  the	  substratum	  [449,	  451],	  we	  aimed	  to	  investigate	  whether	  
suppression	  of	  Rab17	  and	  Liprin-­‐β2	  by	  ERK2	  was	  specific	  to	  3D	  microenvironments.	  To	  
this	  end,	  MDA-­‐MB-­‐231	  cells	  were	  transfected	  with	  non-­‐targeting	  siRNAs	  (NT),	  or	  siRNAs	  
targeting	  ERK1	  or	  ERK2	  and	  plated	  onto	  plastic	  dishes	  (instead	  of	  CDM)	  and	  determined	  
the	  expression	  levels	  of	  Rab17	  and	  Liprin-­‐β2.	  	  
Clearly,	  siRNA	  of	  ERK2	  increased	  expression	  of	  Rab17	  and	  Liprin-­‐β2	  when	  cells	  were	  
plated	  onto	  plastic	  surfaces,	  and	  knockdown	  of	  ERK1	  also	  drove	  Rab17	  and	  Liprin-­‐β2	  
expression,	  but	  to	  a	  lesser	  extent	  (Figure	  4-­‐11).	  These	  data	  indicate	  that	  the	  presence	  of	  a	  
3D	  microenvironment	  is	  not	  a	  prerequisite	  for	  ERK2’s	  ability	  to	  suppress	  Rab17	  and	  
Liprin-­‐β2	  expression,	  but	  that	  ERK1	  may	  also	  acquire	  some	  capacity	  to	  control	  these	  
genes	  when	  cells	  are	  plated	  onto	  plastic.	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Figure 4-11 Knockdown of ERK2 induces Rab17 and Liprin-β2 expression in 2D 
MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNAs targeting ERK1 or ERK2 
and plated onto plastic. Total RNA was isolated and converted into cDNA.  
A-B. qRT-PCR was performed to assess mRNA expression levels after ERK silencing. Data was normalised 
to GAPDH and values relative to the control transfected are expressed as means ± standard error of the mean 
(SEM) of 9 replicates from 3 independent experiments. Statistical significance of differences was determined 
by Mann-Whitney U test analysis. 
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4.2.2.5 Regulation of CSF2, Rab17 and Liprin-β2 is dependent on MEK activity 
In	  an	  attempt	  to	  characterise	  the	  human	  protein-­‐DNA	  interactome,	  ERK2	  was	  identified	  
as	  an	  unconventional	  DNA-­‐binding	  protein,	  which	  can	  bind	  directly	  to	  a	  G/CAAAG/C	  
consensus	  motif	  and	  thereby	  repress	  transcription	  as	  shown	  by	  electrophoretic	  mobility	  
shift	  assays	  and	  cell-­‐based	  luciferase	  analysis.	  Intriguingly,	  this	  role	  as	  a	  transcriptional	  
repressor	  is	  independent	  of	  its	  kinase	  activity	  and	  can	  be	  attributed	  to	  a	  cluster	  of	  
positively	  charged	  residues	  on	  the	  C-­‐terminus	  of	  the	  protein,	  with	  Lys259	  and	  Arg261	  
being	  the	  key	  residues	  required	  for	  DNA	  binding	  [468].	  Having	  identified	  an	  ERK2-­‐specific	  
gene	  expression	  signature,	  we	  wanted	  to	  investigate	  whether	  this	  novel	  role	  as	  a	  
DNA-­‐binding	  protein	  was	  responsible	  for	  regulating	  mRNA	  levels	  of	  CSF2,	  Rab17	  and	  
Liprin-­‐β2.	  
To	  determine	  whether	  phosphorylation	  of	  ERK	  by	  MEK	  was	  necessary	  for	  its	  role	  in	  
regulating	  Rab17,	  Liprin-­‐β2	  and	  CSF2	  expression,	  we	  seeded	  300,000	  cells	  onto	  CDM	  and	  
treated	  them	  with	  DMSO	  (dimethyl	  sulfoxide)	  as	  mock	  or	  the	  MEK	  inhibitor,	  U0126.	  We	  
harvested	  cells	  at	  different	  time	  points	  following	  treatment	  (5	  minutes,	  1	  hour,	  2	  hours	  
and	  24	  hours),	  extracted	  total	  RNA	  and	  performed	  qRT-­‐PCR	  combined	  with	  reverse	  
transcription.	  Intriguingly,	  levels	  of	  CSF2	  mRNA	  were	  maximally	  inhibited	  one	  hour	  after	  
U0126	  treatment,	  indicating	  that	  ERK	  is	  directly	  involved	  in	  driving	  CSF2	  expression,	  and	  
that	  this	  is	  depending	  on	  its	  kinase	  activity	  (Figure	  4-­‐12	  A).	  In	  contrast,	  transcription	  of	  
Rab17	  and	  Liprin-­‐β2	  were	  only	  induced	  24	  hours	  following	  MEK	  inhibition,	  which	  suggests	  
that	  ERK2	  suppresses	  these	  two	  genes	  less	  directly	  than	  it	  affects	  CSF2	  expression	  (Figure	  
4-­‐12	  B/C).	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Figure 4-12 Expression of CSF2, Rab17 and Liprin-β2 is dependent on ERK2’s kinase activity 
MDA-MB-231 cells were treated with DMSO or the MEK inhibitor, U0126. Subsequently, cells were lysed, 
total RNA isolated, and converted into cDNA. qRT-PCR was performed to assess mRNA expression levels 
of CSF2 (A), Rab17 (B), and Liprin-β2 (C) following MEK inhibition. Data was normalised to GAPDH and 
values relative to the control transfected are expressed as means ± standard error of the mean (SEM) of 9 
replicates from 3 independent experiments. Statistical significance of differences was determined by Mann-
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4.2.2.6 Rab17 and Liprin-β2 transcription is suppressed by CSF2 
Given	  that	  expression	  of	  CSF2	  is	  maximally	  reduced	  after	  one	  hour	  of	  U0126	  treatment,	  
but	  Rab17	  and	  Liprin-­‐β2’s	  mRNA	  levels	  are	  only	  altered	  after	  24	  hours,	  we	  wanted	  to	  
investigate	  the	  possibility	  that	  Rab17	  and	  Liprin-­‐β2	  are	  downstream	  effectors	  of	  CSF2,	  
which	  might	  explain	  the	  late	  induction	  in	  gene	  expression.	  To	  test	  this	  interdependency,	  
MDA-­‐MB-­‐231	  cells	  were	  transfected	  with	  NT	  siRNAs,	  or	  oligos	  targeting	  CSF2,	  Rab17,	  or	  
Liprin-­‐β2	  and	  plated	  onto	  cell-­‐derived	  matrix.	  We	  found	  that	  siRNA	  of	  Liprin-­‐β2	  did	  not	  
alter	  levels	  of	  Rab17	  mRNA,	  and	  neither	  did	  Rab17	  knockdown	  affect	  Liprin-­‐β2	  
expression.	  However,	  silencing	  of	  CSF2	  significantly	  induced	  both	  Rab17	  and	  Liprin-­‐β2	  
expression	  (Figure	  4-­‐13	  A/B),	  indicating	  that	  transcription	  of	  these	  two	  genes	  is	  regulated	  
by	  CSF2.	  Next,	  we	  wanted	  to	  investigate	  whether	  expression	  of	  CSF2	  itself	  is	  regulated	  by	  
Rab17	  or	  Liprin-­‐β2	  through	  a	  positive	  or	  negative	  feedback	  loop.	  However,	  we	  observed	  
no	  significant	  changes	  in	  CSF2	  mRNA	  levels,	  when	  either	  Rab17	  or	  Liprin-­‐β2	  were	  
silenced	  (Figure	  4-­‐13	  C).	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Figure 4-13 Rab17 and Liprin-β2 expression is suppressed by CSF2 
MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNAs targeting CSF2, Rab17, or 
Liprin-β2 and plated onto cell-derived matrix. Total RNA was isolated and converted into cDNA. qRT-PCR 
was performed to assess mRNA expression levels of CSF2 (A), Rab17 (B), and Liprin-β2 (C) following 
respective knockdowns. Data was normalised to GAPDH and values relative to the control transfected are 
expressed as means ± standard error of the mean (SEM) of 9 replicates from 3 independent experiments. 
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4.3 Discussion 
4.3.1 Summary 
Chapter	  3	  presented	  data	  demonstrating	  that	  the	  invasiveness	  of	  MDA-­‐MB-­‐231	  cells	  
depends	  specifically	  on	  ERK2	  and	  not	  ERK1.	  Here,	  we	  performed	  a	  gene	  expression	  array	  
to	  identify	  genes	  whose	  expression	  is	  regulated	  by	  ERK2	  but	  not	  ERK1.	  We	  found	  27	  genes	  
whose	  expression	  was	  altered	  after	  knockdown	  of	  ERK2	  and	  restored	  to	  normal	  levels	  
following	  re-­‐expression	  of	  ERK2	  (but	  not	  ERK1).	  Among	  these,	  we	  confirmed	  the	  
ERK2-­‐dependency	  for	  csf2,	  rab17	  and	  liprin-­‐β2	  on	  CDM	  by	  qRT-­‐PCR.	  Moreover,	  siRNA	  of	  
ERK2	  clearly	  increased	  expression	  of	  Rab17	  and	  Liprin-­‐β2	  when	  cells	  are	  grown	  on	  plastic	  
surfaces,	  indicating	  that	  the	  presence	  of	  a	  3D	  microenvironment	  is	  not	  a	  prerequisite	  for	  
ERK2’s	  ability	  to	  suppress	  these	  genes.	  
4.3.2 ERK2 as a regulator of transcriptional initiation 
In	  this	  chapter	  we	  provide	  clear	  evidence	  for	  an	  isoform-­‐specific,	  ERK2-­‐dependent	  gene	  
expression	  signature	  from	  which	  we	  validated	  three	  genes,	  i.e.	  csf2,	  rab17	  and	  liprin-­‐β2.	  
Interestingly,	  we	  observed	  very	  distinct	  kinetics	  of	  changes	  in	  transcript	  levels	  following	  
U0126	  treatment,	  which	  implicates	  that	  ERK2	  can	  regulate	  gene	  expression	  both	  directly	  
and	  indirectly.	  Although	  we	  chose	  not	  to	  investigate	  how	  ERK2	  promotes	  or	  suppresses	  
transcriptional	  events	  in	  an	  isoform-­‐specific	  manner,	  we	  would	  still	  like	  to	  discuss	  various	  
tiers	  of	  gene	  expression	  that	  might	  be	  influenced	  by	  this	  isoform.	  	  
Active	  ERK	  signalling	  has	  been	  implicated	  in	  chromatin	  remodelling	  processes	  giving	  rise	  
to	  both	  open	  [427]	  and	  closed	  chromatin	  structures	  [469].	  The	  downstream	  ERK	  targets	  
involved	  in	  these	  processes	  still	  remain	  to	  be	  elucidated,	  although	  phosphorylation	  of	  
histone	  H3	  and	  HMG-­‐14	  by	  the	  ERK	  effectors	  MSK1/2	  and	  RSK2	  are	  thought	  to	  promote	  
loosening	  of	  chromatin	  by	  recruiting	  histone	  acetyltransferases	  [426-­‐428].	  Moreover,	  
active	  ERK	  has	  been	  shown	  to	  stimulate	  topoisomerase	  IIα	  in	  a	  mechanism	  that	  is	  
independent	  of	  its	  enzymatic	  activity	  [470].	  Thus,	  ERK2	  might	  promote	  or	  suppress	  DNA	  
accessibility	  of	  a	  subset	  of	  genes	  by	  regulating	  the	  phosphorylation	  or	  activity	  of	  
chromatin	  remodelling	  factors,	  such	  as	  topoisomerase	  IIα.	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Once	  the	  chromatin	  is	  loosened,	  transcription	  factors	  bind	  to	  the	  exposed	  DNA	  sequence	  
and	  thereby	  enhance	  or	  suppress	  the	  formation	  of	  the	  transcription	  initiation	  complex.	  As	  
transcriptional	  activators	  and	  repressors	  generally	  compete	  for	  the	  same	  binding	  site	  on	  
the	  DNA,	  alterations	  in	  DNA	  binding	  affinities	  through	  post-­‐translational	  modifications	  
can	  promote	  or	  inhibit	  gene	  transcription	  [471].	  Indeed,	  phosphorylation	  of	  c-­‐Jun	  and	  
N-­‐Myc	  by	  ERK1/2	  was	  shown	  to	  enhance	  the	  transactivation	  and	  transcriptional	  
repression	  activity,	  respectively	  [472,	  473].	  Thus,	  ERK2	  might	  regulate	  gene	  transcription	  
by	  altering	  the	  DNA-­‐binding	  affinity	  of	  transcription	  factors	  through	  direct	  or	  indirect	  
phosphorylation.	  In	  addition,	  ERK2	  has	  recently	  been	  identified	  as	  an	  unconventional	  
DNA-­‐binding	  protein	  [468],	  which	  represses	  interferon	  gamma	  signalling.	  Although	  not	  
reported	  so	  far,	  DNA-­‐binding	  by	  ERK2	  may	  also	  promote	  gene	  transcription.	  Notably,	  both	  
ERK	  isoforms	  contain	  the	  critical	  residues	  involved	  in	  DNA	  binding	  [468],	  which	  argues	  
against	  an	  ERK2-­‐specific	  function	  in	  transcription.	  However,	  amino	  acids	  flanking	  the	  
critical	  arginine	  and	  lysine	  are	  only	  partially	  conserved	  between	  the	  two	  kinases	  (Figure	  
4-­‐14	  A)	  and	  this	  may	  give	  rise	  to	  differing	  DNA	  binding	  grooves.	  Whether	  or	  not	  both	  
kinases	  recognise	  different	  DNA	  consensus	  motifs	  remains	  to	  be	  elucidated.	  	  
Interestingly,	  the	  csf2	  promoter	  region	  contains	  2	  G/CAAAG/C	  motifs	  and	  this	  suggests	  
that	  ERK2	  might	  bind	  to	  its	  5ˊ	  UTR.	  Although	  DNA-­‐binding	  is	  independent	  of	  ERK	  kinase	  
activity	  [468],	  it	  is	  possible	  that	  active	  ERK	  bound	  to	  the	  promoter	  region	  may	  
phosphorylate	  neighbouring	  transcription	  factors	  and	  thereby	  alter	  their	  ability	  to	  
transactivate	  or	  repress.	  Moreover,	  active	  ERK	  might	  be	  recruited	  to	  specific	  genes	  
through	  its	  DNA-­‐binding	  ability.	  Intriguingly,	  CSF2	  mRNA	  levels	  are	  reduced	  by	  knockdown	  
of	  either	  ERK1	  or	  ERK2,	  indicating	  that	  both	  kinases	  are	  involved	  in	  driving	  CSF2	  
expression.	  Yet,	  CSF2	  transcript	  levels	  are	  only	  restored	  to	  control	  levels	  when	  ectopic	  
ERK2	  is	  re-­‐expressed,	  indicating	  that	  ERK	  regulates	  both	  the	  initial	  transcription	  as	  well	  as	  
mRNA	  stability.	  Indeed,	  the	  csf2	  promoter	  region	  contains	  an	  AP-­‐1-­‐binding	  site,	  which	  is	  
critical	  for	  CSF2	  transcription	  (personal	  communication	  with	  Dr.	  Gareth	  Inman).	  The	  AP-­‐1	  
transcription	  factor	  is	  regulated	  both	  transcriptionally	  and	  post-­‐transcriptionally	  by	  both	  
ERK1	  and	  ERK2.	  Thus,	  it	  is	  not	  surprising	  that	  silencing	  of	  either	  gene	  significantly	  reduces	  
CSF2	  mRNA	  levels.	  Yet,	  the	  MEK	  inhibitor	  U0126	  maximally	  reduces	  csf2	  mRNA	  levels	  
within	  one	  hour	  of	  treatment,	  although	  Fra	  and	  Jun	  levels	  only	  decrease	  after	  a	  prolonged	  
inhibition	  of	  MEK	  [378].	  This	  indicates	  that	  there	  are	  AP-­‐1	  independent	  mechanisms,	  
which	  are	  also	  important	  in	  the	  initial	  stages	  of	  csf2	  transcription.	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Figure 4-14 ERK2 as a regulator of gene expression 
A. Comparison of ERK2’s sequence shown to be involved in direct DNA-binding. Crucial basic amino acids 
are coloured in red. Diverging amino acids in the flanking sequences are coloured grey. 
B. Schematic illustration of how ERK2 drives expression of CSF. 
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4.3.3 Post-transcriptional regulation of gene expression 
Messenger	  RNA	  levels	  are	  influenced	  by	  changes	  in	  nuclear	  transcription	  rates,	  mRNA	  
processing	  and	  cytoplasmic	  decay.	  Interestingly,	  mRNA	  degradation	  is	  thought	  to	  be	  a	  
major	  regulator	  of	  gene	  expression	  and	  deregulated	  mRNA	  stability	  has	  been	  linked	  to	  
diseases,	  such	  as	  Alzheimer’s	  disease	  and	  thalassaemia	  [474].	  Eukaryotic	  mRNAs	  are	  
subject	  to	  co-­‐transcriptional	  processing,	  which	  protects	  the	  transcripts	  from	  
phosphatases	  and	  ribonucleases,	  and	  entails	  5ˊcapping,	  3ˊ	  polyadenylation	  and	  
splicing	  [475].	  Moreover,	  mRNA	  stability	  can	  be	  regulated	  through	  sequence-­‐specific	  
elements	  located	  in	  the	  5ˊ	  or	  3ˊ	  UTR.	  For	  example,	  A+U-­‐rich	  elements	  (ARE)	  are	  potent	  
destabilising	  features	  of	  mRNAs,	  which	  promote	  degradation	  by	  recruiting	  RNA-­‐binding	  
proteins,	  such	  as	  tristetraprolin	  [474].	  The	  ERK-­‐MAPK	  pathway	  stimulates	  the	  
phosphorylation	  of	  tristetraprolin	  and	  subsequent	  binding	  to	  14-­‐3-­‐3	  proteins,	  which	  
sequesters	  the	  RNA-­‐binding	  protein	  in	  the	  cytoplasm	  and	  is	  linked	  to	  an	  enhanced	  
stability	  of	  ARE-­‐containing	  mRNAs	  [476,	  477].	  
Intriguingly,	  tristetraprolin	  was	  shown	  to	  enhance	  CSF2	  mRNA	  lability	  by	  promoting	  
mRNA	  deadenylation	  [478].	  Given	  that	  ERK	  promotes	  phosphorylation	  of	  tristetraprolin,	  
this	  may	  represent	  another	  level,	  by	  which	  ERK	  signalling	  can	  impinge	  on	  CSF2	  expression.	  
Indeed,	  our	  data	  are	  consistent	  with	  a	  mechanism	  in	  which	  ERK2	  but	  not	  ERK1	  is	  
important	  in	  stabilising	  CSF2	  mRNA,	  as	  overexpression	  of	  ectopic	  ERK1	  was	  not	  sufficient	  
to	  restore	  normal	  transcript	  levels	  after	  knockdown	  of	  ERK2.	  Taken	  together,	  our	  results	  
suggest	  a	  mechanism	  in	  which	  the	  ERK-­‐MAPK	  pathway	  controls	  csf2	  expression	  at	  various	  
stages	  (Figure	  4-­‐14	  B).	  Firstly,	  both	  ERK	  isoforms	  may	  promote	  gene	  transcription	  by	  
stabilising	  the	  AP-­‐1	  transcription	  factor	  and	  potentially	  inducing	  an	  open-­‐chromatin	  
structure.	  Secondly,	  CSF2	  transcripts	  may	  be	  stabilised	  via	  an	  isoform-­‐specific	  mechanism,	  
which	  might	  involve	  phosphorylation	  of	  tristetraprolin.	  Thirdly,	  ERK	  signalling	  could	  
stimulate	  initiation	  of	  the	  translation	  machinery	  by	  activating	  MNK1	  (MAPK	  interacting	  
kinase	  1),	  which	  in	  turn	  phosphorylates	  and	  activates	  the	  translational	  initiation	  factor	  
eIF4E	  [479].	  
Notably,	  our	  Illumina	  gene	  expression	  array	  also	  identified	  genes,	  whose	  expression	  was	  
induced	  by	  knockdown	  of	  either	  ERK1	  or	  ERK2,	  but	  could	  only	  be	  restored	  to	  control	  
levels,	  when	  ectopic	  ERK2	  (but	  not	  ERK1)	  was	  re-­‐expressed	  and	  suggested	  an	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isoform-­‐specific	  role	  in	  mRNA	  decay.	  Among	  those	  genes	  were	  the	  Selenium-­‐binding	  
protein	  (SELENBP1),	  the	  protein	  DEPP	  (C100RF10)	  and	  the	  G-­‐protein	  coupled	  receptor	  64	  
(GPR64).	  Thus,	  a	  possible	  future	  avenue	  for	  investigation	  may	  be	  to	  determine	  how	  ERK2	  
signalling	  can	  selectively	  control	  stabilisation	  and	  decay	  of	  particular	  transcripts.	  
4.3.4 ERK signalling differs between 2D and 3D microenvironments 
Transmembrane	  proteins,	  such	  as	  integrins	  or	  receptor	  tyrosine	  kinases,	  are	  able	  to	  sense	  
changes	  in	  the	  extracellular	  environment	  and	  relay	  this	  information	  to	  cytoplasmic	  
signalling	  circuits	  like	  the	  ERK-­‐MAPK	  pathway.	  It	  is	  therefore	  not	  surprising	  that	  the	  
microenvironment	  in	  which	  cells	  are	  cultured	  significantly	  influences	  cellular	  signalling	  
pathways	  to	  change	  cellular	  features	  such	  as	  cell	  shape	  and	  migration	  [395,	  451].	  Rab17	  
and	  liprin-­‐β2	  were	  suppressed	  in	  an	  ERK	  isoform-­‐specific	  manner	  when	  cells	  were	  
cultured	  on	  CDM,	  but	  to	  a	  lesser	  extent	  when	  cells	  were	  grown	  on	  plastic.	  This	  
discrepancy	  in	  signalling	  may	  be	  the	  result	  of	  different	  subcellular	  localisations	  of	  the	  two	  
isoforms	  in	  2D	  and	  3D.	  Indeed,	  Aplin	  et	  al.	  have	  demonstrated	  that	  integrin-­‐mediated	  
adhesions	  to	  fibronectin	  enhance	  nuclear	  ERK	  translocation	  via	  a	  mechanism	  that	  is	  
dependent	  in	  the	  organisation	  of	  the	  actin	  cytoskeleton	  [451].	  Thus,	  localising	  ERK	  to	  
distinct	  subcellular	  compartments	  is	  likely	  to	  be	  altered	  by	  extracellular-­‐matrix	  adhesions	  
and	  contribute	  to	  isoform-­‐specific	  signalling.	  Unfortunately,	  there	  are	  currently	  no	  ERK	  
isoform-­‐specific	  antibodies,	  which	  would	  allow	  comparison	  of	  the	  localisation	  of	  the	  two	  
ERKs	  between	  2D	  and	  3D	  substrates.	  However,	  the	  use	  of	  photoactivatable	  ERK	  fusion	  
proteins,	  which	  would	  allow	  the	  monitoring	  of	  isoform-­‐specific	  trafficking	  and	  
localisation,	  might	  provide	  a	  better	  understanding	  of	  how	  ERK	  localisation	  is	  regulated	  in	  
2D	  and	  3D	  microenvironments.	  
4.3.5 Correlation between mRNA abundance and protein levels 
Unfortunately,	  we	  were	  not	  able	  to	  confirm	  that	  the	  measured	  changes	  in	  Rab17	  and	  
Liprin-­‐β2	  transcript	  levels	  were	  reflected	  in	  their	  protein	  levels,	  because	  the	  commercially	  
available	  antibodies	  were	  not	  capable	  of	  specifically	  recognising	  the	  endogenous	  protein	  
(data	  not	  shown).	  Moreover,	  we	  attempted	  to	  raise	  a	  Rab17	  antibody	  by	  injecting	  
purified	  Rab17	  into	  rabbits.	  However,	  the	  resulting	  antiserum,	  although	  able	  to	  
distinguish	  purified	  Rab17	  from	  closely	  related	  Rab20	  and	  Rab24,	  was	  insufficiently	  
sensitive	  to	  specifically	  detect	  endogenous	  Rab17	  in	  cell	  lysates.	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4.3.6 Other potentially interesting microarray hits 
Due	  to	  our	  primary	  interest	  in	  receptor	  trafficking	  and	  its	  role	  in	  regulating	  tumour	  cell	  
migration,	  we	  chose	  to	  focus	  our	  validation	  studies	  on	  targets	  which	  have	  been	  
implicated	  in	  receptor	  trafficking	  or	  integrin	  biology,	  i.e.	  Rab17	  and	  Liprin-­‐β2	  [463,	  464].	  
However,	  other	  candidate	  genes,	  which	  are	  up-­‐	  or	  down-­‐regulated	  in	  an	  ERK2-­‐dependent	  
manner,	  may	  also	  contribute	  to	  the	  invasive	  phenotype	  of	  MDA-­‐MB-­‐231	  cells,	  and	  may	  
therefore	  be	  discussed	  briefly	  in	  the	  following	  paragraphs.	  	  
One	  such	  gene	  encodes	  the	  proteoglycan	  serglycin	  (SRGN)	  and	  this	  has	  recently	  been	  
implicated	  as	  a	  driver	  of	  metastasis.	  Serglycin	  is	  one	  of	  the	  most	  up-­‐regulated	  genes	  
during	  the	  invasion-­‐metastasis	  cascade	  and	  its	  overexpression	  correlates	  with	  an	  
enhanced	  migratory	  phenotype	  [480].	  Given	  that	  ERK	  signalling	  is	  generally	  augmented	  
during	  tumourigenesis	  and	  our	  data	  identified	  ERK2	  as	  a	  driver	  of	  srgn	  transcription,	  it	  is	  
conceivable,	  that	  both	  proteins	  are	  functionally	  linked	  to	  promote	  metastasis.	  
Sulfiredoxin	  is	  another	  interesting	  microarray	  hit,	  which	  has	  already	  been	  linked	  to	  the	  
ERK-­‐MAPK	  pathway	  as	  an	  AP-­‐1	  target	  gene	  by	  Wei	  et	  al.	  and	  was	  shown	  to	  be	  required	  
for	  cellular	  transformation	  [481].	  Moreover,	  sulfiredoxin	  has	  been	  implicated	  in	  
promoting	  lung	  cancer	  progression	  by	  enhancing	  tumour	  cell	  motility	  and	  cellular	  
invasion,	  which	  makes	  this	  protein	  an	  interesting	  target	  for	  anti-­‐cancer	  treatment	  
strategies	  [482].	  Our	  microarray	  data	  suggests	  a	  transcriptional	  regulation	  comparable	  to	  
CSF2,	  where	  knockdown	  of	  either	  ERK1	  or	  ERK2	  resulted	  in	  a	  significant	  decrease	  in	  
sulfiredoxin	  mRNA	  levels,	  which	  could	  only	  be	  restored	  to	  control	  levels	  when	  ERK2	  was	  
re-­‐expressed.	  Thus,	  our	  data	  adds	  to	  the	  current	  literature	  in	  that	  it	  identifies	  sulfiredoxin	  
mRNA	  stability	  as	  a	  regulatory	  mechanism	  for	  gene	  expression,	  which	  may	  be	  exploited	  
clinically.	  
Another	  candidate	  gene	  with	  interesting	  clinical	  implications	  is	  thioredoxin-­‐interacting	  
protein	  (TXNIP),	  whose	  expression	  according	  to	  our	  microarray	  screen	  was	  increased	  by	  
ERK2	  knockdown.	  Intriguingly,	  TXNIP	  is	  frequently	  down-­‐regulated	  in	  ERBB2-­‐positive	  
breast	  cancer	  patients,	  which	  correlates	  with	  poor	  survival	  [483].	  Moreover,	  an	  inverse	  
relationship	  between	  TXNIP	  expression	  and	  carcinogenesis	  has	  been	  shown	  for	  bladder	  
and	  prostate	  cancer	  [484,	  485],	  indicating	  a	  tumour-­‐suppressive	  function	  for	  this	  gene.	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Mechanistically,	  TXNIP	  diminishes	  ERK	  activation	  by	  attenuating	  CXCR4	  expression	  in	  vitro	  
and	  in	  vivo	  [484].	  Our	  work	  expands	  the	  current	  knowledge	  by	  suggesting	  an	  
ERK-­‐dependent	  inhibition	  of	  txnip	  expression,	  which	  warrants	  continuous	  signalling	  
through	  the	  ERK-­‐MAPK	  pathway	  and	  a	  pro-­‐invasive	  phenotype.	  	  
The	  transcriptional	  regulation	  of	  the	  selenium-­‐binding	  protein	  1	  (SELENBP1)	  by	  the	  
ERK-­‐MAPK	  pathway	  represents	  another	  interesting	  observation	  from	  our	  microarray	  
screen.	  Various	  research	  groups	  have	  proposed	  a	  tumour-­‐suppressive	  function	  for	  this	  
protein,	  whose	  expression	  is	  frequently	  reduced	  in	  various	  cancer	  types	  [486-­‐488].	  
Moreover,	  Pohl	  et	  al.	  have	  shown	  a	  clear	  inhibitory	  role	  for	  SELENBP1	  in	  tumour	  cell	  
migration	  and	  carcinogenesis	  [489].	  Given	  that	  the	  highly	  motile	  phenotype	  of	  HCT116	  
cells	  is	  dependent	  on	  ERK	  signalling	  [490]	  and	  overexpression	  of	  SELENBP1	  impairs	  
HCT116	  motility	  in	  vitro,	  it	  is	  possible	  that	  ERK2	  drives	  invasion	  by	  suppressing	  a	  subset	  of	  
anti-­‐migratory	  genes	  including	  SELENBP1,	  Rab17	  and	  Liprin-­‐β2.	  
Taken	  together	  our	  microarray	  screen	  identified	  several	  interesting	  genes	  whose	  
expression	  was	  regulated	  in	  an	  ERK2-­‐dependent	  manner.	  Given	  that	  some	  of	  these	  have	  
previously	  been	  shown	  to	  drive	  or	  suppress	  tumourigenesis,	  it	  would	  be	  interesting	  to	  
determine	  their	  role	  in	  tumour	  cell	  migration	  and	  invasion	  in	  future	  experiments.	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5 Rab17 and Liprin-β2 are inhibitors of tumour cell 
migration and invasion 
5.1 Introduction 
In	  the	  previous	  chapter	  we	  have	  identified	  Ras-­‐related	  protein	  17	  (Rab17)	  and	  
LAR-­‐interacting	  protein-­‐β2	  (Liprin-­‐β2)	  as	  genes,	  whose	  expression	  is	  suppressed	  by	  ERK2	  
in	  3D	  microenvironments.	  Given	  that	  both	  genes	  have	  been	  implicated	  in	  the	  regulation	  
of	  vesicular	  transport	  and	  our	  primary	  research	  interest	  lies	  in	  receptor	  trafficking	  and	  cell	  
migration,	  we	  chose	  to	  investigate	  a	  potential	  role	  for	  these	  two	  microarray	  hits	  in	  
tumour	  cell	  motility.	  
5.1.1 Rab17 - a member of the RAB family of GTPases 
Rab17	  belongs	  to	  the	  RAS-­‐superfamily	  of	  GTPases,	  which	  comprises	  over	  170	  members	  
including	  oncogenic	  H-­‐Ras,	  N-­‐Ras	  and	  K-­‐Ras.	  Most	  family	  members	  share	  the	  common	  
feature	  of	  harbouring	  an	  intrinsic	  hydrolase	  activity,	  which	  converts	  GTP	  (guanosine	  
triphosphate)	  to	  GDP	  (guanosine	  diphosphate).	  Thus,	  GTPases	  represent	  molecular	  
switches,	  which	  cycle	  between	  an	  inactive,	  GDP-­‐bound	  and	  an	  active,	  GTP-­‐bound	  
state	  [491].	  Two	  groups	  of	  regulatory	  proteins,	  i.e.	  guanine	  nucleotide	  exchange	  factors	  
(GEFs)	  and	  GTPase	  activating	  proteins	  (GAPs),	  act	  to	  influence	  the	  GTP-­‐loading	  of	  
GTPases.	  GEFs	  promote	  GDP	  dissociation	  and	  subsequent	  GTP	  binding	  to	  activate	  the	  
GTPases;	  which	  unmasks	  protein	  interaction	  domains;	  while	  GAPs	  enhance	  the	  intrinsic	  
hydrolase	  activity	  to	  accelerate	  the	  formation	  of	  an	  inactive,	  GDP-­‐bound	  state.	  Moreover,	  
GDP-­‐dissociation	  inhibitors	  (GDIs)	  prevent	  GTPase	  activation	  by	  locking	  the	  enzyme	  in	  an	  
inactive	  conformation	  [491].	  
Rab	  proteins	  are	  peripheral	  membrane	  proteins,	  which	  are	  anchored	  to	  destination	  
membranes	  via	  a	  covalently	  linked	  prenyl	  group	  at	  their	  C-­‐terminus.	  Rab	  escort	  proteins	  
(REPs)	  accompany	  newly	  synthesised	  GTPases	  through	  the	  cytoplasm	  by	  binding	  to	  and	  
shielding	  the	  hydrophobic	  prenyl	  group.	  Once	  Rab	  proteins	  reach	  the	  destination	  
membrane,	  they	  insert	  into	  it	  using	  their	  prenyl	  group.	  Notably,	  REPs	  only	  carry	  inactive	  
GDP-­‐bound	  Rabs.	  Thus,	  the	  GTPases	  require	  activation	  following	  membrane	  insertion	  in	  
order	  for	  them	  to	  bind	  to	  Rab	  effector	  proteins,	  through	  which	  the	  GTPases	  function.	  
Following	  membrane	  fusion,	  Rab	  proteins	  are	  recycled	  through	  GDIs,	  which	  like	  REPs	  bind	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to	  the	  prenyl	  group	  of	  inactive	  GTPases	  and	  deliver	  Rabs	  to	  their	  destination	  
membrane	  [492].	  
The	  RAS-­‐superfamily	  of	  GTPases	  can	  be	  subdivided	  into	  five	  subfamilies;	  i.e.	  the	  RAS	  
family	  (due	  to	  their	  homology	  with	  the	  rat	  sarcoma	  genes),	  the	  RHO	  family	  (Ras	  
homologs),	  the	  RAB	  family	  (Ras-­‐related	  proteins),	  the	  ARF	  family	  (ADP	  ribosylation	  
factors)	  and	  the	  RAN	  family	  (Ras-­‐related	  nuclear	  proteins)	  [491].	  The	  RAB	  family	  
represents	  the	  largest	  of	  the	  five	  subclasses	  with	  over	  70	  members	  and	  it	  controls	  
multiple	  stages	  of	  vesicular	  transport,	  such	  as	  vesicle	  formation,	  movement	  and	  
fusion	  [493].	  Although	  endocytic	  vesicles	  are	  thought	  of	  as	  highly	  plastic	  structures,	  there	  
is	  evidence	  that	  functionally	  distinct	  compartments	  exist,	  and	  that	  these	  can	  be	  
characterised	  by	  specific	  Rabs.	  For	  example,	  Rab4	  and	  Rab5	  are	  known	  to	  associate	  with	  
early	  endosomes	  [494,	  495],	  while	  Rab11	  serves	  as	  a	  marker	  for	  recycling	  
endosomes	  [496].	  Moreover,	  Rab7	  has	  been	  shown	  to	  localise	  to	  late	  endosomes	  [495].	  
Rab17	  was	  identified	  as	  a	  cell	  type-­‐specific	  GTPase,	  whose	  expression	  was	  thought	  to	  be	  
restricted	  to	  epithelial	  cells.	  Northern	  blot	  analysis	  of	  various	  tissues	  demonstrated	  Rab17	  
transcripts	  to	  be	  present	  in	  kidney,	  liver	  and	  intestine,	  but	  not	  in	  organs	  lacking	  epithelial	  
cells	  [497].	  Interestingly,	  mesenchymal	  kidney	  precursor	  cells	  do	  not	  express	  Rab17,	  yet	  
its	  expression	  is	  induced	  during	  differentiation	  into	  epithelial	  cells,	  suggesting	  a	  role	  for	  
this	  GTPase	  in	  establishing	  and	  maintaining	  epithelial	  characteristics.	  In	  polarised	  cells	  
with	  distinct	  basolateral	  and	  apical	  surfaces,	  such	  as	  Madin-­‐Darby	  Canine	  Kidney	  (MDCK)	  
cells,	  ectopically	  expressed	  Rab17	  is	  localised	  to	  both	  basolateral	  and	  apical	  structures,	  
which	  suggests	  a	  role	  for	  this	  protein	  in	  cellular	  transcytosis	  [497].	  Indeed,	  subsequent	  
work	  showed	  that	  overexpression	  of	  mutant	  forms	  of	  Rab17	  (defective	  in	  GTP-­‐binding	  or	  
hydrolysis)	  resulted	  in	  an	  increase	  in	  transferrin	  receptor	  transcytosis	  in	  polarised	  Eph4	  
cells	  [462].	  This	  finding	  was	  further	  supported	  by	  Hunziker	  et	  al.	  who	  showed	  that	  ectopic	  
overexpression	  of	  wild	  type	  Rab17	  impaired	  transcytosis	  of	  dimeric	  immunoglobulin	  A	  in	  
MDCK	  cells	  [498].	  Moreover,	  inactive	  GDP-­‐loaded	  Rab17	  mutants	  were	  shown	  to	  
stimulate	  receptor	  recycling	  from	  apical	  endosomes	  to	  the	  apical	  surface	  [462].	  Thus,	  the	  
current	  evidence	  suggests	  an	  inhibitory	  role	  of	  Rab17	  on	  transcellular	  transport	  of	  
proteins	  and	  lipids	  as	  well	  as	  receptor	  recycling.	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Phylogenetically,	  Rab17	  belongs	  to	  the	  Rab5	  subfamily	  and	  shares	  an	  overall	  sequence	  
identity	  of	  approximately	  40%	  with	  Rab5,	  Rab22,	  Rab24	  and	  Rab20	  [497,	  499].	  Rab5	  is	  
one	  of	  the	  best-­‐studied	  Rab	  proteins,	  which	  mainly	  associates	  with	  early	  endosomes	  
when	  activated.	  Rab5’s	  function	  in	  vesicle	  trafficking	  is	  likely	  multifarious,	  as	  the	  GTPase	  
is	  thought	  to	  be	  involved	  in	  processes	  such	  as	  generating	  endocytic	  vesicles	  at	  the	  plasma	  
membrane,	  regulating	  membrane	  fusion	  events	  and	  controlling	  vesicle	  transport	  by	  
recruiting	  microtubule	  motor	  proteins	  [500].	  Like	  Rab5,	  Rab22	  associates	  with	  early	  
endosomes.	  Intriguingly,	  its	  ectopic	  expression	  results	  in	  an	  enlargement	  of	  endocytic	  
vesicles	  in	  the	  perinuclear	  compartment	  and	  a	  decrease	  in	  endocytosis	  as	  measured	  by	  
fluid	  phase	  markers	  [501].	  In	  contrast,	  Rab24	  is	  an	  unusual	  GTPase	  in	  that	  its	  GTPase	  
activity	  is	  impaired	  due	  to	  a	  serine	  in	  codon	  61	  rather	  than	  a	  glutamine.	  Because	  the	  
enzyme	  primarily	  exists	  in	  a	  switched-­‐on	  state,	  Rab24	  does	  not	  associate	  with	  GDIs	  and	  
may	  employ	  novel	  mechanisms	  in	  regulating	  vesicular	  trafficking	  [502].	  Rab20	  is	  also	  an	  
unusual	  in	  that	  it	  contains	  a	  40	  amino	  acid	  insertion	  of	  unknown	  function	  and	  an	  atypical	  
codon	  61	  [503].	  
Several	  putative	  interaction	  partners	  for	  Rab17	  have	  been	  identified	  through	  yeast	  
two-­‐hybrid	  and	  large	  scale	  proteomic	  screens	  (Table	  5-­‐1),	  yet	  none	  of	  these	  have	  been	  
validated	  by	  co-­‐immunoprecipitation	  or	  co-­‐localisation	  experiments.	  Interestingly,	  three	  
of	  the	  proposed	  binding	  partners	  (Rab7A,	  Chmp6,	  and	  Smurf2)	  are	  involved	  in	  receptor	  
degradation.	  Thus,	  it	  is	  likely	  that	  Rab17	  may	  play	  a	  role	  in	  regulating	  the	  degradative	  
pathway	  as	  well	  as	  modulating	  receptor	  internalisation	  and	  recycling.	  To	  add	  to	  this,	  
Rab17	  has	  been	  identified	  as	  a	  regulator	  of	  cilium	  formation,	  as	  overexpression	  of	  the	  
Rab17-­‐specific	  GAP,	  TBC1D7,	  impaired	  cilium	  development	  [504].	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Gene ID Gene name Gene function Ref. 
TBC1D7 TBC1 domain family 
member 7 
GTPase activating protein [504] 
RAB7A Ras-related protein 7A Late endosomal marker [505] 
NUDT3 Nudix type motif 3 Implicated in nucleoside 
phosphate metabolic pathways 
[506] 
CHMP6 Chromatin modifying protein 
6 
Involved in surface receptor 
degradation and the formation of 
endocytic multivesicular bodies 
[507] 
SMURF2 SMAD-specific E3 ubiquitin 
ligase 2 
Involved in protein degradation [508] 
S100A8 S100 calcium binding protein 
A8 
Versatile functions: implicated in 
differentiation and cell cycle 
progression amongst others 
[506] 
RABAC1 Rab acceptor protein 1 GDI displacement factor [505] 
ACVR1 Activin A receptor type 1 belong to the TGFβ superfamily [508] 
Table 5-1 Overview of known and putative Rab17 interaction partners as determined by high-
throughput experiments 
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5.1.2 Liprins – a family of LAR-interacting proteins 
Liprin-­‐β2	  belongs	  to	  the	  family	  of	  LAR	  (leukocyte	  common	  antigen-­‐related)-­‐interacting	  
proteins,	  which	  constitutes	  a	  class	  of	  cytoplasmic	  adaptor	  proteins	  involved	  in	  neuronal	  
and	  non-­‐neuronal	  processes.	  In	  humans	  there	  are	  six	  liprin	  genes,	  which	  are	  subdivided	  
into	  two	  classes	  based	  on	  sequence	  similarities	  and	  binding	  characteristics,	  i.e.	  α-­‐type	  
(Liprin-­‐α1	  to	  α4)	  and	  β-­‐type	  (Liprin-­‐β1	  and	  -­‐β2)	  [464].	  Members	  of	  the	  Liprin	  family	  
demonstrate	  a	  high	  degree	  of	  sequence	  conservation	  over	  a	  250	  amino	  acid	  region	  in	  
their	  C-­‐termini.	  This	  region,	  designated	  the	  Liprin	  homology	  domain,	  is	  unique	  to	  this	  
protein	  family	  and	  thought	  to	  play	  an	  important	  role	  in	  their	  function	  by	  mediating	  
protein-­‐protein	  interactions	  [464,	  509].	  Although	  the	  nomenclature	  suggests	  otherwise,	  
only	  Liprin-­‐α	  proteins	  can	  interact	  with	  LAR	  proteins	  (a	  family	  of	  transmembrane	  protein	  
tyrosine	  phosphatases)	  via	  their	  C-­‐terminal	  domain,	  indicating	  that	  the	  biological	  
functions	  of	  the	  two	  subclasses	  may	  be	  different	  [464].	  Recently,	  Kazrin,	  known	  for	  its	  
role	  in	  desmosome	  assembly,	  was	  identified	  as	  a	  novel	  member	  of	  the	  Liprin	  family	  [510].	  
All	  family	  members	  share	  the	  same	  overall	  structure	  with	  an	  N-­‐terminal	  coiled-­‐coil	  
domain	  and	  a	  distinct	  C-­‐terminus	  comprising	  three	  consecutive	  SAM	  (steryl	  alpha	  motif)	  
domains	  (Figure	  5-­‐1	  A).	  Co-­‐immunoprecipitation	  experiments	  have	  demonstrated	  that	  
Liprins	  homodimerise	  via	  their	  N-­‐terminal	  coiled-­‐coil	  domain	  and	  heterodimerise	  via	  the	  
C-­‐terminal	  region	  [464,	  509].	  Notably,	  heterodimerisation	  of	  the	  two	  Liprin	  subclasses	  is	  
still	  controversial,	  as	  subsequent	  work	  failed	  to	  isolate	  Liprin-­‐α/Liprin-­‐β	  complexes	  in	  
co-­‐immunoprecipitation	  experiments.	  However,	  direct	  interaction	  between	  α-­‐	  and	  
β-­‐Liprins	  was	  recently	  demonstrated	  in	  co-­‐crystallisation	  experiments	  by	  Wei	  et	  al.,	  
arguing	  for	  the	  existence	  of	  heterodimers	  [511].	  Interestingly,	  the	  central	  coiled	  coil	  
domains	  of	  Liprin-­‐βs	  form	  parallel	  homodimers	  and	  are	  predicted	  to	  bring	  all	  six	  SAM	  
domains	  in	  close	  proximity	  [512].	  Thus,	  the	  N-­‐terminal	  regions	  intertwine	  to	  form	  rod-­‐like	  
structures,	  which	  may	  be	  organized	  into	  more	  complex	  molecular	  networks	  as	  reported	  
for	  other	  coiled-­‐coil	  proteins,	  such	  as	  myosin	  II	  heavy	  chains	  or	  intermediate	  
filaments	  [513,	  514].	  In	  addition,	  recent	  computational	  analysis	  identified	  Liprin-­‐β’s	  
second	  SAM	  domain	  as	  a	  potential	  polymer	  forming	  module	  [515].	  Thus,	  
heterodimerisation	  of	  the	  two	  Liprin	  subclasses	  is	  believed	  to	  give	  rise	  to	  either	  closed	  or	  
open	  scaffolds,	  which	  are	  thought	  to	  regulate	  the	  cytomatrix	  organisation	  of	  neuronal	  
and	  non-­‐neuronal	  cells	  (Figure	  5-­‐1	  B)	  [512].	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Studies	  on	  Liprins	  so	  far	  have	  focused	  on	  the	  function	  of	  Liprin-­‐α1	  in	  neuronal	  and	  
non-­‐neuronal	  cells.	  In	  neurons,	  Liprin-­‐α	  proteins	  play	  an	  important	  role	  in	  organizing	  the	  
pre-­‐synaptic	  site	  for	  rapid	  neurotransmitter	  release	  by	  localizing	  LAR	  proteins	  to	  the	  
active	  zone	  [516].	  Furthermore,	  Liprin-­‐α	  and	  LAR	  proteins	  are	  expressed	  in	  post-­‐synaptic	  
sites,	  where	  they	  regulate	  dendrite	  development	  [517].	  Non-­‐neuronal	  functions	  are	  less	  
studied,	  but	  there	  is	  some	  evidence	  for	  a	  role	  for	  Liprin-­‐α1	  in	  cell	  motility	  [509,	  518,	  519].	  
Liprin-­‐α1	  and	  LAR	  colocalise	  to	  focal	  adhesions	  at	  the	  cellular	  rear	  and	  may	  facilitate	  
adhesion	  disassembly,	  a	  prerequisite	  for	  cell	  migration	  [509].	  Moreover,	  overexpression	  
of	  Liprin-­‐α1	  induces	  cell	  spreading	  on	  fibronectin,	  while	  RNAi	  inhibits	  cell	  spreading	  and	  
lamellipodia	  formation	  [519].	  Intriguingly,	  Liprin-­‐α1	  was	  shown	  to	  prevent	  internalisation	  
of	  inactive	  β1	  integrin	  from	  the	  cell	  surface,	  thereby	  increasing	  the	  amount	  of	  integrin	  
available	  for	  ECM	  binding	  and	  activation	  [520].	  
Liprin-­‐β1’s	  biological	  functions	  are	  less	  well	  characterised,	  although	  recent	  evidence	  
suggests	  a	  role	  for	  this	  protein	  in	  lymphatic	  vascular	  development	  [521].	  Moreover,	  
Liprin-­‐β1	  has	  been	  identified	  as	  a	  novel	  binding	  partner	  for	  the	  metastasis-­‐associated	  
protein	  S100A4	  (Mts1).	  The	  binding	  site	  for	  Mts1	  resides	  within	  the	  C-­‐terminal	  portion	  of	  
Liprin-­‐β1,	  indicating	  the	  possibility	  that	  Mts1	  association	  may	  interfere	  with	  
Liprin-­‐α/Liprin-­‐β	  complex	  formation,	  thus	  releasing	  Liprin-­‐α1	  from	  a	  heterodimeric	  
complex	  to	  promote	  LAR	  function	  at	  focal	  adhesions	  [522].	  
Liprin-­‐βs	  have	  been	  proposed	  to	  regulate	  Liprin-­‐αs	  by	  masking	  the	  C-­‐terminal	  
protein-­‐protein	  interaction	  domain	  via	  heterodimerisation.	  Thus,	  Liprin-­‐βs	  may	  indirectly	  
affect	  the	  biological	  functions	  of	  the	  α-­‐types,	  by	  sequestering	  the	  adaptor	  molecules.	  To	  
date,	  Liprin-­‐α1,	  -­‐2	  and	  -­‐3	  have	  been	  identified	  as	  Liprin-­‐β2	  interaction	  partners	  in	  yeast	  
two-­‐hybrid	  experiments	  [464].	  Furthermore,	  large	  scale	  proteomic	  screens	  have	  
identified	  PTPRC,	  TSG101,	  PRNP,	  DTNB	  and	  14-­‐3-­‐3	  σ	  as	  putative	  Liprin-­‐β2	  binding	  
partners	  (Table	  5-­‐2),	  but	  none	  of	  these	  have	  been	  validated	  in	  co-­‐immunoprecipitation	  or	  
pull-­‐down	  experiments.	  However,	  there	  is	  very	  few	  published	  studies	  that	  shine	  light	  on	  
the	  biological	  functions	  of	  Liprin-­‐β2,	  and	  future	  work	  will	  have	  to	  determine	  the	  
functional	  similarities	  and	  disparities	  between	  the	  β-­‐type	  Liprins	  and	  their	  role	  in	  
regulating	  Liprin-­‐αs.	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Figure 5-1 Schematic illustration of Liprin domain organisation and proposed complex formation 
A. The diagram shows the relative sizes and domain composition of Liprin-αs (blue) and Liprin-βs (red) 
B. Speculative scaffold organisations are depicted consisting of Liprin-αs and Liprin-βs. Interactions of the 
three tandem SAM domains can be arranged to form a “closed dimer” or an open scaffold consisting of 
multiple Liprin molecules. 
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Gene ID Gene name Gene function Ref. 
PPFIA1 Liprin-α1 
Proposed scaffolding function for 
the recruitment and anchoring of 
LAR protein tyrosine phosphatases 
[464] PPFIA2 Liprin-α2 
PPFIA3 Liprin-α3 
PTPRC Protein tyrosine phosphatase 
receptor type C 
Essential regulator of B- and T-cell 
antigen receptor signalling 
[464] 
TSG101 Tumour susceptibility gene 
101 
Plays a role in late endosomal 
sorting as part of the ESCRT 
complex, frequently mutated in 
breast cancer 
[523] 
PRNP Prion protein Remains unclear [415] 




14-3-3 σ  p53 effector, important in cell cycle 
control, expression frequently lost 
in cancer 
[524] 
Table 5-2 Overview of known and putative Liprin-β2 interaction partners as determined by high-
throughput experiments 
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5.2 Results 
5.2.1 Knockdown of Rab17 and Liprin-β2 promotes tumour cell invasion of 
MDA-MB-231 cells 
To	  determine	  whether	  Rab17	  and	  Liprin-­‐β2	  influence	  cell	  motility,	  we	  transiently	  knocked	  
down	  their	  expression	  in	  MDA-­‐MB-­‐231	  cells	  using	  siRNA	  SMARTpools	  (consisting	  of	  4	  
individual	  short	  interfering	  RNA	  oligonucleotides).	  Using	  qRT-­‐PCR	  we	  observed	  a	  60%	  
decrease	  in	  Rab17	  mRNA	  levels	  (Figure	  5-­‐2	  A)	  and	  an	  80%	  reduction	  in	  Liprin-­‐β2	  transcript	  
levels	  (Figure	  5-­‐2	  B),	  suggesting	  an	  efficient	  knockdown	  of	  either	  gene.	  
Having	  confirmed	  the	  efficacy	  of	  Rab17	  and	  Liprin-­‐β2	  suppression,	  we	  performed	  inverted	  
invasion	  assays	  to	  test	  whether	  this	  change	  in	  gene	  expression	  would	  affect	  tumour	  cell	  
invasion	  into	  fibronectin-­‐containing	  Matrigel.	  Interestingly,	  knockdown	  of	  Rab17	  
increased	  the	  invasiveness	  by	  approximately	  100%	  (p≤0.01).	  Likewise,	  silencing	  of	  
Liprin-­‐β2	  significantly	  promoted	  invasion	  of	  MDA-­‐MB-­‐231	  cells	  into	  Matrigel	  plugs	  
(p≤0.05)	  (Figure	  5-­‐2	  C/D).	  Taken	  together,	  this	  data	  suggests	  both	  Rab17	  and	  Liprin-­‐β2	  act	  
as	  inhibitors	  of	  invasive	  cell	  migration.	  
Next	  we	  wanted	  to	  investigate	  whether	  this	  increase	  in	  invasiveness	  was	  mirrored	  by	  
changes	  in	  migration	  on	  CDM.	  To	  this	  end,	  MDA-­‐MB-­‐231	  cells	  depleted	  for	  either	  Rab17	  
or	  Liprin-­‐β2	  were	  seeded	  onto	  CDM	  and	  their	  motility	  was	  monitored	  using	  a	  Nikon	  
time-­‐lapse	  microscope	  over	  the	  course	  of	  16	  hours.	  Interestingly,	  we	  observed	  a	  marginal	  
but	  significant	  decrease	  in	  the	  overall	  migration	  velocity	  when	  Rab17	  was	  depleted	  
(Figure	  5-­‐3	  B).	  In	  addition,	  the	  persistence	  of	  cell	  migration	  was	  strongly	  increased	  
following	  Rab17	  silencing	  (p≤0.0001)	  (Figure	  5-­‐3	  C).	  In	  contrast,	  knockdown	  of	  Liprin-­‐β2	  
did	  not	  have	  an	  effect	  on	  the	  overall	  migration	  velocity,	  but	  significantly	  increased	  the	  
migration	  persistence	  (p≤0.05)	  when	  compared	  to	  NT	  siRNA-­‐transfected	  cells	  (Figure	  
5-­‐3	  B/C).	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Figure 5-2 Suppression of Rab17 and Liprin-β2  promotes invasiveness of MDA-MB-231 cells 
A-B. MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or SMARTpools targeting 
Rab17 or Liprin-β2. The effectiveness of the knockdown was assessed by qRT-PCR 48 hrs post transfection. 
Statistical significance of differences was determined by Mann-Whitney U test analysis. 
C. Matrigel plugs were enriched with 25 µg/ml fibronectin and 4x104 cells were plated onto the underside of 
each Transwell 24 hrs post nucleofection. 36 hrs following this, invading cells were visualized by 
Calcein-AM staining. Serial optical sections were captured every 15 µm and are presented as a sequence in 
which the depth increases from left to right. 
D. Invasive migration was quantified by measuring the fluorescence intensity of cells penetrating the 
Matrigel plug to depths of ≥ 45 µm and expressed relative to cells transfected with non-targeting (NT) 
siRNA. Values are means ± standard error of the mean (SEM) of 18 replicates from three independent 
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Figure 5-3 Knockdown of Rab17 and Liprin-β2 increases persistence of MDA-MB-231 cells on CDM 
A. MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or those targeting Rab17 or 
Liprin-β2 and plated onto cell-derived matrix. Images were captured every 10 minutes over a 16 hrs period 
using a Nikon time-lapse microscope. Still images from a representative movie are displayed. Scale bar, 
100 µm. 
B-C. The movement of individual cells was followed using the ImageJ cell tracking software. The overall 
migration velocity (B) and persistence (C) were extracted from the trackplots. Values are means ± SEM of 
>75 trackplots from three independent experiments. Statistical significance of differences was determined by 









































Chapter 5 – Rab17 and Liprin-β2 are inhibitors of tumour cell migration and invasion 194 
5.2.2 Depletion of Rab17 and Liprin-β2 promote invasion of A2780-Rab25 
and BE cells 
To	  assess	  whether	  Rab17’s	  and	  Liprin-­‐β2’s	  inhibitory	  role	  on	  invasive	  cell	  migration	  was	  
specific	  to	  MDA-­‐MB-­‐231	  cells	  or	  more	  generally	  applicable,	  we	  decided	  to	  also	  perform	  
invasion	  assays	  in	  two	  additional	  cell	  lines:	  (i)	  A2780	  ovarian	  carcinoma	  cells	  stably	  
transfected	  with	  Rab25	  and	  (ii)	  BE	  colon	  carcinoma	  cells.	  A2780-­‐Rab25	  and	  BE	  cells	  were	  
transfected	  with	  non-­‐targeting	  siRNA	  oligos,	  or	  those	  targeting	  Rab17	  and	  Liprin-­‐β2.	  
qRT-­‐PCR	  revealed	  a	  50%	  and	  60%	  knockdown	  of	  Rab17	  mRNA	  levels	  in	  A2780-­‐Rab25	  and	  
BE	  cells,	  respectively	  (p≤0.01)	  (Figure	  5-­‐4	  A).	  Likewise,	  Liprin-­‐β2	  transcript	  levels	  were	  
significantly	  diminished	  by	  siRNA	  in	  both	  cell	  lines	  (Figure	  5-­‐4	  B).	  Silencing	  of	  Rab17	  in	  
either	  A2780-­‐Rab25	  or	  BE	  cells	  significantly	  increased	  the	  invasiveness	  by	  50%	  (p≤0.01)	  or	  
200%	  (p≤0.0001),	  respectively	  (Figure	  5-­‐4	  C/D).	  Similarly,	  suppression	  of	  Liprin-­‐β2	  by	  RNAi	  
significantly	  increased	  the	  propensity	  of	  A2780-­‐Rab25	  (increase	  of	  50%,	  p<0.001)	  and	  BE	  
cells	  (increase	  of	  300%,	  p<0.01)	  to	  invade	  into	  Matrigel	  (Figure	  5-­‐4	  C/D).	  Taken	  together,	  
these	  data	  suggest	  that	  Rab17	  and	  Liprin-­‐β2	  act	  as	  inhibitors	  of	  invasive	  cell	  migration	  
into	  fibronectin-­‐supplemented	  Matrigel	  plugs.	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Figure 5-4 Depletion of Rab17 and Liprin-β2 promotes invasiveness of A2780-Rab25 and BE cells 
A-B. A2780-Rab25 and BE cells were transfected with non-targeting siRNAs (NT), or SMARTpools 
targeting Rab17 or Liprin-β2. Efficiency of the knockdown was assessed by qRT-PCR 48 hrs post 
transfection. Statistical significance of differences was determined by Mann-Whitney U test analysis. 
C. Matrigel plugs were enriched with 25 µg/ml fibronectin and 3x104 cells were plated onto the underside of 
each Transwell 24 hrs post nucleofection. 36 hrs following this, invading cells were visualized by 
Calcein-AM staining. Serial optical sections were captured every 15 µm and are presented as a sequence in 
which the depth increases from left to right. 
D. Invasive migration was quantified by measuring the fluorescence intensity of cells penetrating the 
Matrigel plug to depths of ≥ 45 µm and expressed relative to cells transfected with non-targeting (NT) 
siRNA. Values are means ± standard error of the mean (SEM) of 18 replicates from three independent 
experiments. Statistical significance of differences was determined by Mann-Whitney U test analysis. 
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5.2.3 Overexpression of Rab17 and Liprin-β2 impairs invasion into 
Matrigel and migration on cell-derived matrix 
Given	  that	  knockdown	  of	  either	  Rab17	  or	  Liprin-­‐β2	  promoted	  invasiveness,	  we	  wanted	  to	  
investigate	  whether	  their	  overexpression	  would	  decrease	  the	  propensity	  of	  MDA-­‐MB-­‐231	  
or	  A2780-­‐Rab25	  cells	  to	  invade	  into	  Matrigel	  plugs	  or	  to	  migrate	  on	  CDM.	  To	  do	  this,	  cells	  
were	  transfected	  with	  an	  empty	  vector	  control	  (pEGFP-­‐C1),	  pEGFP-­‐Rab17	  and	  
pCMV6-­‐AC-­‐GFP-­‐Liprin-­‐β2.	  Ectopic	  expression	  of	  all	  plasmids	  was	  ensured	  by	  visual	  
inspection	  of	  the	  cells	  on	  a	  fluorescent	  microscope	  prior	  to	  setting	  up	  inverted	  invasion	  
assays.	  Expression	  of	  GFP	  alone	  reduced	  the	  invasive	  potential	  of	  both	  cancer	  cell	  lines	  
and	  prompted	  us	  to	  compare	  the	  relative	  percentage	  of	  cells	  that	  migrated	  beyond	  30	  µm	  
rather	  than	  45	  µm.	  Recombinant	  expression	  of	  GFP-­‐Rab17	  or	  GFP-­‐Liprin-­‐β2	  significantly	  
reduced	  invasion	  of	  MDA-­‐MB-­‐231	  cells	  by	  ≥	  50%	  (p≤0.0001)	  when	  compared	  to	  GFP	  alone	  
(Figure	  5-­‐5).	  Consistent	  with	  this,	  we	  observed	  a	  68%	  decrease	  in	  invasion	  (p≤0.0001),	  
when	  the	  GFP-­‐tagged	  proteins	  were	  overexpressed	  in	  A2780-­‐Rab25	  cells.	  We	  also	  
observed	  a	  significant	  decrease	  in	  the	  overall	  migration	  velocity	  of	  MDA-­‐MB-­‐231	  cells	  
plated	  onto	  CDM	  following	  expression	  of	  either	  ectopic	  Rab17	  or	  Liprin-­‐β2	  when	  
compared	  to	  GFP	  alone	  (data	  not	  shown),	  and	  this	  was	  owing	  to	  both	  a	  decrease	  in	  the	  
momentary	  velocity	  of	  moving	  cells	  (Figure	  5-­‐6	  B)	  and	  an	  increase	  in	  cellular	  resting	  
(Figure	  5-­‐6	  C).	  Thus,	  our	  data	  indicates	  that	  Rab17	  and	  Liprin-­‐β2	  act	  to	  restrict	  carcinoma	  
cell	  migration	  in	  3D	  microenvironments	  in	  much	  the	  same	  way	  as	  does	  knockdown	  of	  
ERK2.	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Figure 5-5 Ectopic expression of Rab17 or Liprin-β2 suppresses invasiveness MDA-MB-231 and 
A2780-Rab25 cells 
MDA-MB-231 and A2780-Rab25 cells were transfected with GFP alone, GFP-Rab17 or GFP-Liprin-β2. 
Expression of various constructs was verified by eye on a fluorescent microscope 24 hrs post nucleofection. 
A. Respective cells were plated onto plugs of fibronectin-supplemented Matrigel. 36 hrs following this, 
invading cells were visualized by Calcein-AM staining. Serial optical sections were captured every 15 µm 
and are presented as a sequence in which the depth increases from left to right.  
B. Invasive migration was quantified by measuring the fluorescence intensity of cells penetrating the 
Matrigel plug to depths of ≥ 30 µm and expressed relative to cells transfected with empty vector control. 
Values are means ± standard error of the mean (SEM) of 18 replicates from three independent experiments. 
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Figure 5-6 Ectopic expression of Rab17 or Liprin-β2 decreases the momentary velocity and increases 
cellular resting in MDA-MB-231 cells 
MDA-MB-231 cells were transfected with empty vector control (GFP alone), GFP-Rab17 or Liprin-β2, and 
plated onto cell-derived matrix. Images were captured every 10 minutes over a 16 hrs period. Cell movement 
was followed using cell-tracking software. 
A. Still images from a representative movie are displayed. Scale bar, 100 µm.  
B. Momentary migration velocities were calculated for each timeframe of the time-lapse experiment giving 
rise to over 7,000 values for each condition. Values are represented as box and whisker plots (whiskers: 10-
90 percentile) and represent three independent experiments. Statistical significance of differences was 
determined by Mann-Whitney U test analysis. 
C. Cellular resting was extracted from manual cell tracking and represents means ± SEM of thee independent 
experiments. Percentage of resting cells is displayed with absolute numbers for each condition above each 
column. 
D. Representative migration trackplots are displayed. The migration speed is denoted by a colour code, the 
scale of which is indicated on the left side of the panels. The points at which cells moved less than 2 μm in 
90 min (cellular resting) are indicated by white dots. Scale bar 100 μm. 
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5.2.4 ERK2 drives invasive cell migration of MDA-MB-231 cells by 
suppressing expression of Rab17 and Liprin-β2 
Having	  established	  that	  Rab17	  and	  Liprin-­‐β2	  act	  to	  restrict	  tumour	  cell	  invasion	  into	  
Matrigel	  plugs	  and	  migration	  on	  CDM,	  we	  wished	  to	  determine	  to	  what	  extent	  ERK2’s	  
suppression	  of	  Rab17	  and	  Liprin-­‐β2	  was	  responsible	  for	  the	  kinase’s	  ability	  to	  drive	  
invasion.	  To	  do	  this,	  we	  silenced	  ERK2	  in	  combination	  with	  knockdown	  of	  either	  Rab17	  or	  
Liprin-­‐β2	  and	  carried	  out	  invasion	  assays.	  Interestingly,	  siRNA	  of	  Rab17	  restored	  invasion	  
of	  ERK2	  knockdown	  cells	  to	  levels	  comparable	  to	  control	  cells	  (Figure	  5-­‐7).	  In	  addition,	  
concomitant	  silencing	  of	  Liprin-­‐β2	  with	  ERK2	  not	  only	  restored	  the	  invasive	  phenotype	  of	  
MDA-­‐MB-­‐231	  cells,	  but	  also	  enhanced	  the	  invasive	  capacity	  when	  compared	  to	  control	  
transfected	  cells	  (p≤0.05)	  (Figure	  5-­‐7).	  Consistent	  with	  this,	  we	  found	  that	  concomitant	  
knockdown	  of	  Rab17	  or	  Liprin-­‐β2	  with	  ERK2	  increased	  the	  momentary	  velocity	  and	  
reduced	  the	  tendency	  of	  ERK2	  knockdown	  cells	  to	  pause	  (cellular	  resting),	  whilst	  
migrating	  on	  CDM	  (Figure	  5-­‐8).	  To	  strengthen	  these	  observations	  made	  using	  SMARTpool	  
siRNAs,	  we	  repeated	  the	  motility	  studies	  on	  CDM	  with	  two	  independent	  oligos	  to	  target	  
Rab17	  and	  Liprin-­‐β2.	  Firstly,	  we	  examined	  the	  knockdown	  efficiency	  of	  the	  four	  RNA	  
duplexes	  constituting	  the	  SMARTpool	  and	  chose	  two	  RNA	  duplexes,	  which	  demonstrated	  
the	  most	  efficient	  knockdown	  (data	  not	  shown).	  Indeed,	  both	  of	  the	  duplexes	  chosen	  to	  
suppress	  Rab17	  and	  Liprin-­‐β2	  were	  able	  to	  reverse	  the	  effect	  that	  ERK2	  knockdown	  had	  
on	  momentary	  velocity	  and	  cellular	  resting	  on	  CDM	  (Figure	  5-­‐8).	  	  
Taken	  together	  these	  data	  indicate	  that	  rab17	  or	  liprin-­‐β2	  are	  novel	  motility	  suppressor	  
genes,	  and	  in	  order	  to	  drive	  invasion	  and	  migration	  of	  carcinoma	  cells	  in	  3D	  
microenvironments,	  ERK2	  must	  reduce	  the	  expression	  of	  at	  least	  one	  of	  these	  genes.	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Figure 5-7 siRNA of Rab17 or Liprin-β2 restores the invasiveness of ERK2 knockdown cells  
MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNAs targeting ERK2 in 
combination those targeting Rab17 or Liprin-β2.  
A. Cells were plated onto plugs of fibronectin-supplemented Matrigel. 36 hrs following this, invading cells 
were visualized by Calcein-AM staining. Serial optical sections were captured every 15 µm and are presented 
as a sequence in which the depth increases from left to right.  
B. Invasive migration was quantified by measuring the fluorescence intensity of cells penetrating the 
Matrigel plug to depths of ≥ 45 µm and expressed relative to cells transfected with non-targeting (NT) 
siRNA. Values are means ± standard error of the mean (SEM) of 18 replicates from three independent 
experiments. Statistical significance of differences was determined by Mann-Whitney U test analysis. 
 	  













































Chapter 5 – Rab17 and Liprin-β2 are inhibitors of tumour cell migration and invasion 201 
 
Figure 5-8 Suppression of Rab17 and Liprin-β2 restores the migratory characteristics of ERK2 
knockdown cells 
MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNAs targeting ERK2 in 
combination those targeting Rab17 or Liprin-β2 and plated onto cell-derived matrix. Images were captured 
every 10 minutes over a 16 hrs period. Cell movement was followed using cell-tracking software. 
(see next page also)   
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A. Momentary migration velocities were calculated for each timeframe of the time-lapse experiment giving 
rise to over 7,000 values for each condition. Values are represented as box and whisker plots (whiskers: 10-
90 percentile) and represent three independent experiments. “SP” denotes SMARTpool. Statistical 
significance of differences was determined by Mann-Whitney U test analysis. 
B. Cellular resting was extracted from manual cell tracking and represents means ± SEM of thee independent 
experiments. Percentage of resting cells is displayed with absolute numbers for each condition above each 
column.  
C. Representative migration trackplots are displayed. The migration speed is denoted by a colour code, the 
scale of which is indicated on the left side of the panels. The points at which cells moved less than 2 μm in 
90 min (cellular resting) are indicated by white dots. Scale bar 100 μm. 
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5.2.5 ERK2 drives migration on plastic surfaces but not through Rab17 
and Liprin-β2 
In	  chapter	  3	  we	  established	  that	  silencing	  of	  ERK2	  (but	  not	  ERK1)	  in	  MDA-­‐MB-­‐231	  cells	  
impaired	  cell	  migration	  on	  CDM	  and	  plastic	  surfaces.	  Thus,	  motility	  of	  these	  cells	  is	  
dependent	  on	  ERK2	  signalling	  irrespective	  of	  the	  microenvironment.	  Moreover,	  in	  
chapter	  4	  we	  demonstrated	  that	  ERK2	  suppressed	  expression	  of	  Rab17	  and	  Liprin-­‐β2	  on	  
CDM	  as	  well	  as	  on	  plastic	  surfaces.	  We,	  therefore,	  wished	  to	  investigate	  the	  requirement	  
for	  suppression	  of	  Rab17	  and	  Liprin-­‐β2	  in	  ERK2-­‐dependent	  cell	  migration	  into	  scratch	  
wounds.	  To	  do	  this,	  we	  silenced	  Rab17	  and	  Liprin-­‐β2	  in	  ERK2	  knockdown	  cells	  and	  
measured	  the	  speed,	  persistence	  and	  FMI	  of	  cell	  migration	  into	  scratch	  wounds.	  As	  
before,	  knockdown	  of	  ERK2	  (but	  not	  ERK1)	  significantly	  reduced	  the	  migratory	  speed	  of	  
cells	  closing	  the	  scratch	  wound	  (Figure	  5-­‐9	  A).	  However,	  by	  contrast	  with	  the	  situation	  in	  
3D	  microenvironments,	  siRNA	  of	  Rab17	  and	  Liprin-­‐β2	  in	  combination	  with	  ERK2	  was	  not	  
sufficient	  to	  restore	  the	  migration	  velocity	  of	  ERK2	  knockdown	  cells	  (Figure	  5-­‐9	  A),	  
although	  the	  persistence	  of	  Rab17	  and	  Liprin-­‐β2	  knockdown	  cells	  was	  marginally	  
increased	  (Figure	  5-­‐9	  B/C).	  Taken	  together,	  these	  data	  indicate	  that	  although	  ERK2	  
controls	  cell	  movement	  in	  3D	  microenvironments	  by	  suppressing	  Rab17	  and	  Liprin-­‐β2,	  the	  
pathways	  by	  which	  ERKs	  control	  cell	  migration	  on	  plastic	  do	  not	  involve	  these	  two	  novel	  
ERK2	  effectors.	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Figure 5-9 RNAi of Rab17 and Liprin-β2 does not restore motility defects of ERK2 knockdown cells on 
plastic 
A-C. MDA-MB-231 cells were transfected with non-targeting siRNAs (NT), or siRNAs targeting ERK2 in 
combination those targeting Rab17 or Liprin-β2. Subsequently, cells were seeded into a 6-well dish, so that 
they were confluent 48 hrs post nucleofection. After scratching, wound closure was monitored and the 
movement of individual cells was followed using ImageJ cell tracking software. The overall migration 
velocity (A), persistence (B) and forward migration index (FMI) (C) were extracted from the trackplots. 
Values are means ± SEM of >75 trackplots from three independent experiments. Statistical significance of 
differences was determined by Mann-Whitney U test analysis. 
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5.2.6 Rab17 localises to early and recycling endosomes 
Rab17	  is	  thought	  to	  play	  a	  role	  in	  vesicular	  transport.	  To	  characterise	  vesicles	  to	  which	  
Rab17	  localises	  in	  tumour	  cell	  lines,	  we	  ectopically	  expressed	  the	  GTPase	  tagged	  to	  either	  
mCherry	  or	  GFP	  in	  both	  MDA-­‐MB-­‐231	  and	  A2780-­‐Rab25	  cells.	  Live	  cell	  imaging	  indicated	  
that	  Rab17	  (irrespective	  of	  the	  tag)	  localised	  to	  vesicular-­‐type	  structures	  that	  were	  
dynamic	  and	  in	  constant	  movement	  (data	  not	  shown).	  Intriguingly,	  small	  Rab17-­‐positive	  
vesicles	  localised	  mainly	  to	  the	  peripheral	  cytoplasm,	  while	  larger	  vesicles	  were	  found	  in	  
the	  perinuclear	  region.	  Next,	  we	  overexpressed	  Rab17,	  plated	  cells	  on	  fibronectin-­‐coated,	  
collagen-­‐coated	  or	  uncoated	  coverslips	  and	  fixed	  cells	  with	  4%	  paraformaldehyde.	  
Fixation	  did	  not	  alter	  the	  distribution	  of	  the	  Rab17-­‐positive	  vesicles,	  nor	  did	  the	  addition	  
of	  fibronectin	  or	  collagen	  affect	  the	  distribution	  of	  Rab17	  vesicles	  (data	  not	  shown).	  We	  
then	  stained	  for	  endogenous	  protein	  (such	  as	  EEA1)	  or	  overexpressed	  fluorescently	  
labelled	  marker	  proteins,	  such	  as	  Rab11,	  Rab7	  and	  Sialin	  in	  combination	  with	  Rab17.	  
Confocal	  imaging	  identified	  Rab17	  on	  all	  EEA1	  positive	  early	  endosomes.	  Moreover,	  
Rab17	  partially	  co-­‐localised	  with	  recycling	  endosomes	  as	  marked	  by	  GFP-­‐Rab11.	  In	  
contrast	  we	  observed	  no	  co-­‐localisation	  of	  Rab17	  with	  late	  endosomes	  as	  marked	  by	  
Rab7,	  or	  with	  Sialin-­‐positive	  lysosomes	  (Figure	  5-­‐10).	  Thus,	  Rab17	  localises	  predominantly	  
to	  early	  endosomes,	  but	  also	  to	  some	  centrally	  located	  recycling	  compartments.	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Figure 5-10 Rab17 associates with early and recycling endosomes 
MDA-MB-231 cells were transfected as stated below, seeded onto coverslips and fixed with 4% 
paraformaldehyde 24 hrs after transfection. Co-localisation was examined using a confocal microscope. 
Scale bars, 10 µm. 
A. Fixed cells were permeabilised and stained for endogenous early endosome antigen 1 (EEA1) (green).  
B. GFP-Rab11 (green) and mCherry-Rab17 (red) were co-transfected. 
C. GFP-Rab17 (green) and RFP-Rab7 (red) were co-transfected. 
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5.2.7 Rab17 vesicles are positive for β1 integrin 
Enhanced	  β1	  integrin	  recycling	  is	  known	  to	  be	  associated	  with	  the	  invasiveness	  of	  cancer	  
cell	  lines	  [380,	  525].	  To	  initiate	  studies	  to	  determine	  whether	  Rab17	  expression	  affected	  
β1	  integrin	  trafficking,	  we	  expressed	  mCherry-­‐Rab17	  and	  stained	  for	  endogenous	  β1	  
integrin.	  Rab17	  was	  associated	  with	  a	  subset	  of	  vesicles,	  whose	  lumen	  stained	  positive	  for	  
β1	  integrin	  (Figure	  5-­‐11	  A),	  indicating	  that	  the	  GTPase	  may	  be	  involved	  in	  sorting	  and/or	  
recycling	  of	  this	  integrin	  receptor.	  	  
A	  previous	  study	  by	  Pellinen	  et	  al.	  identified	  the	  small	  GTPase	  Rab21	  as	  a	  regulator	  of	  cell	  
adhesion	  and	  endosomal	  trafficking	  of	  β1	  integrin.	  Moreover,	  Rab21	  was	  shown	  to	  
directly	  interact	  with	  β1	  integrin’s	  cytoplasmic	  tail	  in	  co-­‐immunoprecipitation	  
studies	  [526].	  Given	  that	  Rab21,	  like	  Rab17,	  belongs	  to	  the	  Rab5	  family	  of	  small	  GTPases,	  
we	  postulated	  that	  Rab17	  may	  compete	  with	  Rab21	  for	  β1	  integrin	  binding.	  To	  test	  this	  
idea,	  we	  nucleofected	  MDA-­‐MB-­‐231	  cells	  with	  an	  empty	  vector	  control	  (GFP	  alone)	  or	  
GFP-­‐Rab17,	  harvested	  cells	  24	  hours	  post	  transfection	  and	  co-­‐immunoprecipitated	  with	  
an	  antibody	  recognising	  GFP.	  We	  were	  not	  able	  to	  demonstrate	  a	  physical	  interaction	  
between	  Rab17	  and	  β1	  integrin	  (Figure	  5-­‐11),	  suggesting	  that	  Rab17	  associates	  to	  β1	  
integrin-­‐containing	  vesicles	  by	  binding	  to	  other	  cargo	  molecules	  or	  adaptor	  proteins.	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Figure 5-11 Rab17 associates with β1 integrin-positive vesicles 
A. MDA-MB-231 cells were transfected with mCherry-Rab17, seeded onto coverslips and fixed with 4% 
paraformaldehyde 24 hrs after transfection. Cells were permeabilised with 0.02% Triton-X 100 and stained 
for endogenous β1 integrin. Co-localisation was examined using a confocal microscope. Scale bars, 20 µm. 
B. MDA-MB-231 cells were transfected with empty vector control (GFP alone) or GFP-Rab17, 
immunoprecipitated using a GFP-antibody (mouse) and blotted with anti-GFP (rabbit) and anti-β1 integrin 
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5.3 Discussion 
5.3.1 Summary 
Here,	  we	  show	  that	  knockdown	  of	  Rab17	  or	  Liprin-­‐β2	  enhances	  invasiveness	  of	  three	  
cancer	  cell	  lines,	  while	  their	  overexpression	  has	  the	  opposite	  effect.	  This	  suggests	  a	  role	  
for	  both	  proteins	  in	  restricting	  carcinoma	  cell	  motility	  in	  3D microenvironments.	  
Importantly,	  knockdown	  of	  either	  Rab17	  or	  Liprin-­‐β2	  restores	  invasiveness	  of	  
ERK2-­‐depleted	  MDA-­‐MB-­‐231	  cells,	  indicating	  that	  ERK2	  drives	  invasion	  by	  suppressing	  
expression	  of	  these	  genes.	  Characterisation	  of	  Rab17-­‐positive	  vesicles	  demonstrated	  a	  
potential	  role	  for	  this	  GTPase	  in	  regulating	  early	  endocytic	  events.	  Moreover,	  
co-­‐localisation	  of	  β1	  integrin	  within	  Rab17	  vesicles,	  suggests	  a	  function	  of	  this	  GTPase	  in	  
integrin	  trafficking.	  	  
5.3.2 Rab17 – a novel suppressor of cell motility 
Rab17	  has	  been	  shown	  to	  influence	  receptor-­‐mediated	  transcytosis	  and	  recycling	  of	  
receptors	  to	  the	  apical	  membrane	  in	  non-­‐transformed	  epithelial	  cells	  [462,	  498].	  
Recently,	  a	  study	  by	  Singh	  et	  al.	  found	  that	  Rab17	  was	  one	  of	  many	  genes	  to	  be	  
up-­‐regulated	  in	  cancer	  cell	  lines	  exhibiting	  a	  more	  epithelial	  morphology,	  whereas	  the	  
GTPase	  was	  down-­‐regulated	  in	  cells	  displaying	  a	  more	  mesenchymal	  morphology	  [527].	  
This	  indicates	  that	  Rab17	  is	  associated	  with	  the	  maintenance	  of	  a	  polarised	  epithelial	  
morphology	  and	  might	  provide	  an	  explanation	  as	  to	  why	  Rab17	  levels	  must	  be	  reduced	  in	  
order	  for	  metastatic	  tumour	  cells	  to	  migrate	  with	  mesenchymal	  characteristics.	  	  
Given	  that	  Rab17	  would	  be	  expected	  to	  control	  membrane	  trafficking,	  it	  is	  interesting	  to	  
speculate	  as	  to	  how	  it	  might	  suppress	  cell	  migration.	  Recycling	  of	  α5β1	  integrin	  is	  known	  
to	  be	  key	  to	  tumour	  cell	  migration	  and	  invasion	  [380,	  525,	  528]	  and	  our	  data	  suggests	  
that	  overexpression	  of	  Rab17	  leads	  to	  the	  accumulation	  of	  β1	  integrin	  within	  large	  
endosomes	  to	  which	  Rab17	  itself	  is	  localised.	  Taken	  together	  with	  reports	  suggesting	  that	  
Rab17	  opposes	  the	  return	  of	  receptors	  to	  the	  plasma	  membrane	  [462,	  498],	  this	  moots	  
that	  Rab17	  may	  be	  an	  integrin	  recycling	  suppressor,	  whose	  expression	  must	  be	  reduced	  
for	  cells	  to	  migrate	  efficiently.	  Moreover,	  as	  Rab17	  has	  been	  proposed	  to	  interact	  with	  
signalling	  molecules	  involved	  in	  receptor	  degradation,	  such	  as	  Rab7a,	  CHMP6	  and	  Smurf2	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(see	  Table	  5-­‐1),	  it	  is	  conceivable	  that	  the	  GTPase	  feeds	  receptors	  into	  the	  degradative	  
pathway,	  thereby	  decreasing	  their	  recycling	  and	  ultimately	  inhibiting	  cell	  migration.	  
5.3.3 Liprin-β2 – a novel inhibitor of cell motility 
The	  role	  of	  Liprin	  family	  members,	  in	  particular	  the	  α-­‐Liprins,	  has	  been	  well	  established	  in	  
synaptic	  transmission.	  It	  is	  clear	  from	  reverse	  genetic	  studies	  in	  vertebrates,	  Drosophila	  
and	  C.	  elegans	  that	  Liprin	  mutants	  have	  defects	  in	  synaptic	  vesicle	  transport,	  in	  which	  
synaptic	  vesicles	  accumulate	  in	  axons	  [516].	  Thus,	  Liprins	  control	  vesicular	  transport,	  and	  
this	  is	  due	  to	  their	  ability	  to	  act	  as	  scaffolds	  to	  recruit	  and	  stabilise	  a	  number	  of	  different	  
proteins	  to	  the	  sites	  of	  exocytosis	  [516].	  	  
Heterodimerisation	  of	  the	  two	  Liprin	  subclasses	  is	  thought	  to	  modify	  the	  biological	  
functions	  of	  α-­‐Liprins,	  who	  have	  been	  implicated	  in	  promoting	  tumour	  cell	  migration	  and	  
invasion	  [518].	  In	  fact,	  Liprin-­‐α1	  is	  part	  of	  the	  human	  11q13	  chromosomal	  region	  that	  is	  
frequently	  amplified	  in	  malignant	  tumours	  [529,	  530]	  and	  was	  shown	  to	  regulate	  receptor	  
clustering	  at	  neuronal	  plasma	  membranes	  by	  interacting	  with	  GIT1	  (G	  protein-­‐coupled	  
receptor	  kinase	  interacting	  ArfGAP	  1)	  [531].	  Moreover,	  Liprin-­‐α1	  binds	  to	  neuron-­‐specific	  
kinesin	  motor	  proteins,	  thereby	  regulating	  synaptic	  vesicle	  trafficking	  [532].	  Consistent	  
with	  this,	  Liprin-­‐α1	  was	  shown	  to	  alter	  integrin	  trafficking,	  which	  may	  provide	  a	  means	  by	  
which	  it	  contributes	  to	  cell	  migration	  [519].	  In	  contrast	  to	  this	  pro-­‐invasive	  function	  of	  
Liprin-­‐α1,	  we	  identify	  Liprin-­‐β2	  is	  a	  novel	  suppressor	  of	  cell	  migration	  and	  invasion	  
downstream	  of	  ERK2.	  Thus,	  the	  question	  arises	  as	  to	  how	  two	  structurally	  related	  
proteins	  can	  have	  such	  opposing	  functions.	  We	  may	  only	  speculate	  on	  this	  matter,	  as	  
apart	  from	  structural	  data	  very	  little	  is	  known	  about	  the	  β-­‐Liprins.	  Firstly,	  β-­‐Liprins	  may	  
act	  to	  antagonise	  the	  biological	  functions	  of	  α-­‐Liprins	  by	  masking	  protein-­‐protein	  
interaction	  domains	  during	  heterodimerisation.	  Indeed,	  studies	  indicating	  that	  the	  
C-­‐terminal	  SAM	  domains	  also	  serve	  as	  docking	  platforms	  for	  protein	  kinases	  (e.g.	  
calcium/calmodulin-­‐dependent	  serine	  protein	  kinase)	  and	  phosphatases	  (e.g.	  LAR,	  PTPσ	  
and	  PTPδ)	  suggest	  that	  this	  is	  a	  possibility	  [464,	  531].	  Alternatively,	  heterodimerisation	  
might	  introduce	  a	  conformational	  change	  in	  the	  N-­‐terminal	  coiled-­‐coil	  domain,	  thereby	  
altering	  association	  with	  proteins	  such	  as	  GIT	  and	  the	  kinesin	  motor	  KIF1A	  [531,	  532].	  
Furthermore,	  it	  is	  also	  possible	  that	  Liprin-­‐β2	  might	  act	  to	  sequester	  α-­‐Liprins	  to	  impair	  its	  
function.	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Interestingly,	  Liprin-­‐α1	  is	  required	  for	  the	  correct	  subcellular	  localisation	  of	  ING4	  
(inhibitor	  of	  growth	  4),	  a	  suppressor	  of	  cell	  spreading	  and	  cell	  migration,	  which	  impairs	  
actin	  polymerisation	  at	  the	  cellular	  front	  [533].	  Thus,	  Liprin-­‐α1	  may	  represent	  a	  
double-­‐edged	  sword	  that	  can	  either	  promote	  or	  inhibit	  cell	  migration	  depending	  on	  its	  
binding	  partners.	  Consistent	  with	  this	  idea,	  a	  recent	  report	  identified	  Liprin-­‐α1	  as	  an	  
inhibitor	  of	  cell	  invasion	  in	  head	  and	  neck	  squamous	  carcinoma	  cells	  [534].	  As	  Liprin-­‐β2	  
may	  form	  a	  scaffold	  to	  organise	  α-­‐Liprins,	  increased	  expression	  of	  Liprin-­‐β2	  could	  
promote	  the	  localisation	  of	  motility	  suppressors	  at	  the	  cellular	  front.	  Thus,	  depending	  on	  
the	  molecular	  signature	  of	  the	  cell	  type	  Liprin-­‐β2	  may	  enhance	  or	  decrease	  cell	  motility	  
by	  organising	  Liprin-­‐αs.	  
5.3.4 Rab17 and Liprin-β2 - members of the same signalling circuit 
In	  this	  chapter	  we	  showed	  that	  knockdown	  of	  either	  Rab17	  or	  Liprin-­‐β2	  was	  sufficient	  to	  
restore	  invasiveness	  of	  ERK2-­‐depleted	  MDA-­‐MB-­‐231	  cells,	  which	  suggests	  that	  both	  
proteins	  are	  part	  of	  the	  same	  signalling	  circuit.	  Given	  that	  Rab17	  is	  expected	  to	  regulate	  
membrane	  trafficking	  and	  Liprins	  have	  also	  been	  shown	  to	  control	  these	  processes,	  we	  
would	  like	  to	  speculate	  as	  to	  how	  the	  two	  proteins	  may	  cooperate	  to	  inhibit	  receptor	  
recycling	  and	  thereby	  inhibit	  cell	  migration.	  
We	  propose	  a	  role	  for	  Rab17	  in	  vesicle	  sorting.	  Thus,	  increased	  expression	  of	  Rab17	  may	  
either	  promote	  receptor	  degradation,	  which	  ultimately	  reduces	  the	  amount	  of	  recycled	  
receptors,	  or	  alter	  the	  recycling	  route	  from	  a	  short	  to	  a	  long	  loop.	  This	  means	  that	  
silencing	  of	  Rab17	  would	  decrease	  receptor	  degradation	  or	  change	  the	  recycling	  route,	  
and	  ultimately	  stimulate	  cell	  migration.	  Liprin-­‐β2	  may	  either	  act	  upstream	  or	  downstream	  
of	  Rab17.	  One	  possibility	  is	  that	  the	  scaffold	  could	  impair	  receptor	  clustering	  at	  the	  
plasma	  membrane,	  which	  would	  result	  in	  a	  decrease	  in	  endocytosis	  and	  diminish	  the	  
internal	  receptor	  pool,	  which	  can	  be	  recycled	  back	  to	  the	  plasma	  membrane.	  If	  this	  was	  
true,	  RNAi	  of	  Liprin-­‐β2	  would	  promote	  cell	  motility	  by	  enhancing	  endocytosis	  and	  thus	  
stimulating	  receptor	  cycling.	  Alternatively,	  Liprin-­‐β2	  may	  also	  act	  downstream	  of	  the	  
GTPase.	  Given	  that	  Liprins	  were	  shown	  to	  recruit	  and	  stabilise	  signalling	  molecules	  at	  the	  
sites	  of	  exocytosis,	  augmented	  expression	  of	  Liprin-­‐β2	  may	  slow	  the	  trafficking	  of	  
recycling	  endosomes	  or	  impair	  fusion	  events	  at	  the	  plasma	  membrane	  (Figure	  5-­‐12).	  
Taken	  together,	  we	  believe	  that	  knockdown	  of	  either	  Rab17	  or	  Liprin-­‐β2	  may	  change	  the	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dynamics	  of	  receptor	  recycling	  to	  promote	  cell	  motility.	  Future	  work	  studying	  receptor	  
internalisation,	  recycling	  and	  degradation	  when	  either	  proteins	  are	  depleted	  or	  
overexpressed	  should	  shed	  light	  on	  the	  signalling	  hierarchy	  and	  molecular	  mechanism	  
with	  which	  both	  Rab17	  and	  Liprin-­‐β2	  impair	  cell	  motility.	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Figure 5-12 Working paradigm 
Schematic illustration on how Liprin-β2 and Rab17 may cooperate to impair receptor recycling. Liprin-β2 
may act upstream of Rab17 by impairing receptor clustering or internalisation. Alternatively, Liprin-β2 may 
affect receptor recycling by slowing down vesicle trafficking or preventing exocytosis of recycling vesicles. 
Rab17 may act to impair cell motility by either promoting receptor degradation or changing the recycling 
route from a short to a long loop. 
  
Chapter 5 – Rab17 and Liprin-β2 are inhibitors of tumour cell migration and invasion 214 
5.3.5 Rab17 and Liprin-β2 and their potential roles in cancer 
We	  have	  demonstrated	  an	  inhibitory	  role	  for	  Rab17	  and	  Liprin-­‐β2	  in	  tumour	  cell	  invasion	  
in	  three	  independent	  carcinoma	  cell	  lines,	  suggesting	  that	  this	  suppressive	  function	  may	  
be	  generally	  applicable	  in	  cancer.	  Indeed,	  when	  assessing	  the	  expression	  profile	  of	  both	  
proteins	  in	  cancer	  (using	  the	  oncomine	  database	  [535]),	  we	  found	  a	  frequent	  decrease	  of	  
Rab17	  and	  Liprin-­‐β2	  transcript	  levels	  in	  tumour	  tissues	  (Figure	  5-­‐13).	  However,	  changes	  in	  
mRNA	  levels	  do	  not	  necessarily	  correlate	  with	  changes	  in	  respective	  protein	  levels	  [536].	  
Thus,	  loss	  of	  expression	  of	  these	  proteins	  should	  ideally	  be	  determined	  by	  
immunohistochemical	  profiling	  of	  tissue	  microarrays.	  Yet,	  the	  current	  lack	  of	  antibodies	  
recognising	  the	  endogenous	  protein	  prevented	  us	  from	  addressing	  this	  issue.	  Future	  
studies	  will	  have	  to	  determine	  whether	  loss	  of	  Rab17	  and/or	  Liprin-­‐β2	  correlates	  with	  
poor	  prognosis	  and	  overall	  survival	  and	  whether	  there	  are	  certain	  subtypes	  of	  cancer,	  
which	  are	  more	  or	  less	  dependent	  on	  the	  expression	  of	  both	  proteins.	  Given	  that	  Rab17	  is	  
highly	  expressed	  in	  the	  kidney	  and	  expression	  levels	  are	  markedly	  reduced	  in	  all	  kidney	  
tumour	  samples	  assessed	  in	  the	  oncomine	  database	  (Figure	  5-­‐13	  A),	  the	  GTPase	  may	  play	  
an	  important	  role	  in	  kidney	  homeostasis.	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Figure 5-13 Expression profiles of Rab17 and Liprin-β2 across various cancer types 
Depicted are mRNA expression profiles of Rab17 (A) and Liprin-β2 (B) across various cancer types, which 
were gathered using the online Oncomine database [535]. Red signifies the gene’s overexpression or copy 
gain, while blue represents the gene’s underexpression or copy loss. Intensity of colour signifies whether the 
gene was in the top 1%, 5%, or 10% of all genes measured. The number in each cell represents the number of 
studies, which met the search criteria as follows fold change ≥1.5, p≤0.05, data type: mRNA and DNA. 
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6 Summary and future directions 
6.1 Final summary 
The	  ERK	  pathway	  is	  hyperactivated	  in	  many	  human	  cancers	  as	  a	  consequence	  of	  
increased	  expression	  or	  activating	  mutations	  of	  upstream	  components	  [314].	  Although	  
the	  canonical	  role	  of	  aberrant	  ERK	  signalling	  is	  its	  positive	  influence	  on	  cell	  survival	  and	  
proliferation	  [283,	  537],	  more	  and	  more	  evidence	  suggests	  a	  link	  between	  this	  pathway	  
and	  tumour	  cell	  migration	  and	  invasion	  [277,	  314,	  377-­‐379].	  Given	  that	  the	  predominant	  
two	  ERK	  kinases	  (ERK1	  and	  ERK2)	  are	  highly	  homologous	  and	  have	  indistinguishable	  
kinase	  activities	  in	  vitro,	  both	  enzymes	  were	  believed	  to	  be	  redundant	  and	  
interchangeable	  [357].	  	  
To	  contrast	  with	  this	  view,	  here	  we	  show	  that	  ERK2	  silencing	  inhibits	  invasive	  cell	  
migration,	  and	  re-­‐expression	  of	  ERK2	  (but	  not	  ERK1)	  restores	  the	  normal	  invasive	  
phenotype;	  arguing	  that	  true	  functional	  disparities	  do	  exist	  between	  these	  kinases	  which	  
are	  not	  just	  a	  consequence	  of	  different	  gene	  dosage.	  A	  detailed	  quantitative	  analysis	  of	  
cell	  movement	  on	  3D	  matrices	  revealed	  that	  ERK2	  depletion	  impairs	  cellular	  motility	  by	  
decreasing	  the	  migration	  velocity	  as	  well	  as	  increasing	  the	  time	  that	  cells	  remain	  
stationary	  (cellular	  resting).	  Thus,	  invasiveness	  of	  cancer	  cells	  is	  directly	  dependent	  on	  the	  
speed	  with	  which	  the	  migration	  machinery	  propels	  the	  cell	  forward	  and	  the	  ability	  of	  cells	  
to	  retain	  a	  motile	  phenotype.	  	  
To	  search	  for	  ERK2-­‐specific	  effectors,	  which	  influence	  cell	  migration	  and	  invasion,	  we	  
performed	  a	  microarray	  study	  using	  the	  rescue	  paradigm	  as	  an	  experimental	  set-­‐up.	  
Interestingly,	  knockdown	  of	  ERK2	  altered	  the	  expression	  of	  a	  large	  number	  of	  genes,	  and	  
in	  most	  cases	  expression	  of	  these	  was	  restored	  to	  normal	  levels	  by	  ectopic	  expression	  of	  
either	  ERK1	  or	  -­‐2.	  However,	  we	  identified	  a	  subset	  of	  27	  genes	  whose	  expression	  was	  
altered	  by	  knockdown	  of	  ERK2,	  but	  restored	  to	  normal	  levels	  following	  re-­‐expression	  of	  
siRNA-­‐resistant	  ERK2	  but	  not	  ERK1.	  Prominent	  amongst	  these	  were	  CSF2	  (reduced	  
expression	  following	  ERK2	  depletion),	  Rab17	  and	  Liprin-­‐β2	  (increased	  expression	  
following	  ERK2	  depletion),	  which	  we	  validated	  by	  qRT-­‐PCR.	  Rab17	  and	  Liprin-­‐β2	  play	  
inhibitory	  roles	  in	  the	  invasive	  behaviour	  of	  three	  independent	  cancer	  cell	  lines.	  
Importantly,	  knockdown	  of	  either	  Rab17	  or	  Liprin-­‐β2	  restores	  invasiveness	  of	  
ERK2-­‐depleted	  cells,	  indicating	  that	  ERK2	  drives	  invasion	  of	  MDA-­‐MB-­‐231	  cells	  by	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suppressing	  expression	  of	  these	  genes.	  Given	  that	  Rab17	  and	  Liprin-­‐β2	  are	  indirect	  
effectors	  of	  ERK2	  and	  silencing	  of	  CSF2	  induces	  transcription	  of	  Rab17	  and	  Liprin-­‐β2,	  we	  
propose	  a	  model	  in	  which	  ERK2	  drives	  tumour	  cell	  migration	  by	  promoting	  CSF2	  
transcription	  and	  translation,	  which	  in	  turn	  suppresses	  expression	  of	  the	  motility	  
inhibitors	  Rab17	  and	  Liprin-­‐β2	  (Figure	  6-­‐1).	  
6.2 Future directions 
The	  identification	  of	  true	  functional	  differences	  between	  ERK1	  and	  ERK2	  poses	  many	  
open	  questions	  with	  regard	  to	  tumourigenesis	  and	  we	  would	  like	  to	  discuss	  the	  ones	  we	  
believe	  to	  be	  most	  pressing.	  Firstly,	  do	  their	  functional	  differences	  arise	  from	  distinct	  
substrate	  profiles	  between	  the	  two	  kinases	  or	  do	  they	  bind	  to	  the	  same	  substrates	  with	  
differing	  binding	  affinities?	  To	  answer	  these	  questions	  it	  would	  be	  necessary	  to	  compare	  
the	  respective	  interactomes	  of	  ERK1	  and	  ERK2	  using	  SILAC	  (stable	  isotope	  labelling	  with	  
amino	  acids	  in	  cell	  culture)	  mass	  spectrometry.	  However,	  a	  meaningful	  comparison	  of	  
ERK1	  and	  ERK2	  substrate	  profiles	  requires	  the	  same	  amount	  of	  bait	  protein,	  which	  on	  an	  
endogenous	  level	  is	  difficult	  to	  achieve	  due	  to	  different	  expression	  levels	  of	  ERK1	  and	  
ERK2.	  Thus,	  we	  propose	  using	  a	  combination	  of	  mass	  spectrometry	  and	  the	  rescue	  
paradigm	  that	  we	  have	  developed	  for	  the	  present	  study.	  As	  both	  constructs	  are	  tagged,	  
recombinant	  kinases	  could	  be	  immunoprecipitated	  using	  FLAG-­‐beads,	  thus	  avoiding	  
problems	  arising	  from	  different	  expression	  levels	  and	  circumventing	  the	  limitation	  of	  
there	  currently	  being	  no	  suitable	  antibody	  for	  immunoprecipitation	  of	  endogenous	  ERK2.	  
The	  present	  work	  has	  identified	  an	  ERK2-­‐specific	  expression	  profile	  and	  suggests	  ERK2	  as	  
a	  regulator	  of	  transcriptional	  and	  translational	  events.	  Intriguingly,	  ERK2	  has	  recently	  
been	  identified	  as	  an	  unconventional	  DNA-­‐binding	  protein,	  which	  can	  directly	  bind	  to	  a	  
G/CAAAG/C	  consensus	  motif	  [468].	  Our	  data	  raise	  the	  question	  whether	  this	  is	  unique	  to	  
ERK2	  and	  if	  so,	  whether	  this	  might	  induce	  expression	  of	  ERK2-­‐specific	  genes,	  such	  as	  csf2.	  
ERK1	  binding	  to	  the	  G/CAAG/C	  motif	  can	  be	  investigated	  by	  electromobility	  shift	  assays	  in	  
vitro	  and	  chromatin	  immunoprecipitation	  in	  vivo.	  If	  both	  ERK	  isoforms	  were	  able	  to	  bind	  
to	  DNA,	  it	  would	  also	  be	  interesting	  to	  compare	  genome-­‐wide	  DNA	  binding	  sites	  using	  
chromatin	  immunoprecipitation	  sequencing	  (ChIP-­‐Seq).	  Additionally,	  one	  could	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Figure 6-1 Working model demonstrating how ERK2 drives invasive cell migration 
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investigate	  whether	  ERK2	  recruits	  transcription	  factors	  to	  the	  promoter	  regions	  it	  binds,	  
and	  thereby	  controls	  transcriptional	  events.	  	  
Given	  the	  published	  role	  of	  the	  N-­‐terminal	  region	  of	  ERK1	  in	  controlling	  nuclear	  shuttling	  
frequencies,	  which	  in	  turn	  may	  influence	  its	  capacity	  to	  regulate	  transcription,	  it	  would	  be	  
interesting	  to	  determine	  whether	  ERK2’s	  function	  in	  driving	  tumour	  cell	  migration	  could	  
be	  localised	  to	  a	  specific	  domain	  of	  the	  kinases,	  such	  as	  the	  N-­‐terminal	  domain.	  This	  could	  
be	  achieved	  by	  generating	  ERK	  chimeras	  and	  performing	  rescue	  experiments.	  Indeed,	  we	  
have	  already	  made	  two	  chimeras,	  one	  containing	  the	  N-­‐terminal	  region	  of	  ERK2	  fused	  to	  
the	  C-­‐terminal	  portion	  of	  ERK1	  (E2>E1)	  and	  another	  corresponding	  chimera	  of	  the	  
N-­‐terminal	  region	  of	  ERK1	  fused	  to	  the	  C-­‐terminal	  portion	  of	  ERK2	  (E1>E2).	  When	  both	  
chimeras	  were	  expressed	  to	  similar	  levels	  on	  an	  ERK2	  knockdown	  background,	  both	  were	  
similarly	  phosphorylated	  at	  the	  TEY	  motif,	  suggesting	  an	  intact	  tertiary	  structure	  (data	  not	  
shown).	  Analysis	  of	  cell	  migration	  on	  CDM	  indicated	  that	  although	  expression	  of	  E1>E2	  
restored	  the	  migratory	  defects	  caused	  by	  ERK2	  knockdown,	  E2>E1	  was	  ineffective	  in	  this	  
regard	  (data	  not	  shown).	  These	  data	  indicate	  that	  the	  information	  conferring	  ERK2’s	  
capacity	  to	  drive	  migration	  is	  not	  located	  within	  the	  divergent	  N-­‐terminal	  portion	  of	  the	  
kinase.	  However,	  there	  are	  other	  regions	  of	  significant	  divergences	  between	  ERK1	  and	  
ERK2	  (for	  example	  a	  20	  amino	  acid	  region	  close	  to	  the	  C-­‐terminus)	  and	  future	  work	  will	  be	  
necessary	  to	  evaluate	  their	  role	  in	  tumour	  cell	  migration	  and	  invasion.	  	  
Our	  gene	  expression	  data	  suggests	  a	  role	  for	  ERK2	  in	  stabilising	  and	  destabilising	  mRNA	  
transcripts.	  So	  far,	  ERK	  has	  only	  been	  implicated	  in	  regulating	  the	  destabilising	  factor	  
tristetraprolin	  post-­‐translationally	  [476,	  477].	  Yet,	  ERK2	  is	  likely	  to	  phosphorylate	  other	  
RNA-­‐binding	  proteins	  and	  future	  work	  will	  have	  to	  investigate	  this.	  It	  is	  possible	  that	  our	  
microarray	  data	  hold	  information	  which	  could	  be	  used	  to	  identify	  novel	  ERK2-­‐regulated	  
RNA-­‐stabilising	  or	  destabilising	  factors.	  By	  comparing	  the	  5ˊ	  and	  3ˊ	  UTRs	  of	  our	  
ERK2-­‐regulated	  genes	  we	  hope	  to	  identify	  known	  regulatory	  elements	  involved	  in	  the	  
recruitment	  of	  RNA-­‐binding	  proteins.	  In	  follow-­‐up	  studies,	  we	  would	  like	  to	  test	  whether	  
these	  stabilising	  or	  destabilising	  factor	  were	  regulated	  by	  the	  ERK-­‐MAPK	  pathway	  and	  
whether	  this	  was	  linked	  to	  the	  gene	  expression	  signature	  we	  observed	  in	  this	  present	  
study.	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One	  of	  the	  strengths	  of	  this	  study	  is	  the	  identification	  of	  Rab17	  and	  Liprin-­‐β2	  as	  ERK	  
targets	  that	  are	  novel	  motility	  suppressors.	  The	  fact	  that	  invasiveness	  of	  three	  
independent	  cell	  lines	  is	  augmented	  following	  knockdown	  of	  either	  of	  these	  proteins,	  
suggests	  that	  their	  function	  in	  inhibiting	  cell	  migration	  is	  generally	  applicable.	  However,	  
whether	  or	  not	  loss	  of	  Rab17	  and/or	  Liprin-­‐β2	  expression	  is	  a	  general	  phenomenon	  during	  
tumourigenesis	  will	  have	  to	  be	  examined	  by	  immunohistochemical	  staining	  of	  various	  
cancer	  tissues.	  To	  date,	  we	  do	  not	  know	  how	  ERK2	  suppresses	  Rab17	  and	  Liprin-­‐β2	  in	  
MDA-­‐MB-­‐231	  cells,	  but	  the	  rate	  at	  which	  they	  are	  upregulated	  following	  ERK	  inhibition,	  
suggests	  that	  the	  rab17	  and	  liprin	  β2	  genes	  are	  targeted	  indirectly.	  Moreover,	  silencing	  of	  
ERK2	  in	  A2780-­‐Rab25	  cells	  does	  not	  alter	  expression	  of	  Rab17	  and	  Liprin-­‐β2	  (data	  not	  
shown),	  indicating	  that	  ERK2	  drives	  tumour	  cell	  invasion	  differently	  in	  these	  cells	  and	  that	  
the	  link	  between	  Rab17/Liprin-­‐β2	  and	  ERK2	  is	  not	  generally	  applicable.	  The	  current	  
literature	  suggests	  a	  role	  for	  both	  proteins	  in	  receptor	  trafficking,	  yet	  the	  molecular	  
mechanism	  by	  which	  Rab17	  and	  Liprin-­‐β2	  reduce	  tumour	  cell	  motility	  will	  have	  to	  be	  
elucidated	  in	  the	  future.	  Firstly,	  what	  are	  the	  biological	  functions	  of	  both	  proteins?	  What	  
drives	  and	  suppresses	  expression	  of	  Rab17	  and	  Liprin-­‐β2?	  Moreover,	  what	  are	  the	  main	  
interacting	  partners	  of	  Rab17	  and	  Liprin-­‐β2?	  Do	  both	  proteins	  impair	  receptor	  
internalisation	  or	  recycling?	  Alternatively,	  do	  they	  promote	  receptor	  degradation?	  What	  
is	  the	  cargo	  of	  Rab17-­‐positive	  vesicles	  and	  what	  is	  its	  function	  in	  tumour	  cell	  migration?	  
Future	  studies	  may	  want	  to	  determine	  the	  interactome	  of	  Rab17	  and	  Liprin-­‐β2	  using	  mass	  
spectrometry.	  Given	  that	  the	  commercial	  antibodies	  we	  have	  tested	  did	  not	  recognise	  
endogenous	  Rab17	  or	  Liprin-­‐β2	  we	  suggest	  overexpression	  of	  the	  tagged	  proteins	  which	  
can	  be	  immunoprecipitated	  using	  a	  GFP	  antibody.	  To	  shine	  light	  on	  how	  Rab17	  signalling	  
suppresses	  tumour	  cell	  motility,	  it	  would	  be	  interesting	  to	  investigate	  if	  knockdown	  or	  
overexpression	  of	  Rab17	  changes	  the	  surface	  proteome	  using	  surface	  labelling	  
approaches	  followed	  by	  quantitative	  mass	  spectrometry.	  Moreover,	  one	  could	  develop	  
new	  techniques	  based	  on	  the	  use	  of	  cleavable	  surface-­‐labelling	  reagents	  to	  measure	  
changes	  in	  the	  internalome	  (all	  of	  the	  internalised	  surface	  proteins)	  and	  recyclome	  (all	  of	  
the	  recycled	  proteins),	  which	  may	  give	  insight	  on	  trafficking	  events	  regulated	  by	  Rab17.	  	  
In	  conclusion,	  this	  study	  has	  identified	  Rab17	  and	  Liprin-­‐β2	  as	  novel	  inhibitors	  of	  cell	  
motility	  whose	  expression	  is	  regulated	  by	  ERK2	  in	  MDA-­‐MB-­‐231	  cells.	  Moreover,	  we	  have	  
demonstrated	  that	  suppression	  of	  either	  Rab17	  or	  Liprin-­‐β2	  can	  completely	  compensate	  
for	  loss	  of	  ERK2.	  Thus,	  we	  propose	  one	  way	  for	  ERK2	  to	  drive	  invasiveness	  is	  by	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suppressing	  Rab17	  and/or	  Liprin-­‐β2.	  The	  potential	  for	  inhibitors	  of	  the	  MAPK	  pathway	  to	  
be	  used	  as	  anticancer	  agents	  is	  now	  being	  assessed	  in	  the	  clinic,	  and	  our	  finding	  that	  
ERK2-­‐mediated	  suppression	  of	  Rab17	  and	  Liprin-­‐β2	  drives	  cancer	  invasiveness	  will	  be	  
important	  in	  the	  interpretation	  of	  data	  from	  these	  studies.
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